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Heterochromatin protein 1 (HP1) was identified as a key component of the 
condensed DNA surrounding centromeres in most eukaryotic cells. Genes placed 
in close proximity to such constitutively dense heterochromatin regions were found 
to be stochastically silenced in a proportion of the cells leading to variegation of 
expression, a classical epigenetic phenomenon known as position effect variegation 
(PEV). Mutagenesis screens identified HP1 and SUV39H as powerful suppressors 
of variegation which were necessary for heterochromatin-mediated PEV. SUV39H 
was found to methylate the histone H3 tail at lysine 9 at heterochromatin providing 
a binding site for HP1. This discovery provided the first direct evidence for a histone 
or epigenetic code in which the ‘writer’ of the code on chromatin would be the 
SUV39H and the ‘reader’ HP1. This mechanism was subsequently found to be 
conserved from S. pombe to humans. A mechanism which shares features with PEV 
2  
has also been implicated in the pathogenesis of repeat-expansion diseases, such as 
Friedreich’s ataxia, in which the affected genes are aberrantly silenced.  In mice 
there are 3 highly conserved HP1 isoforms, HP1α, HP1β and HP1γ. HP1α and β are 
found by microscopy to be localised to constitutive heterochromatic condensed 
regions in the nucleus whereas HP1γ has a pan-nuclear distribution and is therefore 
implicating in regulating euchromatic genes. There is a paucity of data examining 
how and where HP1γ regulates gene expression in vivo at the genome-wide level. 
This thesis employed knockout and knockdown strategies to investigate this. In 
view of the early lethality of mice in which HP1γ has been deleted by homologous 
recombination, the function of HP1γ was studied here by establishing mouse 
embryonic fibroblast cell lines.  Immunoflourescent microscopy revealed for the 
first time that HP1γ was necessary for the localisation of HP1β at constitutive 
heterochromatic regions in the nucleus in most cells. This delocalisation of HP1β 
was associated with aberrant upregulation of the repetitive major satellite DNA 
associated with pericentromeric heterochromatin implying for the first time that 
HP1γ plays an important role in maintaining centromeric heterochromatin in a 
silenced state thought to be important for the maintenance of genome integrity. 
Strikingly, analysis of the transcriptome revealed a large number of genes (4293) to 
be dysregulated in male cells compared to females (1186) where the effect of HP1γ 
deficiency resulted in aberrant expression of immune related genes that would 
normally be repressed. This sexually dimorphic effect was investigated further by 
studying the effect of HP1γ deficiency on the subset of 176 genes found to differ in 
expression between normal males and females. Moreover, HP1γ in males was found 
essential for maintaining the relative repression of 114 genes in males compared to 
females, suggesting that the Y chromosome interacts with HP1γ to reduce the 
expression of these genes. In summary, a novel function for HP1γ in repressing 
pericentromeric DNA and in maintaining sexually dimorphic gene expression was 
discovered. 
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Chapter 1 - Introduction   
 
1.1 Epigenetics - an overview 
 ‘Epigenetics’ describes the mechanisms that regulate gene expression and the 
inheritance of this information (transmission of memory of function) from one 
generation to the next, or through cell division from parental to daughter cells 
without a change in the sequence of DNA (Bird 2007). Thus, epigenetic regulation 
depends on modifications made to DNA or chromatin, the regulatory proteins that 
write, read and erase these modifications as well as the differential incorporation of 
variant histones into chromatin. The landscape of these epigenetic regulatory 
factors is referred to as the ‘epigenome’. A variety of cellular phenomena including 
gene activation and silencing, heterochromatin formation, position effect 
variegation, imprinting and X chromosome inactivation have been described to rely 
on epigenetic regulation. Abnormal changes in the epigenome have also been 
implicated in various diseases. In this thesis, different epigenetic factors and their 
roles in gene regulation will be described and discussed.  
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1.2 Chromatin  
1.2.1 Chromatin structure  
 
Genetic information of eukaryotic organisms is stored by DNA. In eukaryotic nuclei, 
genomic DNA is hierarchically packaged as chromatin. The fundamental unit of 
chromatin is a multifaceted and highly dynamic nucleoprotein complex known as 
the nucleosome (Kornberg 1974) which consists of an octamer of four core histones 
(2 copies each of H2A, H2B, H3 and H4) wrapped around by ~1.65 superhelical 
turns by 147 base pairs (bp) of DNA (Luger, Mader et al. 1997). The core histone 
proteins are composed of a globular domain and flexible ‘histone tails’ at the amino 
terminus which can be subjected to a diversity of post-translational modifications. 
Adjacent individual nucleosomes are connected by linker DNA and form 
‘nucleosomal arrays’ also known as the ‘beads-on-a-string’ organisation (Figure 1.1) 
(Belmont, Dietzel et al. 1999, Horn and Peterson 2002). The length of linker DNA 
ranges between ~20-90bp and varies among species, tissues or even within a single 
cellular genome (van Holde 1988).  Linker DNA at the entry or exit sites of the 
nucleosome is associated with linker histones (e.g. H1 and H5) (Simpson 1978, 
Hamiche, Schultz et al. 1996, Syed, Goutte-Gattat et al. 2010) which influence the 
orientation of linker DNA and also organise the nucleosome arrays into the higher 
order 30nm chromatin fibre (Robinson, Fairall et al. 2006). Further compaction of 
the 30nm chromatin fibre by fibre-fibre interactions leads to the formation of the 
~100nm interphase chromosomes (Belmont, Braunfeld et al. 1989) and visible 
metaphase chromosomes of ~600nm (Belmont, Dietzel et al. 1999). Factors that 
can influence the structure of chromatin include histone variants, histone 
modifications, DNA methylation and the binding of non-histone proteins (Li and 
Reinberg 2011) will be discussed in later sections (see section 1.3 and 1.4).  
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Figure 1.1 Schematic diagram of chromatin organisation. Genomic DNA is packaged by wrapping around the nucleosomes in the nucleus and forms a ‘beads-on-a-string’ organisation. Linker histones assist compaction of this structure which is thought to trigger formation of the 30nm fibre. By fibre-fibre interaction, the structure of chromatin is further compacted into heterochromatin. This figure is adapted and modified from Horn, P. J. and C. L. Peterson (2002). "Molecular biology. Chromatin higher order folding--wrapping up transcription." Science 297(5588): 1824-1827. Reprinted with permission from AAAS. Also with permission from Annual Review of Biophysics and Biomolecular Structure “Hansen, J. C. (2002). ‘Conformational dynamics of the chromatin fiber in solution: determinants, mechanisms, and functions.’ Annu Rev Biophys Biomol Struct 31: 361-392.”(Hansen 2002, Horn and Peterson 2002)  
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1.2.2 Euchromatin and heterochromatin 
 
Chromatin of two distinct structures were first described by Emil Heitz almost nine 
decades ago on the basis of a series of cytogenetic observations that 
‘heterochromatin’ in the nucleus remained condensed whereas ‘euchromatin’ 
underwent cycles of condensation and de-condensation throughout the cell cycle 
(Heitz, 1928). These two types of chromatin show distinct organisation and features 
(Figure 1.2) which contribute to the diverse influences on gene regulation.   
 
Euchromatin, or the ‘true chromatin’ is characterised by its relatively open structure 
and the higher accessibility as measured experimentally by nucleases. It is 
replicated in early S-phase and rich in transcriptionally active genes. In contrast, 
heterochromatin is condensed and highly resistant to nucleases. It is gene poor and 
generally transcriptionally inactive. Heterochromatin is late replicating in S phase 
and rich in repetitive DNA sequences such as satellite repeats, transposable 
elements and retrovirus related repetitive sequences (Reviewed in - Dillon and 
Festenstein 2002, Grewal and Elgin 2002, Grewal and Moazed 2003). Drosophila 
nucleosomes in heterochromatin are regularly spaced with shorter linker DNA 
while nucleosome arrays in euchromatin are relatively disorganised (Wallrath and 
Elgin 1995, Sun, Cuaycong et al. 2001).  Although consistently found surrounding 
structures such as centromeres and telomeres, smaller blocks of heterochromatin 
were also found to be interspersed throughout the chromosome (Reviewed in - 
Grewal and Moazed 2003). Moreover, the two types of chromatin are distinguished 
by a characteristic epigenetic profile. Euchromatin is characterised by 
hypomethylated DNA, abundant acetylation on histone H3/H4 and methylation of 
histone H3 lysine 4 (H3K4) (Reviewed in - Grewal and Jia 2007)  whereas 
heterochromatin is distinguished by DNA methylation (Okano, Bell et al. 1999, 
Lehnertz, Ueda et al. 2003), hypoacetylation of histone (Moazed 2001) and 
enrichment of histone modifications such as methylation of histone 3 lysine 9 
(H3K9), histone 3 lysine 27 (H3K27) and histone 4 lysine 20 (H4K20) (Peters, 
Kubicek et al. 2003, Schotta, Lachner et al. 2004, Ebert, Lein et al. 2006).  
 
Heterochromatin can be further subdivided into constitutive and facultative 
heterochromatin. Constitutive heterochromatin which is composed predominately 
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of long stretches of repetitive DNA elements (such as alpha satellite (α-satellite) 
and γ-satellite variant II (γ-satellite II) (Lin, Sasi et al. 1993) in human  and major 
satellite (Mj-sat) in mice (Mouse Genome Sequencing, Waterston et al. 2002)) is 
found in pericentromeric regions. Also, it remains visibly condensed during 
interphase of the cell cycle (Reviewed in - Dillon and Festenstein 2002). On the 
other hand, facultative heterochromatin is developmentally regulated and able to 
transit between heterochromatic and euchromatic states in response to cellular 
signals and gene activity (Reviewed in - Dillon and Festenstein 2002, Grewal and 
Jia 2007). One classical example of facultative heterochromatin includes the 
inactive X chromosome in female mammals which forms the condensed “Barr body” 
which is visible in interphase nuclei (Reviewed in - Dillon and Festenstein 2002, 
Dillon 2004). It is hypoacetylated and contains methylated histone H3K9me3 and 
H3K27me3 (Jeppesen and Turner 1993, Trojer and Reinberg 2007). It is also 
noteworthy that the two types of heterochromatin feature specific histone 
modifications whereby facultative heterochromatin is marked by high levels of 
H3K27me3 while constitutive heterochromatin is marked by H3K9me3 and 
H4K20me3 (Reviewed in - Trojer and Reinberg 2007).  
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Figure 1.2 Schematic diagram demonstrating the organisation of euchromatin and heterochromatin. Euchromatin is characterised by its relatively open structure whereas heterochromatin is tightly compacted.  Specific epigenetic profile features the two forms of chromatin. Key features of each form of the chromatin is summarised on the top of the diagram.            
Euchromatin - Open structure - Gene rich - Rich in transcriptionally active genes - Highly accessible for nucleases - Early replicating in S-phase - Disorganised nucleosome array - Hypomethylated DNA  - Abundant histone H3/H4 acetylation  - Methylated on H3K4   
Heterochromatin - Highly condensed structure - Gene poor - Rich in repetitive DNA sequences - Generally transcriptionally inactive - Resistant to nucleases - Late replicating in S phase  - Regular nucleosome array - Enriched DNA methylation - Hypoacetylation of histone H3/H4 - Methylated on H3K9, H3K27, H4K20 
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1.3 The epigenetic code 
 
1.3.1 Overview 
 
Intrinsic properties of nucleosomes are determined by distinct sets of epigenetic 
modifications including DNA methylation, histone post-translational modifications 
and the incorporation of histone variants. The combination of these modifications 
have been proposed to function as an ‘epigenetic code’ playing an important role in 
regulating nucleosome dynamics and function of underlying DNA (Jenuwein and 
Allis 2001). In this thesis, most attention will be paid to discussing how histone 
lysine methylation and histone variants affect the properties of chromatin and hence 
regulate gene activity.  
 
 
1.3.2 Histone modifications 
 
1.3.2.1 General introduction 
 
The nucleosome, the fundamental unit of chromatin consists of an octamer of two 
molecules of each of the four core histone proteins. Each of the core histone proteins 
are composed of a globular domain and a flexible amino terminal ‘histone tail’ 
which protrudes from the nucleosome and allows a wide range of post-translational 
modifications. To date, at least eight different types of post-translational 
modifications (acetylation, methylation, phosphorylation, ubiquitinylation, 
sumoylation, ADP ribosylation, deimination, proline isomerisation) have been 
identified over 60 different histone residues (Reviewed in - Kouzarides 2007). 
Figure 1.3 illustrates the common modifications of the core histones.  
 
Histone modifications have at least two modes of function. Firstly, histone 
modifications affect the overall structure of chromatin directly by interfering with 
both inter-nucleosomal and histone/DNA interactions (Reviewed in - Berger 2002, 
Kouzarides 2007, Bannister and Kouzarides 2011). An important example of this 
includes the acetylation on the lysine residues on histones in which basic charges 
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of lysine are neutralised and the histone/DNA interactions are thereby weakened. 
Histone acetylation thus prevents the formation of higher-order chromatin 
structures and hence contributes positively to gene activities by increasing general 
accessibility of gene loci (Reviewed in - Kouzarides 2007, Bannister and 
Kouzarides 2011, Li and Reinberg 2011). On the other hand, histone modifications 
regulate binding of protein factors (positively or negatively) with specific 
regulatory or enzymatic activities to particular gene loci and hence influence 
processes such as  transcription, DNA repair, replication and recombination 
(Reviewed in - Bannister and Kouzarides 2011) and alternative splicing (Luco, Pan 
et al. 2010). The ‘writers’, ‘readers’ and ‘erasers’ of different histone modifications 
have been identified and characterised.  
 
It is also noteworthy that modifications can occur sequentially or in combination on 
one or more histone tails within a nucleosome. In fact, many different histone 
modifications have been found to be synergistic or antagonistic and hence have led 
to the hypothesis of a ‘histone code’, which is defined as the combinations of 
histone modifications that contribute to a unique cellular response (Reviewed in - 
Strahl and Allis 2000). This ‘crosstalk’ between histone modifications adds an extra 
level of complexity in gene regulation and has been suggested to fine-tune the 
overall control (Reviewed in - Bannister and Kouzarides 2011).  
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  Figure 1.3 Schematic diagram showing the main post-translational modifications on core histone proteins. Amino acid sequences of each core histone protein were shown in grey and the numbers on the bottom indicate the amino acid positions. Post-translational modifications (acetylation (A) (blue), methylation (M) (red), phosphorylation (P) (yellow) and ubiquitination (U) (green)) are shown on top of the amino acid sequences. This figure is adapted by permission from Macmillan Publishers Ltd: Nature Biotechnology “Portela, A. and M. Esteller (2010). ‘Epigenetic modifications and human disease.’ Nat Biotechnol 28(10): 1057-1068”, copyright (2010) (Portela and Esteller 2010)  
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1.3.2.2 Histone lysine methylation  
 
To date, seven different lysine residues on histone H3 and H4 have been identified 
as methylation sites. Histone lysine residues can harbor one (mono-methylation), 
two (di-methylation) or three (tri-methylation) methyl groups on their amino groups. 
These different levels of modification state can potentially lead to diverse biological 
outcomes through different ‘readers’ that recognise these marks and hence add an 
extra level of complexity to gene regulation. Unlike acetylation, methylation of 
histone does not alter the charge of histone proteins and thus is considered to 
regulate activity of chromatin by recruiting other effector proteins for downstream 
functions. Rather than largely correlating with gene activation like acetylation, 
methylation of histone lysine exerts both gene activation and repression depending 
on its target lysine residues (Reviewed in - Martin and Zhang 2005, Ng, Yue et al. 
2009, Bannister and Kouzarides 2011). Histone lysine residues with different level 
of methylation state showed similar or distinct genomic distributions and functions 
(Barski, Cuddapah et al. 2007). In general, methylation of H3K9, H3K27 and 
H4K20 are regarded as the repression marks while methylation of H3K4, H3K36 
and H3K79 are regarded as the activation marks (Reviewed in - Kouzarides 2007). 
More recently, studies revealed H3K56 as a methylation site and implicated it in 
DNA replication (H3K56me) and gene silencing (H3K56me3) (Yu, Song et al. 2012, 
Jack, Bussemer et al. 2013). Table 1.1 summarises the different histone lysine 
methylation and their well characterized functions. 
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Histone lysine methylation  
Methylation state Role in gene regulation Genomic distribution  References  
H3K4 H3K4me1 Gene activation  Enhancer, surrounding TSS 1, 2, 3 H3K4me2 Gene activation Surrounding TSS 1, 2, 3 H3K4me3 Gene activation TSS 1, 2, 3 H3K9  H3K9me1 nd Surrounding TSS 1 H3K9me2 Gene repression Broad distribution 1 H3K9me3 Gene repression Broad distribution 3, 4, 5, 6 H3K27 H3K27me1 Gene activation Surrounding TSS, enhancer 1, 7, 8 H3K27me2 Enhancer regulation Broad distribution 1, 8 H3K27me3 Gene repression Broad distribution 1, 9, 10 H3K36 H3K36me1 nd Broad distribution 1 H3K36me2 DNA repair nd 11 H3K36me3 Gene activation Transcribed region 1, 12, 13 H3K56 H3K56me1 DNA replication nd 14 H3K56me3 Gene repression nd 15 H3K79 H3K79me1 nd Broad distribution 1, 16 H3K79me2 nd Broad distribution 1, 16 H3K79me3 Gene activation Promoter 1, 16 H4K20 H4K20me1 Gene activation Downstream of TSS 1, 12, 17 H4K20me2 DNA damage response nd 18 H4K20me3 Gene repression Broad distribution 1, 5  Table 1.1 Summary of the associated functions and the general genomic distribution of the common histone lysine methylation in mammals. TSS, transcription start site; nd, not determined. TSS marks are generally sharply defined whereas other modifications have a broader distribution along genes or regulatory elements as indicated in the table. References used are: (Barski, Cuddapah et al. 2007)1, (Deb, Kar et al. 2014)2, (Shen, Shulha et al. 2014)3, (Bannister, Zegerman et al. 2001)4, (Schotta, Lachner et al. 2004)5, (Kimura 2013)6, (Steiner, Schulz et al. 2011)7, (Ferrari, Scelfo et al. 2014)8, (Boyer, Plath et al. 2006)9, (Lee, Jenner et al. 2006)10, (Fnu, Williamson et al. 2011)11, (Vakoc, Sachdeva et al. 2006)12, (Wagner and Carpenter 2012)13, (Yu, Song et al. 2012)14, (Jack, Bussemer et al. 2013)15, (Kim, Choi et al. 2014)16, (Talasz, Lindner et al. 2005)17, (Jorgensen, Schotta et al. 2013)18   
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1.3.2.2.1 Methylation of histone H3 lysine 9 (H3K9) 
 
Methylation of histone H3 lysine 9 (H3K9) is typically associated with silent 
chromatin domains including constitutive heterochromatin (pericentric and 
telomeric regions). It has been found in silent chromatin domains from yeasts to 
mammals and is regarded as the hallmark of heterochromatin (Jenuwein and Allis 
2001, Peters, Kubicek et al. 2003). However, H3K9 methylation of different levels 
was actually found in different chromatin compartments. In mammals, tri-
methylated H3K9 is enriched in pericentric heterochromatin and associated 
preferentially with silent genes (Bannister, Zegerman et al. 2001). Although di-
methylated H3K9 also shows preference for silent genes, it is more often found in 
euchromatic regions. Interestingly, the relatively less characterised mono-
methylated H3K9 is enriched in euchromatic regions and concentrated in promoter 
regions surrounding the transcriptional start site of actively transcribed genes. This 
observation led to the hypothesis that mono-methylated H3K9 may be implicated 
in transcriptional activation (Peters, Kubicek et al. 2003, Rice, Briggs et al. 2003, 
Barski, Cuddapah et al. 2007). Indeed, a growing number of studies revealed 
association of H3K9 methylation on transcriptionally active genes (Vakoc, Mandat 
et al. 2005, Vakoc, Sachdeva et al. 2006, Barski, Cuddapah et al. 2007, Kim, Kiefer 
et al. 2007) implicating it in other regulatory processes including alternative 
splicing (Saint-Andre, Batsche et al. 2011, Ameyar-Zazoua, Rachez et al. 2012, 
Yearim, Gelfman et al. 2015) and transcription termination (Skourti-Stathaki, 
Kamieniarz-Gdula et al. 2014). These findings suggested that the role of H3K9 
methylation is not solely silencing as was originally shown.  
 
The ‘writers’ of histone lysine methylation are called histone lysine 
methyltransferases (HKMT) which catalyse the transfer of a methyl group from S-
adenosylmethionine (SAM) to the ε-amino group of the histone lysine residues. 
Interestingly, all of the HKMTs identified contain a SET domain which harbors the 
enzymatic activity, except the H3K79 methyltransferase Dot1 enzyme whose 
enzymatic activity come from its catalytic methylase fold (Min, Feng et al. 2003).  
 
In mammals, a number of HKMTs responsible for methylation of H3K9 have been 
identified. SUV39H1 was the first H3K9 HKMT identified in mammals (Rea, 
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Eisenhaber et al. 2000).  SUV39H (suppressor of variegation 3-9 homolog 1 
(Drosophila)) has two isoforms: SUV39H1 and SUV39H2 (Peters, O'Carroll et al. 
2001) which are highly evolutionarily conserved from yeast to human (yeast: Clr4; 
Drosophila: Su(var)3-9; mouse: Suv39h; human: SUV39H). Silencing activities of 
SUV39H are associated with constitutive heterochromatin (Peters, O'Carroll et al. 
2001, Rice, Briggs et al. 2003) as well as euchromatic genes (Nielsen, Schneider et 
al. 2001, Ait-Si-Ali, Guasconi et al. 2004, Duong and Weitz 2014, Zhang, Liu et al. 
2014) and retrotransposon elements (Bulut-Karslioglu, De La Rosa-Velazquez et al. 
2014). SUV39H is responsible for tri-methylation of H3K9 (H3K9me3) and 
provides the binding site for the ‘reader’ protein heterochromatin protein 1 (HP1) 
(Bannister, Zegerman et al. 2001, Lachner, O'Carroll et al. 2001). HP1 is a non-
histone chromosomal protein that binds H3K9me3 with its chromodomain and with 
its chromoshadow domain interacts with a wide range of effector proteins 
(Reviewed in - Hiragami and Festenstein 2005, Kwon and Workman 2011) and 
thereby contributes to downstream functions.  Binding of HP1 to H3K9me3 is also 
likely to be involved in stabilisation of higher order chromatin structure (Bannister, 
Zegerman et al. 2001, Lachner, O'Carroll et al. 2001, Nakayama, Rice et al. 2001, 
Canzio, Liao et al. 2013, Nozawa, Nagao et al. 2013). More details on the function 
of HP1 can be found in section 1.4. 
 
G9a and GLP are another two HKMTs that catalyse mono- and di- methylation of 
H3K9 in mammals. They are closely related paralogs (Dillon, Zhang et al. 2005) 
and have been regarded as the euchromatin histone methyltransferases (EHMTs) 
due to their specificity in methylating H3K9 residues in euchromatic regions but 
not in pericentric heterochromatin (Tachibana, Sugimoto et al. 2001, Tachibana, 
Sugimoto et al. 2002, Peters, Kubicek et al. 2003, Rice, Briggs et al. 2003, 
Tachibana, Ueda et al. 2005). G9a and GLP were initially shown to function as a 
heterodimeric complex (Tachibana, Sugimoto et al. 2002). Subsequent studies 
suggested that the formation of their heterodimer may occur in a tissue- and 
development stage-dependent manner (Reviewed in - Kramer 2015) and it has been 
shown that they can also function independently (Tachibana, Matsumura et al. 2008, 
Liu, Zhang et al. 2015). As well as catalysing the methylation of histone lysine 
residues, G9a and GLP also methylate themselves (Sampath, Marazzi et al. 2007, 
Chang, Sun et al. 2011) and a number of non-histone proteins (Herz, Garruss et al. 
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2013, Lanouette, Mongeon et al. 2014, Biggar and Li 2015). Intriguingly, G9a and 
GLP have been shown to activate transcription independent of their 
methyltransferase activities (Lee, Northrop et al. 2006, Bittencourt, Wu et al. 2012, 
Chaturvedi, Somasundaram et al. 2012, Ohno, Shinoda et al. 2013, Wang, Xu et al. 
2013).  
 
The third H3K9-specific HKMT is SETDB1 (SET domain, bifurcated 1), which is 
also known as ESET. SETDB1 is specific for catalysing di- or tri-methylation of 
H3K9 (Schultz, Ayyanathan et al. 2002, Yang, Xia et al. 2002). It is also able to 
convert di-methylated H3K9 to tri-methylated H3K9 with the help of mAM ATPase 
which enhances the catalytic activity of SETDB1 (Wang, An et al. 2003). Although 
SETDB1 silencing activities have been shown to associate mainly with 
euchromatin (Schultz, Ayyanathan et al. 2002, Yang, Xia et al. 2002, Kim, Geng et 
al. 2003, Carling, Kim et al. 2004, Gazzerro, Abbondanza et al. 2006, Li, Rauch et 
al. 2006), a more recent study showed that it is also responsible for repressing major 
satellite and endogenous retroviral elements in mammals (Matsui, Leung et al. 
2010).  
 
It is important to note that methylation of lysine is a reversible process. ‘Erasers’ of 
histone methylation i.e. the histone demethylases (HDMs) have been identified. Of 
particular interest, H3K9 residues are demethylated by the Jumonji C (JmjC) 
domain demethylases. KDM3A (JHDM2A) has been shown to demethylate mono- 
and di-methylated H3K9 while KDM4A (JHDM3A) and KDM4C (JMJD2C) have 
been shown to demethylate tri-methylated H3K9 (Fodor, Kubicek et al. 2006, Klose, 
Yamane et al. 2006, Whetstine, Nottke et al. 2006). These HDMs were shown to 
associate with transcriptional activation (Yamane, Toumazou et al. 2006, Ishimura, 
Terashima et al. 2009) and a growing number of studies implicate these enzymes in 
tumorigenesis (Cloos, Christensen et al. 2006, Ishimura, Terashima et al. 2009, Luo, 
Chang et al. 2012, Black, Manning et al. 2013, Li, Xue et al. 2014, Mahajan, 
Lawrence et al. 2014, Parrish, Sechler et al. 2015). 
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1.3.3 Histone variants  
 
1.3.3.1 Overview  
 
‘Histone turnover’ is a mechanism which refers to the exchange of subunits of the 
nucleosome or entire nucleosomes with newly synthesised histones or other protein 
components. This swapping mechanism contributes to the dynamic nature of 
chromatin and allows accessibility of factors to DNA to be regulated. These factors 
are involved in processes such as transcription, recombination, repair and 
replication of DNA. Thus, histone turnover regulates chromatin structure and 
functions by promoting (with increased turnover rate) or restricting (with decreased 
turnover rate) the binding of factors such as the transcription machinery (Reviewed 
in - Venkatesh and Workman 2015). It is noteworthy that euchromatin, which has a 
relatively high histone turnover rate, is highly accessible to gene regulatory factors 
while heterochromatin, which has a lower histone turnover rate, is generally 
inaccessible (Dion, Kaplan et al. 2007, Jamai, Imoberdorf et al. 2007, Rufiange, 
Jacques et al. 2007, Deal, Henikoff et al. 2010). Moreover, incorporation of 
different histone variants plays a key role in altering chromatin properties as each 
variant has a different turnover rate and also contributes to the different chemical 
and physical properties of nucleosomes. During transcription, histone turnover can 
be regulated co-operatively or individually by factors such as chromatin modifiers, 
chromatin remodelers and histone chaperones (Reviewed in - Venkatesh and 
Workman 2015). In this section, I will firstly introduce the different types of histone 
variants identified in mammals and compare the differences between canonical H3 
and H3.3 on their properties. The role of mammalian H3.3 in gene regulation will 
also be reviewed.  
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1.3.3.2 Introduction of histone variants  
 
To date, variant form of histones have been described for all histones except histone 
H4. In mammals, eleven forms of H1 (H1.0, H1.1, H1,2, H1.3, H1.4, H1.5, H1t, 
H1T2, HILS1, H1oo and H1x), seven forms of H2A (H2A, H2A.X, H2A.Z.1, 
H2A.Z.2, macroH2A1, macroH2A2 and H2A.Bbd), four forms of H2B (H2B, 
H2BE, TSH2B and H2BFWT) and eight forms of H3 (H3.1, H3.2, H3.3, H3.4, H3.5, 
H3.X, H3.Y and CENP-A) have been identified (Reviewed in - Maze, Noh et al. 
2014, Turinetto and Giachino 2015, Venkatesh and Workman 2015).Variant 
histones are classified into ‘canonical’ or ‘non-canonical’ histones. Canonical 
histones are expressed exclusively during S-phase and incorporated into chromatin 
in a DNA replication-dependent manner (Marzluff, Gongidi et al. 2002). On the 
other hand, non-canonical histones, also known as ‘replacement histones’ are 
expressed throughout the cell cycle and their incorporation is independent of DNA 
replication (Ahmad and Henikoff 2002). Expression of replacement histones can be 
somatic or germline-specific and they may be localised at specific chromatin 
compartments (Reviewed in - Venkatesh and Workman 2015). Replacement 
histones usually differ from the canonical histones by a few amino acids substitution 
or with an additional domain. For example, histone variant H3.3 differs from 
canonical H3.1 by five amino acid differences while histone variant macroH2A has 
an extra macro domain in its carboxyl terminal tail when compared to canonical 
H2A (Reviewed in - Biterge and Schneider 2014). Figure 1.4 summarises the 
structural and amino acid sequence differences between different histone variants.  
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A 
  B 
  Figure 1.4 Schematic diagram summarising the structural and amino acid sequence differences between human canonical or variant core histones (A) and linker histone (B). (A) Each box and line structure represents the linearised structure of each histone variants. Different families of histone proteins are indicated by different colours (H2A (yellow); H2B (red); H3 (blue) and H4 (green)). Black lines represent 
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the unstructured amino terminal domains of histone proteins. Amino acid sequence differences and their positions are indicated by the letter and the number above. (B) Linearised structure of linker histone H1 variants are shown. Globular domains are indicated by dark grey boxes while the unstructured amino and carboxyl terminal domains are indicated by light grey boxes. Purple boxes represent the canonical serine/threonine PXK phosphorylation sites. Due to high degree of sequence divergence between the different H1 variants, amino acid sequence differences are not shown here. aa, amino acid; mH2A1, macroH2A. This figure is adapted by permission from Macmillan Publishers Ltd: Nature Review Genetics “Maze, I., K. M. Noh, A. A. Soshnev and C. D. Allis (2014). ‘Every amino acid matters: essential contributions of histone variants to mammalian development and disease.’ Nat Rev Genet 15(4): 259-271.”, copyright (2014) (Maze, Noh et al. 2014).  
 
 
1.3.3.3 Canonical histone H3 vs. replacement histone H3.3  
 
As mentioned previously, mammalian histone H3 has eight variants (H3.1, H3.2, 
H3.3, H3.4, H3.5, H3.X, H3.Y and CENP-A) in which H3.1 and H3.2 are the 
canonical histones while the others are referred to as replacement histones. These 
variants are considered to have distinct functions in organising chromatin structure. 
Canonical histone H3.1 and H3.2 (generally referred to as histone H3) and the 
replacement histone H3.3 are the most abundant H3 variants which are found in all 
types of tissues and cells. These three variants are implicated in regulation of 
chromatin structure and transcription (Reviewed in - Weber and Henikoff 2014). 
Histone H3.4 and H3.5 are germline-specific variants that can be found in testis and 
sperm (Albig, Ebentheuer et al. 1996, Witt, Albig et al. 1996, Schenk, Jenke et al. 
2011) while H3.X and H3.Y have recently been suggested to regulate cellular 
responses to extracellular stimuli (Wiedemann, Mildner et al. 2010). Lastly, CENP-
A is specifically localised to the centromere and serves as an epigenetic marker for 
the kinetochore formation sites (Palmer, O'Day et al. 1987).  
 
Although canonical H3 and variant H3.3 are both implicated in regulation of 
chromatin structure and gene regulation, they show different features in various 
aspects. Firstly, the genes encoding canonical H3 and variant H3.3 have different 
genomic organisation. Genes encoding canonical histones H3.1 and H3.2 are 
intron-less and clustered in tandem repeat arrays. The mRNAs of these genes are 
not polyadenylated, instead they end with a stem loop structure followed by a 
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stretch of purine-rich sequence that is complementary to the 5’ end of the U7 snRNA 
(Marzluff, Gongidi et al. 2002). This special genomic organisation allows bulk 
expression of canonical histone during S-phase and ensures sufficient supply of 
histone proteins for their incorporation into the chromatin in a DNA replication-
dependent manner (Osley 1991). In contrast, genes encoding replacement histone 
H3.3 (H3f3a and H3f3b, also known as H3.3A and H3.3B) are found singly in the 
genome. These genes contain introns and their mRNAs are polyadenylated. 
Although having different expression patterns and distinct untranslated regions, 
H3f3a and H3f3b encode the identical H3.3 protein (Bramlage, Kosciessa et al. 
1997, Frank, Doenecke et al. 2003). H3f3a and H3f3b are expressed throughout the 
cell cycle and can be incorporated during or outside S-phase of the cell cycle, 
independently from DNA replication (Ahmad and Henikoff 2002).  
 
Histone H3.3 protein differs from the canonical histone H3.1 and H3.2 by five and 
four amino acids respectively (Figure 1.5). The alanine (A) residue at position 31 
in the amino-terminal tail of histone H3.1 and H3.2 is replaced by a serine (S) 
residue in H3.3 which can be phosphorylated during mitosis (Hake, Garcia et al. 
2005). Other amino acid differences can be found at residues 87, 89, 90 and 96 
which are located at the globular domain of histone H3. Amino acid differences 
between the variants do not lead to any structural changes of the nucleosome 
(Tachiwana, Osakabe et al. 2011), however, they are crucial for binding of the 
histone chaperones (Elsasser, Huang et al. 2012, Liu, Xiong et al. 2012), the 
genomic localisation of the histone proteins (Goldberg, Banaszynski et al. 2010) 
and have been proposed to regulate the stability of histone-histone interaction 
(Reviewed in - Hake and Allis 2006).  
 
H3 variants are deposited into the genome via different pathways which are tightly 
regulated by distinct histone chaperone proteins (Ray-Gallet, Woolfe et al. 2011). 
Incorporation of canonical histone H3 is mediated by chromatin assembly factor 1 
(CAF1) during DNA replication (Tagami, Ray-Gallet et al. 2004) and DNA repair 
(Polo, Roche et al. 2006). Deposition of H3.3 in actively transcribed regions is 
mediated by the histone regulator A (HIRA) complex independent of DNA 
synthesis (Tagami, Ray-Gallet et al. 2004, Goldberg, Banaszynski et al. 2010) while 
death domain-associated protein (DAXX) together with the chromatin remodeler 
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α-thalassemia/mental retardation syndrome protein (ATRX) deposits H3.3 at 
telomeric and pericentric heterochromatin (Drane, Ouararhni et al. 2010, Goldberg, 
Banaszynski et al. 2010, Lewis, Elsaesser et al. 2010). Furthermore, H3.3 
deposition at promyelocytic leukemia nuclear bodies (PML-NBs) has recently been 
shown and its implication in heterochromatin organisation has been suggested 
(Corpet, Olbrich et al. 2014).  
 
DNA replication-independent incorporation of replacement histone H3.3 requires 
displacement of existing nucleosomes for its deposition and hence contributes to 
the dynamics of chromatin. Turnover of H3.3 has been suggested to maintain the 
transient exposure of certain genomic regions and hence the access of different 
transcription factors (Reviewed in - Henikoff 2008). H3.3 turnover occurs in 
genomic regions including promoters, enhancers, gene bodies and heterochromatic 
regions. Interestingly, H3.3 turnover rate varies in different genomic regions: it is 
high at active promoters and enhancers, intermediate in gene bodies and low at 
inactive promoters and heterochromatic regions (Huang, Zhang et al. 2013, 
Kraushaar, Jin et al. 2013, Ha, Kraushaar et al. 2014). 
 
Finally, canonical histone H3 and histone variant H3.3 are enriched for different 
sets of post-translational modifications. The histone variant H3.3-containing 
nucleosome is enriched in active chromatin marks such as H4 acetylation, 
methylation on H3K4 and H3K36 and acetylation on H3K9 and H3K14 
(McKittrick, Gafken et al. 2004, Hake, Garcia et al. 2006, Loyola, Bonaldi et al. 
2006). In contrast, canonical histone H3.2 is enriched in silencing marks such as 
H3K27 methylation which is associated with facultative heterochromatin while 
H3.1 is associated with both active and inactive marks (Hake, Garcia et al. 2006). 
Also, Loyola et al showed that H3K9me1 is found on non-nucleosomal histone H3 
thereby priming it for future methylation by SUV39H (H3K9me3 HMT). 
Interestingly, H3K9me1 is enriched on non-nucleosomal H3.1 when compared to 
H3.3. In addition, HP1α, which is found predominantly at heterochromatin (Minc, 
Allory et al. 1999), was found to preferentially associate with H3.1 containing 
purified oligonucleosomes whereas HP1γ, which is found in both euchromatic and 
heterochromatic regions (Minc, Courvalin et al. 2000), associated with both H3.1 
and H3.3 oligonucleosomes (Loyola, Bonaldi et al. 2006). This observation further 
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supports the connection between H3.3 and active transcription. Although enriched 
with active histone marks, H3.3 also harbors silencing marks and plays important 
roles in the genome. A recent study showed that H3.3 dependent H3K9me3 is 
involved in silencing endogenous retroviral elements (ERV)  in mouse embryonic 
stem cells (mESCs) (Elsasser, Noh et al. 2015). Furthermore, in mESCs, H3.3 has 
also been shown to target H3K9me3 to the telomere and repress telomeric repeat 
(TERRA) expression as well as maintaining telomere integrity (Udugama, Chang 
et al. 2015).  
 
 
 
  Figure 1.5 Sequence alignment of mouse histone H3 variants H3.1, H3.2 and H3.3. Differences in amino acids were highlighted by orange boxes and their position is indicated by the number above. Canonical histone H3.1 and H3.2 are very similar to each other with only one amino acid difference at position 96. H3.1 and H3.2 differ from the replacement histone H3.3 by 5 and 4 amino acids respectively at position 31(located at the N terminal tail), 87, 89 and 90 (located at the globular domain). Sequence alignment was generated by the online alignment tool ClustalW2 (powered by EMBL-EBI).                
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1.3.3.4 Distribution and functions of histone variant H3.3  
 
Genome-wide distribution of H3.3 in mammals has been revealed recently by a 
number of studies using chromatin immunoprecipitation followed by high-
throughput sequencing (ChIP-seq). These studies showed localisation of H3.3 to 
elements located in both euchromatic (e.g. promoters, enhancers, gene bodies) and 
heterochromatic regions (e.g. telomeric regions, interspersed repeats) and displays 
important regulatory functions (Goldberg, Banaszynski et al. 2010, Wen, Li et al. 
2014, Elsasser, Noh et al. 2015, Voon, Hughes et al. 2015). Indeed, functions of 
H3.3 in different mammalian models have been studied extensively in recent years. 
Some examples of recent studies on the function of H3.3 are provided here.  
 
 
1.3.3.4.1 Active role of H3.3 in gene regulation 
 
In HeLa cells, H3.3 was implicated in activation of the heat shock induced 
expression of HSP70 genes. Of particular interest, this was found to operate 
coordinately with HP1γ in which binding of these proteins to the HSP70 genes was 
found to be interdependent and correlated with the level of HSP70 expression (Kim, 
Heo et al. 2011).  
 
In mESCs, enrichment of H3.3 around the transcription start site (TSS) of bivalent 
genes was maintained when these genes become transcriptionally active during 
mESC differentiation. H3.3 is also incorporated into the gene body in correlation 
with markers of transcription: histone marks H3K36me3, H3K4me3 and H3k4me3 
as well as serine-5 phosphorylated RNA polymerase II (S5P-RNAPII). However, 
bivalent genes that remained silent showed reduced H3.3 at the TSS upon 
differentiation (Goldberg, Banaszynski et al. 2010).  
 
 
1.3.3.4.2 Repressive role of H3.3 in gene regulation  
 
A number of recent studies implicate H3.3 in regulation of telomere function. 
Udugama and colleagues showed that complete knockout of H3.3 led to a reduction 
50  
in silencing histone marks H3K9me3, H4K20me3 and also the telomere-targeting 
H3.3 chaperone ATRX at telomeres (Udugama, Chang et al. 2015). Also, it has 
been shown in another study that knockdown of ATRX significantly reduced HP1α 
at the telomeres (Wong, McGhie et al. 2010). Both of these studies showed an 
associated telomere dysfunction phenotype with depletion of H3.3 at telomere. 
Moreover, H3.3 at telomeres has been shown to repress telomeric RNA expression 
(Goldberg, Banaszynski et al. 2010, Udugama, Chang et al. 2015). Taken together, 
these studies suggest that H3.3 is important in maintaining heterochromatin 
formation at the telomere and hence its integrity.  
 
Banaszynski et al implicated H3.3 in establishing silencing histone H3K27me3 at 
the promoters of developmentally regulated genes in mESCs. Depletion of H3.3 
also led to dysregulation of bivalent genes upon differentiation and hence altered 
the developmental potential of mESCs. This study suggests that chromatin 
dynamics driven by H3.3 is important in establishing a proper chromatin landscape 
to allow appropriate regulation of genes to developmental cues (Banaszynski, Wen 
et al. 2013).  
 
As mentioned in section 1.3.3.3, H3.3 has been shown to regulate ERVs in mESCs. 
Elsässer et al showed that ATRX/DAXX-mediated H3.3 is important for H3K9me3 
on ERVs. Deletion of H3.3 led to derepression and increased retrotransposition of 
ERVs and dysregulated a subset of endogenous adjacent genes (Elsasser, Noh et al. 
2015).  
 
Finally, H3.3 has also been implicated in regulation of imprinted genes. Failure of 
ATRX-dependent deposition of H3.3 to imprinted loci led to loss of H3K9me3 at 
these loci and hence aberrant allelic expression of these genes although the effects 
on expression were rather minor (Voon, Hughes et al. 2015).  
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1.4 Heterochromatin protein 1 (HP1)  
 
1.4.1 Introduction to heterochromatin protein 1 (HP1) 
 
Heterochromatin protein 1 (HP1) is a non-histone chromosomal protein that was 
shown in Drosophila by mutagenesis screen to act as a dosage dependent modifier 
of position effect variegation (PEV) (James and Elgin 1986, Eissenberg, James et 
al. 1990). HP1 homologues were subsequently observed in other eukaryotic 
organisms (Reviewed in - Hiragami and Festenstein 2005). Indeed, HP1 is highly 
conserved through evolution and its homologues are found in almost all eukaryotes 
except Saccharomyces cerevisiae in which the analogous phenomenon of telomere 
position effect (TPE) relies on the silent information regulatory (SIR) proteins 
(Singh, Miller et al. 1991). 
 
In general, each HP1 molecule consists of two evolutionarily conserved domains: 
the amino terminal chromo domain (CD) and the carboxyl terminal chromoshadow 
domain (CSD). These two domains are joined by a hinge region (Hin) with variable 
length and flanked by stretches of amino acids regarded as the amino (NTE) and 
carboxyl (CTE) terminal extension (Figure 1.6) (Reviewed in - Hiragami and 
Festenstein 2005, Kwon and Workman 2011, Canzio, Larson et al. 2014). The CD 
of HP1 has been regarded as the chromatin binding domain with its specificity in 
recognising di- and tri-methylation of histone H3 lysine 9 (H3K9), a histone mark 
that is predominately found on silenced chromatin (Bannister, Zegerman et al. 2001, 
Lachner, O'Carroll et al. 2001, Jacobs and Khorasanizadeh 2002). Interestingly, 
delocalisation of HP1 was observed in both S. pombe and mouse in response to loss 
of an H3K9 methyltransferase (Bannister, Zegerman et al. 2001, Garcia-Cao, 
O'Sullivan et al. 2004). It has also been shown that removal or mutation of the CD 
abolishes HP1 localisation at centromeric heterochromatin (Cheutin, McNairn et al. 
2003). Interestingly, different HP1 isoforms in the same organism vary in their 
binding affinity to H3K9 methylation. For example, the three mouse HP1 isoforms 
have affinity to H3K9 methylation ranging from ~5–40 µM (Machado, Dans et al. 
2010, Hiragami-Hamada, Shinmyozu et al. 2011). The CSD of HP1 is involved in 
mediating protein-protein interaction (Aasland and Stewart 1995) and is responsible 
for dimerisation of HP1 proteins forming homo- or heterodimer among or between 
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different HP1 isoforms (Nielsen, Oulad-Abdelghani et al. 2001). CSD of HP1 is 
also involved in interactions with other proteins possessing a PxVxL penta-peptide 
motif (Brasher, Smith et al. 2000, Cowieson, Partridge et al. 2000, Li, Kirschmann 
et al. 2002).  However, it is noteworthy that the CSD is not the only domain 
mediating interaction between HP1 and other proteins as some proteins interact 
with HP1 through the CD or Hin regions (Reviewed in - Hiragami and Festenstein 
2005). The Hin of HP1 connecting the CD and CSD is diverse in length and 
sequence among the HP1 isoforms. It contains a nuclear localisation sequence and 
sites for post-translational modifications including phosphorylation and 
SUMOylation (Lomberk, Bensi et al. 2006, Maison, Bailly et al. 2011) which 
contribute to specific functional properties of HP1 proteins. Moreover, Hin is also 
involved in interaction with other proteins as well as binding to DNA (Sugimoto, 
Yamada et al. 1996) and RNA (Muchardt, Guilleme et al. 2002). Interestingly, a 
recent study showed that the DNA binding ability of human HP1α Hin is one of the 
determinants that contribute to the distinct recognition of the nucleosome by human 
HP1α and HP1γ (Mishima, Jayasinghe et al. 2015). Taken together, sequence 
diversity of Hin is the potential key for functional differentiation between different 
HP1 isoforms (Reviewed in - Canzio, Larson et al. 2014).  
 
Most eukaryotes have a number of HP1 isoforms. In mammals, there are three HP1 
isoforms: alpha (HP1α), beta (HP1β) and gamma (HP1γ) which are encoded by the 
Cbx5, Cbx1 and Cbx3 genes respectively (Reviewed in - Eissenberg and Elgin 
2000). HP1 isoforms show high degrees of sequence homology in their CD and 
CSD domains and much less in their Hin, NTEs and CTEs. For example, the CD 
and CSD of human HP1α and HP1β showed 82% sequence homology respectively 
while only 33% in the Hin (Figure 1.6). (Reviewed in - Canzio, Larson et al. 2014). 
Although having a high degree of structural and biochemical similarity (Reviewed 
in - Jones, Cowell et al. 2000), HP1 isoforms appeared to have distinct nuclear 
localisation (Horsley, Hutchings et al. 1996, Minc, Allory et al. 1999, Nielsen, 
Oulad-Abdelghani et al. 2001, Kourmouli, Sun et al. 2005), expression profiles 
(Reviewed in - Kwon and Workman 2011) and non-redundant functions (Dialynas, 
Terjung et al. 2007, Aucott, Bullwinkel et al. 2008, Brown, Bullwinkel et al. 2010, 
Lee, Li et al. 2013, Ha, Pham et al. 2014). Mammalian HP1α and HP1β are 
associated predominately with heterochromatin whereas HP1γ was found in both 
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euchromatin and heterochromatin (Horsley, Hutchings et al. 1996, Minc, Allory et 
al. 1999, Nielsen, Ortiz et al. 1999, Minc, Courvalin et al. 2000). It has also been 
shown that different HP1 isoforms vary in their subnuclear localisation in different 
phases of the cell cycle (Minc, Allory et al. 1999). To date, factors that determine 
differential nuclear localisation and functional specificity or the interdependence of 
the HP1 protein family members remain largely unknown (Dialynas, Terjung et al. 
2007).  
 
As mentioned earlier, the Hin of HP1 can be subjected to post-translational 
modifications. In fact, HP1 proteins are extensively modified in a manner analogous 
to histones (LeRoy, Weston et al. 2009). These modifications including 
phosphorylation, acetylation, methylation, and formylation which have been 
observed in different domains of HP1 including the CD and CSD suggesting a 
potentially important role for these modifications in regulating HP1 activities 
(LeRoy, Weston et al. 2009). Some of these modifications have been implicated in 
specific properties and functions of HP1 proteins. For example, phosphorylated 
HP1γ at serine 93 (S93P-HP1γ) (previously regarded as serine 83) which was found 
to localise exclusively at euchromatic regions and serve as a marker of  transcription 
elongation (Lomberk, Bensi et al. 2006). Recent studies have also implicated S93P-
HP1γ in gene activation (Thorne, Ouboussad et al. 2012, Harouz, Rachez et al. 2014) 
and alternative splicing (Saint-Andre, Batsche et al. 2011). SUMOylation of mouse 
HP1α was shown to be important in targeting HP1α to the pericentric 
heterochromatin (Maison, Bailly et al. 2011). Furthermore, phosphorylation of NTE 
of mouse HP1α by casein kinase II (CK2) has been shown to increase HP1α affinity 
to H3K9me3 peptides by approximately five-fold, bringing overall affinity of HP1α 
CD and H3K9me3 similar to that of HP1β and HP1γ (Hiragami-Hamada, 
Shinmyozu et al. 2011). This modification has also been suggested to be important 
for proper heterochromatic localisation of HP1α as well as maintenance of genome 
integrity (Hiragami-Hamada, Shinmyozu et al. 2011).  
 
Having been shown to interact with the histone mark H3K9 methylation that 
associated predominately with silent heterochromatin (Bannister, Zegerman et al. 
2001, Lachner, O'Carroll et al. 2001) and also to multimerise to interact with the 
H3K9 methyltransferase (Yamamoto and Sonoda 2003), HP1 has been regarded as 
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a silencing protein. However, as well as establishing and maintaining the higher-
order chromatin structure (Yamamoto and Sonoda 2003), HP1 proteins are also 
implicated in a variety of regulatory processes including gene activation or 
repression, transcriptional elongation, PEV, chromosomal segregation, telomere 
maintenance, DNA repair and RNA processing (Reviewed in - Hiragami and 
Festenstein 2005, Kwon and Workman 2011, Canzio, Larson et al. 2014). In the 
following section, more attention will be paid to HP1γ due to the context of this 
thesis.  
 
 
 
  Figure 1.6 Domain maps and sequence identity of human HP1 proteins.  As demonstrated by the domain maps (top) and the percentage of sequence identity (bottom) of the three human HP1 isoforms, HP1α, HP1β and HP1γ showed higher degree of similarity in their chormodomain (CD) and chromoshadow domain (CSD) but vary in the hinge region (H), amino-terminal (NTE) and carboxyl-terminal (CTE) extension. This figure is reprinted from Trends in Cell Biology, Volume 24, Issue 6, Canzio, D., A. Larson and G. J. Narlikar, "Mechanisms of functional promiscuity by HP1 proteins.", 377-386, Copyright (2014), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER] (Canzio, Larson et al. 2014)          
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1.4.2 Introduction to HP1γ  
 
Among the three HP1 isoforms in mammals, HP1γ is distinguished by its unique 
subnuclear localisation pattern in both euchromatic and heterochromatic regions in 
interphase nuclei (Horsley, Hutchings et al. 1996, Minc, Allory et al. 1999, Nielsen, 
Ortiz et al. 1999, Minc, Courvalin et al. 2000). Indeed, HP1 isoforms were 
suggested to have non-redundant functions. This idea is supported not only by the 
difference in their subnuclear localisation patterns but also the isoform-specific 
binding partners identified (Reviewed in - Kwon and Workman 2008). Furthermore, 
by targeted deletion of each isoform, it has been shown that HP1 isoforms, except 
HP1α, are essential and cannot be compensated by the other two. Mice which lack 
HP1β were reported to show perinatal lethality. Moreover, newborn mice that lack 
HP1β exhibited acute respiratory failure and improper brain development (Aucott, 
Bullwinkel et al. 2008). Although no data have been provided, the same study also 
reported no phenotypic difference between HP1α wild type and deficient littermates. 
Of particular interest, deletion of HP1γ is associated with neonatal lethality in mice 
when bred on a pure genetic background (C57BL/6) (Naruse, Fukusumi et al. 2007, 
Takada, Naruse et al. 2011). Although 1% of mice with a mixed genetic background 
(C57BL/6 and 129/Ola) were able to develop into adulthood with HP1γ deletion 
(Brown, Bullwinkel et al. 2010, Takada, Naruse et al. 2011), a range of 
physiological defects including growth retardation and defects in germ cell 
development were found (Brown, Bullwinkel et al. 2010, Abe, Naruse et al. 2011, 
Takada, Naruse et al. 2011, Aydin, Kloos et al. 2015). Taken together, these studies 
indicate that HP1γ is playing a role in the genome that cannot be compensated by 
the other two isoforms.  
 
A large number proteins have been identified as binding partners of HP1γ (Table 
1.2) implicating it in a wide range of processes in both euchromatin and 
heterochromatin in a gene/region-specific manner. The most interesting feature of 
HP1γ is probably its involvement in both repression and activation of genes. 
Examples implying a role for HP1γ in gene repression include: the link to silencing 
of E2F- and MYC-response genes in G0 cells (Ogawa, Ishiguro et al. 2002); 
repression of the MMTV promoter in breast cancer cells (Vicent, Ballare et al. 2006); 
repression of the HIV-1 gene in conjunction with SUV39h1 (du Chene, Basyuk et 
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al. 2007); implicated in the SUMO E3 ligase PIAS1-mediated FOXP3 repression 
during T-cell differentiation (Liu, Tahk et al. 2010); implication in late pluripotency 
reprogramming events by repression of the pluripotency factor Nanog (Sridharan, 
Gonzales-Cope et al. 2013); as part of a repressive complex to silence 20% of 
hormone inducible genes in breast cancer cells (Vicent, Nacht et al. 2013) and more. 
Examples implying a role for HP1γ in gene activation include: the switch from 
HP1β to HP1γ at the promoter of an inducible HIV1 gene upon activation 
(Mateescu, Bourachot et al. 2008) and the association of HP1γ with the gene body 
of transcriptionally active genes in both human and murine cells interacting with 
the elongating form of RNA polymerase II (RNAPII) (Vakoc, Mandat et al. 2005, 
Lomberk, Bensi et al. 2006, Mateescu, Bourachot et al. 2008, Smallwood, Hon et 
al. 2012). In addition, S93P-HP1γ (previously regarded as S83) was shown to serve 
as a marker for transcription elongation (Lomberk, Bensi et al. 2006) and gene 
activation (Thorne, Ouboussad et al. 2012, Harouz, Rachez et al. 2014). Of 
particular interest, HP1γ has been shown to interact with the histone variant H3.3 
which associates predominately with actively transcribed genes. Intriguingly, the 
binding of both H3.3 and HP1γ to the HSP70 genes was found to be interdependent 
and correlated with the level of HSP70 gene expression (Kim, Heo et al. 2011). The 
exact nature and mechanisms of how the active or repressive role of HP1γ is 
determined remains unclear. One might expect that the mode of HP1γ regulation is 
dependent on the ‘context’ i.e. which regulatory factors (including specific 
epigenetic modifications) it interacts with in different nuclear environments (e.g 
euchromatic or heterochromatic). This thesis will address this hypothesis 
experimentally by focusing on the functional interdependence between H3.3 and 
HP1γ in vivo (see section 1.10 for aims of this project).  
 
Apart from regulation of gene expression, HP1γ has also been implicated in the 
regulation of processes including RNA splicing (Saint-Andre, Batsche et al. 2011, 
Smallwood, Hon et al. 2012, Salton, Voss et al. 2014) and transcriptional 
termination (Skourti-Stathaki, Kamieniarz-Gdula et al. 2014). In heterochromatic 
regions, HP1γ has been shown to be involved in maintenance of sister-telomere 
cohesion and telomere length (Canudas, Houghtaling et al. 2011). Moreover, 
knockdown of HP1γ was shown to prevent p53-mediated alternative lengthening of 
telomeres (ALT)-associated PML nuclear bodies (APB) formation which is found 
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exclusively in telomerase-negative cancer cells which use ALT as the main 
mechanism to maintain telomeres. Also, loss of HP1γ was reported to be associated 
with mitotic aberrations in a number of studies (Obuse, Iwasaki et al. 2004, Serrano, 
Rodriguez-Corsino et al. 2009, Shimura, Toyoda et al. 2011, Grzenda, Leonard et 
al. 2013). More recently, HP1γ has also been implicated in DNA damage response 
in a number of studies (Lee, Kuo et al. 2013, Soria and Almouzni 2013, Akaike, 
Kuwano et al. 2014, Wu, Nishikawa et al. 2015).  
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Protein Species  Interacting domain Reference(s) Chromatin associated factors     H1 (K29me2) Human CD 1 H3 Mouse CD 2 H3.3 Human nd 3, 4 H3K9me3 Human, mouse CD 5, 6 HP1α Human, mouse CSD 2, 7 HP1β Human, mouse CSD 2, 7  HP1γ Human, mouse CSD 2, 7 INCENP Human nd 8 TIN2 Human CSD 9 Chromatin modifiers    DNMT1 Human CD 10 DNMT3a Human nd 10 DNMT3b Human nd 10 G9a Human nd 11 G9a (K185me3) Human CD 1, 12 KDM2A Human nd 13 PIM1 Human CSD 14 SUV39H1 Human nd 11, 15 SUV4-20H2 Mouse nd 16 Transcription associated factors     BRCA1 Human nd 17 E2F-6  Human nd 12 IKKα Mouse nd 18 MED29 Mouse nd 19 PAX3 Human nd 20 RNA Mouse nd 21 RNAPII  Human, mouse nd 18, 22-25 TAFII130 (of TFIID) Human CSD 26 TIF1α Mouse CSD 27 TIF1β Human, mouse CSD 27, 28 Splicing associated factors    AGO2 Human nd 29 SRSF1 Human nd 30 Proteins involved in DNA repair    BARD1 Human nd 31 HIPK2 Human nd 32  KU70 Human CSD 24 Proteins involved in nuclear organisation    hMIS12 (kinetochore protein) 
Human  nd 33 
LAMIN B receptor (LBR) Human CSD 34, 35 Nuclear envelope  Mouse CD 36  Table 1.2 Examples of mammalian HP1γ interacting partners. CD, chromodomain; CSD, chromoshadow domain; nd, not determined. References used are:  
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(Ruan, Ouyang et al. 2012)1, (Nielsen, Oulad-Abdelghani et al. 2001)2, (Kim, Heo et al. 2011)3, (Loyola, Bonaldi et al. 2006)4, (Lachner, O'Carroll et al. 2001)5, (Bannister, Zegerman et al. 2001)6, (Rosnoblet, Vandamme et al. 2011)7, (Ainsztein, Kandels-Lewis et al. 1998)8, (Canudas, Houghtaling et al. 2011)9, (Smallwood, Esteve et al. 2007)10, (Fritsch, Robin et al. 2010)11, (Ogawa, Ishiguro et al. 2002)12, (Frescas, Guardavaccaro et al. 2008)13, (Koike, Maita et al. 2000)14, (Stewart, Li et al. 2005)15, (Schotta, Lachner et al. 2004)16, (Choi, Park et al. 2012)17, (Thorne, Ouboussad et al. 2012)18, (Sridharan, Gonzales-Cope et al. 2013)19, (Hsieh, Yao et al. 2006)20, (Muchardt, Guilleme et al. 2002)21, (Mateescu, Bourachot et al. 2008)22, (Smallwood, Hon et al. 2012)23, (Lomberk, Bensi et al. 2006)24, (Vakoc, Mandat et al. 2005)25, (Vassallo and Tanese 2002)26, (Lechner, Begg et al. 2000)27, (Brasher, Smith et al. 2000)28, (Ameyar-Zazoua, Rachez et al. 2012)29, (Salton, Voss et al. 2014)30, (Wu, Nishikawa et al. 2015)31, (Akaike, Kuwano et al. 2014)32, (Obuse, Iwasaki et al. 2004)33, (Polioudaki, Kourmouli et al. 2001)34, (Ye, Callebaut et al. 1997)35, (Kourmouli, Theodoropoulos et al. 2000)36                                       
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1.5 Genomic imprinting  
 
Genomic imprinting is an epigenetic phenomenon that results in mono-allelic 
expression of the identical gene according to the parental inheritance. To date, more 
than 100 genes in mouse were identified as imprinted genes (MouseBookTM). A lot 
of these imprinted genes are implicated in growth and development and also other 
processes including energy homoeostasis, brain function and behaviour (Reviewed 
in - Nordin, Bergman et al. 2014). Most of the imprinted genes are found in small 
clusters (Reviewed in - Regha, Sloane et al. 2007) and the allelic repression is 
control by imprinted control regions (ICRs) (Reviewed in - Delaval and Feil 2004). 
ICRs of either the maternally or paternally inherited allele are marked by DNA 
methylation which provides parental allele specific function to the ICR and hence 
mediates imprinted gene expression (Reviewed in - Kelsey and Feil 2013). In 
general, the imprinted (silent) allele is associated with DNA methylation and 
inactive histone modifications while the active allele is associated with active 
histone marks (Pedone, Pikaart et al. 1999, Singh, Wu et al. 2011).  
 
A classic example of an imprinted gene cluster is the insulin-like growth factor 2 
(Igf2)/H19 cluster. Igf2 and H19 genes are reciprocally expressed from two parental 
alleles. Igf2 is expressed only from the paternal allele and encodes the Igf2 protein 
which is responsible for promoting both foetal and placental growth (Constancia, 
Hemberger et al. 2002). In mice, the Igf2 gene is silent in almost all tissues after 
birth (Constancia, Hemberger et al. 2002). H19 is transcribed only from the 
maternal allele but not translated to a protein (Reviewed in - Nordin, Bergman et al. 
2014). Rather, H19 encodes a 2.3 kb non-coding mRNA (ncRNA) which is 
abundantly expressed in both embryonic and extraembryonic tissues during 
development. However, the exact role of H19 ncRNA is still unclear (Reviewed in 
- Nordin, Bergman et al. 2014). 
 
A well-accepted model for regulation of the Igf2/H19 imprinting cluster involves 
ICR1 which is a genomic region located approximately 2-4 kb upstream of the H19 
transcription start site (Figure 1.7) (Thorvaldsen, Duran et al. 1998). ICR1 is rich 
in CpG residues which allow differential methylation state of the two alleles. The 
paternal allele is methylated whereas the maternal allele is unmethylated and allows 
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binding of the insulator protein CTCF. Binding of CTCF to ICR1 on the maternal 
allele prevents the common enhancer for both Igf2 and H19 gene from acting on 
the Igf2 gene leading to its repression (Thorvaldsen, Duran et al. 1998, Thorvaldsen, 
Fedoriw et al. 2006). Methylation of ICR1 on the paternal allele prevents CTCF 
binding and allows paternal Igf2 expression (Bell and Felsenfeld 2000, Hark, 
Schoenherr et al. 2000). Little is known about potential global regulation of 
imprinted genes although it is possible that HP1 is involved. This will be 
experimentally addressed in this thesis (see result section 3.1.7). 
 
 
 
  
Figure 1.7 Schematic diagram demonstrating model for regulation of Igf2/H19 imprinting cluster by ICR1. ICR1 which locates upstream of the H19 transcription start site is rich in CpG residues which allow differential methylation state of the two alleles. Methylated paternal allele inhibits binding of CTCF. The common enhancer can then act on the Igf2 and allow its paternal expression. Binding of CTCF to ICR1 on the unmethylated maternal allele prevents the common enhancer from acting on the Igf2 gene. Maternal H19 is hence expressed.            
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1.6 Position Effect Variegation (PEV) 
 
When some genes are abnormally juxtaposed by rearrangement or transposition 
from their original euchromatic position to a location close to heterochromatin, they 
show variegation of expression resulting in stochastic silencing of the affected gene 
in a proportion of cells that would normally express it. This phenomenon, resulting 
from changing the position of the gene in the genome is termed ‘position effect 
variegation’ (PEV). These rearrangements are thought to remove the normally 
existing genetic boundary elements or ‘buffer zone’, allowing ‘spreading’ of 
heterochromatin along the chromosome from the adjacent constitutive 
heterochromatin and hence lead to silencing (Reviewed in - Elgin and Reuter 2013). 
However, whether this is regulated by multiple processes or a dominant mechanism 
remain unclear (Reviewed in - Brummelkamp and van Steensel 2015). It is thought 
that the decision to activate or silence in PEV occurs early in the development of a 
specific lineage and this decision is maintained by epigenetic modifications as cells 
progress through successive cell divisions (Reviewed in - Festenstein and Kioussis 
2000).  
 
PEV was first described by Hermann Muller in 1930 with the observation that 
translocation of the Drosophila white gene in close proximity to a block of 
centromeric heterochromatin resulted in variegation of red eye colour in a 
proportion of eye cells in Drosophila (Muller and Altenburg 1930) (Figure 1.8). 
Phenomena that resemble PEV have subsequently been observed in other organisms 
including yeasts (Allshire, Javerzat et al. 1994) and mammals (Cattanach 1974, 
Pravtcheva, Wise et al. 1994, Festenstein, Tolaini et al. 1996, Milot, Strouboulis et 
al. 1996).  One of the examples of a phenomenon similar to PEV that occurs in 
mammals includes the variable silencing of a coat colour gene in mice upon 
insertion onto the inactive X chromosome in females as a consequence of X 
inactivation by heterochromatinisation (Cattanach 1961, Russell and Bangham 
1961). It has also been shown that silencing of CD2 and β-globin transgenes was 
induced when integrated into the pericentromeric regions (Festenstein, Tolaini et al. 
1996). Intriguingly, PEV-induced silencing of these transgenes can be overcome 
completely by the addition of locus control regions (LCRs) on the transgene 
(Festenstein, Tolaini et al. 1996, Milot, Strouboulis et al. 1996). These are gene 
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regulatory elements that control the establishment of gene expression in cis in all 
cells of a given cell lineage (Reviewed in - Kioussis and Festenstein 1997). Of 
particular interest, the variegation phenotype was also observed when the CD2 
transgene was put in close proximity to DNA triplet repeats found in human 
diseases including the GAA repeats associated with Friedreich’s Ataxia (Saveliev, 
Everett et al. 2003). This observation led to the hypothesis that the silencing effect 
induced by pathological triplet repeat expansion might be exerted by mechanisms 
resembling heterochromatin-mediated PEV (Saveliev, Everett et al. 2003).  
 
A large number of PEV modifier which suppress (suppressor of variegation 
(Su(var))) or enhance (enhancer of variegation (E(var))) PEV were identified by 
mutagenesis screens of Drosophila (Reviewed in - Wallrath 1998). These PEV 
modifiers display dosage dependent effects whereby overexpression of Su(var)s 
enhances heterochromatic gene silencing and the downregulation causes 
suppression of PEV or vice versa for E(var)s (Reviewed in - Festenstein and 
Kioussis 2000). Of note, two of the suppressors of variegation identified include 
heterochromatin protein 1 (HP1) and the H3K9 methyltransferase Su(var)3-9 that 
are homologues of mammalian HP1 and SUV39H respectively (Reviewed in - 
Elgin and Reuter 2013).  
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Figure 1.8 Model of position effect variegation (PEV) in Drosophila. Translocation of the white gene to the proximity of centromere caused the variegation of white gene expression and hence the variegated phenotype (red eye colour) in a proportion of cells in the Drosophila eye.                              
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1.7 Sexual dimorphism  
 
Sex dimorphism refers to the genotypic and phenotypic differences between males 
and females of the same species. The fact that specific diseases may be more 
prevalent and severe in one gender than the other (Miller, Kaplan et al. 2011, 
Voskuhl 2011, Karastergiou, Smith et al. 2012, Sandberg and Ji 2012) increases our 
appreciation and interest in sex differences in physiology and disease (Reviewed in 
- Arnold 2014).  
 
Sex differences are determined by three main factors: activational effect of gonadal 
steroid hormones, organisational effects of gonadal steroid hormones and sex 
chromosomes (Reviewed in - Arnold 2009). Hormonal secretion by testes and 
ovaries in adult (predominately of androgens, estrogens and progestins) act on 
different tissues to induce gonadal phenotypes in males and females (Reviewed in 
- Rinn and Snyder 2005, Isensee and Ruiz Noppinger 2007). These hormonal effects 
are reversible as they are eliminated by adult gonadectomy in hours to weeks and 
classified as activational effects (Reviewed in - Arnold 2014). However, some 
sexual differences driven by gonadal hormones cannot be eliminated after 
gonadectomy. Examples include the sexual differentiation of the genitals as well as 
the specific sexual differences in the brain and behaviour (Jost, Vigier et al. 1973, 
Arnold and Gorski 1984, Breedlove, Cooke et al. 1999, McCarthy and Arnold 2011). 
These long-lasting or permanent changes caused by gonadal hormones are referred 
to as organisational effects (Phoenix, Goy et al. 1959).  
 
The primary sex-determining factors are encoded by the sex chromosomes (X and 
Y chromosomes) which are the only factors that differ in male and female zygotes 
and thus give rise to all downstream sex differences (Reviewed in - Arnold, Chen 
et al. 2012). All sexual differences are hence under the control of a genetic 
imbalance conferred by the gender-specific sex chromosome complements (‘XX’ 
in females and ‘XY’ in males) (Burgoyne 1993, Thornhill and Burgoyne 1993, 
Burgoyne, Thornhill et al. 1995).  
 
The male specific Y chromosome harbors male-specific genes that act only in XY 
cells. It carries the testis-determining Sry gene (Reviewed in - Goodfellow and 
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Lovell-Badge 1993) as well as other genes that are critical for spermatogenesis 
(Reviewed in - Arnold 2014). The X chromosomes can be found in both males and 
females. While one of the X chromosomes in females is inactivated by epigenetic 
mechanisms, X genes escaping X inactivation may then be expressed at a higher 
level in XX than XY cells (Reviewed in - Berletch, Yang et al. 2010, Arnold 2014). 
Moreover, as females inherit X chromosomes from both parents, female XX cells 
receive both paternal and maternal imprints on X chromosomes while male XY 
cells receive only maternal imprint. The effects of imprinting on X chromosomes 
in female cells thus depends on which X chromosome is active in a specific cell. 
This difference in male and female cells could hence contribute to sexual 
dimorphism (Reviewed in - Arnold, Chen et al. 2012). Furthermore, the sex-specific 
heterochromatic state of X and Y chromosome segments may alter the availability 
of factors which modulate epigenetic status of all chromosomes and hence regulate 
gene expression on autosomes in a sex-specific manner. The existence of this sex 
specific effect is supported by the studies in Drosophila showing that the large 
heterochromatic Y chromosome may act as a ‘sink’ for heterochromatic factors 
(indeed it is a powerful modifier of PEV) and thereby alter gene expression of 
autosomal genes by affecting the epigenetic status of the autosomes due to a relative 
deficiency in heterochromatic factors (Jiang, Hartl et al. 2010, Lemos, Branco et al. 
2010). Although mechanistic evidence for a similar Y chromosome effect is lacking 
in mammalian cells where the Y chromosome is relatively small (Reviewed in - 
Arnold 2014), the heterochromatic inactive X chromosome present only in XX 
mammalian cells could alter the availability of heterochromatic factors and hence 
the epigenetic status of specific autosomal loci (Wijchers, Yandim et al. 2010, 
Wijchers and Festenstein 2011). Indeed, the sex chromosome complement sensitive 
genes were enriched for genes that are repressed by HP1β (Wijchers, Yandim et al. 
2010) which suggested that HP1 might be a regulator of sexually dimorphic gene 
expression – a hypothesis which has been directly addressed in this thesis (see 
section 1.10 for aims of this project).  
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1.8 Friedreich’s Ataxia (FRDA)  
 
Friedreich’s Ataxia (FRDA) is DNA repeat-expansion disease where the repeats 
have been implicated in aberrant gene silencing at the heterochromatin level. It is 
an autosomal recessive neurodegenerative disease (Campuzano, Montermini et al. 
1996). It is the most common inherited ataxia in Caucasians affecting 1 in 30,000 
to 50,000 people (Reviewed in - Koeppen 2011, Koeppen 2013). This disease 
normally presents in childhood (Reviewed in - Festenstein 2006) primarily affecting 
the nervous system and the heart (Campuzano, Montermini et al. 1996). FRDA 
features a range of symptoms and signs including dis-coordination, muscle 
weakness, dysarthria, diabetes mellitus, peripheral neuropathy, cardiomyopathy and 
frequently leads to severe disability by early adulthood (Reviewed in - Festenstein 
2006, Schmucker and Puccio 2010). At present, no effective disease modifying 
treatment is available for FRDA (Reviewed in - Libri, Yandim et al. 2014).  
 
FRDA is caused by the deficiency of the mitochondrial protein frataxin which is 
evolutionarily conserved and expressed in all cell types (Reviewed in - Schmucker 
and Puccio 2010). Deficiency of frataxin leads to severe disruption of iron-sulfur 
cluster biosynthesis, overload of mitochondrial iron and increased sensitivity of the 
cells to oxidative stress which subsequently results in cell death (Reviewed in - 
Schmucker and Puccio 2010). It has been shown that silencing of the FXN gene by 
RNA interference causes large scale cell death in differentiated neuron-like cells 
associated with upregulation of pro-apoptotic factors including p53, PUMA and 
Bax (Palomo, Cerrato et al. 2011).  
 
The majority of cases of FRDA are caused by pathological expansion of a 
trinucleotide GAA repeat within intron 1 of the FXN gene, leading to partial 
silencing of the gene and hence deficiency of frataxin protein (Campuzano, 
Montermini et al. 1996). Healthy individuals normally have 8-33 GAA repeats 
while FRDA patients carry ~70 to more than 1000 triplet repeats (Durr, Cossee et 
al. 1996). Most FRDA patients carry GAA repeat expansions at both alleles which 
lead to a large reduction in FXN expression in all tissues to only 10-25% of normal 
levels (Campuzano, Montermini et al. 1996, Campuzano, Montermini et al. 1997). 
A small fraction of FRDA patients are compound heterozygous who have GAA 
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repeat expansions at only one FXN allele and a point mutation on the other allele 
(Cossee, Durr et al. 1999, Gellera, Castellotti et al. 2007). Due to the recessive 
nature of the disease, heterozygous carriers have only one affected allele and are 
asymptomatic and have ~50% of normal frataxin levels (Campuzano, Montermini 
et al. 1997, Pandolfo 2002).  
 
The molecular mechanisms by which GAA repeat expansions induce FXN gene 
silencing have been studied intensively and two non-exclusive models have 
emerged. Firstly, it has been shown by numerous biochemical studies that GAA 
repeat expansions can adopt abnormal DNA structures such as non-B DNA 
conformation (Ohshima, Montermini et al. 1998), the so-called ‘sticky DNA’ 
structure (Sakamoto, Chastain et al. 1999, Sakamoto, Ohshima et al. 2001) as well 
as RNA-DNA hybrids (Grabczyk, Mancuso et al. 2007). These structures can 
potentially act as a physical blockage for the elongating RNAPII to pass through 
the FXN gene (Sakamoto, Ohshima et al. 2001). Secondly, it has been suggested 
that GAA repeat expansions may silence the FXN gene by inducing 
heterochromatin formation through epigenetic mechanisms (Reviewed in - 
Schmucker and Puccio 2010, Yandim, Natisvili et al. 2013).  This idea originated 
following the discovery that expanded GAA repeats can induce silencing of a linked 
heterochromatin-sensitive human reporter gene (hCD2) in transgenic mice resulting 
in a phenomenon that resembled PEV (Saveliev, Everett et al. 2003). Moreover, this 
study has also shown that GAA repeats-induced variegated silencing could be 
enhanced by overexpression of the PEV modifier HP1β (Saveliev, Everett et al. 
2003). Heterochromatin-mediated silencing triggered by GAA repeat expansions 
was further supported by several more recent studies showing that the chromatin of 
the flanking regions of FXN alleles with GAA repeat expansions have 
hypoacetylation of histone H3 and H4 as well as methylation of histone H3K9 and 
H3K27, modifications that are characteristic of transcriptionally silent 
heterochromatin (Herman, Jenssen et al. 2006, Greene, Mahishi et al. 2007, Al-
Mahdawi, Pinto et al. 2008, Rai, Soragni et al. 2008, Chan, Torres et al. 2013, Libri, 
Yandim et al. 2014). Intriguingly, two recent clinical studies have shown that oral 
administration of histone deacetylase (HDAC) inhibitors by patients is able to 
increase frataxin level with associated epigenetic changes at the FXN locus. Libri 
et al showed that oral intake of the HDAC inhibitor nicotinamide is able to increase 
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both FXN mRNA and frataxin protein level towards asymptomatic carriers’ level 
and reduce the level of trimethylated H3K9 on the FXN gene in primary 
lymphocytes derived from FRDA patients (Libri, Yandim et al. 2014). Soragni et al 
showed that FRDA patients treated with a novel class II HDAC inhibitor have 
increased FXN mRNA level as well as H3K9 acetylation in their lymphocytes 
(Soragni, Miao et al. 2014). Such results suggest that HP1 might be responsible for 
the aberrant silencing in FRDA (see section 3.4).  
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1.9 Genome-wide studies of the transcriptome and epigenome  
 
1.9.1 Overview  
 
The human genome is comprised of approximately 25,000 genes which give rise to 
>80,000 protein coding transcripts and estimated to produce 250,000 to 1 million 
proteins (Reviewed in - de Klerk and 't Hoen 2015). The large number of transcripts 
and proteins per gene indicate the complexity of gene regulation 
mechanisms/networks which take place at different levels: genetic, epigenetic, 
transcriptional, post-transcriptional and translational level. In the last decade, 
methodologies which are based on next-generation sequencing for genome-wide 
profiling of the transcriptome (Nagalakshmi, Wang et al. 2008), the epigenome 
(Barski, Cuddapah et al. 2007, Johnson, Mortazavi et al. 2007, Robertson, Hirst et 
al. 2007) and chromosome conformation (Reviewed in - de Wit and de Laat 2012) 
have emerged. The transcriptome is defined as the complete set of RNA transcripts 
and their quantity in a cell (Wang, Gerstein et al. 2009) while the epigenome is 
defined as the landscape of epigenetic regulatory factors across the genome 
(Bernstein, Meissner et al. 2007). These technologies provide global insight and 
enhance our understanding of the complex genome. They also allow extensive 
comparison between cells at different developmental stages or under different 
physiological conditions. In this section, the features of the methodologies looking 
at the transcriptome and epigenome will be introduced.  
  
 
1.9.2 RNA sequencing (RNA-seq) for studying the transcriptome  
 
RNA sequencing (RNA-seq) is a methodology which provides profiling and 
quantification of the transcriptome based on next generation sequencing and allows 
measurement and comparison of gene expression patterns at high resolution 
(Reviewed in - Finotello and Di Camillo 2015). RNA-seq is not limited to 
measuring messenger RNA (mRNA) transcripts derived from protein coding genes 
but also small RNAs and non-coding RNAs (Reviewed in - Wang, Gerstein et al. 
2009). High accuracy of RNA-seq for quantifying expression levels has been 
confirmed using qRT-PCR (Nagalakshmi, Wang et al. 2008) and ‘spike-in’ RNA 
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controls of known concentration (Mortazavi, Williams et al. 2008). As RNA-seq is 
a sequence-based approach which directly determines the cDNA sequences, it can 
be used to detect transcripts that do not correspond to existing genomic sequence 
(Reviewed in - Wang, Gerstein et al. 2009). This feature makes RNA-seq an 
attractive tool for non-model organisms with undetermined genomic sequences 
(Vera, Wheat et al. 2008). Moreover, the high resolution of RNA-seq to a single 
base allows the precise localisation of transcription boundaries (Reviewed in - 
Wang, Gerstein et al. 2009) as well as revealing sequence variations such as single 
nucleotide polymorphisms (SNPs) in the transcribed regions (Cloonan, Forrest et 
al. 2008, Morin, Bainbridge et al. 2008). In conjunction with novel computational 
tools, RNA-seq is also a powerful tool for determining the expression of alternative 
RNA isoforms produced by the key regulatory process of alternative splicing 
(Anders, Reyes et al. 2012).    
 
 
1.9.3 Chromatin immunoprecipitation sequencing (ChIP-seq) for studying 
the epigenome 
 
Chromatin immunoprecipitation (ChIP) was developed more than one decade ago 
for mapping epigenetic features including histone modifications and transcription 
factors’ binding sites across different genomic regions in their native chromatin 
context (Ren, Robert et al. 2000, Iyer, Horak et al. 2001, Lieb, Liu et al. 2001, Horak 
and Snyder 2002, Weinmann, Yan et al. 2002). Hence, in vivo localisation of these 
epigenetic factors can be determined. The sequence identities of the precipitated 
DNA fragments in ChIP experiments are commonly detected by standard PCR and 
qRTPCR although Southern and western blot analysis have also been used (Orlando, 
Strutt et al. 1997, Singal, vanWert et al. 2002, Wells and Farnham 2002). However, 
these methods are associated with the limitation that existing knowledge of the 
target gene is required in order to design specific primers and probes for detection.  
More recently, ChIP followed by high-throughput sequencing (ChIP-seq) has been 
developed (Barski, Cuddapah et al. 2007, Johnson, Mortazavi et al. 2007, Robertson, 
Hirst et al. 2007). This technique allows identification of regions of a genome that 
are associated with a given protein or epigenetic modification and assessment of 
their relative enrichment in a genome-wide manner, hence enabling characterisation 
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of the ‘epigenome’. The data obtained from ChIP-seq can be at high resolution as 
it provides actual DNA sequences of the precipitated fragments (Reviewed in - 
Mundade, Ozer et al. 2014).  
 
In order to obtain high quality ChIP-seq data, several technical aspects have to be 
properly controlled. Firstly, being a technique which relies on the use of antibody, 
the quality of antibody used is key. Antibodies should therefore provide high 
specificity and sensitivity to allow detection of enrichment peaks without 
substantial background noise (Reviewed in - Kidder, Hu et al. 2011). In cases where 
antibodies of good quality are not available, epitope-tagged proteins can be 
employed. In this strategy, epitope-tagged proteins are expressed in targeted model 
systems and antibody recognising the epitope can be employed for ChIP. Examples 
of commonly used epitopes include hemagglutinin (HA), Flag, Myc, V5 and green 
fluorescent protein (GFP) (Kolodziej, Pourfarzad et al. 2009, Goldberg, 
Banaszynski et al. 2010, Chen, Stempor et al. 2014). Secondly, sufficient numbers 
of cells per ChIP reaction are required to help ensure a high signal-to-noise ratio. In 
order to control for bias in chromatin fragmentation and sequencing reactions, 
‘input’ control which reflects the total material used for ChIP is necessary. 
Specificity of antibody used can be controlled by performing ChIP on samples with 
the factor of interest depleted. In this case, as the level of target protein is diminished 
to background level, any binding events revealed can be assumed to be non-specific. 
Moreover, biological replicates of experiments are required to ensure reliability of 
data. Although there is no consensus on the best number of replicates for ChIP-seq, 
a minimum of duplicate biological experiments has been suggested (Chen, Negre 
et al. 2012). Furthermore, DNA fragments of about 150-300 bp which is equivalent 
to mono- and dinucleosome chromatin fragments have been considered to be the 
optimal size-range of chromatin for ChIP-seq analysis. DNA fragments of this size 
provide good resolution for ChIP-seq analysis and work well for next-generation 
sequencing platform (Reviewed in - Chen, Negre et al. 2012). Finally, the number 
of sequencing reads has to be sufficient for reasonable genomic coverage. The 
number of sequencing reads required is dependent on the affinity of antibody as 
well as the abundance of target sites in the genome (Reviewed in - Chen, Negre et 
al. 2012).  
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1.10 Aims of this project  
 
Heterochromatin protein 1 (HP1) is a non-histone chromosomal protein that was 
shown in Drosophila by mutagenesis screen to act as a dosage dependent modifier 
of the archetypal epigenetic phenomenon of position effect variegation (PEV). 
HP1γ, one of the mammalian HP1 isoforms is distinguished by its subnuclear 
localisation to both heterochromatic and euchromatic regions within the nucleus. 
Interestingly, it is implicated in a wide range of processes in both euchromatin and 
heterochromatin in a gene/region-specific manner and involved in both repression 
and activation of genes. It has been shown to bind to the histone modification 
H3K9me3 (Bannister, Zegerman et al. 2001, Lachner, O'Carroll et al. 2001) and 
interact with the histone variant H3.3 (Loyola, Bonaldi et al. 2006, Kim, Heo et al. 
2011). In the triplet-repeat expansion disease, Friedreich’s Ataxia, the FXN gene is 
heterochromatinised and silenced and decorated with H3K9me3 and HP1γ binding 
(De Biase, Chutake et al. 2009, Chan, Torres et al. 2013). However, the exact nature 
and mechanisms of how the active or repressive role of HP1γ is determined remains 
uncertain. This project set out to investigate the role of HP1γ by a classical gene 
knockout and knockdown approach.  
 
In this project, using mouse embryonic fibroblasts which are wild type or 
homozygous knockout for HP1γ. I aimed to experimentally address the following 
general questions: 
 
 What is the role of HP1γ in the regulation of gene expression? 
 What is the role of HP1γ in the regulation of heterochromatin? 
 Is the activatory or repressive role of HP1γ correlated with its association 
with the interacting histone variant H3.3? 
 Can the aberrantly silenced FXN gene be re-activated by decreasing HP1γ 
dosage? 
 Does HP1γ participate in regulation of sexually dimorphic gene expression? 
 Does HP1γ regulate imprinted genes? 
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Chapter 2 - Materials and Methods 
 
 
2.1 Generation of Mouse Embryonic fibroblasts (MEFs)  
 
Pregnant female mice were sacrificed at day 13.5 of gestation (E13.5) (considering 
the day of vaginal plug found as day 0). The uterus was obtained and placed in cold 
1x PBS. Embryos were removed from the uterus and transferred to a fresh petri dish 
containing cold 1x PBS. Under the light microscope, placenta and yolk sack were 
separated from the embryo and the head and internal organs were removed. The 
body of embryo was transferred to 1ml of PBS and finely minced. 1.5 ml of 0.25% 
trypsin-EDTA (Sigma) was added to the suspended tissue and incubated at 37°C for 
1.5min. To inactivate trypsin, 10ml of culture medium was added to the suspension 
and the sample was passed through a 0.7µm cell strainer. The cell strainer was 
rinsed once with 10ml culture medium giving a final cell suspension volume of 
22.5ml. Cells in the suspension were then collected by centrifugation at 300 x g at 
room temperature for 5min. The supernatant was discarded and the cell pellet was 
resuspended in 5ml culture medium, transferred to a 6cm culture dish and incubated 
overnight at 37°C, 5% CO2. Culture medium was replaced the following day. The 
cells were then cultured and expanded according to growth rate. Culturing 
conditions and details of genotyping can be found in later sections (2.2.2.1 and 2.4).  
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2.2 Cell culture  
 
2.2.1 Culturing and Passaging  
 
2.2.1.1 Mouse Embryonic fibroblasts (MEFs)  
 
MEF cells were cultured until 95% confluent in 10cm dishes. Culture media were 
discarded and the cells were washed once with 1x PBS. Cells were detached by 
adding 1ml of 0.25% Trypsin-EDTA per dish followed by 3 min incubation at 
37ºC for 5 min. Trypsin was inactivated by addition of 5ml culture media and the 
cells were transferred to Falcon tubes. The cells were collected by centrifugation 
at 300 x g at room temperature for 5 min. Supernatant was discarded and the cell 
pellet was resuspended in fresh culture media. One-third of cells were seeded into 
each fresh 10cm dish with final culture media volume as 10ml and cultured at 
37ºC, 5% CO2. 
 
 
2.2.1.2 Human fibroblast cell lines  
 
Human fibroblast cell lines derived from healthy individuals or FRDA patients used 
in this project were purchased from the Coriell Cell Repository, Camden, New 
Jersey, USA. Human fibroblast cell lines were cultured until 95% confluent in 10cm 
dishes. Culture media were discarded and the cells were washed once with 1x PBS. 
Cells were detached by adding 1ml of 0.25% Trypsin-EDTA per dish followed by 
5 min incubation at 37ºC for 5 min. Trypsin was inactivated by addition of 5ml 
culture media and the cells were transferred to falcon tube. The cells were collected 
by centrifugation at 300 x g at room temperature for 5 min. Supernatant was 
discarded and the cell pellet was resuspended in fresh culture media. One-fourth of 
cells were seeded into each fresh 10cm dish with a final culture media volume of 
10ml and cultured at 37ºC, 5% CO2. 
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Human fibroblast cell lines used: 
Coriell Catalog number 
Cell type  Species Pheno-type  GAA-repeat size  
Gender Race Age of sample taken (Years) GM07492 Fibro-blast Homo Sapiens Un-affected 6-34 repeats (normal) 
Male  Cauca-sian 17 
GM04503 Fibro-blast Homo Sapiens Un-affected 6-34 repeats (normal) 
Female Cauca-sian 31 
GM04078 Fibro-blast Homo Sapiens FRDA 541/420 in either alleles 
Male Cauca-sian 30 
GM03665 Fibro-blast Homo Sapiens FRDA 445/740 in either alleles 
Female  Cauca-sian 13 
 
 
2.2.1.3 Human Embryonic fibroblast 293T cells (HEK293T)  
 
HEK293T cells were cultured until 95% confluent in 10cm dishes. Culture 
medium was discarded and the cells were washed once with 1x PBS. Cells were 
detached by adding 1ml of 0.25% Trypsin-EDTA per dish followed by 2 min 
incubation at 37ºC for 5min. Trypsin was inactivated by addition of 5ml culture 
media and the cells were transferred to falcon tubes. The cells were collected by 
centrifugation at 300 x g at room temperature for 5 min. Supernatant was 
discarded and the cell pellet was resuspended in fresh culture media. One-fourth 
of cells were seeded into each fresh 10cm dishes with a final culture media 
volume of 10ml and cultured at 37ºC, 5% CO2. 
 
 
2.2.1.4 HeLa cells  
 
HeLa cells were cultured until 95% confluent in 10cm dishes. Culture medium 
was discarded and the cells were washed once with 1x PBS. Cells were detached 
by adding 1ml of 0.25% Trypsin-EDTA per dish followed by 2 min incubation at 
37ºC for 5 min. Trypsin was inactivated by addition of 5ml culture media and the 
cells were transferred to falcon tubes. The cells were collected by centrifugation at 
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300 x g at room temperature for 5 min. Supernatant was discarded and the cell 
pellet was resuspended in fresh culture media. One-fifth of cells were seeded into 
each fresh 10cm dishes with final culture media volume of 10ml and cultured at 
37ºC, 5% CO2. 
 
 
2.2.2 Freezing and thawing cells  
 
106 viable human fibroblasts and HeLa cells or 95% confluent dish of MEFs 
(passage 1) and HEK293T cells were harvested. The cell pellets were resuspended 
in freezing solution (90% FBS, 10%DMSO) and transferred to 2ml Cryovial. The 
cells were then frozen down in a Nalgene® Cryo 1°C “Mr. Frosty” freezing 
container and kept at -80 ºC overnight. Cryovials were stored in liquid nitrogen the  
next day.  
 
To recover the cells, the cryovial was taken out from liquid nitrogen and place 
immediately in a 37ºC water bath. The cell mixture was then transferred into 5 ml 
culture medium and centrifuged at 300 x g at room temperature for 5 min. 
Supernatant was discarded and the cell pellet was resuspended in 10ml of fresh 
culture medium, transferred to 10ml dish and culture at 37ºC, 5% CO2.  
 
 
2.2.3 Culture media  
 
MEFs and human fibroblast cell lines: 
DMEM high glucose (GIBCO ®), Fetal bovine serum (Sigma) (15% v/v), Penicillin 
(GIBCO ®) (1% v/v), GlutaMAXTM-I 100x (GIBCO ®) (1% v/v) 
 
HEK293T and HeLa cells: 
DMEM high glucose (GIBCO ®), Fetal bovine serum (Sigma) (10% v/v), Penicillin 
(GIBCO ®)  
(1% v/v), GlutaMAXTM-I 100x (GIBCO ®) (1% v/v) 
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2.3 Experimental mice  
 
2.3.1 Animal handling 
 
Animals used for completion of this thesis were maintained and handled according 
to the Imperial College Subcommittee for Animal Research guidelines and the 
British Home Office regulations. 
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2.3.2 Transgenic mouse models  
 
2.3.2.1 HP1γ knockout (HP1γ-KO) mice  
 
HP1γ-KO mice were generated by Naruse and colleagues with a gene trap method 
where a single gene-trap retroviral vector (ROSAN β-geo) was inserted into intron 
1 (998bp downstream of exon 1) of the Cbx3 gene (encoding HP1γ) (Figure 2.1) 
(Naruse, Fukusumi et al. 2007). With the insertion of the gene trap vector, a fusion 
transcript containing HP1γ exon 1 and β-geo of the gene-trap vector is generated 
and transcription terminated prematurely at the inserted polyadenylation site (pA). 
Hence, functional HP1γ protein cannot be produced. HP1γ-KO mice which were 
originally on a C57BL/6 background were back-crossed at least ten times on to the 
CBA/ca background.  
 
 
 
  
Figure 2.1 Schematic diagram demonstrating the insertion site of the gene trap vector in the Cbx3 gene in the HP1γ-KO mice. A single gene-trap retroviral vector (ROSANβ-geo) was inserted into intron 1 of the Cbx3 gene. Insertion leads to generation of pre-mature non-functional transcript. Genotyping PCR primers are indicated: HP1γ common forward (F), HP1γ wild-type reverse (wtR), HP1γ mutant reverse (mtR). This figure is adapted with permission from The Company of Biologists Ltd: Development “Takada, Y., C. Naruse, Y. Costa, T. Shirakawa, M. Tachibana, J. Sharif, F. Kezuka-Shiotani, D. Kakiuchi, H. Masumoto, Y. Shinkai, K. Ohbo, A. H. Peters, J. M. Turner, M. Asano and H. Koseki (2011). ‘HP1gamma links histone methylation marks to meiotic synapsis in mice.’ Development 138(19): 4207-4217.” Copyright (2011)    
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2.3.2.2 H3.3B-EGFP mice 
 
H3.3B-EGFP mice containing knock-in construct of H3.3B-EGFP were generated 
by Dr. Vineet Sharma (Imperial College London, London, U.K.) and Dr. Buhe 
Nashun (MRC Clinical Science Centre, London, U.K.). H3.3B-EGFP mice were 
generated by inserting the EGFP gene downstream of the coding sequence (CDS) 
of the H3f3b gene (encoding histone variant H3.3b) (Figure 2.2). Hence, animals 
containing this target knock-in will produce H3.3B-EGFP fusion proteins.  
 
 
 
  
Figure 2.2 Schematic diagram demonstrating the H3.3B-EGFP knock-in construct in the H3.3B-EGFP mice. The EGFP construct was inserted downstream of the coding sequence of the H3.3B gene. Genotyping primers (2) were used for this thesis. This figure is reprinted from Molecular Cell, Nashun, B., P. W. Hill, S. A. Smallwood, G. Dharmalingam, R. Amouroux, S. J. Clark, V. Sharma, E. Ndjetehe, P. Pelczar, R. J. Festenstein, G. Kelsey and P. Hajkova “Continuous Histone Replacement by Hira Is Essential for Normal Transcriptional Regulation and De Novo DNA Methylation during Mouse Oogenesis.” Copyright (2015) with permission from Elsevier. (Nashun, Hill et al. 2015)  
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2.3.2.3 HP1γ knockout H3.3B-EGFP (HP1γ H3.3B-EGFP) mice 
 
HP1γ H3.3B-EGFP mice having heterozygous knockout of HP1γ (HP1γ+/-) and 
expressing H3.3B-EGFP fusion protein (H3.3B-EGFP +/-) were generated by 
mating the HP1γ-KO mice (HP1γ+/-) with the H3.3B-EGFP mice (H3.3B-EGFP 
+/-). By interbreeding these mice, E13.5 embryos which express the H3.3B-EGFP 
fusion protein and are either wild type (WT) (HP1γ+/+, H3.3B-EGFP +/-) or 
homozygous knockout for HP1γ (HP1γ-/-, H3.3B-EGFP +/-) were generated. MEFs 
were subsequently derived from these embryos and used for experiments. Figure 
2.3 illustrates the mating scheme of this line.  
 
 
 
  Figure 2.3 Schematic diagram demonstrating the mating scheme of the HP1γ H3.3B-EGFP mice. Mice with heterozygous knockout of HP1γ and expressing H3.3B-EGFP (HP1γ+/-, H3.3B-EGFP +/-) were generated by mating the HP1γ-KO mice (HP1γ+/-) with the H3.3B-EGFP knock-in mice (H3.3B-EGFP +/-). By interbreeding these mice, E13.5 embryos with either WT or homozygous knockout HP1γ which express H3.3B-EGFP fusion protein were generated and MEFs were then derived from these embryos.  
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2.3.2.4 HP1γ heterozygous knockout mice with hFXN transgene (HP1γ-KO 
hFXN mice)  
 
HP1γ-KO hFXN mice which are heterozygous knockout of HP1γ and carrying hFXN 
transgene were generated by mating the HP1γ-KO mice (HP1γ+/-) with the hFXN mice 
which carry the pathological human frataxin transgene (hFXN). hFXN mice were 
previously generated by rescuing frataxin knockout mice with YAC FRDA transgenes 
which contain the entire FXN gene with (GAA)n repeat expansions. More details of the 
hFXN mice can be found in “Rescue of the Friedreich’s ataxia knockout mouse by human 
YAC transgenesis” by Pook M. et al published in Neurogenetics (Pook, Al-Mahdawi et al. 
2001). HP1γ-KO hFXN mice were generated, maintained and genotyped by Dr. Mark Pook 
and colleagues (Brunel University London, United Kingdom).  
 
 
 
2.4 Genotyping  
 
For genotyping of transgenic mice, earclip samples were lysed in 200µl of lysis buffer 
(0.1M Tris HCl pH8.0, 5mM EDTA pH8.0, 0.2M NaCl, 0.2% SDS) supplemented freshly 
with proteinase K (200 μg/ml) (Roche). For genotyping of MEFs, heads of embryos were 
lysed in 1ml of lysis buffer supplemented with proteinase K (200 μg/ml). DNA from 
samples were extracted and purified with phenol/chloroform (section 2.5) and precipitated 
with ethanol. Precipitated DNA was resuspended in sterile water and used for PCR 
genotyping with BiotaqTM DNA polymerase (Bioline). PCR products were analyzed by 
running in DNA agarose gel electrophoresis. List of primers used can be found in section 
2.21.1.  
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2.4.1 Genotyping PCR conditions  
 
2.4.1.1 HP1γ genotyping   
 
This PCR was performed to determine whether the transgenic mice or embryos are WT, 
heterozygous or homozygous knockout of HP1γ. PCR on HP1γ WT mice will give a single 
band of 501bp in WT allele PCR and no band for the mutant allele PCR. Homozygous PCR 
on HP1γ-KO mice will give a single band of 525bp for the mutant allele PCR and no band 
for the WT allele PCR. PCR on heterozygous HP1γ-KO mice will have both 501bp and 
525bp bands i.e. the WT and mutant allele PCR respectively. Examples of PCR results can 
be found in Figure S1 in appendix. 
 
PCR reaction mix: 
Component  WT allele PCR Mutant allele PCR 10x NH4 reaction buffer 2.5μl 2.5μl MgCl2 (50mM) 1.25μl 1.25μl BSA (10mg/ml) 0.75μl 0.75μl dNTPs (10mM)  0.5μl 0.5μl HP1γ common forward(10mM) 0.5μl 0.5μl HP1γ wild-type reverse (10mM) 0.5μl 0μl HP1γ mutant reverse (10mM) 0 μl 0.5μl DNA template  (50ng)  (50ng) BiotaqTM DNA polymerase 0.2μl 0.2μl Water Up to 25μl Up to 25μl Total 25μl 25μl  
PCR condition: 
Cycles Temperature  Time 1 96 ºC 3 min 5 96 ºC 15 sec  70 ºC (-1 ºC/cycle) 15 sec  72 ºC 40 sec  30 96 ºC 15 sec  58 ºC 15 sec  72 ºC 45 sec 1 72 ºC 10 min 1 12 ºC hold  
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2.4.1.2 GFP-H3.3 genotyping   
 
This PCR was performed to determine whether the transgenic mice contain H3.3B-
EGFP knock-in constructs. PCR on DNA from mice with this knock-in construct 
will give a single band of 272bp whilst DNA from WT mice will give no band. 
Examples of PCR results can be found in Figure S1 in appendix.  
 
PCR reaction mix: 
Component   10x NH4 reaction buffer 2.5μl MgCl2 (50mM) 1.25μl BSA (10mg/ml) 0.75μl dNTPs (10mM)  0.5μl GFP (F) (10mM) 0.5μl GFP (R) (10mM) 0.5 μl DNA template  (50ng)  BiotaqTM DNA polymerase 0.2μl Water Up to 25μl Total 25μl  PCR condition: 
Cycles Temperature  Time 1 96 ºC 5 min 35 96 ºC 30 sec  65 ºC  30 sec  72 ºC 30 sec   1 72 ºC 10 min 1 12 ºC hold  
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2.4.1.3 Kdm5d genotyping for sex determination of embryos 
 
In order to determine the sex of the embryos harvested for generation of MEFs in 
this thesis, PCR on the Y chromosome gene Kdm5d was performed. PCR on DNA 
from male mice will give a single band of 597bp while DNA from female mice will 
give no band. Examples of PCR results can be found in Figure S1 in appendix. 
 
PCR reaction mix: 
Component   10x NH4 reaction buffer 2.5μl MgCl2 (50mM) 1.25μl BSA (10mg/ml) 0.75μl dNTPs (10mM)  0.5μl Kdm5d (F) (10mM) 0.5μl Kdm5d (R) (10mM) 0.5 μl DNA template  (25ng)  BiotaqTM DNA polymerase 0.2μl Water Up to 25μl Total 25μl  PCR condition: 
Cycles Temperature  Time 1 96 ºC 5 min 35 96 ºC 30 sec  60 ºC  30 sec  72 ºC 15 sec  1 72 ºC 10 min 1 12 ºC hold  
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2.5 Phenol/Chloroform extraction and purification of DNA  
 
DNA in aqueous solution was extracted and purified with equal volumes of 
phenol/chloroform solution (phenol: chloroform: isoamylalcohol (25: 24: 1)). 
Samples were mixed vigorously and centrifuged at 12,000 x g, 4°C for 15min. 
Upper aqueous layer was obtained and the DNA was precipitated by mixing with 
1:10 volume of 3 M of sodium acetate (NaOAc) pH 5.2 and two volumes of absolute 
ethanol. The samples were then incubated at -20°C or -80°C for at least 1 hour and 
centrifuged at 12,000 x g 4°C for 30min. The precipitated DNA pellet was washed 
with 70% ethanol and centrifuged at 12,000 x g 4°C for 15min. The DNA pellet 
was air-dried and resuspended in DNAse-free water. DNA concentration was 
estimated by NanoDrop® Spectrophotometer ND-1000 with ND-1000 v3.3.1 
software. 
 
 
 
2.6 Lentiviral-mediated short hairpin-RNA (shRNA) knockdown  
             
pGIPZ shRNA lentiviral vectors (Open Biosystems) containing specific shRNA 
sequences were employed for knockdown experiments in human fibroblast cell 
lines and HeLa cells. All constructs were extracted and purified using HiSpeed® 
Plasmid Maxi kit (#12643, Qiagen) following manufacturer’s protocol and verified 
by DNA sequencing prior to the experiment.  
 
On day 0, HEK293T cells of 95% confluence in 10cm culture dishes were split 1:4 
and incubated overnight at 37ºC, 5% CO2.  
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On day 1, transfection of HEK293T cells were performed by adding the transfection 
mix dropwise and incubated at 37ºC, 5% CO2 for 3 hours. The component of the 
transfection mix is shown below: 
Component  Amount (μg) pMD2.G (envelop plasmid) 2  psPAX2 (packaging plasmid) 8 pGIPZ shRNA construct with target insert  20  Poly-ethyleneimine (PEI) (linear MW25,000) (Polysciences) 90  HEPES buffered saline (HPS) (Add up to total volume of 1ml) Culture media were then discarded and replaced by 10ml fresh media. Transfected 
HEK293T cells were incubated at 37ºC, 5% CO2 overnight. 
 
On day 2, the culture media of HEK293T cells were discarded and replaced by 10ml 
fresh media (DMEM for experiments on human fibroblasts and HeLa cells and 
incubated overnight at 37ºC, 5% CO2. The cells were incubated at 37ºC, 5% CO2 
overnight. 1.7 x 105 human fibroblast cells and 2 x 105 HeLa cells were seeded in 
each well of the 6-well plate with 3ml medium and incubated overnight at 37ºC, 
5% CO2.  
 
On day 3, culture media containing specific lentivirus from the transfected 
HEK293T cells were obtained and filtered through 0.45µm cellulose acetate syringe 
filter. Polybrene (Sigma) was added to the viral supernatant to a final concentration 
of 8µg/ml and mixed well. Fresh media was then added to the transfected HEK293T 
cells and incubated at 37ºC, 5% CO2 for 3 hours. For lentiviral infection of human 
fibroblast cell lines and HeLa cells, 2.5ml of 2-fold diluted or undiluted viral 
supernatant was added to the cells in each well of the 6-well plate and incubated at 
37ºC, 5% CO2 for 3 hours. Infection of cells were then repeated by replacing the 
viral supernatant from human fibroblasts or HeLa cells with the culture media from 
transfected HEK293T cells and incubated overnight at 37ºC, 5% CO2. Fresh media 
was then added to transfected HEK293T cells and incubated at 37ºC, 5% CO2 
overnight.  
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On day 4, infection of cells was repeated once as described and the cells were 
subcultured according to density and recovered in fresh media. Puromycin (Sigma) 
selection of positive clones was performed on day 7 which were cultured in 
puromycin containing media until cell number was sufficient for experiments. 
Puromycin concentrations used are listed below: 
Cell type  Puromycin concentration (µg/ml) Human Fibroblast cell lines  2  HeLa 1  
 
Target  Open Biosystem clone identifier shRNA construct shRNA sequences (5’->3’) CBX3 (HP1γ) V2LHS_258350  shHP1γ1 GTGAACAGTGGTTAATAAATTA CBX3 (HP1γ) V3LHS_300370  shHP1γ2 TGAAGTGTCCTCAAATTGTATA Scramble (Cat.# RHS4349) Scr CTCTCGCTTGGGCGAGAGTAAGTA Empty vector (Cat.# RHS4346) Em (N/A) Table 2.1. Sequences of shRNA used for knockdown experiment 
 
pGIPZ sequencing primer: 5’ GCATTAAAGCAGCGTATC 3’  
Maps of plasmid constructs pMD2.G, psPAX2 and pGIPZ shRNA construct can be 
found in appendix (Figure S2 –Figure S4).  
 
 
 
2.7 DNA sequencing 
 
150-300ng of plasmid DNA was sequenced with the Applied Biosystems 3730xl 
DNA Analyzer (MRC CSC Genomics Laboratory). Sequences obtained were 
analyzed using SnapGene® (GSL Biotech) software.  
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2.8 Total RNA Extraction 
 
Total RNA from MEFs, human fibroblast cell lines, HeLa cells and mouse 
cerebellum was extracted using TRIZOL® Reagent (Invitrogen) following the 
protocol provided. 
 
0.5x 106 MEF cells or 106 human fibroblast cell lines and HeLa cells were used per 
RNA extraction reaction. Cells were pelleted by centrifugation at 300 x g, room 
temperature for 5min and lysed with 1ml TRIZOL® Reagent.  For mouse cerebella, 
frozen tissue samples were homogenised using the IKA ultra-turrax T25 
homogeniser at highest power in 1ml TRIZOL® Reagent. Samples were then 
centrifuged at 12,000 x g, 4 ºC for 5min. The fatty top layer was removed and the 
clear homogenate solution was transferred to a fresh tube. Homogenised cell and 
tissue samples were incubated for 5min at room temperature. Afterwards, 200μl 
chloroform per 1ml TRIZOL® Reagent was added to each sample which was 
vigorously shaken for 15sec. Samples were incubated at room temperature for 5 
min and centrifuged at 12,000 x g, 4 ºC for 15min. The aqueous phase was 
transferred to a fresh tube and mixed with 500μl isopropanol per 1ml TRIZOL® 
Reagent. Samples were incubated at room temperature for 10min and centrifuged 
at 12,000 x g, 4 ºC for 25min. Supernatant was discarded and 1ml 70% ethanol per 
1ml TRIZOL® Reagent was added to the precipitated RNA pellet. Samples were 
mixed by vortex and centrifuged at 7500 x g, 4 ºC for 15min. Supernatant was 
discarded and the RNA pellets were air-dried followed by DNase treatment with 
Ambion® DNA free kit (Invitrogen). It was performed by resuspending the air-
dried RNA pellet in 40μl master mix containing 33μl RNase free water, 2μl 
SUPERase.INTM RNase inhibitor (Thermo Fisher Scienctific), 4μl 10x DNaseI 
buffer and 1μl DNaseI followed by subsequent incubation at 37ºC for 30min. 
Reactions were then stopped by addition of 4μl of inactivation reagent to the 
samples and incubation at room temperature for 2min. Samples were centrifuged at 
10,000 x g for 2min and 35μl supernatant which contained the isolated RNA was 
retained for subsequent analysis or otherwise stored at -80°C. 
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2.9 Complementary DNA (cDNA) synthesis and amplification  
 
ThermoScript® kit (Invitrogen) was used to reverse transcribe the total RNA 
extracted (with TRIOZOL® Reagent) into complementary DNA (cDNA) using a 
non-gradient cycler PCR machine (Peltier Thermal Cycler (PTC-200, BIORAD)). 
1-2 μg of RNA was incubated at 65°C for 5min with 50ng of random hexamer and 
2μl of 10mM dNTP. 4μl of cDNA synthesis buffer (5x), 1μl of DTT (0.1M) and 1μl 
of ThermoScriptTM reverse transcriptase (15U/μl) was added to the reaction and 
incubated at 50°C for 60min and then at 85°C for 5 min. cDNAs generated were 
then analysed using quantitative real time polymerase chain reaction (qRT-PCR) or 
stored at -20°C.  
 
 
 
2.10 Chromatin Immunoprecipitation (ChIP) 
 
1.8x106 cells were seeded in each 10cm tissue culture dish and incubated at 37°C, 
5% CO2 overnight to obtain about 2.5x106 cells per dish the next day. The culture 
medium per dish was adjusted to 10ml and the cells were fixed in 1% formaldehyde 
at room temperature for 10min. The formaldehyde fixation reaction was quenched 
with 125mM glycine for 5min at room temperature. The cells were washed three 
times by ice-cold PBS and incubated in 4ml swelling buffer at 4°C for 10min. Cells 
were collected by scraping and the nuclei were isolated using a dounce homogeniser 
with tight pestle (40 strokes). Nuclei were then collected by centrifuging at 3,000 x 
g 4°C for 5min.  
 
To generate chromatin, nuclei pellet generated from 107 cells was resuspended in 
1ml sonication buffer and transferred to a 15ml polystyrene tube. The nuclei 
suspension was sonicated using a Bioruptor® (Diagenode) at high energy, 30sec 
on-30sec off, with probe for 20min. Sonicated material was then centrifuged at 
16,000 x g 4°C for 30min and the sheared chromatin in the supernatant was retained. 
50μl chromatin sample was reverse crosslinked by adding 100μl water, 5μl 
proteinase K (10μg/μl) and 6μl 5M NaCl and incubated at 65°C for 4 hours. 
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Sonication efficiency was checked on agarose gel (see Figure S5 in appendix for 
representative sonication gel picture).  
 
For immunoprecipitation, specific antibodies were added to 200μl chromatin 
aliquots (equivalent to 2x106 cells) and incubated in the Bioruptor® for 45min, at 
low energy, 30sec on - 30sec off. Samples were centrifuged at 12,000 x g, 4°C for 
10min and the supernatant was added to 50μl Dynabeads® Protein G (Invitrogen) 
washed three times with sonication buffer and incubated overnight at 4°C.  
 
The next day, beads with antibody-chromatin complex were washed one time with 
sonication buffer, wash buffer A, wash buffer B and twice with 1xTE buffer for 
5min at 4°C with rotation. Elution of immune complexes and purification of DNA 
were performed using IPure Kit (Diagenode). In brief, 100μl of elution buffer 
(composed of 96.2% buffer A and 3.8% buffer B from kit) was added to washed 
beads and incubated at 65°C for at least 4h with continuous shaking. For the input 
sample, 10μl of chromatin samples were mixed with 90μl elution buffer prepared 
as stated above and incubated at 65°C for at least 4h with continuous shaking. 
Supernatant was obtained and mixed with 2μl of ‘carrier’ provided by the kit and 
100μl of 100% isopropanol. 15μl of DNA-binding magnetic beads was then added 
to each sample and incubated at room temperature for 1h with rotation. The 
supernatant was discarded and beads/DNA complexes were washed once with 
100μl wash buffer 1 and then wash buffer 2 for 5min at room temperature with 
rotation. Captured DNA was eluted by incubating with twice with 25μl buffer C 
from the kit at room temperature for 15min and giving sample with total volume of 
50μl. Samples were then used for downstream applications (qRT-PCR or ChIP-
sequencing library preparation), or stored at -20°C until further use. A list of 
antibodies used in ChIP can be found in section 2.22.1 
 
ChIP on human primary lymphocytes was carried out as previously described (Chan, 
Torres et al. 2013).  
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2.11 Quantitative real-time polymerase chain reaction (qRT-PCR) 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyse 
samples from ChIP experiments and check the expression level of genes after RNA 
extraction and cDNA synthesis. qRT-PCR reactions were prepared using SYBR® 
Green JumpstartTM Taq ReadyMixTM (Sigma-Aldrich®) as follows and performed 
in Low 96-well White Multiplate® PCR platesTM (BIORAD).  
 
PCR reaction mix: 
Component   SYBR® 10μl Forward primer (10mM) 0.5μl Reverse primer (10mM) 0.5μl DNA template  Δ  Water Up to 20μl Total 20μl  
PCR condition: 
Cycles Temperature  Time 1 95 ºC 10 min 40 95 ºC 30 sec  58 ºC  30 sec  72 ºC 30 sec  (Plate read) 80 ºC 1 sec (Plate read) 82 ºC 1 sec (Plate read) 85 ºC 1 sec Melting curve read from 70℃ to 96 ºC, read every 0.5 ºC, hold 1 sec  
Full list of primers used for qRT-PCR can be found in section 2.21.2 and 2.21.3. 
The efficiency of all the primers used in this thesis were calculated by a standard 
curve generated by qRT-PCR on serial diluted DNA samples. Efficiency of primers 
in percentage were calculated by the formula:  
 
Primer efficiency (%) = (10(-1/slope)-1)*100 
 
where the slope is the slope of the standard curve generated. This value represents 
the increased amount of PCR product after each PCR cycle. All primers used in this 
thesis have primer efficiency of 90-110%. (Representative curve see Figure S6 in 
appendix). For analysis of qRT-PCR data, 2–ΔΔCT method was used.  
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2.12 RNA sequencing library preparation and sequencing  
 
RNA sequencing libraries were prepared using the TruSeq® RNA sample 
preparation kit v2 (Illumina®) following ‘Low Sample (LS) protocol’ provided by 
the manufacturer. 0.5μg of good quality RNA checked by Agilent 2100 Bioanalyzer 
(Agilent Technologies, Inc.) using the RNA 6000 Nano kit (#5067-1511, Agilent 
Technologies) was used per RNA-seq library preparation reaction. Prepared 
libraries were validated by Agilent 2100 Bioanalyzer using High Sensitivity DNA 
Analysis Kits (#5067-4626, Agilent Technologies, Inc.) following the 
manufacturer’s protocol. Samples of sufficient quality were sequenced with 
HiSeq2500 (Illumina®). Representative Bioanalyzer results for good quality RNA 
and RNA sequencing libraries are shown in Figure S7 and Figure S8 in appendix.  
 
 
 
2.13 RNA sequencing analysis  
 
Raw data obtained from sequencing were processed using RTA (ver. 1.17.21.3) with 
default filter and quality settings from Illumina®. The reads were demultiplexed 
with CASAVA 1.8.2 (allowing 0 and 1 mismatch). Raw reads (fastq files) were 
aligned to the mouse genome (mm10) using Tophat aligner (tophat2 ver. 2.0.11) 
(Trapnell, Roberts et al. 2012). Aligned read counts data were generated by htseq 
work package (ver. 0.5.4p3). Differential expression analysis was performed using 
DESeq2 Bioconductor package (Love, Anders et al. 2014). Raw p-values were 
adjusted for multiple testing using the Benjamini-Hochberg procedure. All GO 
categories overrepresented with adjusted p-value of less than 0.05 were obtained. 
Gene ontology (GO) analysis was performed using the GOstats Bioconductor 
package (Falcon and Gentleman 2007). Statistical overrepresentation test was 
performed using the Panther classification system (http://pantherdb.org/) (Mi, 
Muruganujan et al. 2013). The mouse imprinted genes list was taken from World 
Wide Web Site - Mouse Imprinting Data and References - 
http://www.har.mrc.ac.uk/research/genomic_imprinting/ (link is external). 
Williamson CM, Blake A, Thomas S, Beechey CV, Hancock J, Cattanach BM, and 
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Peters J (2013), MRC Harwell, Oxfordshire. Venn diagrams presented in this thesis 
were generated by Venny 2.0.2 (Oliveros, J.C. (2007-2015) Venny. An interactive 
tool for comparing lists with Venn's diagrams. 
(http://bioinfogp.cnb.csic.es/tools/venny/index.htm)) 
 
 
 
2.14 ChIP sequencing (ChIP-seq) library preparation and sequencing  
 
ChIP-seq libraries were prepared using the NEBNext® UltraTM DNA Library Prep 
Kit for Illumina® (#E7370, New England BioLabs®). Input and ChIP DNA were 
estimated by Quant-iT™ PicoGreen® dsDNA Assay (#11496, InvitrogenTM). 8-
10ng of DNA was obtained per ChIP-seq library preparation reaction. End repair 
reaction was prepared as follow: 
 
End repair reaction mix: 
Component of end repair reaction  End Prep Enzyme Mix 3μl End Repair Reaction Buffer (10X) 6.5μl Input/ChIP DNA (8-10ng) Water Δ Total 65μl  
 
End repair reaction samples were incubated at 20°C for 30min, 65°C for 30min 
and held at 4°C. Sequencing adaptor ligation was then performed as follow: 
Adaptor ligation reaction mix: 
Component of adaptor ligation  End-repaired DNA sample 65μl Blunt/TA Ligase Master Mix 15μl NEBNext® Adaptor for Illumina® (1.5µM)*  2.5μl Ligation Enhancer 1μl Total 83.5μl *NEBNext® Multiplex Oligos for Illumina® (#E7335, New England BioLabs®) 
 
Samples were incubated at 20°C for 15min. 3μl of the USERTM Enzyme was added 
to each ligation reaction samples and incubated at 37°C for 15min.  
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To clean up adaptor-ligated DNA, 86.5μl of Agencourt AMPure®XP Beads 
(#A63881, Beckman Coulter) was added to each sample and incubated at room 
temperature for 5min. Supernatant was discarded and the beads were washed twice 
with 200μl freshly prepared 80% ethanol. Beads were air-dried for 5min and the 
bound-fraction was eluted in 20μl 0.1xTE.  
 
Cleaned-up adaptor ligated DNA samples were enriched by PCR amplification as 
follows: 
 
 PCR amplification reaction mix: 
Component   Adaptor Ligated DNA Fragments 20μl NEBNext® High Fidelity 2X PCR Master Mix 25μl Index Primer* 2.5μl Universal PCR Primer* 2.5μl Total 50μl *NEBNext® Multiplex Oligos for Illumina® (#E7335, New England BioLabs®) 
  PCR condition: 
Cycles Temperature  Time 1 98 ºC 5 min 12 98 ºC 10 sec  65 ºC  30 sec  72 ºC 30 sec  1 72 ºC 5 min 1 4 ºC hold  
Enriched DNA samples were resolved in 2% agarose gels (prepared with 0.5X TAE). 
DNA fragments of 200-400bp were extracted and cleaned up by a QIAquick® Gel 
extraction kit (#28706 Qiagen) following manufacturer’s protocol. Prior to 
sequencing, the purified DNA fragments (ChIP sequencing library) were analysed 
with the Agilent 2100 Bioanalyzer using High Sensitivity DNA Analysis Kits 
(#5067-4626, Agilent Technologies, Inc.) following the manufacturer’s protocol 
(see Figure S9 in appendix for representative Bioanalyzer result). Samples of 
sufficient quality were sequenced with HiSeq2500 (Illumina®).  
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2.15 ChIP sequencing analysis 
 
ChIP-seq reads were aligned to the mouse genome version mm9 using bwa version 
0.7.5a. Peak calling was performed using macs/1.4.1. Quality control plot and 
statistics were generated using ChIPQC package from Bioconductor (Carroll et al., 
in press). Feature visualisation and normalisations were carried out with soGGi 
package from Bioconductor (Dharmalingam and Carroll, 2015). 
 
 
 
2.16 Immunofluorescence (IF) 
 
MEFs cells were grown on coverslips (12mm diameter, 0.085 - 0.130mm thick) 
without coating. Coverslips with adhered cells were washed once in 1x PBS and 
fixed with 4% paraformaldehyde in PBS at room temperature for 10min. Coverslips 
were washed three times in 2x PBS and incubated in 30% glycerol in 1xPBS for 
10min at room temperature. Coverslips in glycerol were then snap frozen in liquid 
nitrogen and stored at -80°C for later use.  
 
For immunofluorescence, coverslips were thawed from -80°C and washed three 
times with 1xPBS. To permeabilise MEF cells on coverslips, 0.5% Triton-X 100 in 
PBS was added and incubated at room temperature for 30min. Fixed and 
permeablised cells on coverslips were then washed three times with 1xPBS and 
incubated in 20mM glycine in PBS at room temperature for 30min. In order to block 
the non-specific antibody binding sites, coverslips were incubated in PBS+ 
(blocking solution) at room temperature for 1 hour.  Subsequently, cells on 
coverslips were incubated in primary antibody pre-diluted in blocking solution and 
incubated in dark for 2 hours at room temperature. Cells on coverslips were washed 
with blocking solution and incubated with secondary antibody pre-diluted in 
blocking solution and incubated in the dark for 1 hour at room temperature. Cells 
on coverslips were washed with blocking solution and1xPBS and incubated in 
DAPI (5ng/ul) pre-diluted in 1xPBS for 15min at room temperature. Finally, stained 
cells on coverslips were mounted with 6-7μl Vectashield mounting medium (Vector 
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Laboratories) and examined under a Leica confocal microscope or Leica widefield 
fluorescence microscope and analysed with Leica LAS AF Lite Software (Leica) or 
ImageJ (NIH, USA). The list of antibodies used in IF can be found in section 2.22.5 
and 2.22.6. All the cells examined with immunofluorescence were in passage 1.  
 
 
2.17 Co-immunoprecipitation (Co-IP) 
 
6 x 106 MEFs were used per co-immunoprecipitation experiment. Cells were 
pelleted at 300 x g, room temperature for 5min and washed once with 500μl buffer 
A followed by centrifugation at 300 x g, 4°C for 5 min. Supernatant was discarded 
and the cell pellets were lysed with 500μl buffer A containing 0.2% Triton X-100 
and incubated on ice for 10 min. Samples were then centrifuged at 600 x g, 4°C for 
5 min and the nuclei pellets were obtained. Nuclei were resuspended in 250μl of 
buffer A containing 2mM CaCl2 and 1U of Micrococcal Nuclease (MNase) (Sigma) 
and incubated at 1400rpm, 4°C for 50 min. The reaction of MNase was stopped by 
addition of EGTA to a final concentration of 10mM. 5M NaCl was added to each 
sample to a final concentration of 340mM and the samples were incubated at 4°C 
for 60 min with gentle mixing. Samples were centrifuged at 8,000 x g, 4°C for 5min 
and the supernatants (nuclear extract) were obtained. Equilibration buffer was 
added to each sample to lower the salt concentration to 150mM NaCl.  
 
For immunoprecipitation, specific antibody was mixed with nuclear lysate and 50μl 
Protein G Dynabeads® (Invitrogen) washed three times with buffer A. Samples 
were then incubated overnight at 4°C. Beads were then washed three times in 200μl 
wash buffer by vortexing. Immunoprecipitated material was eluted in 30μl SDS 
Sample buffer and boiled for 10min. Dithiothreitol (DTT) was then added to final 
concentration of 1mM and boiled again for 10min. Samples were then analysed by 
western blotting. Details of antibodies used for immunoprecipitaiton can be found  
in section 2.22.2. 
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2.18 Protein extraction  
 
Unless otherwise stated, protein lysate used for experiments in this thesis was 
prepared using RIPA buffer (supplemented with protease inhibitors freshly before 
use) and the protein concentration was estimated using a bovine serum albumin 
(BSA) dilution standard curve with the Bradford Protein Assay (BIO-RAD). Prior 
to loading into the gel for western blotting, protein sample were mixed 1:1 with 2x 
Laemmlli buffer and denatured by heating at 100°C for 10min. Protein samples 
were stored at -20°C.  
 
 
 
2.19 Frataxin protein measurement using Quantity Dipstick Assay Kit 
 
Frataxin Protein Quantity Dipstick Assay Kit (ab109881, Abcam®) was used to 
measure Frataxin protein level in healthy and FRDA human fibroblast cell lines. 
About 106 cells were pelleted and resuspended in 200μl buffer A provided by the 
kit. Samples were incubated on ice for 20min and centrifuged at 16000 x g, 4°C 
for 20min. Supernatant (protein lysate) was retained and the protein concentration 
of the samples was estimated using a BSA standard curve with the bicinchoninic 
acid (BCA) assay kit (Sigma®) according to manufacturer’s protocol.  25μl of 
protein samples at 1.6μg/μl was mixed with 25μl 2x buffer B and added to the 
microplate well provided, incubated at room temperature for 5min and followed 
by gently vortex in order to dissolve the dried gold-conjugated secondary antibody 
in each well of the microplate. Dipsticks were then put carefully onto each well 
and let to soak in the entire protein sample at room temperature. To wash the 
dipstick, 30μl of buffer C was added to each well letting the wash soak up 
completely onto the dipstick by capillary action. The dipsticks were then air-dried 
at room temperature for 20min and the signal intensity of the bands corresponding 
to Frataxin protein were measured by the Mitosciences MS1000® dipstick reader. 
Frataxin protein concentration in each sample was estimated using a recombinant 
Frataxin standard curve (Figure S10 in appendix). 
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2.20 Western blotting  
 
10-30μg of denatured protein samples were resolved in denaturing SDS-PAGE gels 
prepared as follows using the BIO-RAD Mini-PROTEAN® Tetra Systems (BIO-
RAD) with 1mm plate separation.  
 Resolving gel (12.5%) Stacking gel (4%) Water  3.125ml 6ml 30% Acrylamide 4.17ml 1.33ml 1.5M Tris pH8.8 2.5ml 0ml 0.5M Tris pH6.8 0ml 2.5ml 10% SDS 100μl 100μl 10% ammonium persulphate (APS) 100μl 100μl Tetramethylethylenediamine (TEMED)  10μl 10μl Total 10ml  10ml  Protein samples were resolved by running the SDS-PAGE gel at 150V for 70-90min. 
After electrophoresis was completed, the SDS-PAGE gel was then incubated in 1x 
transfer buffer. The transfer stack was prepared by sandwiching the SDS-PAGE gel 
and the Hybond-N+ PVDF membrane (GE Healthcare) (activated by incubating in 
100% methanol for about 2min and subsequently rinsed with 1x transfer buffer) 
with 3 pieces of Whatman 3MM filter papers on either side and placed into the Mini 
Trans-Blot® system (BIO-RAD) with the PVDF membrane and the SDS-PAGE gel 
facing the negative and positive electrode respectively. Protein in the SDS-PAGE 
gel was transferred to the membrane at 100V, 4°C for 1h. After transfer, the 
membrane was blocked for 1 hour at room temperature with 5% milk (in 
PBST/TBST) Primary antibody diluted in 5% milk or 5% BSA (in PBST/TBST) 
was added to the membrane and incubated at room temperature for 2 hours or 4°C 
overnight. The membrane was then washed three times for 10min at room 
temperature with PBST or TBST and incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody diluted in 5% milk (in PBST/TBST) for 1 hour at 
room temperature. Next, the membrane was washed three times with PBST or 
TBST for 10min at room temperature and the blot was developed using Amersham 
ECL Prime Western Blotting Detection Reagent (GE Healthcare) following the 
manufacturer’s protocol in the darkroom. A list of antibodies used in western 
blotting can be found in section 2.22.3 and section 2.22.4. 
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2.21 Lists of primers 
 
2.21.1 List of primers used for genotyping: 
Primer name Purpose Primer sequences (5’-3’) HP1γ common forward HP1γ genotyping GAGTGATTACCGACACCACCA HP1γ wild-type reverse  HP1γ genotyping TTTAATCGGAGACTTGAAGAGC HP1γ mutant reverse  HP1γ genotyping GTTCGCTTCTCGCTTCTGTT GFP (F) H3.3B-EGFP genotyping GACCGCTTCCTCGTGCTTTA GFP (R) H3.3B-EGFP genotyping GAGCCACAGTGCTCACATCA Kdm5d (F) Sex determination  ACAAAGTGGGGGCAAAAAGT Kdm5d (R) Sex determination AGTTATGACCCTCACCACAAGA  
 
2.21.2 List of primers used for qRT-PCR checking gene expression level: 
Primer name Gene target Species  Primer sequences (5’-3’) human β-ac (F) ACTB (β-actin) Human GCGGGAAATCGTGCGTGACAT human β-ac (R) ACTB (β-actin) Human GATGGAGTTGAAGGTAGTTTCGTG AL-sat (F) α-Satellite Human AACTCACAGAGTTGAACGATCC AL-sat (R) α-Satellite  Human ACCTCAAAGCGGCTGAAAT m_HP1beta (F)2 Cbx1 (HP1β) Mouse GCCCTGACCTTATTGCTGAG m_HP1beta (R)2 Cbx1 (HP1β) Mouse CCTCGTGGCTTTTCTGACTC HP1γ 1435 Cbx3 (HP1γ)  Mouse GGTCCAGGTCAGCCAGTCTA HP1γ 1554 Cbx3 (HP1γ) Mouse CCAGCCACGATTCTATTTCC h_HP1gamma (F) CBX3 (HP1γ) Human GCTGGCAAAGAAAAAGATGGTAC h_HP1gamma (R) CBX3 (HP1γ) Human  CATCAATTCTCCACTGCTGTCTGT m_HP1alpha (F) Cbx5 (HP1α) Mouse GGAAATCCAGTTTCTCCAACA m_HP1alpha (R) Cbx5 (HP1α) Mouse GCTCCGATGATCTTTTCTG FXN mRNA (F) FXN (Frataxin) Human ATGTCTCCTTTGGGAGTGGTGTCT FXN mRNA (F) FXN Human CCCAGTCCAGTCATAACGCTTA
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(Frataxin) GGT GSATII (F) γ-Satellite(II) Human ACGAAAGTGCCTTCCCATC GSATII (R) γ -Satellite(II) Human CACCTCCCCTCCCTCAAAC Mj-sat (F) Major-Satellite  Mouse GACGACTTGAAAAATGACGAAATC Mj-sat (R) Major-Satellite Mouse CATATTCCAGGTCCTTCAGTGTGC 18S (F) Rn18s (18S rRNA) Mouse ATGGTAGTCGCCGTGCCTAC 18S (R) Rn18s (18S rRNA) Mouse CCGGAATCGAACCCTGATT  
 
2.21.3 List of primers used for ChIP-qRT-PCR: 
Primer name Gene target Species  Primer sequences (5’-3’) EF1α (F) Eef1a1 Mouse CGGGTACCGGGATTATGGGTTATGAGAA EF1α (R) Eef1a1 Mouse TAGGGATAGATTCTGGCCGCCCTCTTG Gapdh+4K(F) Gapdh Mouse GAGCCCTCCCTACTCTCTTGAAT Gapdh+4K(R) Gapdh Mouse ACACCGCATTAAAACCAAGGA Gapdh(F) Gapdh Mouse AGTCCGTATTTATAGGAACCCGGATGGTGG Gapdh(R) Gapdh Mouse ATGAGAGAGGCCCAGCTACTCGCGGCTTTA Mj-sat (F) Major-Satellite  Mouse GACGACTTGAAAAATGACGAAATC Mj-sat (R) Major-Satellite Mouse CATATTCCAGGTCCTTCAGTGTGC Myl3 (F) Myl3  Mouse TGCCGTCAGCTAGAGTCTGCTGTGTCAAGG Myl3 (R) Myl3  Mouse GTATTGAGAAAGAGAAAAGTGGGGGAGGGG Neurod6(F) Neurod6 Mouse TTTTTCCCTATCAGTCTAACCTCCTGTGTTGA Neurod6(R) Neurod6 Mouse AAAAGTGACATTGATGCCAACTGCCAGAGC  
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2.22 Lists of antibodies  
 
2.22.1 List of antibodies for chromatin immunoprecipitation (ChIP): 
Antibody Type/Isotype  Dilutions Company  Catalogue no. Anti-GFP Rabbit polyclonal, IgG 10µg/IP Abcam Ab290 Anti-H3 Rabbit polyclonal, IgG 6ug/IP Abcam Ab1791 Anti-H3 (acetyl K9+K14+K18+ K23+K27) 
Rabbit polyclonal, IgG 8µg/IP Abcam  Ab47915 
Anti-H3.3 Rabbit polyclonal 10µg/IP Millipore 09-838 Anti-H3K9me3  Rabbit polyclonal, IgG 6µg/IP Millipore 07-442 Anti-H3K27me3 Mouse monoclonal IgG3 8µg/IP Abcam Ab6002 Anti-H4 (acetyl K5+K8+K12+ K16) 
Rabbit polyclonal IgG 8µg/IP Millipore 06-866 
Anti-HP1γ Mouse monoclonal, IgG1 8µg/IP Millipore 05-690  
 
2.22.2 List of antibodies for co-immunoprecipitation (co-IP): 
Antibody Type/Isotype  Dilutions Company  Catalogue no. Anti-GFP Rabbit polyclonal, IgG 10µg/IP Abcam Ab290 Anti-GFP Mouse monoclonal, IgG1 5µg/IP Abcam Ab1218 Anti-HP1γ Rabbit polyclonal, IgG 5µg/IP Abcam  Ab10480 Mouse IgG Normal mouse IgG 5µg/IP Santa-cruz sc-2025 Rabbit IgG Normal rabbit IgG 5µg/IP Millipore PP64B  
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2.22.3 List of primary antibodies for western blot: 
Antibody Type/Isotype  Dilutions Company  Catalogue no. Anti-α-tubulin Mouse monoclonal, IgG1 1:10000 Sigma T5168 Anti-GFP Rabbit polyclonal, IgG 1:1000 Abcam Ab290 Anti-H3 Rabbit polyclonal, IgG 1:1500 Abcam Ab1791 Anti-H3.3*  Rabbit polyclonal 1:500 Millipore 09-838 Anti-H3K9me3*  Rabbit polyclonal, IgG 1:1000 Abcam  Ab8898 Anti-HP1α Mouse monoclonal, IgG1 1:250 Millipore MAB3446 Anti-HP1β Mouse monoclonal, IgG1 1:500 Millipore MAB3448 Anti-HP1γ Mouse monoclonal, IgG1 1:5000 Millipore MAB3450 *Antibodies that require the use of BSA 
 
 
2.22.4 List of Secondary antibodies for western blot: 
Antibody Dilutions Company  Catalogue no. Goat anti-Mouse IgG, HRP-conjugated  1:20000 Life Technologies G21040 Goat anti-Rabbit IgG, HRP-conjugated 1:20000 Santa-cruz sc-2004 Goat anti-Rabbit IgG, HRP-conjugated 1:20000 Pierce 1858415  
 
2.22.5 List of primary antibodies for immunofluorescence (IF): 
Antibody Type/Isotype  Dilutions Company  Catalogue no. Anti-GFP Rabbit polyclonal, IgG 1:5000 Abcam Ab290 Anti-H3K9me3 Rabbit polyclonal, IgG 1:50 Millipore 07-442 Anti-HP1α Mouse monoclonal, IgG1 1:50 Millipore 05-689 Anti-HP1β Mouse monoclonal, IgG1 1:50 Millipore MAB3448 Anti-HP1γ Mouse monoclonal, IgG1 1:5000 Millipore MAB3450  
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2.22.6 List of secondary antibodies for immunofluorescence (IF): 
Antibody Dilutions Company  Catalogue no. Goat anti-Mouse IgG, Alexa Fluor® 488 conjugated 1:600 Life Technologies A11029 Dockey anti-Mouse IgG, Alexa Fluor® 568 conjugated 1:600 Life Technologies A10037 Goat anti-Rabbit IgG, Alexa Fluor® 488 conjugated 1:600 Life Technologies A11008 Goat anti-Rabbit IgG, Alexa Fluor® 568 conjugated 1:600 Life Technologies A11036  
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2.23 Solutions  
 
0.5x TAE - 20 mM Tris acetate, 0.5 mM EDTA 
10x TE - 100 mM Tris-HCl, 10 mM EDTA 
5x TBE - 450 mM Trisborate, 10 mM EDTA 
Buffer A (co-immunoprecipitation) - 20mM HEPES, pH 7.9, 10mM KCl, 1.5mM 
MgCl2, 0.34M sucrose, 10% glycerol supplemented with 1mM dithiothreitol (DTT), 
1 mM PMSF and 0.5μl of protease inhibitor cocktail per 1ml buffer freshly 
Equilibration buffer (co-immunoprecipitation) - 20mM HEPES, pH7.9, 1.5mM 
MgCl2, 0.2mM EGTA, 25% glycerol. Supplemented with 0.5 mM PMSF, 0.5μl of 
protease inhibitor cocktail per 1ml buffer freshly 
HEPES buffered saline (HPS) - 137mM NaCl, 5.1mM KCl, 0.7mM Na2PO4, 
21mM HEPES, 0.1% (w/v) glucose, pH7.05 
Laemmli buffer (2X) (western blot) - 4% SDS, 10% 2-mercaptoehtanol, 20% 
glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl 
LB - 1% tryptone, 0.5% yeast extract,1% NaCl, adjust pH to 7.0-7.5 by NaOH 
LB agar - 1% tryptone, 0.5% yeast extract,1% NaCl, adjust pH to 7.0-7.5 by NaOH, 
1.5% agar 
Lysis buffer (genotyping) - 0.1M Tris HCl pH8.0, 5mM EDTA pH8.0, 0.2M NaCl, 
0.2% SDS  
Phenol/chloroform solution - Prepared by mixing 25:24:1 
Phenol:chloroform:isoamylalcohol and equilibrated with 10 mM Tris-HCl, pH 8.0 
Phenylmethysulfonyl Fluoride (PMSF) (0.1M) - Prepared in isopropanol 
Phosphate buffered saline (PBS) -171mM NaCl, 3.3mM KCl, 10.1mM Na2PO4, 
1.8 mM KH2PO4, pH7.4 
Phosphate buffered saline with Tween-20 (PBST) (western blot) - 171mM NaCl, 
3.3mM KCl, 10.1mM Na2PO4, 1.8 mM KH2PO4, 0.1% Tween-20, pH7.4 
RIPA (Radio Immuno Precipitation Assay buffer) buffer (protein extraction) -  
150 mM NaCl, 1.0% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% 
SDS, 50 mM Tris, pH 8.0. Supplemented with 0.5 mM PMSF, 0.5μl of protease 
inhibitor cocktail per 1ml buffer freshly 
Running buffer (western blot) - 25 mM Tris base, 190 mM glycine, 0.1% SDS, 
pH 8.3. 
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SDS Sample buffer (co-immunoprecipitation) - 100 mM Tris, pH 6.8, 4% SDS, 
and 20% glycerol 
Sonication buffer (chromatin immunoprecipitation) - 50 mM HEPES pH 7.9, 140 
mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Sodium deoxycholate, 0.1% SDS, 
pH 7.9. Supplemented with 0.5 mM PMSF, 0.5μl of protease inhibitor cocktail per 
1ml buffer freshly 
Swelling buffer (chromatin immunoprecipitation) - 25 mM HEPES pH 7.9, 1.5 
mM MgCl2, 10 mM KCl, 0.1% NP-40, pH 7.9. Supplemented with 0.5 mM PMSF, 
0.5μl of protease inhibitor cocktail per 1ml buffer freshly 
TBST (western blot) - 50 mM Tris.HCl, pH 7.4 and 150 mM NaCl, 0.1% Tween-
20, pH7.5 
Transfer buffer (western blot) - 25 mM Tris base, 190 mM glycine, 20% methanol, 
pH 8.3 
Wash buffer (co-immunoprecipitation) - 20mM HEPES, pH7.9, 150mM NaCl, 
1.5mM MgCl2, 0.2mM EGTA, 0,2% Triton X-100, 10% glycerol. Supplemented 
with 0.5 mM PMSF, 0.5μl of protease inhibitor cocktail per 1ml buffer freshly 
Wash buffer A (chromatin immunoprecipitation) - 50 mM HEPES pH 7.9, 500 
mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Sodium-deoxycholate, 0.1% SDS, 
pH 7.9 
Wash buffer B (chromatin immunoprecipitation) - 20 mM Tris pH 8.0, 1 mM 
EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Sodium-deoxycholate, pH8.0 
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Chapter 3 – Results 
 
 
3.1 Investigation of the role of HP1γ in gene regulation  
 
HP1γ is a member of the mammalian HP1 protein family. Notably, unlike HP1α 
and HP1β, it is found in both euchromatic and heterochromatic regions in interphase 
nuclei (Horsley, Hutchings et al. 1996, Minc, Allory et al. 1999, Nielsen, Ortiz et 
al. 1999, Minc, Courvalin et al. 2000). Perhaps surprisingly, this protein is thought 
to be involved in both the activation and repression of genes (see introduction 
section 1.4.2). Here, the role of HP1γ in gene regulation was studied systematically 
by transcriptomic analysis of cells with or without HP1γ. This study sought to 
provide better insight into the role of HP1γ in the regulation of gene expression and 
associated physiology.  
 
 
3.1.1 Mouse Embryonic fibroblasts (MEFs) are a good model for studying the 
role of HP1γ in gene regulation 
 
As mentioned in the introduction section 1.4.2, deletion of HP1γ is associated with 
neonatal lethality in mice when bred on a pure genetic background (Naruse, 
Fukusumi et al. 2007, Takada, Naruse et al. 2011). Furthermore, even with a mixed 
genetic background, only a small percentage of mice with HP1γ deletion were able 
to develop to adulthood (Brown, Bullwinkel et al. 2010, Takada, Naruse et al. 2011). 
Although the heterozygous HP1γ knockout mice with one Cbx3 gene (encoding 
HP1γ) disrupted show no phenotype and develop into adulthood, variation of HP1γ 
mRNA level was observed in the thymocytes obtained from these mice (Figure S11 
in appendix). Thus, study of alternative models with complete HP1γ deficiency 
would be likely to reveal more profound effects.  
 
In this project, mouse embryonic fibroblasts (MEFs) derived from E13.5 embryos 
from a cross between heterozygous HP1γ-KO mice were employed (see methods 
and material section 2.3.2.1). There is a 25% chance of getting wild type (WT) or 
homozygous knockout (HOM) embryos from this cross and the HP1γ WT and 
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HOM MEFs derived from these embryos were used for experiments. The 
expression level of HP1γ mRNA and protein were checked by qRT-PCR and 
western blot. Figure 3.1 shows that HP1γ mRNA levels were significantly reduced 
in HP1γ HOM MEFs, showing only 1.5% of that of the WT MEFs. Moreover, these 
cells showed undetectable level of HP1γ protein (Figure 3.1). Diminished level of 
HP1γ mRNA and protein in HP1γ HOM MEFs make it a good model for studying 
the loss of function of HP1γ. 
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   Figure 3.1 Expression of HP1γ in Mouse Embryonic fibroblasts (MEFs) derived from HP1γ homozygous knockout embryos. (A) Relative expression of HP1γ mRNA in HP1γ wild type (WT) and HP1γ homozygous knockout (HOM) mouse embryonic fibroblasts (MEFs). HP1γ HOM MEFs showed 1.5% of HP1γ mRNA comparing to WT MEFs. Student’s t-test: ***P<0.0001 compared to WT after being normalised against 18S expression. Error bars: SEM, n≥16. (B) Western blot analysis showing HP1γ protein level in HP1γ WT and HOM MEFs. HP1γ HOM MEFs showed undetectable HP1γ protein level. Alpha-tubulin (α-tubulin) was used as loading control. Western blots presented here are 3 representative experiments from MEFs derived from three 3 individual embryos.          
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3.1.2 HP1γ is implicated in both activating and repressing gene expression 
and the magnitude of effect is sex dependent 
 
In order to reveal the effect of HP1γ on global gene expression patterns in vivo, 
high-throughput sequencing was performed on the total RNA extracted (RNA-seq) 
from HP1γ WT and HOM MEFs. In this experiment, RNA extracted from three WT 
and three HOM MEF lines from both genders were analysed.  
 
Differentially expressed genes in response to HP1γ knockout were identified and 
the sample-to-sample distance (similarity) between technical and biological 
replicates from HP1γ WT and HOM MEFs were explored for both male and female 
by clustering analysis (Figure 3.2A and B). The results are displayed as the 
dendrogram in Figure 3.2A. The technical replicates (obtained from two individual 
sequencing reactions) from each sample showed high similarity whereby they 
found clustered together as shown by the dendrogram. Also, the high degree of 
similarity between replicates were indicated by the dark blue colour in the heat map 
which depicts a sample-to-sample distance matrix where low distance (high 
similarity) is represented by dark blue. Although the three male HP1γ WT and HOM 
samples were found in well-defined clusters according to their genotype, there was 
clearly variation between biological replicates which was greater in the HP1γ HOM 
samples than the WT samples. The cells were morphologically indistinguishable 
and had the characteristic appearance expected of fibroblasts which argues against 
clonal outgrowth as in explanation of the variation between biological replicates. In 
contrast, although high similarity between technical replicates was also observed, 
the female biological replicates of the same genotypes did not cluster together well. 
For example, the WT sample ‘WT1Frep1 and WT1Frep2’ clustered together with 
the HOM sample ‘HOM1Frep1 and HOM1Frep2’ as indicated by the dendrogram 
and the blue colour in the heat map. Also, the dendrogram of the female samples 
does not show clear branches to distinguish the WT and HOM samples. This data 
indicates that this experiment is technically sound with high similarity observed 
between technical replicates. The RNA-seq data obtained from male HP1γ WT and 
HOM MEFs show a high degree of similarity and is consistent between members 
within the same genotype group. However, relatively poor distinction between WT 
and HOM samples within females was revealed. Taken together, this result suggests 
111  
that the transcriptome male samples of the same genotype have a higher similarity 
compared to that of the female. This analysis suggests that HP1γ deficiency has a 
more profound effect in males than females.  
 
Indeed, our RNA-seq data revealed a much higher number of differentially 
expressed genes in male MEFs comparing to female MEFs. In response to HP1γ 
knockout, a total of 4293 (18.3% of total) and 1187 genes (5.1% of total) were 
differentially expressed with P-value<0.05 in males and females respectively. In 
male MEFs, 2645 genes (61.6% of total number of dysregulated genes) were 
upregulated and 1648 genes (38.4% of total number of dysregulated genes) were 
downregulated (Figure 3.3A) while only 1009 genes (85.1% of total number of 
dysregulated genes) were upregulated and 177 genes (14.9% of total number of 
dysregulated genes) were downregulated in female MEFs by at least 1.5 fold 
(Figure 3.3B). Also, the downregulated genes in female showed a smaller 
magnitude of fold change when compared to male. Importantly, the observed 
difference is unlikely to be a consequence of the difference in HP1γ expression level 
as no significant difference was observed between HP1γ mRNA level in WT male 
and female MEFs examined by qRT-PCR (Figure S12 in appendix). Interestingly, 
there was a higher number as well as a bigger degree of change of upregulated genes 
than downregulated genes revealed in both males and females suggesting that HP1γ 
may act more often as a silencer in the genome. This result indicates that HP1γ 
indeed plays a role in both activating as well as repressing gene expression in our 
cell model. Also, the different magnitude of effect of HP1γ on gene regulation 
observed in the two genders suggests that males have a higher dependency on HP1γ 
in maintaining their normal gene expression profile.  
 
In order to further investigate the similarities between male and female samples 
from each genotype, the top 30 expressed genes were sampled and the similarity in 
expression level of these genes were compared between the biological replicates. 
Heat maps were constructed to demonstrate the changes in expression level of these 
top 30 expression genes upon HP1γ knockout. Consistent with the clustering 
analysis presented above (Figure 3.2), high similarity was observed between 
technical replicates for both male and female samples as indicated by their similar 
colours on the heat maps (Figure 3.4A and B). Male samples of the same genotypes 
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show a very similar colour on the heat map for most of the genes tested indicating 
their high degree of similarity (Figure 3.4A). A number of differentially expressed 
genes were also revealed here. In particular, a strong effect was observed on the 
Igf2 gene which is subject to genomic imprinting. As shown in Figure 3.4A, all of 
the male WT MEF samples showed a higher expression level of the Igf2 gene (as 
indicated by dark blue colour) relative to HP1γ HOM MEFs (as indicated by pale 
green to white colour). Thus, deficiency in HP1γ results in repression of Igf2 gene 
(see below section 3.1.7). This data indicates a high consistency between male 
samples with the same genotype.  
 
Female samples of the same genotype also showed similar colour on the heat map 
for most of the sampled genes. However, the HP1γ HOM sample HOM3Frep1 and 
HOM3Frep2 showed different levels of expression of many of the genes when 
compared to the other two samples of the same genotype (Figure 3.4B). This 
particular sample was previously shown, in clustering analysis, to be furthest away 
from the wild type cluster (Figure 3.2B). For example, the expression of the Igf2 
gene which is dramatically downregulated in male HP1γ HOM MEFs (Figure 3.4A) 
was found to be variable in female samples (Figure 3.4B). Thus, the HOM3Frep1 
and HOM3Frep2, unlike the other female samples showed very low Igf2 expression 
compared to WT. This low level of Igf2 was similar to the previous observation in 
HP1γ HOM males (Figure 3.4A and B). In fact, more variation in Igf2 gene 
expression was observed in the WT female samples. For example, WT1Frep1 and 
WT1Frep2 showed higher Igf2 expression when compared to WT3Frep1 and 
WT3Frep2. Taken together, these data suggest that the expression profile between 
male MEFs of the same genotype is more consistent than females. Although a 
bigger effect of HP1γ was observed in male MEFs upon HP1γ knockout, certain 
females may also rely heavily on HP1γ for maintaining the expression level of 
certain genes.  
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  Figure 3.2 Clustering analysis of RNA-seq samples looking at similarities between samples. Sample clustering for RNA-seq data obtained from male (A) and female (B) HP1γ WT and HOM MEFs. Variance-stabilising transformation was applied to obtain this data. Dark blue colour of heat map represents zero (highly similar) distance while pale green colour represents a large distance (dissimilar). (A) Clustering analysis of samples from males HP1γ WT and HOM MEFs showed good clustering between technical replicates as well as biological replicates of the same genotype indicating the high similarity of these samples. Male WT samples and their technical replicates are: WT1Mrep1 and WT1Mrep2; WT2rep1 and WT2rep2; WT3rep1 and WT3rep2. Male HOM samples and their technical replicates are: 
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HOM1Mrep1 and HOM1Mrep2; HOM2Mrep1 and HOM2Mrep2; HOM3Mrep1 and HOM3Mrep2. (B) Female samples showed good clustering between technical replicates, however, the biological replicates did not. Female WT samples and their technical replicates are: WT1Frep1 and WT1Frep2; WT2Frep1 and WT2Frep2; WT3Frep1 and WT3Frep2. Female HOM samples and their technical replicates are: HOM1Frep1 and HOM1Frep2; HOM2Frep1 and HOM2Frep2; HOM3Frep1 and HOM3Frep2.   
 
 
 
A                                                  B         
      
Figure 3.3 Volcano plots demonstrating the differentially expressed genes in male and female HP1γ HOM MEFs relative to WT. Red and green dots represent genes that were down- or up-regulated by at least 1.5 fold respectively. Grey dots represent genes that are not significantly changed. X axes of these plots represent the log2 fold change of the differentially expressed genes while Y axes represent the –log2 P-value. (A) Male HP1γ HOM MEFs showed 2645 upregulated genes and 1648 downregulated genes which were differentially expressed by at least 1.5 fold relative to WT. (B) The effect of HP1γ knockout in female was much smaller compared to male. In female HP1γ HOM MEFs, only 1009 genes and 177 genes were up- or downregulated by at least 1.5 fold respectively. P-value<0.05, n=3.              
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Figure 3.4 Heat maps demonstrating the expression level of the top 30 expressed genes in males (A) and females (B) HP1γ WT and HOM MEFs. Variance-stabilising transformation was applied to obtain this data. The dark blue colour of the heat map represents high expression level while white colour represents low expression level. (A) Male HP1γ WT and HOM MEFs showed high degree of similarity in expression level between technical replicates as well as biological replicates in most cases as indicated by the colour on the heat map. Dysregulation of the Igf2 gene was revealed in which all of the male WT MEFs samples showed a higher expression level of this gene than HP1γ HOM MEFs. Male WT samples and their technical replicates are: WT1Mrep1 and WT1Mrep2; WT2rep1 and WT2rep2; WT3rep1 and WT3rep2. Male HOM samples and their technical replicates are: HOM1Mrep1 and HOM1Mrep2; HOM2Mrep1 and HOM2Mrep2; HOM3Mrep1 and HOM3Mrep2. (B) Female HP1γ WT and HOM MEFs showed high degree of similarity in expression level between technical replicates as well as biological replicates in most cases as indicated by the colour on the heat map. However, variation between biological replicates were observed in some genes including Igf2 between biological replicates of both WT and HOM. Female WT samples and their technical replicates are: WT1Frep1 and WT1Frep2; WT2Frep1 and WT2Frep2; WT3Frep1 and WT3Frep2. Female HOM samples and their technical replicates are: HOM1Frep1 and HOM1Frep2; HOM2Frep1 and HOM2Frep2; HOM3Frep1 and HOM3Frep2.         
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3.1.3 HP1γ regulates distinct subsets of genes in males and females  
 
The different magnitude of effect revealed in male and female HP1γ HOM MEFs 
prompted us to ask whether a common or distinct subset of genes were differentially 
expressed in male and female. For this, differentially expressed genes identified in 
male and female samples were compared and presented in a Venn diagram (Figure 
3.5). As shown in Figure 3.5, 2258 genes and 623 genes were found to be 
upregulated only in male or female respectively. Similarly, there are 1569 genes and 
97 genes which were downregulated only in male or female respectively. Two 
subsets of commonly regulated genes by both gender were also revealed. 378 genes 
and 71 genes are found up- or downregulated respectively in both male and female. 
Interestingly, two subsets of genes were found dysregulated in male and female in 
opposite directions in response to HP1γ knockout. There are 9 genes upregulated in 
male and downregulated in female while 8 genes were downregulated in male and 
upregulated in female. These genes together with the fold change in response to 
HP1γ deletion are listed in Table 3.1 and Table 3.2.  
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   Figure 3.5 Venn diagram demonstrating the common or different subsets of genes differentially expressed in male and female HP1γ HOM MEFs. Differentially expressed genes identified in male and female HP1γ HOM MEFs relative to WT were compared. Common or distinct subsets of genes that are regulated by HP1γ in male or female MEFs were revealed. Interestingly, genes that were differentially expressed in opposite directions in male and female were also revealed. Differentially expressed gene presented here are dysregulated for at least 1.5 fold with P-value<0.05. This figure is generated by Venny 2.0.2 (Oliveros, J.C. (2007-2015) Venny. An interactive tool for comparing lists with Venn's diagrams. (http://bioinfogp.cnb.csic.es/tools/venny/index.htm))                    
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Genes UPregulated in male and DOWNregulated in female in response to HP1γ knockout  
Fold UPregulation in male relative to WT Fold DOWNregulation in female relative to WT 
Gda 6.68 2.07 Ccl8 19.16 2.00 Spp1 2.46 2.41 Pgm2l1 1.90 1.56 Nxpe5 2.39 2.79 Fbxw10 1.90 1.66 Mmp13 2.64 2.14 Ppbp 2.22 2.62 Tgm2 1.69 1.52  Table 3.1 List of identified genes which are upregulated in male and downregulated in female MEFs in response to HP1γ deletion. A subset of genes were found dysregulated in male and female in opposite direction upon HP1γ knockout in which 9 genes were upregulated in male but downregulated in female as shown in this table.   
 
Genes DOWNregulated  in male and UPregulated in female in response to HP1γ knockout 
Fold DOWNregulation in male relative to WT Fold UPregulation in female relative to WT 
Mdk 2.07 2.23 Ppp2r2b 1.95 2.79 Adamtsl2 2.62 2.14 Hif3a 4.29 2.38 Slc2a4 2.91 2.17 Col26a1 2.99 2.11 Hnrnph3 1.67 1.55 Pappa2 2.20 1.95  Table 3.2 List of identified genes which are downregulated in male and upregulated female MEFs in response to HP1γ deletion. A subset of genes were found dysregulated in male and female in opposite direction upon HP1γ knockout in which 8 genes were downregulated in male but upregulated in female as shown in this table.             
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3.1.4 Gene Ontology (GO) analysis implicates HP1γ in important biological 
processes  
 
In order to investigate the physiological functions influenced by the loss of HP1γ, 
Gene Ontology (GO) analysis was employed to identify functional groupings of the 
differentially expressed genes. Due to the difference in magnitude of effect 
observed in males and females as shown in the previous section, this analysis was 
done separately on male and female samples.  
 
As expected, a much higher number of functional groups were associated with 
dysregulated gene in males compared to females. GO analysis revealed a total of 
486 and 539 functional groups associated with genes upregulated and 
downregulated upon HP1γ deletion respectively in males (Table S1 and S2 in 
appendix). In contrast, there are only 5 and 70 functional groups associated with 
genes upregulated and downregulated respectively upon HP1γ deletion in females 
(Table S3 and S4 in appendix). This result suggest that males have a higher 
dependency on HP1γ in maintaining their normal functions.  
 
 
3.1.4.1 GO analysis of the effect of HP1γ deficiency in males  
 
Among the affected biological processes (BP) associated with genes downregulated 
upon HP1γ deletion in male, enrichment of certain functional groups were observed. 
These enriched functional groups include those related to cell cycle and RNA 
processing which is consistent with previously published studies: RNA processing 
(Saint-Andre, Batsche et al. 2011, Smallwood, Hon et al. 2012), cell cycle 
progression (Abe, Naruse et al. 2011) and chromatid segregation (Obuse, Iwasaki 
et al. 2004, Serrano, Rodriguez-Corsino et al. 2009, Shimura, Toyoda et al. 2011, 
Grzenda, Leonard et al. 2013) (Table S2 in appendix). 
 
Relatively less pronounced enrichment of groups related to DNA damage response, 
regulation of gene expression, and some histone/chromatin related groups were also 
observed. Enrichment of functional groups in regulation of gene expression and 
histone/chromatin related processes is consistent with the role of HP1γ being an 
120  
epigenetic modifier involved in regulation of gene expression (Reviewed in - 
Hiragami and Festenstein 2005, Kwon and Workman 2011). Moreover, that HP1γ 
has been implicated in DNA damage repair has been previously suggested by a 
number of studies (Lee, Kuo et al. 2013, Soria and Almouzni 2013, Akaike, 
Kuwano et al. 2014, Wu, Nishikawa et al. 2015).  
 
Interestingly, these functional groups are almost exclusively associated with genes 
downregulated upon loss of HP1γ implying that the presence of HP1γ is important 
for maintaining the expression level of these genes and hence their associated 
biological functions. The question arises as to how HP1γ maintains transcriptional 
activity of these genes (see discussion section 4.1).  
 
Within the group of genes upregulated upon HP1γ deletion, there was enrichment 
of a large number of functional groups related to regulation of immune responses 
including immune-cell specific processes (Table S1 in appendix). Given that the 
cell model we used in this experiment is a fibroblast and not a specialised immune 
cell, this result suggests that HP1γ might be involved in maintaining the cell type 
specific silencing of genes. For further analysis of this dataset addressing cell-type 
specificity see section 3.15.   
 
 
3.1.4.2 GO analysis of the effect of HP1γ deficiency in females  
 
Enrichment of functional groups related to cell cycle were also found to be 
associated with downregulated genes in females (Table S4 in appendix). However, 
a smaller number of these groups were observed associated with female when 
compared to male. This difference in number suggests that regulation of cell cycle 
may also be affected in female MEFs in response to knockout of HP1γ. However, 
the magnitude of the effect is likely to be smaller.   
 
There are only 5 functional groups associated with upregulated gene in female in 
response to HP1γ knockout and none of these groups were related to regulation of 
immune response which has been observed in male (Table S3 in appendix). 
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Collectively, these data suggest that HP1γ is indeed playing diverse roles: positively 
regulating genes for essential cellular processes as well as negatively regulating 
genes for cell type specific functions. Also, this experiment implicates that HP1γ in 
the regulation of important biological processes in MEFs. However, an unbiased 
analysis is required to test for the significance of this observation (see next section). 
Moreover, the higher number of affected biological processes revealed in males 
compared with females suggest that males have a higher dependency on HP1γ for 
maintaining their normal gene expression profile.  
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3.1.5 Statistical overrepresentation test implicates HP1γ in important 
biological processes 
 
In order to have an unbiased way to confirm the observed enrichment of functional 
groups with the GO analysis presented in section 3.1.4, a statistical 
overrepresentation test (Mi, Muruganujan et al. 2013) was employed. In this 
analysis, dysregulated genes associated with males or females in response to HP1γ 
knockout were compared to the mouse reference gene list and the fold enrichment 
of significantly over- or underrepresented GO biological processes were determined 
(Table S5 to S8 in appendix). The definition of the top 10 overrepresented biological 
processes can be found in appendix Table S9 to S12.  
 
In general, genes dysregulated in males showed a higher number of significantly 
(P<0.05) over- and underrepresented BP groups than females. A total of 41 and 39 
groups were found to be associated with genes upregulated and downregulated upon 
HP1γ deletion respectively in males (Table S5 and S6 in appendix). In contrast, 
there were only 22 and 9 functional groups associated with genes upregulated and 
downregulated respectively upon HP1γ deletion in females (Table S7 and S8 in 
appendix). 
 
 
3.1.5.1 Statistical overrepresentation test of the effect of HP1γ deficiency in 
males  
 
Consistent with the observation reported in the previous section (section 3.1.4), 
analysis of downregulated genes in HP1γ HOM males revealed overrepresentation 
of groups related to cell cycle and RNA processing (Table S6 in appendix). Among 
the processes related to cell cycle, ‘regulation of cell cycle’ showed the highest 
enrichment of 6.94 fold. ‘Regulation of cell cycle’ is also the highest enriched group 
revealed among the whole list. The group ‘chromosome segregation’ also showed 
high enrichment of 4.12 fold. Other cell cycle related groups revealed include 
‘mitosis’ (2.49 fold enriched) and ‘cell cycle’ (2.05 fold enriched). All of the 
revealed groups related to RNA processing showed a similar magnitude of 
overrepresentation. These groups include ‘mRNA splicing, via spliceosome’ (3.16 
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fold enriched), ‘RNA splicing, via transesterification reactions’ (2.82 fold enriched), 
‘RNA splicing’ (2.76 fold enriched) and ‘mRNA processing’ (2.39 fold enriched). 
Moreover, ‘DNA repair’ which was observed in the GO analysis as presented in the 
previous section (section 3.1.4) was also found to be overrepresented with an 
enrichment of 3.95 fold.  
 
Consistent with the observation reported in the previous section (section 3.1.4), 
enrichment of processes related to the immune response were found to be associated 
with the upregulated genes in males in response to HP1γ knockout (Table S5 in 
appendix). These processes include some relatively general functions which can 
potentially be found in many cell types: ‘response to interferon-gamma’ (3.61fold 
enriched), ‘antigen processing and presentation’ (3.37 fold enriched), ‘Immune 
response’ (2.08 fold enriched), and ‘Immune system process’ (1.92 fold enriched). 
Also, processes which are apparently specific to immune cells were revealed. These 
processes include the ‘B cell mediated immunity’ (2.42 fold enrichment) which was 
defined as "any process involved with the carrying out of an immune response by a 
B cell, through, for instance, the production of antibodies or cytokines, or antigen 
presentation to T cells" and ‘macrophage activation’ (2.28 fold enrichment) which 
was defined as "a change in morphology and behaviour of a macrophage resulting 
from exposure to a cytokine, chemokine, cellular ligand, or soluble factor". The 
genes contributing to these immune cell specific processes are shown in Table S13 
and S14 in appendix. Indeed, some of these genes were specific to B cell or 
macrophage functions perhaps indicating that HP1γ might be regulating tissue 
specific gene expression and prevently inappropriate expression in male MEFs.  
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3.1.5.2 Statistical overrepresentation test of the effect of HP1γ deficiency in 
females  
 
Unlike the male samples and the GO analysis presented in the previous section, the 
statistical overrepresentation test of the downregulated genes in female HP1γ HOM 
MEFs did not reveal overrepresentation of groups related to cell cycle, RNA 
processing and DNA repair (Table S8 in appendix). Rather, most of the 
overrepresented groups revealed are related to developmental processes.  
 
In contrast to the data obtained from male MEFs, none of the overrepresented BP 
groups associated with upregulated genes in female HP1γ HOM MEFs are related 
to regulation of immune response (Table S7 in appendix). Instead, 
overrepresentation of some processes involved in cell adhesion were revealed. All 
of these groups showed similar levels of enrichment. ‘Cell-cell adhesion’ showed 
3.51 fold enrichment while ‘cell adhesion’ and ‘biological adhesion’ showed 2.88 
and 2.75 fold enrichment respectively.  
 
Taken together, the results obtained from the statistical overrepresentation test are 
largely in line with the GO analysis. Data obtained suggest that HP1γ is implicated 
in regulation of important biological processes in both male and female MEFs. In 
the analysis of male samples, HP1γ was shown to play diverse roles: positively 
regulating genes for essential cellular processes (cell cycle, RNA processing and 
DNA damage response) as well as negatively regulating genes for cell type specific 
functions (B cell and macrophage mediated immunity). The higher number of over- 
and underrepresented biological processes revealed in males compared with 
females suggests that males have a higher dependency on HP1γ for maintaining 
their normal gene expression profile. However, the level of dependency on HP1γ 
for males and females may actually be process-specific in that the GO terms 
obtained from female samples were different from that of the males. These results 
therefore may reflect sexual dimorphism in both gene expression and response to 
HP1 deficiency. It is possible that HP1 is compensating for an underlying difference 
in gene expression between the sexes that is due to the different sex chromosome 
complement (XX versus XY).    
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3.1.6 HP1γ is implicated in regulation of sexually dimorphic expression of 
genes  
 
Observed differences between the sexes in response to HP1γ knockout (Figure 3.3) 
prompted as to ask whether HP1γ plays a role in regulating sexually dimorphic 
expression of genes. To address this question, I firstly identified the genes that are 
differentially expressed in HP1γ WT male and female MEFs (Figure 3.6 and Figure 
3.7). Thus, 176 genes were found to be differentially expressed by at least 1.5 fold 
(P-value <0.05) in HP1γ WT male and female MEFs (Figure 3.6 and Figure 3.7, 
Table S15 and S16 in appendix). 114 genes had higher expression in females while 
62 genes had higher expression in males (Figure 3.6 and Figure 3.7). Among these 
176 sexually dimorphic genes, 10 of them are X- or Y-linked genes (Figure 3.7, 
yellow and red dots) while 166 genes are autosomal genes (Figure 3.7, blue dots). 
As expected, the Y chromosome genes were only expressed in males while the X 
chromosome genes were expressed in both sexes (Figure 3.7).  
 
Next, the sensitivity of these 176 sexually dimorphic genes to HP1γ deficiency was 
tested in both male and female. In response to HP1γ knockout, 121 of the sexually 
dimorphic genes were dysregulated by at least 1.5 fold (P-value <0.05) in males 
(Figure 3.8A). Among these 121 dysregulated genes, 86 (71.1% of total number of 
dysregulated genes) of them were upregulated while 35 (28.9% of total number of 
dysregulated genes) of them were downregulated upon HP1γ knockout (Figure 
3.8A). The percentage of upregulated sexually dimorphic genes (86/176 i.e. 48.9%) 
was significantly enriched in this subset of genes compared to the percentage of the 
total number of upregulated genes (2645/23420 i.e. 11.3%) in males (Chi-square 
test: P<0.0001). The number of dysregulated genes was much lower in females 
where only 38 genes were significantly changed (Fold change >1.5 fold, P-value 
<0.05) (Figure 3.8B). 20 (~52.6% of total number of dysregulated genes) and 18 
(47.4% of total number of dysregulated genes) genes were up- and downregulated 
respectively in female HP1γ HOM MEFs (Figure 3.8B). In females, the percentage 
of upregulated sexual dimorphic genes (38/176 i.e. 21.6%) was also enriched 
compared to the percentage of the total number of upregulated genes (1009/23420 
i.e. 4.3%) (Chi-square test: P<0.0001). 
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The higher number of upregulated than downregulated genes revealed in both males 
and females suggests that HP1γ acts more often as a silencer to repress the 
expression of these sexually dimorphic genes. Also, the higher magnitude of effect 
(number of dysregulated genes) of HP1γ on the regulation of sexually dimorphic 
genes in males suggests that males have a higher dependency on HP1γ for 
maintaining the expression level of these sexual dimorphic genes which are set at a 
lower level in WT males than WT females.   
 
In order to investigate whether HP1γ is playing a role in maintaining the gender-
specific expression of the sexually dimorphic genes, the genes that are expressed at 
a relatively higher level in males (62 genes) (Figure 3.10A) or females (114 genes) 
(Figure 3.9A) were tested for their sensitivity to HP1γ deficiency separately in 
males and females. 82 genes out of the 114 genes that are expressed at a higher level 
in WT females were significantly changed upon HP1γ knockout in males (Figure 
3.9B). Strikingly, all of these genes were upregulated in the absence of HP1γ 
(Figure 3.9B). This result suggests that in a WT condition, HP1γ may prevent these 
genes from being much higher in males and hence maintain the difference between 
males and females. In female, most of these genes (91 genes out of 114 genes) were 
not significantly changed (Figure 3.9C). Among the 23 dysregulated genes, 7 and 
16 genes were up- and downregulated in female HP1γ HOM MEFs respectively 
(Figure 3.9C).  
 
The 62 genes that are expressed at a higher level in WT males were also analysed 
(Figure 3.10A). In male, 38 of these genes were dysregulated significantly (Figure 
3.10B). Most of these dysregulated genes were downregulated upon HP1γ knockout 
(35 genes) while only 3 genes were upregulated (Figure 3.10B) indicating that in 
males most of these genes require HP1γ to keep them at a higher level than that 
seen in females. In contrast, out of the 15 dysregulated genes in female, except 2 
gene, all of these genes were upregulated in response to HP1γ knockout (Figure 
3.10C). This indicates that in females HP1γ plays a predominantly repressive role 
on this group of genes. Overall, this result again suggests HP1γ may be playing a 
role in maintaining the expression level of these sexual dimorphic genes in both 
males and females and hence to maintain the difference between the two genders.  
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Figure 3.6 Volcano plot demonstrating the differentially expressed genes in HP1γ WT male and female MEFs. Red and green dots represent genes that were differentially expressed by at least 1.5 fold. Grey dots represent genes that are not significantly changed. X axes of these plots represent the log2 fold change of the differentially expressed genes while Y axes represent the –log2 P-value. Out of the total of 176 differentially expressed genes, 114 genes have higher expression in female while 62 genes have higher expression in male. Fold change >1.5, P<0.05, n=3.       
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  Figure 3.7 Density plot of differentially expressed genes comparing HP1γ WT male and female MEFs. Blue dots represent autosomal genes that were differentially expressed by at least 1.5 fold when comparing males and females. Green and red dots represent the sexually dimorphic X- and Y-linked genes respectively. Grey dots represent genes that are not significantly changed. Dotted black line indicates fold change of 1. 176 genes were found to be differentially expressed in WT male and female MEFs by at least 1.5 fold. Among these 176 differentially expressed genes, 114 genes were expressed at a higher level in females (genes represented by the dots below the orange line) while 62 genes were expressed at a higher level in males (genes represented by the dots above the orange line). Fold change >1.5, P<0.05, n=3.                    
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Figure 3.8 Density plots showing the effect of HP1γ deficiency on the expression of the 176 sexually dimorphic genes identified in male and female MEFs. Blue dots represent autosomal genes that were differentially expressed by at least 1.5 fold when comparing WT and HP1γ deficient MEFs (HOM). Pink dots represent the sexually dimorphic Y-linked genes that were not significantly changed. Light green dots represent the sexually dimorphic X-linked genes that were not significantly changed. Green dot represents the sexually dimorphic X-linked gene that was significantly changed upon HP1γ knockout. Grey dots represent the sexually dimorphic genes that are not significantly changed upon HP1γ knockout. Dotted black line indicates fold change of 1. (A) In response to HP1γ knockout, 121 of the 
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sexual dimorphic genes were dysregulated by at least 1.5 fold in male. 86 genes were upregulated (genes represented by the dots above the black line) while 35 genes were downregulated (genes represented by the dots below the balck line). (B) A relatively milder effect was observed in female in which only 38 genes were significantly changed by at least 1.5 fold. 20 genes and 18 genes were up- (genes represented by the dots above the black line) and downregulated (genes represented by the dots below the black line) respectively in female HP1γ HOM MEFs. Fold change >1.5, P<0.05, n=3.                                                 
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Figure 3.9 Density plots demonstrating the changes in the expression level of the 114 sexually dimorphic genes with higher expression level in WT female MEFs in response to HP1γ knockout in both genders. Blue dots represent autosomal genes that were differentially expressed by at least 1.5 fold. Green and red dots represent the significantly changed sexually dimorphic X- and Y-linked genes respectively. Pink dots represent the sexually dimorphic Y-linked genes that were not significantly changed. Light green dots represent the sexually dimorphic X-linked genes that were not significantly changed. Grey dots represent genes that are not significantly changed. Dotted black line indicates fold change of 1. (A) There are 114 genes which are expressed at a higher level in WT female MEFs compared to WT male MEFs. (B) In male MEFs, 82 of these 114 sexual dimorphic genes were dysregulated in absence of HP1γ. All of these 82 dysregulated genes were downregulated. (C) In female MEFs, 23 of these 114 sexual dimorphic genes were dysregulated in absence of HP1γ. 7 and 16 genes were up- and downregulated upon HP1γ knockout. Fold change >1.5, P<0.05, n=3.                                       
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Figure 3.10 Density plots demonstrating the changes in the expression level of the 62 sexually dimorphic genes which have higher expression level in WT male MEFs in response to HP1γ knockout in both genders. Blue dots represent autosomal genes that were differentially expressed by at least 1.5 fold. Green and red dots represent the significantly changed sexually dimorphic X- and Y-linked genes respectively. Pink dots represent the sexually dimorphic Y-linked genes that were not significantly changed. Light green dots represent the sexually dimorphic X-linked genes that were not significantly changed. Grey dots represent genes that are not significantly changed. Dotted black line indicates fold change of 1. (A) There are 62 genes which are expressed at a higher level in WT male MEFs compared to WT female MEFs. (B) In male MEFs, 38 of these 62 sexual dimorphic genes were dysregulated in absence of HP1γ. 35 out of 38 dysregulated genes were downregulated. (C) In female MEFs, 15 of these 62 sexual dimorphic genes were dysregulated in absence of HP1γ. 13 of these dysregulated genes were upregulated except 2 genes which was downregulated. Fold change >1.5, P<0.05, n=3.                                         
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3.1.7 HP1γ is implicated in regulation of a subset of imprinted genes 
 
As mentioned in section 3.1.2 of this chapter, dysregulation of the imprinted gene 
Igf2 was revealed in male MEFs in response to HP1γ knockout (Figure 3.4A). This 
finding prompted us to ask whether other imprinted genes were also affected.  
 
Out of the 121 imprinted genes on our gene list, 13 genes showed no reads from the 
RNA-seq data obtained. 49 imprinted genes (~40% of total number of imprinted 
genes) were found to be dysregulated by at least 1.5 fold with an adjusted P-value 
<0.05 upon HP1γ knockout (Figure 3.11). The percentage of dysregulated imprinted 
genes was significantly enriched compared to percentage of total dysregulated 
genes (~24%) of total number of gene in male (Chi-square test: P<0.0001). Among 
the 49 affected imprinted genes, 17 and 32 of these genes were up- and 
downregulated respectively (Figure 3.11) (Table S17 and S18 in appendix). This 
differs from the proportion of total genes affected (section 3.1.2) where more 
affected genes were upregulated, here more of the affected imprinted genes were 
downregulated. Interestingly, two of the most dramatically downregulated genes 
are the Igf2 and H19 genes which were downregulated by 12.9 and 13.3 fold 
respectively in response to HP1γ knockout (Figure 3.12).  
 
As mentioned in the introduction section 1.5, Igf2 and H19 genes are located in the 
same locus and are reciprocally expressed from both alleles according to the 
parental inheritance. In order to reveal whether imprinting is affected, methodology 
which is able to distinguish allelic specific expression is required. However, in this 
case RNA-seq cannot distinguish the allelic origin of the transcripts, and therefore 
we cannot determine whether genomic imprinting of the Igf2/H19 cluster is affected 
in response to HP1γ knockout.  
 
However, if the imprint of the Igf2/H19 cluster is dependent on HP1γ, upon its 
removal, one might expect to see upregulation of H19 and downregulation of Igf2 
genes (Figure 3.13B). Instead, dramatic downregulation to the same degree 
(approximately 13 fold) was observed for both Igf2 and H19 genes upon HP1γ 
knockout. This result suggests that imprinting of this locus is unlikely to be affected. 
Rather, mechanisms which regulate expression of both genes may be affected. 
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Hence, we speculate that HP1γ might be involved in regulating activity of the 
common enhancer of Igf2 and H19 genes (Figure 3.13C). However, this hypothesis 
has to be addressed by further experiments.  
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 Figure 3.11 Fold change of imprinted genes upon HP1γ knockout in male MEFs. Deficiency of HP1γ in male MEFs led to dysregulation of 49 imprinted genes by at least 1.5 fold. 17 and 32 of these dysregulated genes were up- and downregulated respectively. Adjusted P-value <0.05, n=3.   
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Figure 3.12 Expression of Igf2 (A) and H19 (B) mRNA in HP1γ WT and HOM MEFs. RNA-seq revealed downregulation of Igf2 (A) and H19 (B) mRNA expression by 12.9 and 13.3 fold respectively in response to HP1γ knockout. Mean expression represent the average of counts normalised by size factors (total number of reads). ***Adjusted P-value <0.0001, n=3.      
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   Figure 3.13 Schematic diagram demonstrating the putative model of regulation of the Igf2/H19 gene cluster. (A) Model of the regulation of Igf2/H19 gene cluster in the wild type situation. In wild type, methylation of the paternal ICR1 prevents binding of CTCF. The common enhancer can then act on the Igf2 gene and allow its paternal expression. Binding of CTCF to ICR1 on the unmethylated maternal allele prevents the common enhancer from acting on the Igf2 gene. Maternal H19 is hence expressed. Our data showed that removal of HP1γ caused dramatic downregulation of both Igf2 and H19 genes to the same degree. This result suggests that HP1γ might be involved in regulating activity of the common enhancer of Igf2 and H19 genes by an unknown mechanism (see also Figure 3.13C). (B) Putative model of the regulation of Igf2/H19 gene cluster if the maternal imprint has failed. 
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In this case, diminished DNA methylation on the ICR1 of the paternal allele allows binding of CTCF. CTCF on the paternal allele would block the enhancers from acting on the Igf2 gene. In this situation, both paternal and maternal H19 would be expressed causing overall upregulation of the H19 gene. On the other hand, both paternal and maternal Igf2 are repressed causing overall downregulation of the Igf2 gene. (C) Putative model for the regulation of Igf2/H19 gene cluster if enhancer function failed. In the case where enhancer mediated activation is compromised, both paternal Igf2 and maternal H19 which are both active in the wild type situation, would be repressed. Hence, overall expression of both H19 and Igf2 gene would be downregulated.   
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3.1.8 Summary of result section 3.1  
 
This section focused on the role of HP1γ in the regulation of gene expression. The 
main findings were as follows: 
 
1. HP1γ deficient MEFs were created and shown to have no HP1γ expression 
providing a model system for studying the role of HP1γ ex vivo.  
 
2. Transcriptomic analysis shows that HP1γ plays a role in both activating and 
repressing gene expression in MEFs 
 
3. HP1γ regulates distinct subsets of genes in males and females 
 
4. The transcriptome of samples are more consistent amongst males within the 
same genotype group than females 
 
5. The higher number of differentially expressed genes revealed in male MEFs 
compared to female MEFs suggests that males have a higher dependency on 
HP1γ in maintaining their gene expression profile. 
 
6. HP1γ is implicated in regulating important biological processes and 
silencing of tissue specific genes. Difference in the number of biological 
processes in MEFs from the two genders suggests that males have a higher 
dependency on HP1γ for maintaining their normal function.  
 
7. HP1γ is implicated in regulation of sexually dimorphic expression of genes 
 
8. HP1γ is implicated in regulation of a subset of imprinted genes. In the case 
of the Igf2/H19 imprinted cluster, HP1γ might be involved in regulation of 
the common enhancer and is required for high-level expression of both 
genes.   
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3.2 Investigation into the role of HP1γ in the regulation of heterochromatin  
 
 
3.2.1 Loss of HP1γ causes derepression of mouse major satellite transcripts  
 
The pericentromere of the mouse chromosome is a distinct chromatin structure that 
is adjacent to the centromere in the long arm of the chromosome (Reviewed in - 
Mouse Genome Sequencing, Waterston et al. 2002, Hall, Mitchell et al. 2012). It is 
composed predominately of the highly repetitive major satellite (Mj-sat) element 
(Joseph, Mitchell et al. 1989) and characteristic features consist of DNA 
methylation (Lewis, Meehan et al. 1992) and histone modifications H3K9me3 and 
H4K20me3 (Peters, O'Carroll et al. 2001, Lehnertz, Ueda et al. 2003, Schotta, 
Lachner et al. 2004).  
 
Transcripts derived from the pericentromere, the so-called pericentric transcripts, 
were detected in various organisms including S. pombe, mouse and human 
(Reviewed in - Eymery, Callanan et al. 2009). In mammals, pericentric transcripts 
are normally expressed at low level (Eymery, Horard et al. 2009) and their 
expression has been considered to be a characteristic of instability and loss of 
integrity of heterochromatin (Eymery, Horard et al. 2009, Wang, Zhou et al. 2013) 
and thus a likely prerequisite for oncogenesis (Eymery, Callanan et al. 2009, 
Eymery, Horard et al. 2009). In fact, upregulation of these transcripts has not only 
been observed in some of the human cancers (Eymery, Horard et al. 2009, Ting, 
Lipson et al. 2011) but also a variety of processes including stress response, 
development, cell differentiation and potentially heterochromatin formation in 
mammals (Reviewed in - Eymery, Callanan et al. 2009). Although it is still unclear 
as to how the expression of these transcripts in mammals is regulated, the observed 
upregulation of these transcripts with these various processes indicates the 
importance in controlling the expression of these transcripts for maintenance of 
genome stability.   
 
In the previous section (result section 3.1.2), transcriptomic analysis showed that 
HP1γ is involved in both activation and repression of euchromatic genes. In order 
to elucidate its function in pericentric heterochromatin, HP1γ WT and HOM MEFs 
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were examined for their Mj-sat expression by qRT-PCR. Deficiency of HP1γ in 
MEFs led to an average of 5 fold (range from 3.1 to 37.6 fold) upregulation of Mj-
sat relative to WT (Figure 3.14A). In view of the difference in magnitude of effect 
previously observed following transcriptomic analysis of male and female MEFs 
(see result section 3.1.2), this data was also analysed for the two genders 
individually. Figure 3.14B showed that there is no significant difference between 
the expression level of Mj-sat in male and female WT MEFs (Figure 3.14B). In 
response to HP1γ knockout, both sexes showed similar levels of upregulation of 
Mj-sat expression in which the male and female MEFs have an average of 4.8 fold 
(range from 6.8 to 45.3) and 5.1 fold (range from 3.1 to 37.6 fold) upregulation 
relative to WT respectively (Figure 3.14C and D). Moreover, analogous effects have 
been observed in a human cell line. In HeLa cells, short hairpin RNA (shRNA)-
mediated knockdown of HP1γ led to an average of 5.5 and 14.4 fold upregulation 
of the human pericentric repeat elements α-satellite  and γ-satellite variant II (γ-
satellite II) expression relative to scramble control (Scr) respectively (Figure 3.15). 
Taken together, these results suggested that HP1γ is a regulatory factor maintaining 
heterochromatin silencing. This effect is not gender-specific in mice and potentially 
conserved in human.  
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Figure 3.14 Relative expression of major satellite in HP1γ WT and HOM MEFs. (A) Deficiency of HP1γ in MEFs led to an average of 5 fold upregulation of major satellite (Mj-sat) in HP1γ HOM MEFs relative to WT. (B) Male and female HP1γ WT MEFs showed similar level of Mj-sat expression. (C and D) Both male and female MEFs showed approximately 5 fold upregulation of Mj-sat expression in absence of HP1γ. Student’s t-test: ***P<0.001 (compared to WT after being normalised against 18S expression). Error bars: SEM. n≥27 for (A); n≥12 for (B and C); n≥15 for (D). 
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 Figure 3.15 Relative expression of α-satellite and γ–satellite (II) in HeLa cells upon shRNA-mediated HP1γ knockdown. (A) HP1γ mRNA levels were significantly reduced in HeLa upon shRNA-mediated knockdown by HP1γ-targeting lentivirus (shHP1γ2) to 10.3% of that of the non-targeting control with scrambled shRNA sequence (Scr). (B and C) Upon knockdown of HP1γ, α-satellite and γ –satellite (II) were upregulated by an average of 5.5 and 14.4 fold respectively. Student’s t-test: **P<0.005; *P<0.05; ns = not significant (relative to scramble control (Scr) after being normalised against β-actin expression). Error bars: SEM. n=3.                     
145  
3.2.2 Loss of HP1γ does not affect H3K9me3 and HP1α nuclear distribution 
but HP1β is redistributed in passage 1 nuclei 
 
The upregulation of Mj-sat expression in HP1γ HOM MEFs prompted us to ask 
whether the epigenetic signature of pericentric heterochromatin is disrupted in these 
cells. As mentioned previously (section 3.2.1), heterochromatin is characterised by 
its highly condensed structure and enrichment of the histone mark H3K9me3 which 
provides a binding site for the HP1 proteins (Bannister, Zegerman et al. 2001, 
Lachner, O'Carroll et al. 2001). Thus, the integrity of heterochromatin was 
examined using immunofluorescence microscopy to look at the staining pattern for 
4',6-diamidino-2-phenylindole (DAPI) (for staining of DNA dense region), and 
deposition of the silencing histone mark H3K9me3 as well as heterochromatic HP1 
isoforms HP1α and HP1β in HP1γ WT and HOM MEF cells.  
 
Firstly, the knockout phenotype of HP1γ HOM MEFs was confirmed by 
immunofluoresence staining with HP1γ-targeting antibody in which no detectable 
signal of HP1γ was obtained in these cells (Figure 3.16C and D, right panels). This 
also acted as a negative control for HP1γ antibody demonstrating that it is highly 
specific. In response to HP1γ depletion, the staining pattern of DAPI did not show 
significant difference (Figure 3.16A to D, left panels) indicating condensed 
heterochromatin is still present in these cells. Consistent with previous studies, 
HP1γ was detected in both euchromatin and heterochromatin compartments (Figure 
3.16 A and B, right panels) (Minc, Allory et al. 1999, Nielsen, Ortiz et al. 1999, 
Kourmouli, Theodoropoulos et al. 2000, Minc, Courvalin et al. 2000, Nielsen, 
Oulad-Abdelghani et al. 2001). Two different staining patterns for HP1γ were 
observed in HP1γ WT MEFs: pan-nuclear distribution (81.9%) (Figure 3.16A) and 
its concentration within DAPI-dense regions (18.1%) (Figure 3.16B). These 
different distribution patterns might reflect different stages of the cell cycle (Minc, 
Allory et al. 1999).  
 
As expected, staining of H3K9me3 of WT MEFs showed clear and distinct co-
localisation with DAPI-dense regions (Figure 3.17A, right panel). However, no 
significant differences were observed with the depletion of HP1γ (Figure 3.17B, 
right panel). The level of H3K9me3 on pericentric heterochromatin was also 
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examined by chromatin immunoprecipitation (ChIP) in WT and HP1γ HOM MEFs. 
Figure 3.20A shows that the HP1γ level on Mj-sat was dramatically reduced in 
HP1γ HOM MEFs compared to WT. In response to the reduction of HP1γ, no 
significant change was observed in H3K9me3 enrichment on Mj-sat as determined 
by ChIP (Figure 3.20B). These results suggest that large scale loss of H3K9me3 is 
unlikely to be responsible for the derepression of heterochromatin transcripts 
observed in HP1γ HOM MEF. It is also consistent with a recent study showing that 
HP1 proteins are dispensable for the establishment of SUV39H-mediated 
H3K9me3 accumulation at the pericentromeric region (Muramatsu, Singh et al. 
2013).  
 
The nuclear localisation pattern of the other two HP1 isoforms (HP1α and HP1β) 
was also tested in the presence and absence of HP1γ. Consistent with previous 
studies, about 97% and 79% of the nuclei stained with anti-HP1α (Figure 3.18A, 
right panel) and anti-HP1β (Figure 3.19A, right panel)  antibody respectively 
showed distinct, but not exclusive association with heterochromatic regions as 
revealed by DAPI staining in WT MEFs  (Minc, Allory et al. 1999, Nielsen, Ortiz 
et al. 1999, Kourmouli, Theodoropoulos et al. 2000, Minc, Courvalin et al. 2000, 
Nielsen, Oulad-Abdelghani et al. 2001). Both HP1α and HP1β were also found 
diffusely staining the nucleus in a small proportion of cells (3% for HP1α (Figure 
3.18B, right panel) and 21% for HP1β (Figure 3.19B, right panel)). In contrast, 
immunoflourescent labeling of HP1γ revealed that the majority of nuclei showed a 
diffuse pan-nuclear pattern (82%) (Figure 3.16A), while a small proportion of 
nuclei (18%) showed co-localisation of HP1γ with DAPI-dense regions (Figure 
3.16B). In response to deficiency of HP1γ, no dramatic changes were observed in 
the distribution pattern of HP1α indicating that recruitment of HP1α to 
heterochromatic regions is independent of HP1γ (Figure 3.18C, right panel). 
Strikingly, the proportion of cells that showed pan-nuclear distribution of HP1β 
increased from 21.2% in the wild type to 74% in HP1γ HOM MEFs (Figure 3.19A 
and C, right panel). As previous analysis of MEFs from these mice showed no 
disruption in the cell cycle this shift in distribution of patterns of staining are 
unlikely to reflect skewing of the cell cycle. It is possible that following removal of 
HP1γ which is known to target euchromatic regions, HP1β is now redistributed to 
these sites (see discussion section 4.5). Expression levels of HP1α and HP1β mRNA 
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were then examined by qRT-PCR. Figure 3.21 shows that both HP1γ WT and HOM 
MEFs had similar levels of HP1α and HP1β mRNA. This data indicates that the 
different staining pattern of HP1β in HP1γ HOM MEFs is unlikely to be due to 
changes in the expression level of this protein. Table 3.3 (page 152) summarises the 
number of nuclei in passage 1 with different staining patterns scored and their 
percentage of total.  
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Figure 3.16 Immunofluorescence analysis of HP1γ in HP1γ WT and HOM MEFs. Representative images of nuclei of different genotype are shown. (A and B) HP1γ WT MEFs stained with anti-HP1γ antibody displayed two different patterns of HP1γ: pan-nuclear distribution and the preferential distribution concentrated within DAPI-dense region. (A to D) No significant difference in DAPI pattern was observed in HP1γ WT and HOM MEFs. (C and D) No detectable signal of HP1γ was obtained in HP1γ HOM MEFs demonstrating the high specificity of antibody. Percentages of counted nuclei that displayed the described phenotype are indicated by white text at the bottom right corners of the images. Scale bar, 5μm. These images were generated by Leica widefield fluorescence microscope and analysed with ImageJ. 
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  Figure 3.17 Immunofluorescence analysis of H3K9me3 in HP1γ WT and HOM MEFs. Representative images of nuclei of different genotype are shown. (A) WT MEFs showed clear and distinct co-localisation of H3K9me3 and DAPI signals. (B) No significant difference between H3K9me3 staining pattern in HP1γ WT and HOM MEFs were observed. Percentages of counted nuclei that displayed the described phenotype are indicated by white text at the bottom right corners of the images. Scale bar, 5μm. These images were generated by Leica widefield fluorescence microscope and analysed with ImageJ.   
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  Figure 3.18 Immunofluorescence analysis of HP1α in HP1γ WT and HOM MEFs. Representative images of nuclei of different genotype are shown. (A and B) Majority of nuclei stained with anti-HP1α antibody showed distinct but not exclusive association with DAPI dense regions in WT MEFs. (C) No dramatic changes were observed in the distribution pattern of HP1α in response to deletion of HP1γ. Percentages of counted nuclei that displayed the described phenotype are indicated by white text at the bottom right corners of the images. Scale bar, 5μm. These images were generated by Leica widefield fluorescence microscope and analysed with ImageJ.   
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  Figure 3.19 Immunofluorescence analysis of HP1β in HP1γ WT and HOM MEFs. Representative images of nuclei of different genotype are shown. (A and B) Most (78.8%) of nuclei stained with anti-HP1β antibody showed distinct but not exclusive association with DAPI dense regions in WT MEFs while relatively small proportion of nuclei (21.2%) showed diffuse staining. (C and D) Staining pattern of HP1β was changed in response to deletion of HP1γ in which most (73.9%) of the nuclei showed diffuse staining of HP1β. Percentages of counted nuclei that displayed the described phenotype are indicated by white text at the bottom right corners of the images. Scale bar, 5μm. These images were generated by Leica widefield fluorescence microscope and analysed with ImageJ.   
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 Antibody Genotype Preferential distribution to DAPI-dense regions 
Pan-nuclear distribution Total number of nuclei scored  HP1α WT 96.8% (399)  3.2% (13)  412  HOM  100% (393) 0% (0) 393 HP1β WT 78.8% (330)  21.2% (89)  419  HOM  26.1% (131) 73.9% (370) 501 HP1γ WT 18.1% (154)  81.9% (697)  851  HOM  N/A N/A N/A H3K9me3 WT 100% (525)  0% (0)  525  HOM  100% (440) 0% (0) 440  Table 3.3. A summary of quantitative analysis on the number of HP1γ WT and HOM MEFs nuclei with differential staining patterns revealed by immunofluorescence. Number of nuclei with different staining patterns were scored as shown in brackets. These numbers were then converted into percentages of the total number of cells scored. N/A, not applicable. Chi-square test: P=0.0003 for HP1α; P<0.0001 for HP1β data.   
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 Figure 3.20 Relative enrichment of HP1γ and H3K9me3 on major satellite in HP1γ WT and HOM MEFs by ChIP. (A) HP1γ HOM MEFs showed 15.6% signal of HP1γ relative to WT which can be considered as the background given the absence of HP1γ in these cells. (B) Relative enrichment of H3K9me3 on Mj-sat did not show significant difference between HP1γ WT and HOM MEFs. Student’s t-test: **P<0.01 (compared to WT after being normalised to input signal). Error bars: SEM. n≥10 for (A); n≥13 for (B).     
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Figure 3.21 Relative expression of HP1α and HP1β mRNA in HP1γ WT and HOM MEFs. (A and B) Both HP1γ WT and HOM MEFs showed similar level of HP1α and HP1β mRNA. Error bars: SEM. n≥5. P-values were stated on the graph (compared to WT after being normalised against 18S expression).   
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3.2.3 Summary for result section 3.2  
 
This section focused on the role of HP1γ in maintaining transcriptional silencing at 
constitutive heterochromatin which is mainly composed of the Mj-sat repeat. The 
main findings were as follows: 
 
1. HP1γ is a regulatory factor which maintains silencing of Mj-sat transcripts 
in MEFs from both male and female mice and its role is potentially 
conserved in human.   
 
2. Consistent to previous studies, HP1γ was detected in both euchromatin and 
heterochromatin compartments but showed two different staining patterns 
under immunofluorescence microscopy: pan-nuclear distribution and the 
concentration within DAPI-dense regions. 
 
3. Knockout of HP1γ did not lead to changes in the level of H3K9me3 on the 
Mj-sat repeats element indicating that loss of H3K9me3 is either a) unlikely 
to be responsible for the derepression of Mj-sat transcripts observed in HP1γ 
depleted MEFs or b) the derepression only occurs on a small subset of Mj-
sat repeats and therefore the reduction in H3K9me3 might not have been 
detected.   
 
4. Knockout of HP1γ led to an increased proportion of cells with diffuse pan-
nulcear pattern of HP1β compared to WT. 
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3.3 Investigation into the context-dependent gene regulation of HP1γ in vivo  
 
In the section 3.1.2, RNA-seq data showing a large subset of genes up- or 
downregulated in male MEFs upon removal of HP1γ were presented. This finding 
is consistent with various previous studies (see introduction section 1.4.2), 
implicating HP1γ in regulation of both gene activation and repression. Affected 
physiological functions upon deletion of HP1γ were also revealed by GO term 
analysis (see section 3.1.4 and 3.1.5) indicating the importance of the presence of 
HP1γ in maintaining the normal function of the cell.  
 
This interesting feature of HP1γ being able to regulate both gene activation and 
repression in the genome prompted us to ask how the active or repressive role of 
HP1γ is determined and its nature and mechanisms. We hypothesised that the mode 
of HP1γ regulation might be dependent on the ‘context’, that is which regulatory 
factors (including specific epigenetic modifications) it interacts with in different 
nuclear environments (e.g euchromatic or heterochromatic). 
 
One obvious potential determinant of the function of HP1γ is the histone mark 
H3K9me3 which has been shown to specifically interact with HP1 proteins and 
recruit them to the silent chromatin (Bannister, Zegerman et al. 2001, Lachner, 
O'Carroll et al. 2001, Jacobs and Khorasanizadeh 2002). Moreover, co-enrichment 
of HP1γ and H3K9me3 has been observed in the coding regions of several active 
genes (Vakoc, Mandat et al. 2005) and implicated in the alternative splicing of a 
reporter gene (Saint-Andre, Batsche et al. 2011).  
 
Another potential determinant of the function of HP1γ is the histone variant H3.3. 
This idea originated from previous studies which showed specific interaction 
between H3.3 and HP1γ but not HP1α and β (Loyola, Bonaldi et al. 2006, Kim, Heo 
et al. 2011). Intriguingly, the binding of both H3.3 and HP1γ to the promoter of the 
HSP70 genes was found to be interdependent, in which H3.3 binding required 
expression of HP1γ and vice versa, and both were required for HSP70 gene 
expression (Kim, Heo et al. 2011). Moreover, differential enrichment of H3.3 on 
different chromosomal regions has been reported to be dependent on HP1 level in 
Drosophila (de Wit, Greil et al. 2007).  
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In this thesis, we set out to investigate whether co-enrichment of H3K9me3 or H3.3 
with HP1γ contributes to different gene expression outcomes in vivo. In order to 
reveal the genomic distribution pattern of these proteins and histone modification, 
chromatin immunoprecipitation followed by high throughput sequencing (ChIP-seq) 
were performed. By comparing the binding pattern between these factors and HP1γ 
and correlating this with the RNA-seq data, genes or regions that are cooperatively, 
separately or independently regulated by these factors might be revealed. This study 
might also provide insight into the role of HP1γ in gene regulation and identify 
genes that might be directly or indirectly regulated by HP1γ.  
 
 
 
3.3.1 H3.3 and H3K9me3 specifically associate with HP1γ in MEFs 
 
In order to confirm the association between HP1γ with H3.3 or H3K9me3 in our 
cell model, co-immunoprecipitation experiments were performed in MEFs. In this 
experiment, lysed MEF nuclei were treated with micrococcal nuclease (MNase) 
followed by high salt (340mM NaCl) in order to enrich for histone proteins in the 
chromatin fraction as well as the closely-associated proteins (Figure S13 in 
appendix). Endogenous HP1γ protein or H3.3B-EGFP fusion protein were pulled 
down using anti-HP1γ antibody and anti-GFP antibody respectively. These ‘pulled-
down’ fractions which contain HP1γ or H3.3B-EGFP fusion protein and their 
associated protein partners were then tested by western blotting using specific 
antibodies. The efficiency of this experiment was firstly assessed by checking for 
the presence of HP1γ protein in the pulled-down fraction generated using the anti-
HP1γ antibody by western blotting. Figure S14A in appendix showed strong 
enrichment of HP1γ protein in the pull-down fraction (right lane). Also, HP1γ 
protein was diminished in the unbound fraction (middle lane) indicating high 
efficiency of pull down (Figure S14A in appendix).  
 
This pull-down fraction was then tested for the presence of histone H3, H3.3 and 
H3K9me3 with specific antibodies. Figure 3.22A shows that H3, H3.3 and 
H3K9me3 were all co-immunoprecipitated with HP1γ (Figure 3.22A). However, 
interaction was not revealed with the IgG control. This result indicates the specific 
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interaction between HP1γ and histone H3, H3.3 and H3K9me3 in our cell model.  
 
I next ask whether H3.3 also interacts with other HP1 isoforms. Due to the lack of 
availability of efficient antibodies for pulling down HP1α and HP1β, GFP-antibody 
was employed to pull down H3.3B-EGFP fusion protein in the HP1γ H3.3B-EGFP 
MEFs (see methods and material section 2.3.2.2 for details of this mouse model) 
and tested for the association with the different HP1 isoforms. Given that H3.3 
proteins derived from the H3f3a (H3.3a) and H3f3b (H3.3b) genes have the same 
amino acid sequences and hence protein structure, this experiment should reflect 
the interaction between total H3.3 and HP1 isoforms. 
  
As shown in the input lanes, weaker signal was revealed for both HP1α and HP1β 
relative to HP1γ (Figure 3.22B). This difference can be explained by the difference 
in antibody efficiency. GFP-antibody pull-down fractions were tested by western 
blotting using anti-HP1α, HP1β or HP1γ antibodies. Figure 3.22B shows that 
H3.3B-EGFP co-immunoprecipitated specifically with HP1γ. A weak interaction 
was also revealed for HP1α but not HP1β (Figure 3.22B). Importantly, no signal 
was detected when performing this experiment in WT MEFs that do not express 
H3.3B-EGFP fusion protein, indicating that detected signal was specific (Figure 
S14B in appendix). Taken together, these results indicate the specific association 
between HP1γ with histone H3, H3.3 as well as the histone H3K9me3 in MEFs.  
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A 
          B 
  Figure 3.22 Co-immunoprecipitation analysis of HP1γ with histone H3, H3K9me3 and H3.3. (A) Histone H3, H3.3 and H3K9me3 were all co-immunoprecipitated with endogenous HP1γ. No interaction was revealed with IgG control. (B) H3.3B-EGFP co-immunoprecipitated specifically with endogenous HP1γ. Weak interaction was also observed between H3.3B-EGFP and HP1α. Asterisks indicate IgG bands.           
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3.3.2 H3.3 and H3K9me3 co-localise with HP1γ in MEFs 
 
Immunofluorescence microscopy was employed to visualise the sites of interaction 
between HP1γ, H3.3 or H3K9me3 in WT MEFs. Specific antibody targeting 
endogenous HP1γ and H3K9me3 were used whereas anti-GFP antibody was used 
for visualising the H3.3B-EGFP fusion proteins. For a more accurate analysis of the 
subnuclear co-localisation of these proteins, confocal microscopy which provides 
images of higher optical resolution and contrast was employed.  
 
Consistent with previous presented data in section 3.2.2, two different staining 
patterns of HP1γ were revealed in WT MEFs nuclei. HP1γ was found enriched in 
DAPI-dense regions characteristics of heterochromatin clusters in a subset of cells 
(WT(1)) while the others showed diffuse staining of HP1γ (WT(2)) (Figure 3.23 
and Figure 3.24, left two column). Staining of H3K9me3 in WT MEFs showed clear 
and distinct co-localisation with DAPI-dense regions (Figure 3.23) as previously 
described (Figure 3.17 in section 3.2.2). H3K9me3 and HP1γ were found co-
localised predominately in the DAPI-dense regions of WT MEFs nuclei. As 
presented in section 3.2.2 (Figure 3.17), no obvious change in H3K9me3 was 
observed in response to knockout of HP1γ (Figure 3.23, right two column). 
 
In WT MEFs, H3.3B-EGFP was found predominately in euchromatin regions and 
excluded from DAPI-dense regions in most cases (Figure 3.24). Similar pattern has 
also been observed for endogenous H3.3B-EGFP without anti-GFP antibody 
staining (Figure S15 in appendix). Distribution of H3.3 and HP1γ are not excluded 
from each other and sites with high levels of both H3.3 and HP1γ co-localisation 
were observed (Figure 3.24). These co-localisation sites were found predominately 
in euchromatic regions but not in DAPI-dense regions (Figure 3.24, indicated by 
red arrows in enlarged images). In response to HP1γ deletion, no significant 
changes in H3.3B-EGFP distribution were observed (Figure 3.24).  
 
Taken together, this experiment suggests that interaction between HP1γ and 
H3K9me3 or H3.3 take place in specific subnuclear compartments. Removal of 
HP1γ does not lead to significant changes of H3K9me3 and H3.3 localisation at 
least at the resolution of microscopic analysis. However, further experiments are 
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required to get a better insight into whether HP1γ affects the distribution of 
H3K9me3 and H3.3 at the genomic level.  
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Figure 3.23 Immunofluorescence analysis of HP1γ and H3K9me3 co-localisation in HP1γ WT and HOM MEFs. Two different staining patterns of HP1γ were observed. Enrichment of HP1γ in DAPI-dense regions as was shown in a subset of nuclei (WT(1), first left column) while other nuclei showed diffuse staining of HP1γ (WT(2), second left column). H3K9me3 showed clear and distinct co-localisation with DAPI-dense regions in WT MEFs. HP1γ and H3K9me3 co-localise predominately at DAPI-dense regions in WT MEFs. Upon knockout of HP1γ, no significant change of H3K9me3 was observed. Scale bar, 10μm. These images were generated by Leica confocal microscope and analysed with Leica LAS AF Lite Software. 
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Figure 3.24 Immunofluorescence analysis of HP1γ and H3.3B-EGFP co-localisation in WT and HOM HP1γ H3.3B-EGFP MEFs. Two different staining patterns of HP1γ were observed. Enrichment of HP1γ in pericentric (DAPI-dense) regions were shown in a subset of nuclei (WT(1), first left column) while other nuclei showed diffuse staining of HP1γ (WT(2), second left column). H3.3B-EGFP was found predominately in euchromatin regions. Co-localisation of HP1γ and H3.3 were observed predominately in euchromatic regions but not in DAPI-dense regions. Upon knockout of HP1γ no significant change of H3K9me3 was observed. Enlarged parts of the nuclei (indicated by the red boxes) were shown on the right of left two rows for WT(1) and WT(2). Regions of strong co-localisation of HP1γ and H3.3 were indicated by the red arrows. Scale bar, 10μm. These images were generated by Leica confocal microscope and analysed with Leica LAS AF Lite Software.                  
165  
3.3.3 Chromatin immunoprecipitation (ChIP) for localising HP1γ, H3K9me3 
and H3.3B-EGFP in the MEF’s genome 
 
In order to gain a better insight into the distribution of HP1γ, H3K9me3 and H3.3 
in the genome, chromatin immunoprecipitation (ChIP) was performed. Each ChIP 
experiment using specific targeting antibody was validated by examining target 
protein enrichment on specific genomic regions by qRT-PCR.  
 
Anti-HP1γ and anti-H3K9me3 antibodies were used to target endogenous HP1γ and 
H3K9me3 in MEFs. As presented in section 3.2.2, enrichment of HP1γ was 
observed on major satellite (Mj-sat) repeat elements which agrees with the 
immunofluorescence experiment in which localisation of HP1γ was detected in 
both heterochromatic and euchromatic regions (Figure 3.16 in section 3.2.2, Figure 
3.23 and 3.24 in section 3.3.2). Enrichment of HP1γ has also been confirmed on the 
region 4kb downstream of the transcription start site of the Gapdh gene (Gapdh+4K) 
as reported by Vakoc et al previously (Vakoc, Mandat et al. 2005) (Figure 3.25). 
Knockout of HP1γ caused significant reduction of HP1γ enrichment on these 
regions indicating the specificity of the anti-HP1γ antibody used. Level of HP1γ 
revealed in HP1γ HOM MEFs would therefore provide a measure of background.  
 
Similar results were obtained in the H3K9me3 ChIP experiment where it was found 
to be enriched on Mj-sat and the Gapdh+4K region (Figure 3.26) This observation 
is again consistent with the previously presented immunofluorescence data showing 
co-localisation of H3K9me3 with DAPI-dense regions (Figure 3.17 in section 3.22, 
Figure 3.23 in section 3.3.2) as well as a previous published study (Vakoc, Mandat 
et al. 2005). Observed enrichment of both H3K9me3 and HP1γ indicates that 
H3K9me3 provides potential binding sites for HP1γ in these regions. Enrichment 
of H3K9me3 has also been examined on the promoters of silent (Neurod6 and Myl3) 
and active (EF1α and Gapdh) genes. As one might expect, a relatively high 
enrichment of the silencing mark H3K9me3 was revealed on the Neurod6 and Myl3 
genes which are silent in fibroblasts while a relatively low enrichment of H3K9me3 
was found on the housekeeping genes EF1α and Gapdh (Figure 3.26).  
 
As a specific antibody targeting endogenous H3.3 for ChIP became available only 
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very recently and has a low efficiency (Figure S16 in appendix), therefore an anti-
GFP antibody was employed to reveal the distribution pattern of the H3.3B-EGFP 
fusion protein in the WT HP1γ H3.3B-EGFP MEFs (see methods and material 
section 2.3.2.3 for details of the mouse model). The specificity of this antibody was 
first tested by comparing results obtained from WT CBA or HP1γ H3.3B-EGFP 
MEFs which express the H3.3B-EGFP fusion protein. As shown in Figure 3.27A, 
H3.3B-EGFP was enriched on the promoter of the expressed housekeeping genes 
EF1α and Gapdh (Figure 3.27A), consistent with a previously published study 
(Harada, Okada et al. 2012). In contrast, the signal for H3.3B-EGFP was greatly 
reduced in WT CBA MEFs on this region indicating the specificity of this antibody 
for the ChIP experiment (Figure 3.27A).  
 
Binding of H3.3B-EGFP was then further analysed on different genomic regions 
including the promoter of the silent genes Neurod6 and Myl3 as well as the Mj-sat 
repeat element. As expected, a low level of H3.3B-EGFP was revealed on Mj-sat 
(Figure 3.27C) which is in line with the previously presented immunofluorescence 
data showing that H3.3B-EGFP is largely excluded from DAPI-dense regions 
(Figure 3.24 section 3.3.2). Consistent with this was the recent finding of low levels 
of H3.3 on Mj-sat in mESC and neural progenitor cells (NPC) (Elsasser, Noh et al. 
2015). Unexpectedly, the experiment shown here showed a high level of H3.3B-
EGFP on the promoter of the silent genes Neurod6 and Myl3 compared to the 
transcriptionally active EF1α and Gapdh genes (Figure 3.27C) relative to total input. 
This result may be explained by the fact that the promoter regions of the actively 
transcribed genes are more susceptible to the shearing energy during the sonication 
step of the ChIP experiment due to their open structure and low nucleosome 
occupancy. As a consequence, chromatin fragments derived from these regions 
were enriched in the input material. Importantly, as histone H3.3 is a component of 
the nucleosome, normalising H3.3B-EGFP signal to total input may not reflect the 
proportion of nucleosomes containing H3.3B-EGFP in these regions. In order to 
estimate the proportion of H3.3B-EGFP containing nucleosomes on these regions, 
ChIP using anti-H3 antibody on the same chromatin samples was performed and 
used as a normalisation control. 
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As expected, the level of histone H3 which represents the nucleosome occupancy 
was found to be diminished at the active genes EF1α and Gapdh whereas a high 
level of H3 was revealed on the silent genes Neurod6 and Myl3 as well as at the 
pericentric Mj-sat repeats (Figure 3.27B). High levels of H3.3B-EGFP were 
revealed on the promoters of the active genes EF1α and Gapdh relative to H3 
(Figure 3.27D). In contrast, silent genes Neurod6 and Myl3 as well as the pericentric 
Mj-sat repeats showed low levels of H3.3B-EGFP relative to H3 (Figure 3.27D). 
This result indicates that there is a high proportion of H3.3 on the promoter of the 
active genes tested while that of the silent genes and Mj-sat elements was relatively 
low.  
 
Taken together, results obtained from the ChIP experiments using different 
antibodies agree with previous published studies (Vakoc, Mandat et al. 2005, 
Harada, Okada et al. 2012) as well as the data obtained from immunofluorescence 
microscopy. The ChIP material generated was therefore suitable for interrogation 
by high-throughput sequencing to reveal the genome-wide distribution pattern of 
these proteins.  
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  Figure 3.25 Relative enrichment of HP1γ on various genomic regions in HP1γ WT and HOM MEFs as revealed by ChIP. Enrichment of HP1γ was observed on major satellite (Mj-sat) repeat elements and on the region 4kb downstream of the transcription start site of the Gapdh gene (Gapdh+4K). Deletion of HP1γ caused significant reduction of HP1γ enrichment on these regions indicating the specificity of the anti-HP1γ antibody used. Level of HP1γ revealed in HP1γ HOM MEFs represents the background noise of the experiment. Student’s t-test: *P<0.05, **P<0.01 (compared to WT after being normalised to input signal). Error bars: SEM. n≥10.        
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  Figure 3.26 Relative enrichment of H3K9me3 on various genomic regions in HP1γ WT MEFs as revealed by ChIP. Enrichment of H3K9me3 was observed on silent genes Neurod6 and Myl3 and the Mj-sat repeat element. Low level of H3K9me3 was revealed on EF1α and Gapdh promoter which are actively expressed housekeeping genes. Moreover, enrichment of H3K9me3 has also been observed on the region 4kb downstream of the Gapdh gene (Gapdh+4K) which is consistent with a previously published study (Vakoc, Mandat et al. 2005). Error bars: SEM. n=6.       
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  Figure 3.27 Relative enrichment of H3.3B-EGFP on various genomic regions in WT HP1γ H3.3B-EGFP MEFs as revealed by ChIP. (A) H3.3B-EGFP signal was obtained from the transcriptionally active housekeeping genes EF1α and Gapdh in HP1γ H3.3B-EGFP MEFs which express the H3.3B-EGFP fusion protein. Low signal on these regions were obtained in the WT CBA MEFs indicating the specificity of the anti-GFP antibody used in this ChIP experiment. n=2 (qRT-PCR technical replicates). (B) Level of histone H3 which represents the nucleosome occupancy was diminished at the promoter of active genes EF1α and Gapdh and high in silent genes Neurod6 and Myl3 as well as the Mj-sat. Error bars: SEM. n=4. (C) H3.3B-EGFP was enriched on the promoters of silent genes Neurod6 and Myl3 and diminished on the active genes EF1α and Gapdh as well as Mj-sat relative to total input. Error bars: SEM. n=10. (D) High levels of H3.3B-EGFP were revealed 
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on the promoters of the active genes EF1α and Gapdh relative to H3 indicating the high proportion of H3.3B-EGFP containing nucleosomes in these regions. Error bars: SEM. n=3.   
 
 
3.3.4 Removal of HP1γ did not significantly change the level of H3K9me3 and 
H3.3B-EGFP on selected gene regions 
 
Having shown the reliability of the ChIP experiment in the previous section, I then 
asked whether H3K9me3 or H3.3B-EGFP occupancies on the regions tested were 
changed upon HP1γ knockout. As shown in Figure 3.28A and B, deletion of HP1γ 
caused an apparent reduction of H3K9me3 in all regions tested except the EF1α 
promoter. However, as the signal of H3K9me3 on EF1α was very near to 
background and thus subject to increased error which likely resulted in an erroneous 
fold change as reflected by the lack of statistical significance. The changes in 
H3K9me3 enrichment of other regions tested were also not individually statistically 
significant except at the inactive gene Myl3 (Figure 3.28A and B).  
 
HP1γ deficiency also resulted in a reduction of H3.3B-EGFP at all regions 
examined. The relative fold change of H3.3B-EGFP enrichment was minimal at 
Mj-sat and small in the two inactive genes Neurod6 and Myl3 while bigger effects 
were observed in Gapdh and EF1α which are transcriptionally active. However, 
none of these detected changes were statistically significant (Figure 3.28C and D). 
 
Taken together, these results showed that removal of HP1γ has apparently only 
minor effects on distribution of H3K9me3 and H3.3B-EGFP protein on the 
regions tested. In order to have a better idea of whether this will be affected in 
other regions of the genome, ChIP samples generated here were analysed by high 
throughput sequencing (ChIP-seq) (see sections 3.3.5).  
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Figure 3.28 Relative enrichment of H3K9me3 and H3.3B-EGFP on various genomic regions in HP1γ WT and HOM MEFs. (A) Except EF1α, all of the regions tested showed reduction of H3K9me3 in response to HP1γ knockout. However, only Myl3 showed a statistically significant change in level of H3K9me3 relative to WT. Student’s t-test: **P<0.01 (compared to WT after being normalised to input signal). Error bars: SEM. n≥5. (B) Relative fold change of H3K9me3 signal detected on each region in response to HP1γ knockout relative to WT. (C) All regions examined showed reduction of level of H3.3B-EGFP upon HP1γ knockout. However, none of these changes were statistically significant. Error bars: SEM. n≥8. (D) Relative fold change of H3.3B-EGFP signal detected on each region in response to HP1γ knockout relative to WT.                
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3.3.5 Investigation into the effect of HP1γ deletion in H3.3B-EGFP 
distribution genome wide 
 
As mentioned earlier, histone variant H3.3 is a potential determinant of the function 
of HP1γ suggested by their specific interaction (Figure 3.22) as well as their 
observed coorperation in allowing expression of the HSP70 genes as discussed 
above (Loyola, Bonaldi et al. 2006, Kim, Heo et al. 2011). In order to get a better 
insight into the effect of HP1γ in H3.3 distribution, ChIP-seq using anti-GFP 
antibody which targets the H3.3B-EGFP was performed in both HP1γ WT and 
HOM MEFs.  
 
The general distribution patterns of H3.3B-EGFP are very similar in HP1γ WT and 
HOM MEFs. As shown in Figure 3.29, pronounced peak of enrichment around the 
TSS as well as the transcription end site (TES) were observed (Figure 3.29).  
Interestingly, in both WT and HOM MEFs H3.3B-EGFP showed a dip at the TSS. 
These observation is consistent with a previously published study in both mESCs 
and NPCs (Goldberg, Banaszynski et al. 2010).  
 
In order to determine whether H3.3B-EGFP enrichment correlates with gene 
activity, the genes in MEFs were grouped in four tiers by expression level and tested 
for their level of H3.3B-EGFP by ChIP-seq. High level of binding of H3.3B-EGFP 
was observed in both HP1γ WT and HOM MEFs on highly expressed genes (Figure 
3.30, Fourth Quartile) while the lowest expressed genes have a relatively low level 
of H3.3B-EGFP. In WT MEFs, enrichment of H3.3B-EGFP was observed at the 
TES as well as the regions around TSS at a relatively lower level on the top quartile 
of highly expressed genes (Figure 3.30, Fourth Quartile). There is a dip at the TSS 
as shown previously (Figure 3.29) and is consistent with a study in murine ESCs 
(Goldberg, Banaszynski et al. 2010). Interestingly, both the peak with this central 
dip at the TSS was preserved on the highest expressed genes (Fourth Quartile) but 
lost on the lowest expressed genes (Figure 3.30, First Quartile). Surprisingly, in 
response to HP1γ knockout, enrichment of H3.3B-EGFP at the region around the 
TSS was increased on the top quartile of highly expressed genes (Figure 3.30, 
Fourth Quartile). A summary of statistical analysis on the TES to TSS binding ratio 
of H3.3B-EGFP is shown in table 3.4. Thus, particularly in highly expressed genes 
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it seems that HP1γ rather than recruiting H3.3 appears to inhibit its incorporation. 
Given that surprising nature of this observation, and the fact that the active 
promoters looked at by qRT-PCR showed a reduction in H3.3 following HP1γ 
knockout it would be important to confirm the result with an independent biological 
replicate.  
 
In order to investigate whether HP1γ sensitive genes have differential H3.3B-EGFP 
binding, distribution of H3.3B-EGFP were examined separately for genes that were 
upregulated, downregulated or not significantly changed upon HP1γ knockout. In 
HP1γ WT MEFs, the overall distribution patterns of H3.3B-EGFP were very similar 
among the three groups of genes in which pronounced enrichment of H3.3B-EGFP 
was observed in both TSS and transcriptional end site (TES) (Figure 3.31). Genes 
that were upregulated upon HP1γ knockout showed a higher level of enrichment of 
H3.3B-EGFP in general (Figure 3.31). Genes whose expression level was not 
changed upon HP1γ knockout showed enrichment of H3.3B-EGFP with a very 
similar level to the upregulated genes (Figure 3.31). In contrast, the genes that were 
downregulated by HP1γ knockout showed a similar pattern of H3.3 but at a lower 
level than the upregulated genes.  
 
In HP1γ HOM MEFs, again we observed similar overall distribution patterns of 
H3.3B-EGFP among the three groups of genes with pronounced enrichment of 
H3.3B-EGFP at both TSS and TES (Figure 3.31). Also, higher enrichment of 
H3.3B-EGFP was observed on both the unchanged genes and the upregulated genes 
compared to downregulated genes (Figure 3.31). Interestingly, in response to HP1γ 
knockout, a more pronounced enrichment of H3.3B-EGFP was observed at the 
regions around TSS. This indicates that HP1γ seems to prevent H3.3 loading at the 
TSS in all three subsets of these genes. A representative genome browser track for 
gene Gpr165 is also shown (Figure 3.32). However, it is possible that the increased 
H3.3 at the TSS in the upregulated genes might contribute to the upregulation by 
influencing transcriptional initiation. As this enrichment for H3.3 at the TSS occurs 
on all the subsets it is unlikely to be simply a consequence of altered transcription.  
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Figure 3.29 Average profile plot for H3.3B-EGFP enrichment in HP1γ WT and HOM MEFs. X-axis shows the normalised length where ‘Start’ indicates that transcription start site (TSS) and ‘End’ indicates the transcription end site (TES). Y-axis shows the coverage in windows. Data is shown as a proportion of input. HP1γ WT (left panel) and HOM (right panel) MEFs showed very similar distribution pattern of H3.3B-EGFP in which pronounced peaks of enrichment were observed around TSS as well as TES. A central dip at the TSS was shown in both HP1γ WT and HOM MEFs. n=1.  
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Figure 3.30 Average profile plot for H3.3B-EGFP of genes grouped into four tiers by expression level in HP1γ WT and HOM MEFs.  X-axis shows the normalised length where ‘Start’ indicates that transcription start site (TSS) and ‘End’ indicates the transcription end site (TES). Y-axis shows the coverage in windows. Distribution pattern of HP1γ and H3K9me3 to genes with different expression level were revealed. ‘First Quartile’ represents genes with lowest expression level while “Fourth Quartile’ represents genes with highest expression level. Data is shown as a proportion of input. In both HP1γ WT and HOM MEFs, high level of H3.3B-EGFP enrichment was observed on highly expressed genes. High level of binding of H3.3B-EGFP was observed in both HP1γ WT and HOM MEFs on highly expressed genes (Fourth Quartile) while lowest expressed genes have relatively low level of H3.3B-EGFP. The central dip at TSS was preserved on the highest expressed genes (Fourth Quartile) but lost on the lowest expressed genes (First Quartile). In HP1γ HOM MEFs, enrichment of H3.3B-EGFP at the region around the TSS was increased on the top quartile of highly expressed genes. n=1.  
 
 
Group  TES to TSS ratio P-value  WT Fourth Quartile 0.155 1.33 x 10-6 HOM Fourth Quartile 0.409 4.03 x 10-6  Table 3.4 A summary of statistical analysis on the TES to TSS binding ratio of H3.3B-EGFP. Wilcox test.        
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Figure 3.31 Average profile plot for H3.3B-EGFP of genes differentially expressed in HP1γ knockout in HP1γ WT and HOM MEFs. X-axis shows the normalised length where ‘Start’ indicates that transcription start site (TSS) and ‘End’ indicates the transcription end site (TES). Y-axis shows the coverage in windows. Data is shown as a proportion of input. The overall distribution patterns of H3.3B-EGFP were very similar among the three groups of genes in both HP1γ WT (left panel) and HOM (right panel) MEFs in which pronounced enrichment of H3.3B-EGFP was observed in both TSS and TES. In response to HP1γ knockout (right panel), a more pronounced enrichment of H3.3B-EGFP was observed at the regions around TSS. n=1.       
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Figure 3.32 Genome brower view of representative gene Gpr165.  Gpr165 showed increased H3.3B-EGFP binding upon HP1γ knockout (as indicated by red arrows).   
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3.3.6 Summary of result section 3.3 
 
This section focused on investigation in the potential ‘context’ (H3K9me3, H3.3) 
which may determine the mode of function of HP1γ. The main findings were as 
follows: 
 
1. HP1γ is specifically associated with histone H3, H3.3 as well as H3K9me3 
in MEFs as shown by co-immunoprecipitation.  
 
2. Removal of HP1γ does not lead to significant changes of H3K9me3 and 
H3.3 localisation at the resolution of microscopic analysis. 
 
3. Preliminary data reveal that deficiency of HP1γ caused an increase in 
H3.3B-EGFP enrichment at the TSS.  
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3.4 Investigation into FXN silencing in Friedreich’s Ataxia  
 
In FRDA, patients carry GAA-TCC DNA triplet repeats with sizes ranging from 90 
to 1000 repeats in intron 1 of the FXN gene which leads to FXN silencing. Data 
implicating epigenetic mechanisms in silencing of the FXN gene in FRDA have 
been provided by a number of studies (for details see introduction section 1.8) 
including three from our group (Saveliev, Everett et al. 2003, Chan, Torres et al. 
2013, Libri, Yandim et al. 2014). In these studies, I showed that the silencing histone 
marks H3K9me3 and H3K27me3 were enriched on the FXN gene with pathological 
GAA triplet-repeat expansions in FRDA primary lymphocytes relative to healthy 
control (Figure 3.33B). Interestingly, treatment of these cells with the class III 
HDAC inhibitor nicotinamide was able to reduce these silencing histone marks at 
the FXN gene locus in FRDA (Figure 3.33B). A similar result was also obtained 
from the cerebellum of a mouse model which carries the pathological human 
frataxin (hFXN) transgene (Figure 3.33C). Moreover, histone H3 and H4 
acetylation at the FXN gene locus was increased upon nicotinamide treatment in 
FRDA primary lymphocytes (Figure 3.33D) (Chan, Torres et al. 2013). Intriguingly, 
oral intake of nicotinamide was able to increase both FXN mRNA and protein level 
towards asymptomatic carriers’ level and significantly reduce the level of 
H3K9me3 on the FXN gene in primary lymphocytes derived from FRDA patients 
(Figure 3.34) (Libri, Yandim et al. 2014). Taken together, these findings suggested 
that silencing of the FXN gene in FRDA is at least in part regulated by epigenetic 
mechanisms. Importantly, these data suggested that the silencing of FXN gene can 
be reversed by modulating the protein factors that play a role in epigenetic 
mechanisms.  
 
As introduced in section 1.6, position effect variegation (PEV) is a biological 
phenomenon that describes the stochastic silencing of a gene located abnormally 
close to heterochromatin in a proportion of cells. This process is modulated by PEV 
genetic modifiers which are suppressors in a dosage dependent manner whereby 
their overexpression enhances gene silencing and downregulation causes reduced 
silencing (Festenstein, Sharghi-Namini et al. 1999, Festenstein and Kioussis 2000). 
It has been shown in previous studies of our group that PEV occurs when the 
affected gene is in close proximity to classical constitutive heterochromatin which 
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is composed of repetitive DNA elements (Reviewed in - Dillon and Festenstein 
2002), as well as CTG and GAA pathological triplet-repeat expansions which occur 
in the human diseases, Myotonic Dystrophy and Friedreich’s Ataxia (FRDA) 
respectively (Saveliev, Everett et al. 2003).  
 
Furthermore, the extent of GAA-repeat induced silencing in mammals can be 
modulated in vivo by changing the dose of HP1β, a reader of H3K9me3. This result 
implicated HP1β in pathological silencing of the FXN gene and therefore as a 
potential disease modifier (Saveliev, Everett et al. 2003).  
 
In line with this finding, a previously published study showed in cell culture where 
HP1γ was significantly enriched on the region between the transcription start site 
and exon 1 of the FXN gene in an FRDA fibroblast cell line compared to healthy 
control (De Biase, Chutake et al. 2009) These results prompted us to investigate 
whether the aberrantly silenced FXN gene in FRDA can be reversed by modulating 
the reader of H3K9me3, HP1γ. This project would potentially enhance our 
understanding of the pathophysiological mechanisms of the expanded DNA triplet 
repeats in mediating aberrant silencing of the FXN gene in FRDA. 
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  B        
  C                           
  D                
   Figure 3.33 Silencing histone marks are enriched on the FXN gene in FRDA and can be reduced by treatment of nicotinamide. (A) Schematic representation of the FXN gene locus. The position and name of the primer sets used are indicated. (B) Silencing histone marks H3K9me3 and H3K27me3 were enriched on the FXN gene in FRDA primary lymphocytes relative to healthy control. Treatment of these cells 
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with nicotinamide reduced these silencing histone marks on the FXN gene relative to untreated control. (C) Six days treatment of nicotinamide was able to reduce silencing histone marks on the pathological hFXN transgene in the cerebella of the transgenic mouse. (D) Treatment of nicotinamide increased histone H3 and H4 acetylation level on FXN gene in FRDA primary lymphocytes relative to untreated control. There was a collaborative study in the lab from design and optimisation of ChIP to performing the definitive experiments. Panel D was entirely my experiment whereas I contributed to the other panels by preparing chromatin samples. This figure is adapted by permission from Oxford University Press: Human Molecular Genetics “Chan, P. K., R. Torres, C. Yandim, P. P. Law, S. Khadayate, M. Mauri, C. Grosan, N. Chapman-Rothe, P. Giunti, M. Pook and R. Festenstein (2013). ‘Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3.’ Hum Mol Genet.” copyright (2013). (Chan, Torres et al. 2013)                           
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Figure 3.34 Oral intake of nicotinamide reduced the level of H3K9me3 on the FXN gene in primary lymphocytes derived from FRDA patients. Nicotinamide treatment of FRDA patients orally was able to increase both FXN mRNA and frataxin protein level towards asymptomatic carriers’ level (data not shown). This upregulation of FXN gene was associated with significant reduction of the H3K9me3 level on the regions flanking GAA repeat expansions of the pathological FXN gene relative to untreated control in primary lymphocytes derived from FRDA patients. The position and name of the primer sets used are indicated in Figure 3.32A. There was a collaborative study in the lab together with another PhD student, Theona Natisivili, from design and optimisation of ChIP to performing the definitive experiments. This figure is adapted by permission from Elsevier (under the terms of the Creative Commons Attribution License): The Lancet “Libri, V., C. Yandim, S. Athanasopoulos, N. Loyse, T. Natisvili, P. P. Law, P. K. Chan, T. Mohammad, M. Mauri, K. T. Tam, J. Leiper, S. Piper, A. Ramesh, M. H. Parkinson, L. Huson, P. Giunti and R. Festenstein (2014). ‘Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.’ Lancet 384(9942): 504-513.”, copyright (2014). (Libri, Yandim et al. 2014)                     
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3.4.1 shRNA-mediated knockdown of HP1γ does not affect FXN expression 
in Healthy and FRDA fibroblasts 
 
In order to investigate whether HP1γ mediates silencing of FXN gene in FRDA, a 
knockdown strategy was adopted to deplete HP1γ in human fibroblast cell lines 
derived from healthy or FRDA individuals.  Expression level of FXN mRNA and 
frataxin protein were subsequently measured and compared. In this experiment, 
four HP1γ-targeting shRNA lentiviral constructs were screened (appendix Figure 
S17) and two of them were employed (shHP1γ1 and shHP1γ2) to deplete HP1γ in 
healthy (GM07048, GM04503) and FRDA (GM04078, GM03665) cell lines with 
pathologically expanded GAA repeats.  
 
By qRT-PCR, it was confirmed that FXN mRNA levels in the FRDA cell lines 
(GM04078, GM03665) were at levels similar to those found in patients that is 
significantly lower than healthy control levels. Thus, FXN mRNA level of FRDA 
cell lines GM04078 and GM03665 were 40% and 27% of that of the healthy cell 
line GM07492 respectively (Figure 3.35A). Frataxin protein levels were also 
measured in these cell lines using a frataxin Protein Quantity Dipstick Assay Kit 
(Dipstick Assay). Consistent with the qRT-PCR result, frataxin protein levels in the 
FRDA cell lines were lower than healthy controls. Thus, FRDA cell lines GM04078 
and GM03665 showed frataxin protein levels of about 66% and 25% of healthy 
control GM07492 (Figure 3.35B).  
 
Upon HP1γ-targeting lentiviral infection, HP1γ mRNA and protein levels were 
significantly reduced in healthy and FRDA cells lines as analysed by qRT-PCR 
(Figure 3.36) and western blot analysis (Figure 3.37) respectively. Among the two 
HP1γ targeting shRNA constructs used in this experiment, construct shHP1γ2 
showed the most efficient reduction in HP1γ level, giving 10-23% HP1γ mRNA of 
untreated control (UT) and undetectable HP1γ protein level measured by western 
blotting (Figure 3.37) in different cell lines whereas construct shHP1γ1 showed a 
relatively mild effect giving 38-79% reduction in HP1γ mRNA level.   
 
In response to HP1γ-KD, construct shHP1γ1 showed upregulation of FXN mRNA 
of about 1.5 fold in healthy fibroblast GM07492 and GM04503 (Figure 3.38A and 
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C). Unexpectedly, infection by construct shHP1γ1 gave a mild reduction of FXN 
mRNA level in FRDA cell line GM04078 while that of GM03665 was slightly 
increased (Figure 3.38B and D). Infection by construct shHP1γ2 which gave the 
greatest HP1γ reduction did not show increase of FXN mRNA expression of about 
1.2 and 2.2 fold respectively in healthy fibroblast GM07492 and GM04503 (Figure 
3.38A and C). FXN mRNA level was slightly reduced in FRDA cell line GM04078 
(Figure 3.38B). Although construct shHP1γ2 led to 2 fold upregulation of FXN 
mRNA in GM03665, the control vectors with scramble shRNA (Scr) and no insert 
empty vector (Em) were both able to upregulate FXN mRNA in this cell line (Figure 
3.38D) indicating the effect observed may not be due to depletion of HP1γ level.  
 
Frataxin protein levels were also measured in these cell lines with or without HP1γ-
targeting lentiviral infection by Dipstick Assay. Upon HP1γ-KD, both construct 
shHP1γ1 and shHP1γ2 did not give any statistical significant effect on frataxin 
protein level in all the cell lines except GM04078 in which infection by construct 
shHP1γ2 caused a mild reduction in frataxin protein level (Figure 3.39B).  
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 Figure 3.35 Relative expression of FXN mRNA and protein in healthy and FRDA fibroblasts. Relative expression of FXN mRNA (A) and frataxin protein (B) in human fibroblast cells derived from healthy (GM07492, GM04503) or FRDA (GM04078, GM03665) individuals were measured by qRT-PCR and dipstick assay respectively. (A) FXN mRNA levels were significantly lower in FRDA cell lines compared to healthy controls. Student’s t-test: *P<0.05; **P<0.01 (compared to GM07492 or GM04503 after being normalised against β-actin expression). Error bars: SEM, n≥3. (B) Frataxin protein levels are higher in healthy fibroblasts (GM07492, GM04078) comparing to FRDA fibroblasts (GM04078, GM03665). Student’s t-test: *P<0.05; **P<0.01; ns = not significant (compared to GM07492 or GM04503). Error bars: SEM, n=2.      
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 Figure 3.36 Relative expression of HP1γ mRNA in healthy and FRDA cell lines upon shRNA-mediated HP1γ knockdown. HP1γ mRNA levels were efficiently reduced in each fibroblast cell line upon shRNA-mediated knockdown by two different HP1γ-targeting lentiviruses (shHP1γ1 and shHP1γ2). Non-targeting control with scrambled shRNA sequence (Scr) or no shRNA insert (Em) were also included. shHP1γ2 showed a generally better efficiency in depleting HP1γ level giving 10-23% HP1γ mRNA of untreated control (UT) whereas shHP1γ1 showed a relatively mild effect giving 38-79% reduction in HP1γ mRNA level. Levels HP1γ mRNA compared to untreated control are shown in percentage on top of the data bars. Student’s t-test: ***P<0.0005; **P<0.01; *P<0.05; ns = not significant (compared to UT after being normalised against β-actin expression). P-values of 04503 and 04078 treated with construct shHP1γ1 were indicated on the graph. Error bars: SEM. n≥3 for GM07492 and GM04078; n≥2 for GM04503 and GM03665.    
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Figure 3.37 Western blot analysis showing HP1γ protein level in healthy and FRDA fibroblasts upon shRNA-mediated HP1γ knockdown. Upon shRNA-mediated knockdown, HP1γ was greatly reduced in cells treated with HP1γ-targeting lentivirus shHP1γ1 while HP1γ was undetectable in cells treated with lentivirus shHP1γ2. Non-targeting control with scrambled shRNA sequence (Scr) or no shRNA insert (Em) showed similar level of HP1γ comparing to untreated control (UT). Alpha-tubulin (α-tubulin) was used as loading control. Western blots presented here are representative of at least 3 experiments.                      
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Figure 3.38 Relative expression of FXN mRNA in healthy and FRDA fibroblasts upon shRNA-mediated HP1γ knockdown. Although cells treated with HP1γ-targeting lentiviruses shHP1γ1 and shHP1γ2 showed upregulation of FXN mRNA comparing to untreated control (UT) in most cases, none of these data are statistically significant. Of note, the control vectors with scramble shRNA (Scr) and no insert (Em) were both be able to upregulate FXN mRNA in GM03665 indicating the non-specific effect by shRNA treatment. Fold change of FXN mRNA compared to UT are shown on top of the data bars. Student’s t-test: *P<0.05; all other data are statistically significant (compared to UT after being normalised against β-actin expression). Error bars: SEM, n≥3 for GM07492 and GM04078; n≥2 for GM04503 and GM03665.       
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Figure 3.39 Frataxin protein level in healthy and FRDA fibroblasts upon shRNA-mediated HP1γ knockdown. No significant change in Frataxin protein level was observed in healthy and FRDA fibroblasts upon HP1γ knockdown except GM04078 treated with lentivirus shHP1γ2 which caused a mild reduction in Frataxin protein level. n=2.   
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3.4.2 Heterozygous knockout of HP1γ did not affect FXN expression in mice 
cerebella  
 
In order to investigate further the potential effect of HP1γ on FXN gene regulation 
in vivo, double transgenic mice with heterozygous HP1γ knockout and hFXN 
transgene with pathologically expanded GAA repeats were generated MEFs (see 
methods and material section 2.3.2.4 for details of the mouse model). Cerebella 
which are affected in FRDA patients were obtained from these mice and analysed 
by qRT-PCR. Figure 3.40 shows that the HP1γ mRNA in the mice with 
heterozygous HP1γ knockout (HET) was significantly lower than that of the mice 
with WT HP1γ (Figure 3.40A). However, reduced level of HP1γ did not lead to 
significant change in FXN mRNA level in the cerebella of these animals (Figure 
3.40B).  
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Figure 3.40 Relative expression of HP1γ and FXN mRNA in the cerebella of HP1γ wild type or heterozygous knockout mice carrying pathological hFXN transgene. (A) HP1γ heterozygous (HET) knockout mice showed significant lower level of HP1γ mRNA in their cerebulla comparing to WT. (B) HP1γ HET knockout mice showed similar level of FXN mRNA comparing to WT. Student’s t-test: **P<0.01; ns = not significant (compared to WT after being normalised against β-actin expression), Error bars: SEM, n≥5.         
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3.4.3 Summary of result section 3.4 
 
This section focused on the mechanisms of the silencing of FXN gene in FRDA. 
The main findings were as follows: 
 
1. Pathological FXN gene silencing in FRDA could be reversed by a histone 
deacetylase inhibitor (nicotinamide) which resulted in a gain in histone H3 
and H4 acetylation and a concomitant loss of the classical heterochromatin 
modifications H3K9me3. 
 
2. It has been shown previously that GAA-repeat induced silencing in 
mammals can be modulated in vivo by changing the dose of the ‘reader’ of 
H3K9me3 HP1β, implicating HP1β as a potential disease modifier. HP1γ 
(an isoform of HP1β) was shown, here and by others, to bind to the FXN 
gene. However, shRNA-mediated knockdown of HP1γ did not affect FXN 
expression in healthy and FRDA fibroblasts. 
 
3. In order to investigate whether HP1γ was important for maintaining 
pathological FXN silencing in vivo, mouse model which carries 
pathological hFXN transgene was crossed to heterozygous HP1γ knockout 
mice and the offspring was analysed. Despite very low levels of HP1γ, 
hFXN expression in the cerebella of these mice was unaffected. Thus, 
HP1γ does not seem to contribute to FXN silencing in FRDA.  
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Chapter 4 - Discussion and Future work 
 
 
4.1 HP1γ acts as an activator as well as repressor in the genome of MEFs but 
the exact mechanisms of regulation remain uncertain 
 
HP1γ is an isoform of the HP1 family protein and is distinguished by its distinct 
localisation pattern in both the euchromatic and heterochromatic compartments in 
interphase nuclei (Horsley, Hutchings et al. 1996, Minc, Allory et al. 1999, Nielsen, 
Ortiz et al. 1999, Minc, Courvalin et al. 2000). Interestingly, HP1γ has been 
implicated in both activation and repression of genes (see introduction section 
1.4.2).  
 
In order to gain a better insight into the role of HP1γ in the regulation of gene 
expression in vivo, genome-wide transcriptional profiling was performed on MEFs 
with or without HP1γ. In this experiment, a large number of upregulated (3684 
genes) or downregulated (2005 genes) genes were revealed in male samples in 
response to HP1γ deletion. A similar result was obtained for female samples 
although the magnitude of effect was smaller (597 upregulated genes and 148 
downregulated genes were revealed) (see section 4.2 for discussion on males and 
females difference).  
 
This finding is in line with two previously published studies (Smallwood, Hon et 
al. 2012, Sridharan, Gonzales-Cope et al. 2013), however, a much smaller number 
of dysregulated genes were reported. Smallwood et al revealed 340 upregulated and 
367 downregulated genes by at least two fold upon shRNA-mediated HP1γ 
knockdown in the human colorectal carcinoma cell line HCT116 (Smallwood, Hon 
et al. 2012). Although a more stringent threshold in terms of fold change was used 
in this study (2 fold), than our study (1.5 fold), the number of dysregulated genes 
was still higher in our study even when the 2 fold threshold was applied to our data. 
Thus, 2629 upregulated genes and 982 downregulated genes by at least 2 fold 
(adjusted P-value <0.05) upon HP1γ knockout. Similar to this study, Sridharan and 
colleagues showed 352 upregulated and 368 downregulated genes by at least 1.5 
fold upon siRNA mediated HP1γ knockdown in mouse pre-iPSCs (Sridharan, 
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Gonzales-Cope et al. 2013). Moreover, our study revealed more upregulated genes 
than downregulated genes in both males and females suggesting HP1γ might act 
more often as a silencer than an activator. In contrast, a similar number of up- and 
downregulated genes were reported by both Smallwood et al and Sridharan et al.  
 
There are several possible explanations for the difference between our study and 
the previous studies. Firstly, the genes regulated by HP1γ and the level of effect 
may be cell type and species specific. Secondly, the threshold in terms of statistical 
significance (P-value) that these studies set may not be the same as shown here. 
Thirdly, to identify genes regulated by HP1γ, both of these studies employed a 
knockdown approach where HP1γ mRNAs were targeted for degradation by 
shRNA or siRNA for a period of time. This post-transcriptional silencing approach 
may not provide complete removal of the target mRNA and hence the protein. In 
our study, we employed a knockout approach where no functional mRNA transcript 
of HP1γ was produced. This approach provided cells with complete removal of 
functional mRNA transcripts and hence protein for the entire life of the cell. These 
differences in the experimental setups suggest that the expression of some genes 
may not be affected as the low level of HP1γ present in the knockdown may still be 
able to establish and/or maintain their gene expression levels. Their dysregulation 
might only occur when the HP1γ level is lower than a certain threshold which would 
be achieved in the knockout. It is also noteworthy that HCT116 is a male cell line 
which suggests that the difference in the number of observed dysregulated genes 
between the study by Smallwood et al and ours is unlikely to be due to sex 
difference.  
 
The underlying mechanisms of how these differentially expressed genes are 
regulated by HP1γ directly or indirectly remain unclear. The potential regulatory 
mechanisms are summarised and discussed here: 
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4.1.1 Potential direct mechanisms of gene regulation by HP1γ 
 
Firstly, HP1γ may recruit other regulatory factors to the target genes that it binds 
to. For example, HP1γ has been shown to interact with both initiating and 
elongating forms of RNAPII (Vakoc, Mandat et al. 2005, Lomberk, Bensi et al. 
2006, Mateescu, Bourachot et al. 2008, Smallwood, Hon et al. 2012) and suggested 
to stabilise ongoing transcription (Reviewed in - Kwon and Workman 2011). Also, 
HP1γ was shown to interact with the co-repressor TIF1β (Brasher, Smith et al. 2000, 
Lechner, Begg et al. 2000) and the DNA methyltransferase Dnmt1 (Smallwood, 
Esteve et al. 2007). A list of HP1γ interacting partners can be found in the 
introduction section 1.4.2.  
 
Secondly, HP1γ may also play a role in promoting the formation of local higher 
order chromatin structures and in turn maintain silencing of the target genes. This 
idea stems from the finding of a physical interaction between HP1γ and the 
H3K9me3 HMTs SUV39H1 (Stewart, Li et al. 2005, Fritsch, Robin et al. 2010) 
and G9a (Fritsch, Robin et al. 2010). Recruitment of H3K9me3 HMT to the target 
gene locus might induce further methylation of H3K9 at the locus. These 
methylated H3K9 residues then provide binding sites for HP1γ as well as the other 
HP1 isoforms. Thus, target gene loci with dense H3K9me3 and HP1 protein binding 
might result in tight crosslinking of nucleosomes, by dimerisation of HP1 proteins, 
and hence the formation of a condensed chromatin structure (Figure 4.1) (Reviewed 
in - Hiragami and Festenstein 2005).  
 
Moreover, HP1γ which has been implicated in regulation of RNA processing 
(Saint-Andre, Batsche et al. 2011, Ameyar-Zazoua, Rachez et al. 2012, Smallwood, 
Hon et al. 2012) may maintain gene expression levels by ensuring proper splicing 
of the mRNA transcripts and hence prevent degradation of mis-spliced transcripts. 
To address this hypothesis, Saint-Andre et al hybridised the total RNA obtained 
from HeLa cells with HP1γ knockdown onto exon arrays to test for their exon 
composition (Saint-Andre, Batsche et al. 2011). The authors reported 10.5% of 
genes analysed on the arrays showed changes in their exon composition in the 
absence of HP1γ. However, only one-third of these genes had disrupted gene 
expression. More recently, Smallwood et al identified 1037 transcripts showing a 
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marked increase in intronic expression in HCT116 cells upon HP1γ knockdown 
(Smallwood, Hon et al. 2012). Significant enrichment of HP1γ by ChIP has also 
been shown on genes with increased unspliced transcripts upon knockdown of 
HP1γ suggesting a direct effect of HP1γ. However, only 85 genes out of the 367 
downregulated genes in HP1γ knockdown cells showed increased unspliced 
transcripts. Taken together, these studies suggested that HP1γ regulates expression 
of a subset of genes by maintaining their proper splicing. However, it may also 
regulate gene expression by alternative mechanisms.  
 
  
  Figure 4.1 Schematic diagram demonstrating the potential mechanism of HP1γ in promoting heterochromatin formation. HP1γ can potentially affect gene expression directly by promoting the local higher order chromatin structure formation. HP1γ which bound to H3K9me3 on the nucleosome can recruit the H3K9me3 HMTs SUV39H1 or G9a to the target locus and hence promote further methylation of the locus. Methylated H3K9 residues then provide binding sites for HP1γ as well as other HP1 isoforms. HP1 proteins can dimerise to form homo- or heterodimers and hence crosslink the nucleosomes into condensed chromatin structure.       
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4.1.2 Potential indirect mechanisms of gene regulation by HP1γ 
 
Firstly, HP1γ may indirectly affect gene expression by regulating genes (e.g. genes 
encoding transcription regulators) which in turn regulate other genes or groups of 
genes.  
 
Secondly, HP1γ may affect gene expression by regulating nearby regions of 
heterochromatin including annotated repeats or pericentric repeats. As mentioned 
earlier, HP1γ can potentially establish and/or maintain heterochromatin by its 
interaction with the H3K9me3 HMTs. HP1γ, hence, may mediate spreading of 
heterochromatin and cause silencing of genes in nearby regions.  
 
Thirdly, HP1γ may also affect gene expression by indirectly regulating mRNA 
splicing. This hypothesis is supported by the GO term analysis presented here 
(Table S2 in appendix) as well as the statistical overrepresentation test showing 
enrichment of functional groups involved in RNA processing associated with the 
downregulated genes upon HP1γ knockout (Table S6 in appendix) (see also result 
section 3.1.4 and 3.1.5). This result suggested that HP1γ might regulate expression 
of components of the splicing machinery and hence indirectly affect the proper 
processing of mRNA transcripts. Improperly spliced transcripts may then be 
degraded.  
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4.2 HP1γ is implicated in regulation of sexually dimorphic expression of 
genes  
 
Males and females are different in physiology, behaviour as well as susceptibility 
to many diseases (Reviewed in - Wijchers and Festenstein 2011). As mentioned in 
the introduction (section 1.7), sexual differences are determined by three main 
factors: activational effects and organisational effect of gonadal steroid hormone 
and sex chromosomes (Reviewed in - Arnold 2009).  
 
Previously, a study by our group showed a significant number of autosomal genes 
that are epigenetically regulated by sex chromosome complement (XY or XX) 
rather than phenotypic sex using a ‘sex-reversal’ mouse model in which the mice 
were either deficient or transgenic for the sex determining Sry gene (Wijchers, 
Yandim et al. 2010). Thus, XX mice carrying the Sry transgene become phenotypic 
males and XY mice with the Sry gene deleted become phenotypic females. 
Interestingly, XY cells displayed significantly more heterochromatin-mediated 
silencing in a mammalian model for PEV than XX cells irrespective of phenotypic 
sex. Moreover, a greater proportion of HP1β sensitive genes (identified by 
microarray analysis comparing HP1β overexpressing cells compared with WT) 
were found in the XY cells suggesting a role for HP1β in regulating sexual 
dimorphic gene expression that is dependent on sex chromosome complement 
rather than gender (Wijchers, Yandim et al. 2010).  
 
Interestingly, it was shown in this thesis by RNA-seq analysis that there is a much 
higher number of dysregulated genes in male MEFs (total of 5689 genes) compared 
with female MEFs (total of 745 genes) in response to the removal of the HP1 
isoform HP1γ. Some of these dysregulated genes are commonly regulated by both 
males and females but genes regulated solely by either males or females were also 
identified. However, while Wijchers et al showed that PEV is sexual dimorphic 
(Wijchers, Yandim et al. 2010) and the higher expression of Mj-sat transcripts were 
revealed in the four core genotype mice in female thymus versus male (Marta Mauri 
MSc thesis, Imperial College London), it is shown here that pericentric Mj-sat 
expression is not dimorphic in its expression but dependent on HP1γ in both male 
and female MEFs to the same extent. In the investigation of the physiological 
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functions influenced by HP1γ deficiency, we found by GO term analysis that there 
are a higher number of dysregulated functional gene groups associated with males 
rather than females in response to HP1γ knockout. This is consistent with there 
being a greater number of genes affected in males than females. Also, distinct 
functional groups were found to be associated with males and females in response 
to HP1γ knockout. These findings suggest that males have a higher dependency on 
HP1γ for maintaining their normal gene expression profile. Taken together, these 
results may reflect sexual dimorphism in both gene expression and response to 
HP1γ deficiency. HP1γ may compensate for an underlying difference in gene 
expression between sexes that is due to sex chromosome complement.    
 
 
4.2.1 The effect of HP1γ in regulating the 130 genes that show sexually 
dimorphic gene expression in WT MEFs 
 
To address this hypothesis, we tested the genes that were differentially expressed in 
males and females for their sensitivity to HP1γ deficiency. Among the 130 sexually 
dimorphic genes, 85 genes have higher expression in WT females (normally 
repressed in males) and 45 genes have higher expression in WT males (normally 
repressed in females). 97 out of the 130 sexually dimorphic genes were found to be 
dysregulated in males while only 29 genes were found to be dysregulated in females. 
These data indicated that genes showing sexually dimorphic expression are 
enriched in HP1γ sensitive genes. Moreover, a greater proportion of HP1γ sensitive 
genes were found in the males than females. Regarding the repressive role of HP1γ, 
compared to the percentage of the total number of upregulated genes (3684/23425, 
15.7% for males and 597/23425, 2.5% in females) the percentage of the 130 genes, 
which showed sexually dimorphic expression, that were upregulated in response to 
HP1γ knockout was significantly skewed in both males (72/130, 55.4%) and female 
(18/130, 13.8%). Taken together, these findings suggest that males have a higher 
dependency on HP1γ for maintaining the expression level of these sexual dimorphic 
genes which are set at a lower level in males than females. Also, the higher number 
of upregulated genes revealed in both males and female suggests that HP1γ acts 
more often as a silencer to repress the expression of these sexually dimorphic genes. 
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4.2.2 The effect of HP1γ deficiency on the genes repressed more in WT males 
than females 
 
Indeed, in the investigation into the role of HP1γ in maintaining gender-specific 
expression of the sexually dimorphic genes, we found that removal of HP1γ caused 
derepression of almost all significantly changed genes (69/70 significantly changed 
genes upregulated in response to HP1γ knockout in males) that were normally 
repressed in WT males (85 genes). Notably, little effect of HP1γ deficiency on the 
130 genes with sexually dimorphic expression was shown in females where only a 
small number of them were significantly changed (16/85 genes) and both up- (6 
genes) and downregulation (10 genes) of genes were observed. These data indicated 
that HP1γ is playing a role in repressing these 85 genes in WT males but not in WT 
females.  
 
 
4.2.3 The effect of HP1γ deficiency on the genes that are activated more in 
WT males than females   
 
45 of the 130 genes showing sexually dimorphic expression were higher in WT 
males (45 genes) than WT females. Removal of HP1γ caused repression of 24 of 
these genes, whilst only 3 were upregulated and the remainder unaffected. In 
females only 13 of the 45 of these sexually dimorphic genes were affected by 
HP1gamma deficiency. Interestingly, almost all of those significantly changed 
(12/13 significantly changed genes) were found to be upregulated in response to 
HP1γ knockout in females. These data indicate that HP1γ is playing an opposite 
role in regulating these 45 genes in WT males and females. These opposite effects 
suggest that different mechanisms are operating in males versus females which 
would also be secondary to the possible sex chromosome complement effects 
described above. 
 
Overall, these results suggest that HP1γ is playing a role in maintaining sexual 
differences by maintaining the sex-specific difference in expression of these 
sexually dimorphic genes. Moreover, these results also highlighted two interesting 
features of HP1γ in gene regulation: (1) HP1γ appears to have a relatively clear-cut 
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male-specific repressive role on a subset of the sexually dimorphic genes; (2) HP1γ 
appears to have opposite roles in males versus females on those genes that are 
normally expressed at a higher level in males than females.  
 
As the study was performed in MEFs derived from E13.5 embryos the result implies 
that these sex-specific effects are likely to be due to sex chromosome complement 
rather than sex hormones as the latter are only produced in significant quantities 
much later in development.  There are several possible ways in which the XY and 
XX chromosome complements might be responsible for the effects described here.  
 
Firstly, the Y chromosome carries male specific genes several of which are known 
chromatin modifiers for example Kdm5d and Uty which were found to be expressed 
in the MEFs analysed here. Kdm5d is a histone demethylase which targets the active 
modification H3K4me3 and would therefore be a good candidate for participating 
in gene repression. Indeed, knockdown of this gene in MEFs has been shown in our 
lab to upregulate Mj-sat repeats (Marta Mauri and Raquel Silva MSc theses, 
Imperial College London). It is therefore possible that HP1γ interacts in some way 
with either this gene or other Y-specific genes to silence the 85 genes here shown 
to be repressed in WT males compared with females. Previous attempts to knockout 
Y chromosome genes in ES cells proved virtually impossible but now with the 
advent of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 
technology it is possible (Wang, Yang et al. 2013). Hence, the genetic interaction of 
these Y-specific genes with HP1γ could be investigated in the future work.  
 
Secondly, the phenomenon of genes escaping X-inactivation in XX cells (Carrel 
and Willard 2005) might also be responsible for protecting females from the 
repressive effect of HP1γ on the 85 genes that are normally expressed at a lower 
level in males compared with females.  
 
Thirdly, another possibility is that the inactive X-chromosome in females might be 
acting as a heterochromatic ‘sink’ thereby sequestering silencing factors away from 
the euchromatic regions (Chadwick and Willard 2003) allowing higher expression 
of the 85 genes that show higher expression in WT females compared to males. The 
simplest model would be that HP1γ would be sequestered to the inactive X in 
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females in line with the finding that H3K9me3 decorates the inactive X-
chromosome (Heard, Rougeulle et al. 2001).  However, it was reported in the same 
paper that HP1 isoforms are not enriched on the inactive X although the data were 
not shown and the isoforms not specified (Heard, Rougeulle et al. 2001).  
 
Taken altogether, the results obtained implicate HP1γ in the regulation of sexually 
dimorphic expression of genes and are consistent with previous studies from our 
lab which demonstrated that heterochromatin-mediated silencing was subject to 
sex-chromosome complement effect. (Wijchers, Yandim et al. 2010).  
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4.3 HP1γ is likely to be regulating the common enhancer rather than 
imprinting of the Igf2/H19 locus  
 
Genomic imprinting is an epigenetic process that maintains allelic expression of 
genes according to their parental origin (Reviewed in - Morison, Ramsay et al. 
2005). (Reviewed in - Kelsey and Feil 2013). A lot of these imprinted genes are 
important for growth and development as well as other processes such as energy 
homoeostasis, brain function and behaviour (Reviewed in - Nordin, Bergman et al. 
2014). Dysregulation of imprinted genes has also been found to be associated with 
various diseases (Reviewed in - Morison, Ramsay et al. 2005).  
 
In our investigation into the loss of function of HP1γ, significant enrichment of 
dysregulated imprinted genes were revealed in which ~40% of the total number of 
imprinted genes were up- or downregulated by at least 1.5 fold in response to HP1γ 
deletion. In this analysis, dramatic dysregulation of the Igf2 and H19 genes were 
observed in which both of these genes were downregulated by 12.9 and 13.3 fold 
respectively in response to HP1γ knockout.  
 
There are several possible mechanisms by which HP1γ might regulate the Igf2/H19 
locus. Firstly, a previous study showed concentration of HP1γ at the 3’ end of active 
genes (Vakoc, Mandat et al. 2005, Smallwood, Hon et al. 2012) and its interaction 
with both serine-2 and serine-5 phosphorylated RNAPII (Vakoc, Mandat et al. 
2005), HP1γ might therefore stabilise the transcripts of Igf2 and H19 and hence 
maintain their expression level. Also, HP1γ which has been implicated in the 
regulation of RNA processing (Saint-Andre, Batsche et al. 2011, Ameyar-Zazoua, 
Rachez et al. 2012, Smallwood, Hon et al. 2012) may maintain the expression levels 
of the Igf2 and H19 gene by ensuring proper RNA splicing to produce correct 
mRNA transcripts and hence preventing degradation of mis-spliced transcripts by 
nonsense-mediated decay. HP1γ could also possibly indirectly regulate the 
expression of these genes by regulating the expression of the upstream activator of 
the Igf2 and H19 gene. 
 
Our data do not provide strong evidence which favour any of these possible 
mechanisms. However, as mentioned in introduction section 1.5, Igf2 and H19 
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genes which are located at the same locus are reciprocally expressed from both 
alleles according to the parental inheritance and their expression is regulated by a 
common enhancer. The fact that both of these genes were downregulated by a 
similar magnitude (fold change) raised the possibility that HP1γ might be regulating 
the enhancer function which has not been suggested previously. 
 
In this case, HP1γ might regulate the Igf2/H19 locus by promoting the 
promoter/enhancer communication. It is tempting to speculate that this mechanism 
might involve direct binding of HP1γ to the promoters (Igf2 promoter on the 
paternal allele and H19 promoter on the maternal allele) and/or the common 
enhancers on both alleles. Binding of HP1γ to both promoter and enhancer may 
allow its homodimerisation and hence the promoter and enhancer might be brought 
in close proximity for promotion of gene activation. HP1γ may also bind either 
promoter or enhancer and interact with other promoter/enhancer specific factors to 
assist the promoter/enhancer interaction. Of course another possibility is that HP1γ 
deficiency might affect such looping by an indirect, as yet undetermined 
mechanism. Association of HP1γ to the gene promoter has been shown by ChIP-
seq analysis in MEFs induced to become pre-iPSCs (Sridharan, Gonzales-Cope et 
al. 2013). Moreover, association of HP1γ with an enhancer has been shown 
previously in regulatory T (Treg) cells in which HP1γ, together with H3K9me3 and 
SUV39H associated with the Treg-specific demethylation region (TSDR) enhancer 
element of the FOXP3 gene. However, association of HP1γ, H3K9me3 and 
SUV39H on TSDR functioned to promote silencing of the FOXP3 gene (Sarmento, 
Svingen et al. 2015) rather than playing an activation role as observed in the case 
of Igf2/H19 locus.  
 
To investigate whether HP1γ is playing a role in promoter/enhancer interaction, the 
MEF-specific enhancer element for the Igf2/H19 locus has to be identified. This 
can be facilitated by aligning the profile of H3K27ac and H3K4me which are the 
histone modifications that mark enhancer elements (Barski, Cuddapah et al. 2007, 
Creyghton, Cheng et al. 2010). The level of HP1γ enrichment on the enhancer 
element can hence be determined by ChIP followed by qRT-PCR or high throughput 
sequencing. Moreover, to determine whether promoter/enhancer interaction is 
compromised in the absence of HP1γ, chromosome conformation capture (3C) 
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would allow determination of interaction frequency between selected genomic 
regions in cell populations (de Wit and de Laat 2012) can be performed in HP1γ 
WT and HOM MEFs. These experiments can also extend our current study further 
to see whether HP1γ is an enhancer regulatory factor which is currently largely 
unknown. Taken together, these findings bring to light a potential role for HP1γ in 
gene regulation by regulating enhancer activity.  
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4.4 HP1γ is implicated in silencing of the pericentric Mj-sat expression  
 
Pericentric heterochromatin which is adjacent to the centromere of a mouse 
chromosome is essential for proper chromatin segregation in mitosis as well as 
maintenance of genome integrity (Reviewed in - Allshire and Karpen 2008, 
Saksouk, Simboeck et al. 2015). Pericentric heterochromatin is composed 
predominately of the AT-rich major satellite (Mj-sat) repeat units of up to ≥10,000 
copies which contribute to ~3% of the genome (Mouse Genome Sequencing, 
Waterston et al. 2002).  
 
In S. pombe, transcripts derived from pericentric heterochromatin is involved in 
establishment of heterochromatin formation by an RNA interference (RNAi)-
mediated mechanism (Reviewed in - Grewal and Jia 2007). While RNAi machinery 
can also be found in mammals, relatively little evidence suggest its involvement in 
establishment of heterochromatin (Reviewed in - Saksouk, Simboeck et al. 2015).  
 
However, various studies suggest that non-coding RNA derived from pericentric 
heterochromatin potentially has important roles in mammalian cells. Firstly, 
expression of heterochromatic transcripts are tightly coupled to the cell cycle (Lu 
and Gilbert 2007) and synthesised into double-stranded RNA (dsRNA) by 
birdirectional transcription (Martens, O'Sullivan et al. 2005). Secondly, RNA 
derived from pericentric heterochromatin was implicated in heterochromatin 
formation during early mouse development (Probst, Okamoto et al. 2010, Santenard, 
Ziegler-Birling et al. 2010). Also, it has been shown that accumulation of H3K9me3 
and HP1 proteins to heterochromatic regions was compromised upon RNAse A 
treatment suggesting the role of an RNA component in maintaining the structure of 
heterochromatin (Maison, Bailly et al. 2002). Moreover, expression of pericentric 
transcripts was detected in some human cancers (Eymery, Horard et al. 2009, Ting, 
Lipson et al. 2011). Hence, expression of pericentric transcripts has been considered 
to be a characteristic of genome instability and loss of integrity of heterochromatin 
(Eymery, Horard et al. 2009, Wang, Zhou et al. 2013) and thus a likely prerequisite 
for oncogenesis (Eymery, Callanan et al. 2009, Eymery, Horard et al. 2009). 
Controlling expression of pericentric transcripts in mammalian cells therefore 
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appears key for maintaining genome stability. However, the exact mechanism by 
which the expression of these transcripts are regulated has not been fully elucidated.  
 
HP1γ of the HP1 protein family has been implicated predominantly in regulating 
euchromatic genes rather than heterochromatin due to its nuclear distribution in 
both euchromatic and heterochromatic compartment in interphase nuclei (Horsley, 
Hutchings et al. 1996, Minc, Allory et al. 1999, Nielsen, Ortiz et al. 1999, Minc, 
Courvalin et al. 2000). Also, recent studies revealed a positive correlation between 
level of enrichment of HP1γ and gene activity (Smallwood, Hon et al. 2012, 
Sridharan, Gonzales-Cope et al. 2013). Moreover, localisation of HP1γ to the 
heterochromatic region has been reported to be dependent on HP1α and HP1β 
(Dialynas, Terjung et al. 2007, Mosch, Franz et al. 2011). These results led to the 
notion that HP1γ is predominately associated with euchromatic gene regulation.  
 
In this thesis, the function of HP1γ in pericentric heterochromatin was investigated. 
Interestingly, knockout of HP1γ in both male and female MEFs showed an average 
of 5 fold increase in Mj-sat expression as detected by qRT-PCR. Similar results 
were also observed here in the human cell line, HeLa with knockdown of HP1γ. 
These data suggest that HP1γ is a silencer of the pericentric Mj-sat transcripts and 
potentially plays an important role in regulating pericentric heterochromatin 
silencing.   
 
A variety of protein factors have also been implicated in maintaining the silencing 
of the pericentric Mj-sat transcripts expression in mammals. Interestingly, many of 
these factors are interacting partners of HP1γ in mammals. These factors include 
the chromatin modifiers SUV39H1 and SUV39H2 (Lehnertz, Ueda et al. 2003, 
Martens, O'Sullivan et al. 2005, Mosch, Franz et al. 2011) and KDM2A (Frescas, 
Guardavaccaro et al. 2008), as well as the transcription factors PAX3 (Bulut-
Karslioglu, Perrera et al. 2012) and BRCA1 (Zhu, Pao et al. 2011). For references 
for their interaction with HP1γ see Table 1.2 in introduction section 1.4.2. It is also 
noteworthy that Mj-sat derepression has also been reported in cells upon removal 
of both HP1α and HP1β (Mosch, Franz et al. 2011). Discussion regarding the 
relationship between the three HP1 isoforms can be found in section 4.5.  Removal 
or reduction of these factors in various mammalian model systems were found not 
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only to be associated with derepression of Mj-sat expression but also various 
epigenetic changes in the pericentric heterochromatin such as reduction of 
H3K9me3 (for PAX3, SUV39H), reduction in H4K20me3 (for PAX3), reduction 
of DNA methylation (for SUV39H1), reduction of mono-ubiquitinated H2A (for 
BRCA1) and an increase in H3K36me2 (for KDM2A).  
 
In our study, immunofluorescence microscopy showed that deletion of HP1γ did 
not lead to a pronounced change in pericentric heterochromatin as indicated by 
DAPI staining. Also, localisation of H3K9me3 in DAPI-dense regions which 
contains the pericentric heterochromatin was not significantly changed. Enrichment 
levels of H3K9me3 at the pericentric regions were also analysed by ChIP-qRT-
PCR on Mj-sat regions and no significant changes were observed in response to 
HP1γ depletion. These results are rather surprising given that HP1γ can recruit 
SUV39H1 (Stewart, Li et al. 2005, Fritsch, Robin et al. 2010) which establishes 
and/or maintains H3K9me3 at pericentromeres (Lehnertz, Ueda et al. 2003). 
Nonetheless, a recent study showed that HP1 proteins are dispensable for the 
establishment of SUV39H1-mediated H3K9me3 accumulation at the 
pericentromeric region (Muramatsu, Singh et al. 2013). Moreover, similar results 
have been shown in cells with double knockout of HP1α and HP1β in which 
upregulation of Mj-sat transcripts were not associated with H3K9me3 changes as 
analysed by immunofluorescence microscopy (Dialynas, Terjung et al. 2007, 
Mosch, Franz et al. 2011). Our results suggest that large scale loss of H3K9me3 is 
unlikely to be responsible for the derepression of heterochromatin transcripts 
observed in HP1γ HOM MEFs. Other silencing marks such as H4K20me3 or DNA 
methylation may be in play. Alternatively, HP1γ may mediate pericentric 
heterochromatin silencing by inhibiting active modifications such as histone 
acetylation on these regions. As mentioned above, there are estimated to be ≥10,000 
copies of Mj-sat repeat units in the genome. It is also possible that if derepression 
only occurs in a small subset of Mj-sat repeats, associated changes in H3K9me3 
may not be detectable due to the sensitivity of the methodology used.  
 
Given that HP1γ interacts with factors involved in silencing of pericentric 
heterochromatin and its deficiency in male cells results in dysregulation of ~5000 
genes, it seems likely there might be some commonality between the silencing 
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mechanisms in these cases. Thus, mRNA expression changes of these factors upon 
HP1γ knockout were checked in our RNA-seq data (Table 4.1). Our data showed 
that mRNA expression of all these factors were not statistically significantly 
changed in female MEFs. In males, expression of these factors were only modestly 
downregulated (~1.2-2.4 fold) in response to HP1γ knockout except PAX3 which 
upregulated by ~5 fold. As we observed similar magnitude of upregulation of Mj-
sat in both males and females (Figure 3.14 in section 3.2.1), these data suggest that 
HP1γ is unlikely to be derepressing Mj-sat expression by greatly reducing the 
expression level of these factors. However, we cannot rule out the possibility that 
there are other as yet unknown heterochromatin regulatory factors whose 
expression is regulated by HP1γ.  
 
 Gene  Fold change in response to HP1γ knockout (Male) 
Adjusted P-value  Fold change in response to HP1γ knockout (female) 
Adjusted P-value  
Brca1 2.37 (down) 6.21E-13 1.08 (down) 0.80 Kdm2a 1.15 (down) 6.39E-05 1.12 (down) 0.48 Pax3 4.97 (up) 1.77E-06 3.09 (up) 0.16 Suv39h1 1.57 (down) 8.50E-08 1.04 (up) 0.79 Suv39h2 2.1 (down) 1.22E-09 1.00 0.99  Table 4.1 Table summarises the fold change in mRNA expression level of factors which have been implication in pericentric heterochromatin silencing in response to HP1γ knockout in MEFs.   
Interestingly, it has been shown that knockout of BRCA1 led to reduction of the 
protein level of all the HP1 isoforms (Zhu, Pao et al. 2011) and knockdown of 
KDM2A caused HP1γ delocalisation from heterochromatic regions (Frescas, 
Guardavaccaro et al. 2008). It is also noteworthy that mitotic defects were found to 
be associated with depletion of both BRCA1 and KDM2A (Frescas, Guardavaccaro 
et al. 2008, Zhu, Pao et al. 2011) which has also been reported in various models 
with HP1γ deficiency (Obuse, Iwasaki et al. 2004, Serrano, Rodriguez-Corsino et 
al. 2009, Shimura, Toyoda et al. 2011, Grzenda, Leonard et al. 2013). These results 
suggest that HP1γ may be in the same regulatory pathway with these proteins, 
possibly acting as a downstream factor. To address this hypothesis, the epigenetic 
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changes associated with BRCA1 and KDM2A deficiency i.e. the mono-
ubiquitinated H2A and H3K36me2 can be tested in our model.   
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4.5 Increased proportion of cells with diffuse staining of HP1β in absence of 
HP1γ  
 
In result section 3.2.2, immunofluorescence microscopy revealed two different 
distribution patterns of HP1β in WT MEF nuclei (the pan-nuclear distribution and 
the concentration within DAPI-dense regions) which has also been described 
previously although this was not quantified (Dialynas, Makatsori et al. 2006, 
Dialynas, Terjung et al. 2007). Our experiment also showed that the proportion of 
cells showing diffuse pan-nuclear staining of HP1β was increased upon HP1γ 
depletion. However, removal of HP1γ did not affect HP1α distribution in the 
nucleus. And this effect is not a consequence of changes in overall expression level 
of the HP1β estimated by qRT-PCR upon HP1γ depletion.  
 
Three explanations may be able to account for this observation. Firstly, it has been 
shown previously in HeLa cells that the nuclear distribution of HP1β incorporation 
is cell cycle-dependent where it stably incorporates in heterochromatic domains in 
late S-phase and at the end of mitosis (Minc, Allory et al. 1999, Dialynas, Makatsori 
et al. 2006). Although a previous experiment on a different genetic background 
revealed no cell cycle disruption in MEFs upon HP1γ depletion (Abe, Naruse et al. 
2011), our GO analysis in male MEFs as well as the statistical overrepresentation 
test suggested that HP1γ is implicated in cell cycle regulation. And its implication 
in regulating different stages of the cell cycle has also been suggested by several 
previous studies in a number of mammalian models e.g. reduction in cell growth 
(Caillier, Thenot et al. 2010) and mitotic defects (Serrano, Rodriguez-Corsino et al. 
2009, Shimura, Toyoda et al. 2011) upon HP1γ depletion. In the light of the GO 
analysis presented here and my anecdotal observation that the male MEFs might be 
proliferating at a slower rate than WT, we now need to take this further and 
investigate in more detail whether HP1γ might have a role in maintaining normal 
cycling of cells in a gender specific manner. Female MEFs have very recently been 
investigated in this respect and found to have same cell cycle profiles and 
proliferation rate (using PI staining) when comparing WT MEFs with HP1γ 
deficient MEFs (Lakshmi Devi Regnier Cadavieco MSc thesis, Imperial College 
London). 
  
213  
Secondly, given that HP1β and HP1γ are two structurally and biochemically similar 
proteins of the same protein family (Jones, Cowell et al. 2000), another possibility 
is that HP1β may bind to sites previously occupied by HP1γ thereby potentially 
compensating for the loss of HP1γ and leading to re-distribution of HP1β to 
euchromatic regions that are normally occupied by HP1γ. To address this 
hypothesis, ChIP-seq can be employed to reveal the global binding pattern of HP1β 
WT and HP1γ knockout MEFs. ChIP with antibodies against HP1β has proved 
problematic in several laboratories making this experiment a technical challenge. 
The Festenstein lab has been developing transgenic mice carrying HP1β fused to a 
biotin tag to overcome this technical hurdle (Dr. Patrick Wijchers, personal 
communication).  
 
Thirdly, HP1 proteins are known to form homodimers or heterodimers. Interaction 
between HP1 isoforms has previously been shown by an in vitro assay and pull-
down assay using tag fusion proteins (Nielsen, Oulad-Abdelghani et al. 2001). 
Their interaction has also been shown by using mass spectrometry methodologies 
in a human cell line (Rosnoblet, Vandamme et al. 2011). Their interaction suggests 
the possibility that HP1γ may recruit HP1β by direct interaction to the 
heterochromatic regions. Loss of HP1γ may hence affect the localisation of HP1β 
to densely stained heterochromatic regions and lead to its pan-nuclear localisation. 
Intriguingly, Dialynas et al and Mosch et al showed in 2007 and 2011 that there 
was no detectable enrichment of HP1γ at DAPI-dense regions in MEFs with double 
knockout of HP1α and HP1β (Dialynas, Terjung et al. 2007, Mosch, Franz et al. 
2011). These authors hence suggested that HP1α and HP1β are necessary for HP1γ 
localisation to pericentromeric heterochromatin. Taken altogether, these data 
suggest the hypothesis that various HP1 homo- or heterodimers that are composed 
of different combinations of HP1 proteins may contribute to distinct functions in 
the genome and raises the possibility that specific HP1 dimers are crucial for 
specific physiological processes, a question which remains as yet unanswered.  
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4.6 Investigation into the context dependent regulation of gene expression by 
HP1γ in vivo 
 
This thesis, as well as various previous studies, implicated HP1γ in regulation of 
both gene activation and repression (see introduction section 1.4.2 and result section 
3.1.2). This interesting feature of HP1γ being able to regulate both gene activation 
and repression in the genome prompted us to ask how the active or repressive role 
of HP1γ is determined and its nature and mechanisms.  
 
We hypothesised that the mode of HP1γ regulation is dependent on the ‘context’ 
i.e. which regulatory factors (including specific epigenetic modifications) it 
interacts with in different nuclear environments (e.g euchromatic or 
heterochromatic). 
 
Indeed, results presented by a number of studies are pointing towards this idea. For 
example, the study by Smallwood and colleagues in 2007 where the functional 
cooperation between HP1 proteins and the DNA methyltransferase DNMT1 was 
investigated. In this study, all of the mammalian HP1 isoforms (HP1α, HP1β and 
HP1γ) were shown to associate with and be able to stimulate the activity of DNMT1 
in vitro. They have also shown in vivo by use of a reporter system that the three 
HP1 proteins were capable of inducing eight to thirteen fold repression of the 
responsive reporter gene by inducing DNMT1-mediated DNA methylation of the 
reporter gene. These results suggested that HP1γ, similar to HP1α or HP1β is able 
to repress gene expression in collaboration with DNMT1 (Smallwood, Esteve et al. 
2007). However, when investigating this cooperation in vivo, they found that HP1γ 
was associated with the active promoter of the endogenous gene Survivin. 
Interestingly, upon induced silencing of Survivin, the Survivin promoter lost 
enrichment of HP1γ binding and gained enrichment of HP1α and HP1β together 
with DNMT1, G9a and H3K9me2. In cells in which DNMT1 was deleted, induced 
silencing of Survivin failed but enrichment of HP1γ remained. Failure of repression 
was also correlated with loss of enrichment for HP1α, HP1β, DNMT1, G9a and 
H3K9me2 at the Survivin promoter. Similar results were also presented for cdc2 
and cdc25 genes in the wild type situation (Smallwood, Esteve et al. 2007). Taken 
together, these experiments suggest that whether HP1γ is an activator or repressor 
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is dependent on the genomic context. Yet, the exact nature of what defines the 
response to HP1γ is largely unknown.  
 
Another example includes a recent study which implicated all three mammalian 
HP1 isoforms in regulating expression of alternative exons. Interestingly, HP1 
isoforms can act to either promote or inhibit exon inclusion alternative exons. 
Further study into the role of HP1β in alternative splicing in relation to DNA 
methylation revealed the context dependent regulation of alternative exon 
expression by HP1β: positive regulation of exon inclusion by HP1β is correlated 
with high level of both DNA methylation and HP1β in the body of alternative exons 
whereas negative regulation of exon inclusion by HP1β is correlated with lower 
levels of DNA methylation in the body of exon and binding of HP1β in upstream 
intron (Yearim, Gelfman et al. 2015). This study again supports the hypothesis that 
the function of HP1 is dependent on the ‘context’.  
 
We hypothesise that histone variant H3.3 is one of the potential determinants of the 
function of HP1γ suggested by its specific interaction with HP1γ but not HP1α and 
β as shown here and by others (Loyola, Bonaldi et al. 2006, Kim, Heo et al. 2011). 
Intriguingly, binding of both H3.3 and HP1γ to the promoters of the HSP70 genes 
was found to be interdependent in which knockdown of HP1γ was found to cause 
a reduction of H3.3 at the promoters of HSP70 genes and vice versa (Kim, Heo et 
al. 2011). Binding of both H3.3 and HSP70 is also correlated with the expression 
level of HSP70 genes (Kim, Heo et al. 2011).  
 
In order to see whether a similar mechanism also takes place in other genes, the 
genome-wide distribution pattern of H3.3 was investigate in this project by ChIP-
seq using anti-GFP antibody in a mouse model expressing the tagged version of 
H3.3 (H3.3B-EGFP) in both HP1γ WT and HOM MEFs. Rather surprisingly, 
instead of reducing enrichment of H3.3 proteins, a more pronounced enrichment of 
H3.3B-EGFP at the regions around the TSS was observed upon HP1γ knockout. 
Moreover, the increased enrichment was found in genes that were upregulated, 
downregulated or unchanged upon HP1γ knockout. These data indicate that HP1γ 
may act to prevent H3.3 loading at the TSS. However, we do not know yet whether 
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the increased level of H3.3 at the TSS in the upregulated genes might contribute to 
their increased expression.  
 
Future experiments should focus on revealing genome-wide distribution of HP1γ 
and hence identify genes with HP1γ binding and correlate this with the H3.3 level 
as well as the transcription changes due to HP1γ knockout to find out whether 
removal of HP1γ might directly affect H3.3 enrichment and gene expression.  
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4.7 Results in the current study indicate that HP1γ is not required for 
heterochromatic silencing of the FXN gene in FRDA 
 
The neurodegenerative disease Friedreich’s Ataxia (FRDA) is the most commonly 
inherited ataxia in Caucasians affecting 1 in 30,000 to 50,000 people (Reviewed in 
- Koeppen 2011, Koeppen 2013). However, no effective disease modifying 
treatment for FRDA is available to date (Reviewed in - Libri, Yandim et al. 2014).  
 
A number of previous studies provided evidence suggesting that abnormal FXN 
silencing induced by the GAA triplet-repeat expansions in FRDA is at least partly 
regulated by epigenetic mechanisms (Reviewed in - Schmucker and Puccio 2010, 
Yandim, Natisvili et al. 2013). In particular, enrichment of the silencing histone 
marks H3K9me3 and H3K27me3 on the FXN gene suggests heterochromatinisation 
of the FXN gene locus. Intriguingly, it has also been shown that silencing of the 
FXN gene in FRDA in various model systems as well as FRDA patients can be 
reversed by HDAC inhibitor which led to modification of the histone modification 
signature at the FXN gene locus (Chan, Torres et al. 2013, Libri, Yandim et al. 2014, 
Soragni, Miao et al. 2014). 
 
A previous study from our group showed that GAA-repeat induced silencing in 
mammals can be modulated in vivo by changing the dose of the reader of H3K9me3 
HP1β, implicating HP1β as a potential disease modifier (Saveliev, Everett et al. 
2003). In line with this finding, higher levels of the HP1 isoform HP1γ at the FXN 
gene locus has been shown in FRDA fibroblast cell lines in a previous study (De 
Biase, Chutake et al. 2009). This result suggested that HP1γ may play a role in 
abnormal silencing of the FXN gene in FRDA. Thus, the role of HP1γ has then been 
investigated further in the current study. 
 
Data in the current study indicated that shRNA-mediated knockdown of HP1γ 
might have led to an increase in FXN mRNA level in the two healthy fibroblast cell 
lines (GM07492 and GM04503) and one of the FRDA lines (GM03665). However, 
data were not statistically significant due to high variability between experiments. 
Upregulation of FXN mRNA has also been observed in GM03665 when treated 
with control scramble or empty vectors indicating the potential non-specific effect 
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of the technique. Increased FXN mRNA level did not lead to increased frataxin 
protein level in these cells. Dipstick analysis showed no increase in frataxin protein 
level in all of the healthy and FRDA fibroblasts tested upon HP1γ knockdown or in 
cells treated with the control vectors.  
 
The role of HP1γ was also investigated in vivo with a mouse model which carried 
the hFXN transgene with pathologically expanded GAA repeats (Pook, Al-
Mahdawi et al. 2001). FXN mRNA level in the cerebella of these mice with 
heterozygous knockout of HP1γ were tested. However, no significant change of 
FXN mRNA was observed. This result was different from the one obtained 
previously (Figure 3.35A) and might reflect a variation in the GAA-repeat length 
which has been shown to increase in length across generations (Anjomani Virmouni, 
Ezzatizadeh et al. 2015).  
 
The result obtained here may be explained by the fact that HP1γ protein is not 
completely removed in both of the FRDA models tested. Residual HP1γ proteins in 
these models are still functional and may be able to maintain abnormal silencing of 
the FXN gene. To test this hypothesis, alternative FRDA models with complete 
knockout of HP1γ are required. However, it was not possible to examine HP1γ 
homozygote mice as the gene is essential (Takada, Naruse et al. 2011). Conditional 
knockout mice which allow homozygous knockout of HP1γ in FRDA affected 
tissues would potentially be a better model for this study. Moreover, CRISPR/Cas9 
technology which provides efficient knockout may also be employed to target the 
CBX3 gene (which encodes HP1γ) in cell models.  
 
The unchanged frataxin level upon reduction of HP1γ suggests that removing HP1γ 
alone is not sufficient to reverse silencing of FXN in FRDA. One might suspect that 
other isoforms of HP1 may compensate for the HP1γ deficiency and maintain 
silencing of the FXN gene in FRDA. For example, HP1β which was implicated in 
GAA-repeats mediated silencing of a reporter gene (Saveliev, Everett et al. 2003) 
may potentially play a role in FRDA. Moreover, removal of HP1γ, a reader of the 
silencing histone mark H3K9me3 may not be sufficient to reactivate the FXN gene 
in FRDA. Rather, the ‘writers’ of the silencing histone mark H3K9me3 (SUV39H, 
G9a or SETDB1) or H3K27me3 (components of the polycomb PRC2 complex) 
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could potentially be targeted to reduce the level of these silencing marks on the 
FXN gene to reverse silencing.  
 
At this stage, the result obtained does not support the hypothesis that HP1γ is 
required for maintenance of heterochromatic silencing in FRDA. Further 
experiments are required to address this hypothesis or to identify alternative factors 
that mediate silencing of the FXN gene in FRDA.  
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4.8 Future Work 
 
In this thesis, it was shown that HP1γ has both an activatory and repressive role in 
the regulation of gene expression and is implicated in a variety of physiological 
processes. It is also involved in silencing of pericentric Mj-sat transcript which is 
associated with de-localisation of HP1β. Of particular interest, males showed a 
higher dependency on HP1γ in maintaining their normal gene expression profile 
compared to females. Our results also suggest that HP1γ is playing a role in 
maintaining sexual differences by maintaining the sex-specific expression of the 
sexually dimorphic genes. Furthermore, preliminary analysis surprisingly revealed 
increased enrichment level of H3.3 at the TSS in response to HP1γ knockout. 
Further experiments are now required to investigate the precise mechanisms 
whereby HP1γ might mediate these processes.   
 
Several of the main questions which would be interesting to explore in future 
studies are discussed in the following sections. 
 
 
4.8.1 Further investigation into the role of HP1γ in regulation of sexually 
dimorphic expression of genes 
 
1) To investigate whether Y-specific genes are contributing to the male-specific 
repressive role of HP1γ on a subset of the sexually dimorphic genes and whether X 
escapees from X-inactivation are having a protective effect in females from HP1γ 
mediated repression, CRISPR/Cas9 technology can be employed to knockout these 
X- or Y-specific genes in MEFs. CRISPR/Cas9 technology allows knockout of 
genes on the highly heterochromatic Y chromosome which was previously 
impossible (Wang, Yang et al. 2013). Also, such candidate factors could be 
overexpressed as transgenes in WT or HP1γ HOM MEFs. The changes in the 130 
sexually dimorphic genes in the cells with the candidate genes knocked out or 
overexpressed can then be compared to that of the HP1γ knockout cells. Thus, the 
Y-specific factors that act in the same pathway with HP1γ contributing to the 
repressive effects or the X-specific factors that contribute to a potential ‘protective’ 
effect against repression by HP1γ on the 85 genes that are normally expressed at a 
221  
lower level in males than female might be identified.  
 
2) To investigate whether the X chromosome is acting as a heterochromatic ‘sink’ 
to sequester HP1γ and lead to the higher expression of the 85 genes in female, a 
mouse model which contains XIST on an autosome providing a potential autosomal 
‘sink’ (Anton Wutz – collaboration) might be employed. Use of such of an 
autosomal model would potentially overcome potential problems in testing the 
‘sink’ effect from the inactive X chromosome which would be difficult to be 
distinguished from the gene escapee effects as mice which possess multiple X 
chromosomes (XX and XXX) although they would have additional ‘sink’ due to 
inactivation of all but one X would also have higher expression of the X 
chromosome escapees.  
 
3) To investigate whether HP1γ directly regulates the 130 sexually dimorphic genes, 
we can take the advantage of the HP1γ ChIP-seq data when available and test for 
the binding of HP1γ on these genes. Moreover, the DNA sequence of these 130 
genes can be scanned in an unbiased way using bioinformatics tools (e.g. 
Bioprospector) to look for common sequence motifs of these genes which may 
potentially serve as binding sites for HP1γ or its interacting partner.    
 
 
4.8.2 Investigation into the context dependent regulation of gene expression by 
HP1γ in vivo 
 
Given that HP1β was shown by IF to re-distribute away from pericentromeric 
heterochromatin to euchromatin (Figure 3.19) , it would be interesting to investigate 
whether HP1β binds to sites previously occupied by HP1γ in absence of HP1γ and 
whether various HP1 homo- or heterodimers that are composed of different 
combinations of HP1 proteins may contribute to distinct functions in the genome, 
we may make use of the transgenic mice carrying HP1β fused to a biotin tag being 
developed in the Festenstein lab to reveal genome-wide distribution of HP1β in 
presence or absence of HP1γ. 
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4.8.3 Investigation into the role of HP1γ in the regulation of heterochromatin  
 
As HP1γ deletion was shown in this project to lead to upregulation of the Mj-sat 
repeats as detected by qRT-PCR, it will be interesting to determine whether the 
genes nearby pericentric regions were also affected upon HP1γ knockout. To 
address this question, genes located in nearby regions of the 42 intergenic Mj-sat 
sequences interspersed in the mouse genome can be identified using the 
bioinformatics algorithm developed by Dr. Thomas Carroll (Bioinformatics, MRC 
CSC, UK). These nearby genes can then be tested for their sensitivity to HP1γ 
knockout using the existing RNA-seq data obtained from male and female HP1γ 
WT and HOM MEFs.  
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Appendix 
  A                                   B                                 C 
               
Figure S1 Representative genotyping results. Genotype of transgenic animals or E13.5 embryos were determined by PCR followed by visualisation of PCR products on DNA agarose gel. (A) PCR result for HP1γ genotyping. PCR for HP1γ genotyping showed a 501bp band for wild type allele and a 525bp band for mutant allele. (B) PCR result for H3.3B-EGFP genotyping. Animals which express H3.3B-EGFP fusion protein showed a 272bp band while wild type animals show no band on gel. (C) PCR result for Kdm5d genotyping for sex determination of embryos. Male animals showed a 597bp band while female animal showed no band.           
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Figure S2 Schematic map of pMD2.G plasmid construct used for shRNA-mediated knockdown experiment. This figure is adapted from Addgene website. pMD2.G was a gift from Didier Trono (Addgene plasmid # 12259, https://www.addgene.org/12259/).                  
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Figure S3 Schematic map of psPAX2 plasmid construct used for shRNA-mediated knockdown experiment. This figure is adapted from Addgene website. psPAX2 was a gift from Didier Trono (Addgene plasmid # 12260, http://www.addgene.org/12260/).               
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Figure S4 Schematic map of pGIPZ plasmid construct used for shRNA-mediated knockdown experiment. This figure is generated by Snapgene® version 2.3.5 (GSL Biotech).     
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Figure S5 Representative gel for sheared chromatin. Chromatin from MEFs was prepared using Bioruptor® (Diagenode) to obtain sample enriched in chromatin fragments with size of about 150-300bp.                             
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A       
                                                  B 
       
Figure S6 Representative standard curve for qRT-PCR primer efficiency test. Standard curves were generated by qRT-PCR on serial diluted DNA samples for calculation of qRT-PCR primer efficiency. Representatve standard curve for (A) 18S and (B) Gadph+4k primers were shown here. Efficiency of these primers in percentage were calculated by the formula: Primer efficiency (%) = (10(-1/slope)-1)*100 and shown in red on the figure.                    
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Figure S7 Representative result obtained from Bioanalyzer RNA 6000 Nano Assay for checking quality of RNA. Quality of TRIZOL® extracted RNA was checked prior RNA sequencing library preparation. (A) Gel image of RNA showed intact and clear 28S, 18S and 5S rRNA bands which indicate good quality of RNA. (B)  Electropherograms of RNA samples and the RNA integrity number (RIN), a classification system of RNA quality developed by Agilent Technologies, were shown for each sample. RIN of 1 refers to the most degraded profile while 10 refers to the most intact. RNA with RIN of ≥8.5 were used in this thesis for RNA sequencing library preparation.             
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Figure S8 Representative result obtained from Bioanalyzer High Sensitivity DNA Analysis for checking size and quality of RNA sequencing library. (A) Gel image and (B) electropherograms of the prepared RNA sequencing library showing DNA fragment a band at approximately at 260bp, indicating good quality of RNA sequencing library as suggested by Illumina® protocol.                 
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Figure S9 Representative result obtained from Bioanalyzer High Sensitivity DNA Analysis for checking size and quality of ChIP sequencing library. (A) Gel image and (B) electropherograms of the prepared ChIP sequencing library showing enrichment of DNA fragment of about 200-400bp which indicate the size of DNA to be sequenced are of about 150-350bp (without ligated adaptors).          
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Figure S10 Representative standard curve for frataxin dipstick assay. Standard curves were generated by Quantity Dipstick Assay Kit on serial diluted recombinant frataxin protein using a MS1000 dipstick reader. This standard curve was used to calculate the frataxin protein levels of human fibroblasts protein samples by interpolation.                             
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Figure S11 Relative expression of HP1γ mRNA in HP1γ WT and heterozygous knockout (HET) thymocytes. In average, HP1γ mRNA level in HP1γ HET thymocytes was reduced by half (54% of WT remaining). However, the change is not significant due to variation of data. Student’s t-test: ns = not significant (compared to WT after being normalised against β-actin expression). Error bars: SEM, n≥3.               
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Figure S12 Relative expression of HP1γ mRNA in HP1γ WT male and female MEFs. No significant difference in HP1γ mRNA expression level was observed in male and female WT MEFs. Student’s t-test: ns = not significant (compared to male after being normalised against 18S expression). Error bars: SD, n≥10.                              
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Figure S13 Micrococcal nuclease (MNase) and high salt treatment enriched chromatin fraction of histone in MEFs nuclear lysate. (A) Representative gel image of the phenol/chloroform purified DNA obtained from MEFs nuclear lysate with (right lane) or without (left lane) MNase and followed by high salt (340mM NaCl) treatment. Treatment of MNase enriched chromatin fraction in the nuclear lysate as indicated by the recovered DNA of size of mono-, di- and tri-nucleosome. In contrast, no DNA was recovered in nuclear lysate without MNase treatment. (B) Western blot analysis of nuclear lysate with (right lane) or without (left lane) MNase and followed by high salt (340mM NaCl) treatment using anti-H3 antibody. Treatment of MNase enriched histone H3 recovery in the nuclear lysate while there is no detectable histone H3 in nuclear lysate without MNase treatment. This result indicates the enrichment of chromatin fraction with MNase treatment.     
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Figure S14 Validation of co-immunoprecipitation experiment. (A) HP1γ protein was enriched in the pulled-down fraction prepared using anti-HP1γ antibody and diminished in the unbound fraction. This result indicates the high efficiency of pull down. (B) Co-immunoprecipitation experiment in WT MEFs using anti-GFP antibody revealed no HP1γ in the pulled-down fraction indicates the signal detected between H3.3B-EGFP and HP1γ in H3.3B-EGFP MEFs was not an artifact.                   
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Figure S15 Immunofluorescence analysis of H3.3B-EGFP protein in WT HP1γ H3.3B-EGFP MEFs. H3.3B-EGFP was found predominately in euchromatin regions and excluded from DAPI-dense regions in most cases. Pattern of endogenous H3.3B-EGFP was very similar to that revealed by anti-GFP antibody staining. Scale bar, 5μm. These images were generated by Leica widefield fluorescence microscope and analysed with ImageJ.                                
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Figure S16 Relative enrichment of H3.3 on various genomic regions in WT HP1γ H3.3B-EGFP MEFs. (A & B) Enrichment of H3.3 signal on the promoter of the active housekeeping genes EF1α and Gapdh revealed by anti-H3.3 antibody (B) are comparable to the H3.3B-EGFP signal revealed anti-GFP antibody (A). (C) Level of H3.3 enrichment (in percentage of total input) obtained by anti-GFP antibody was much higher than that of the anti-H3.3 antibody. n=1.           
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Figure S17 Screening of HP1γ-targeting shRNA constructs in human fibroblast cell line. Four HP1γ-targeting shRNA lentiviral constructs (shHP1γ1, shHP1γ2, shHP1γ3 and shHP1γ4) were screened using fibroblast cell line GM04078. shHP1γ1 and shHP1γ2 which reduce HP1γ to different extent were employed for the full experiment (see result section 3.4.1). Non-targeting control with scrambled shRNA sequence (Scr) or no shRNA insert (Em) were also included. Error bars: SEM, n=2.                          
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Table S1 Biological processes (BP) revealed by gene ontology (GO) analysis associated with upregulated genes upon HP1γ knockout in male MEFs. The number of ‘count’ represent the number of dyregulated genes contribute to each term. Adjusted P-value <10-5.  GOBPID Adjusted P-value Count Term 1.  GO:0030036 3.85E-05 139 actin cytoskeleton organisation 2.  GO:0030029 2.10E-05 150 actin filament-based process 3.  GO:0002253 1.80E-15 111 activation of immune response 4.  GO:0002218 8.34E-12 55 activation of innate immune response 5.  GO:0002250 1.51E-07 92 adaptive immune response 6.  GO:0002460 4.06E-09 84 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains 7.  GO:0006066 2.16E-06 95 alcohol metabolic process 8.  GO:0046631 3.77E-05 42 alpha-beta T cell activation 9.  GO:0042886 9.88E-05 75 amide transport 10.  GO:0006820 8.64E-05 129 anion transport 11.  GO:0019882 4.83E-07 47 antigen processing and presentation 12.  GO:0019884 5.54E-07 19 antigen processing and presentation of exogenous antigen 13.  GO:0002478 7.44E-09 18 antigen processing and presentation of exogenous peptide antigen 14.  GO:0019886 2.36E-05 11 antigen processing and presentation of exogenous peptide antigen via MHC class II 15.  GO:0048002 1.30E-06 32 antigen processing and presentation of peptide antigen 16.  GO:0002495 8.37E-07 14 antigen processing and presentation of peptide antigen via MHC class II 17.  GO:0002504 1.59E-05 14 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II 18.  GO:0050851 4.34E-05 37 antigen receptor-mediated signaling pathway 19.  GO:0006915 1.99E-07 424 apoptotic process 20.  GO:0097190 6.01E-05 151 apoptotic signaling pathway 21.  GO:0019439 1.41E-07 291 aromatic compound catabolic process 22.  GO:0006914 1.06E-08 60 autophagy 23.  GO:0042113 3.30E-06 81 B cell activation 24.  GO:0050853 1.57E-06 21 B cell receptor signaling pathway 25.  GO:0007610 4.93E-06 194 behaviour 26.  GO:0022610 5.75E-09 279 biological adhesion 
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27.  GO:0007596 4.40E-05 52 blood coagulation 28.  GO:0006816 9.33E-05 99 calcium ion transport 29.  GO:0019722 2.21E-06 42 calcium-mediated signaling 30.  GO:1901136 1.01E-13 270 carbohydrate derivative catabolic process 31.  GO:1901135 2.25E-14 445 carbohydrate derivative metabolic process 32.  GO:0005975 1.07E-08 198 carbohydrate metabolic process 33.  GO:0046395 2.91E-05 62 carboxylic acid catabolic process 34.  GO:0019752 4.85E-06 220 carboxylic acid metabolic process 35.  GO:0046942 6.33E-05 77 carboxylic acid transport 36.  GO:0009056 8.10E-23 659 catabolic process 37.  GO:0006812 1.44E-08 272 cation transport 38.  GO:0001775 2.74E-16 254 cell activation 39.  GO:0002263 7.62E-07 71 cell activation involved in immune response 40.  GO:0007155 5.37E-09 277 cell adhesion 41.  GO:0060326 1.85E-05 66 cell chemotaxis 42.  GO:0008219 5.13E-08 456 cell death 43.  GO:0030154 1.39E-05 769 cell differentiation 44.  GO:0016477 4.66E-10 291 cell migration 45.  GO:0000902 3.44E-05 258 cell morphogenesis 46.  GO:0048870 1.32E-09 309 cell motility 47.  GO:0030030 2.66E-08 294 cell projection organisation 48.  GO:0008283 9.08E-07 429 cell proliferation 49.  GO:0016337 4.85E-05 111 cell-cell adhesion 50.  GO:0007267 1.81E-06 208 cell-cell signaling 51.  GO:0043603 3.89E-08 57 cellular amide metabolic process 52.  GO:0044248 1.68E-17 564 cellular catabolic process 53.  GO:0032989 5.96E-05 273 cellular component morphogenesis 54.  GO:0006928 2.59E-10 386 cellular component movement 55.  GO:0016043 1.35E-05 1052 cellular component organisation 56.  GO:0048869 3.37E-06 823 cellular developmental process 57.  GO:0044242 4.03E-08 62 cellular lipid catabolic process 58.  GO:0044255 1.57E-15 257 cellular lipid metabolic process 59.  GO:0051641 2.92E-12 578 cellular localisation 60.  GO:0044237 1.08E-07 2029 cellular metabolic process 61.  GO:0006575 4.25E-05 59 cellular modified amino acid metabolic process 62.  GO:0044270 1.09E-07 289 cellular nitrogen compound catabolic process 63.  GO:0006464 7.89E-05 637 cellular protein modification process 64.  GO:0070887 5.41E-10 469 cellular response to chemical stimulus 65.  GO:0071345 3.30E-06 115 cellular response to cytokine stimulus 66.  GO:0071310 3.54E-06 354 cellular response to organic substance 67.  GO:0071356 1.80E-06 31 cellular response to tumor necrosis 
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factor 68.  GO:0006672 6.19E-05 28 ceramide metabolic process 69.  GO:0048878 4.46E-08 231 chemical homeostasis 70.  GO:0006935 3.52E-06 136 chemotaxis 71.  GO:0050817 2.10E-05 54 coagulation 72.  GO:0051187 6.04E-05 11 cofactor catabolic process 73.  GO:0001816 2.94E-13 179 cytokine production 74.  GO:0002367 7.98E-05 25 cytokine production involved in immune response 75.  GO:0050663 6.64E-06 48 cytokine secretion 76.  GO:0016265 7.65E-08 456 death 77.  GO:0006952 7.58E-18 330 defense response 78.  GO:0098542 4.44E-06 113 defense response to other organism 79.  GO:0051607 1.31E-05 59 defense response to virus 80.  GO:0032502 1.47E-05 1149 developmental process 81.  GO:0006897 7.09E-18 167 endocytosis 82.  GO:0007173 1.19E-05 30 epidermal growth factor receptor signaling pathway 83.  GO:0038127 4.66E-06 33 ERBB signaling pathway 84.  GO:0070371 7.89E-05 58 ERK1 and ERK2 cascade 85.  GO:0051234 5.83E-37 1134 establishment of localisation 86.  GO:0051649 3.77E-13 511 establishment of localisation in cell 87.  GO:0045184 1.08E-13 397 establishment of protein localisation 88.  GO:0006887 6.39E-09 92 exocytosis 89.  GO:0097191 4.85E-06 78 extrinsic apoptotic signaling pathway 90.  GO:0006631 8.33E-07 106 fatty acid metabolic process 91.  GO:0048699 2.19E-05 315 generation of neurons 92.  GO:0002467 6.04E-05 11 germinal center formation 93.  GO:0006749 2.19E-06 24 glutathione metabolic process 94.  GO:0046486 1.60E-09 97 glycerolipid metabolic process 95.  GO:0006650 3.58E-08 71 glycerophospholipid metabolic process 96.  GO:1901658 2.94E-10 236 glycosyl compound catabolic process 97.  GO:1901657 5.21E-09 267 glycosyl compound metabolic process 98.  GO:0006184 2.80E-10 178 GTP catabolic process 99.  GO:0046039 3.06E-10 181 GTP metabolic process 100. GO:1901069 9.08E-11 181 guanosine-containing compound catabolic process 101. GO:1901068 4.18E-10 183 guanosine-containing compound metabolic process 102. GO:0007599 1.67E-05 54 hemostasis 103. GO:0046700 8.48E-08 291 heterocycle catabolic process 104. GO:0042592 1.09E-08 352 homeostatic process 105. GO:0007249 8.05E-10 83 I-kappaB kinase/NF-kappaB signaling 
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106. GO:0002252 3.83E-16 190 immune effector process 107. GO:0006955 8.06E-30 326 immune response 108. GO:0002429 2.23E-06 45 immune response-activating cell surface receptor signaling pathway 109. GO:0002757 6.31E-15 93 immune response-activating signal transduction 110. GO:0002768 9.06E-07 50 immune response-regulating cell surface receptor signaling pathway 111. GO:0002764 1.90E-15 99 immune response-regulating signaling pathway 112. GO:0002376 3.31E-35 585 immune system process 113. GO:0006954 1.18E-12 171 inflammatory response 114. GO:0045087 1.33E-17 164 innate immune response 115. GO:0002758 5.13E-11 51 innate immune response-activating signal transduction 116. GO:0048017 7.89E-05 41 inositol lipid-mediated signaling 117. GO:0032607 6.04E-05 11 interferon-alpha production 118. GO:0032608 6.93E-06 20 interferon-beta production 119. GO:0032635 2.19E-06 41 interleukin-6 production 120. GO:0035556 6.25E-29 630 intracellular signal transduction 121. GO:0046907 5.54E-07 317 intracellular transport 122. GO:0050801 3.30E-06 166 ion homeostasis 123. GO:0034220 1.79E-06 218 ion transmembrane transport 124. GO:0006811 1.22E-13 397 ion transport 125. GO:0007254 5.11E-05 56 JNK cascade 126. GO:0045321 1.19E-14 224 leukocyte activation 127. GO:0002366 7.62E-07 71 leukocyte activation involved in immune response 128. GO:0007159 4.02E-05 21 leukocyte cell-cell adhesion 129. GO:0030595 3.29E-06 54 leukocyte chemotaxis 130. GO:0043299 2.91E-05 22 leukocyte degranulation 131. GO:0002521 3.78E-07 144 leukocyte differentiation 132. GO:0002443 3.40E-08 91 leukocyte mediated immunity 133. GO:0050900 6.44E-09 85 leukocyte migration 134. GO:0070661 1.53E-06 90 leukocyte proliferation 135. GO:0008610 4.28E-06 150 lipid biosynthetic process 136. GO:0016042 2.86E-12 102 lipid catabolic process 137. GO:0010876 1.44E-06 72 lipid localisation 138. GO:0006629 2.47E-21 365 lipid metabolic process 139. GO:0030258 5.38E-08 64 lipid modification 140. GO:0006869 6.99E-07 84 lipid transport 141. GO:0051179 6.81E-39 1364 localisation 142. GO:0051674 9.59E-06 189 localisation of cell 143. GO:0040011 1.37E-11 371 locomotion 144. GO:0007626 8.69E-06 72 locomotory behaviour 145. GO:0046649 3.07E-10 183 lymphocyte activation 146. GO:0002449 5.80E-05 65 lymphocyte mediated immunity 147. GO:0072676 6.70E-05 22 lymphocyte migration 148. GO:0046651 3.37E-06 86 lymphocyte proliferation 
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149. GO:0007040 8.22E-09 23 lysosome organisation 150. GO:0033036 1.42E-13 546 macromolecule localisation 151. GO:0042116 9.16E-05 21 macrophage activation 152. GO:0000165 5.97E-10 187 MAPK cascade 153. GO:0045576 5.35E-07 27 mast cell activation 154. GO:0043303 8.41E-05 17 mast cell degranulation 155. GO:0006643 2.47E-05 51 membrane lipid metabolic process 156. GO:0061024 2.09E-06 143 membrane organisation 157. GO:0006509 6.93E-06 20 membrane protein ectodomain proteolysis 158. GO:0033619 6.80E-06 22 membrane protein proteolysis 159. GO:0008152 2.70E-10 2387 metabolic process 160. GO:0030001 5.74E-06 207 metal ion transport 161. GO:0032787 3.27E-06 132 monocarboxylic acid metabolic process 162. GO:0032943 2.19E-06 87 mononuclear cell proliferation 163. GO:0002275 2.95E-07 29 myeloid cell activation involved in immune response 164. GO:0002274 3.25E-11 63 myeloid leukocyte activation 165. GO:0002444 3.74E-07 30 myeloid leukocyte mediated immunity 166. GO:0097529 9.15E-06 46 myeloid leukocyte migration 167. GO:0043066 1.63E-05 183 negative regulation of apoptotic process 168. GO:0048519 3.96E-10 933 negative regulation of biological process 169. GO:0043086 1.26E-05 184 negative regulation of catalytic activity 170. GO:0050866 6.49E-07 54 negative regulation of cell activation 171. GO:0010648 2.35E-10 267 negative regulation of cell communication 172. GO:0060548 4.19E-05 197 negative regulation of cell death 173. GO:0048523 6.36E-10 844 negative regulation of cellular process 174. GO:0045744 1.12E-05 29 negative regulation of G-protein coupled receptor protein signaling pathway 175. GO:0002683 8.56E-10 93 negative regulation of immune system process 176. GO:0032715 6.51E-05 14 negative regulation of interleukin-6 production 177. GO:1902532 1.51E-06 105 negative regulation of intracellular signal transduction 178. GO:0002695 1.22E-06 51 negative regulation of leukocyte activation 179. GO:0045833 3.03E-05 27 negative regulation of lipid metabolic process 180. GO:0051250 1.67E-05 43 negative regulation of lymphocyte activation 181. GO:0044092 1.22E-06 238 negative regulation of molecular function 
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182. GO:0032088 3.32E-05 29 negative regulation of NF-kappaB transcription factor activity 183. GO:0045936 1.67E-05 110 negative regulation of phosphate metabolic process 184. GO:0010563 1.67E-05 110 negative regulation of phosphorus metabolic process 185. GO:0042326 2.09E-05 98 negative regulation of phosphorylation 186. GO:0043069 4.22E-05 184 negative regulation of programmed cell death 187. GO:0001933 9.74E-05 81 negative regulation of protein phosphorylation 188. GO:0048585 1.39E-12 313 negative regulation of response to stimulus 189. GO:0009968 1.54E-10 255 negative regulation of signal transduction 190. GO:0023057 4.83E-10 265 negative regulation of signaling 191. GO:0007399 2.04E-06 448 nervous system development 192. GO:0022008 7.82E-06 336 neurogenesis 193. GO:0048666 1.81E-05 176 neuron development 194. GO:0030182 8.26E-05 282 neuron differentiation 195. GO:0031175 1.07E-06 202 neuron projection development 196. GO:0007269 7.58E-05 36 neurotransmitter secretion 197. GO:0006836 9.05E-06 53 neurotransmitter transport 198. GO:0034655 2.08E-06 272 nucleobase-containing compound catabolic process 199. GO:0055086 2.42E-09 343 nucleobase-containing small molecule metabolic process 200. GO:0009164 8.59E-10 232 nucleoside catabolic process 201. GO:0009116 9.06E-09 262 nucleoside metabolic process 202. GO:1901292 4.16E-09 245 nucleoside phosphate catabolic process 203. GO:0006753 1.54E-09 334 nucleoside phosphate metabolic process 204. GO:0009143 6.85E-09 225 nucleoside triphosphate catabolic process 205. GO:0009141 1.79E-09 243 nucleoside triphosphate metabolic process 206. GO:0009166 5.21E-09 242 nucleotide catabolic process 207. GO:0009117 2.13E-09 331 nucleotide metabolic process 208. GO:0016054 2.91E-05 62 organic acid catabolic process 209. GO:0006082 7.89E-06 235 organic acid metabolic process 210. GO:0015849 8.49E-05 77 organic acid transport 211. GO:0015711 1.08E-05 103 organic anion transport 212. GO:1901361 5.38E-08 301 organic cyclic compound catabolic process 213. GO:1901615 2.85E-08 133 organic hydroxy compound metabolic process 214. GO:0015850 9.09E-05 53 organic hydroxy compound transport 215. GO:1901575 1.99E-17 590 organic substance catabolic process 
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216. GO:0071704 2.06E-06 2145 organic substance metabolic process 217. GO:0071702 1.80E-18 593 organic substance transport 218. GO:1901565 9.08E-14 309 organonitrogen compound catabolic process 219. GO:1901564 7.34E-15 529 organonitrogen compound metabolic process 220. GO:0090407 9.19E-06 135 organophosphate biosynthetic process 221. GO:0046434 3.03E-10 265 organophosphate catabolic process 222. GO:0019637 1.37E-17 449 organophosphate metabolic process 223. GO:0043436 6.29E-06 232 oxoacid metabolic process 224. GO:0002221 4.03E-11 50 pattern recognition receptor signaling pathway 225. GO:0006518 7.43E-09 44 peptide metabolic process 226. GO:0006909 3.07E-10 56 phagocytosis 227. GO:0090382 6.85E-05 10 phagosome maturation 228. GO:0006796 5.56E-27 919 phosphate-containing compound metabolic process 229. GO:0046488 4.96E-07 49 phosphatidylinositol metabolic process 230. GO:0006644 2.18E-08 95 phospholipid metabolic process 231. GO:0006793 5.33E-26 926 phosphorus metabolic process 232. GO:0016310 9.08E-14 517 phosphorylation 233. GO:0030168 1.80E-06 31 platelet activation 234. GO:0002821 5.56E-07 36 positive regulation of adaptive immune response 235. GO:0002824 2.16E-06 33 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains 236. GO:0050871 8.33E-07 32 positive regulation of B cell activation 237. GO:0030890 1.53E-05 21 positive regulation of B cell proliferation 238. GO:0048518 5.79E-18 1083 positive regulation of biological process 239. GO:0043085 8.38E-09 257 positive regulation of catalytic activity 240. GO:0050867 9.28E-08 85 positive regulation of cell activation 241. GO:0010647 2.16E-09 311 positive regulation of cell communication 242. GO:0008284 5.35E-06 212 positive regulation of cell proliferation 243. GO:0048522 1.09E-12 938 positive regulation of cellular process 244. GO:0032270 4.18E-05 223 positive regulation of cellular protein metabolic process 245. GO:0032722 6.19E-05 18 positive regulation of chemokine 
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production 246. GO:0001819 1.23E-07 84 positive regulation of cytokine production 247. GO:0050715 4.59E-05 30 positive regulation of cytokine secretion 248. GO:0031349 7.18E-09 81 positive regulation of defense response 249. GO:0051094 1.38E-05 243 positive regulation of developmental process 250. GO:0043547 3.73E-05 64 positive regulation of GTPase activity 251. GO:0043123 3.75E-06 49 positive regulation of I-kappaB kinase/NF-kappaB signaling 252. GO:0002699 7.37E-06 52 positive regulation of immune effector process 253. GO:0050778 2.20E-18 148 positive regulation of immune response 254. GO:0002684 4.18E-21 216 positive regulation of immune system process 255. GO:0045089 5.82E-09 61 positive regulation of innate immune response 256. GO:0045359 4.22E-05 7 positive regulation of interferon-beta biosynthetic process 257. GO:1902533 4.02E-10 209 positive regulation of intracellular signal transduction 258. GO:0033674 8.45E-05 113 positive regulation of kinase activity 259. GO:0002696 3.88E-07 80 positive regulation of leukocyte activation 260. GO:0070665 2.58E-05 45 positive regulation of leukocyte proliferation 261. GO:0045834 3.47E-05 44 positive regulation of lipid metabolic process 262. GO:0051251 6.91E-07 73 positive regulation of lymphocyte activation 263. GO:0050671 7.58E-05 42 positive regulation of lymphocyte proliferation 264. GO:0044093 8.49E-10 322 positive regulation of molecular function 265. GO:0032946 4.49E-05 43 positive regulation of mononuclear cell proliferation 266. GO:0051240 9.68E-07 176 positive regulation of multicellular organismal process 267. GO:0051092 1.33E-05 42 positive regulation of NF-kappaB transcription factor activity 268. GO:0045937 1.06E-05 222 positive regulation of phosphate metabolic process 269. GO:0010562 1.06E-05 222 positive regulation of phosphorus metabolic process 270. GO:0042327 9.47E-06 200 positive regulation of phosphorylation 271. GO:0051247 1.98E-06 255 positive regulation of protein metabolic process 272. GO:0031401 4.22E-05 198 positive regulation of protein 
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modification process 273. GO:0001934 3.25E-05 168 positive regulation of protein phosphorylation 274. GO:0048584 4.24E-14 409 positive regulation of response to stimulus 275. GO:0032321 6.28E-05 31 positive regulation of Rho GTPase activity 276. GO:0009967 5.63E-09 291 positive regulation of signal transduction 277. GO:0023056 6.67E-09 307 positive regulation of signaling 278. GO:0051347 7.89E-05 117 positive regulation of transferase activity 279. GO:0051050 2.79E-08 200 positive regulation of transport 280. GO:0044238 3.56E-06 2052 primary metabolic process 281. GO:0012501 6.67E-08 435 programmed cell death 282. GO:0008104 4.67E-12 483 protein localisation 283. GO:0036211 7.89E-05 637 protein modification process 284. GO:0006468 8.91E-09 377 protein phosphorylation 285. GO:0009306 2.91E-06 74 protein secretion 286. GO:0015031 6.26E-14 379 protein transport 287. GO:0006152 1.61E-09 229 purine nucleoside catabolic process 288. GO:0042278 1.30E-09 254 purine nucleoside metabolic process 289. GO:0009146 5.82E-09 224 purine nucleoside triphosphate catabolic process 290. GO:0009144 1.88E-09 239 purine nucleoside triphosphate metabolic process 291. GO:0006195 2.48E-08 234 purine nucleotide catabolic process 292. GO:0006163 1.90E-08 290 purine nucleotide metabolic process 293. GO:0046130 1.61E-09 229 purine ribonucleoside catabolic process 294. GO:0046128 1.24E-09 253 purine ribonucleoside metabolic process 295. GO:0009207 9.46E-09 222 purine ribonucleoside triphosphate catabolic process 296. GO:0009205 2.18E-09 237 purine ribonucleoside triphosphate metabolic process 297. GO:0009154 3.05E-09 231 purine ribonucleotide catabolic process 298. GO:0009150 4.46E-09 284 purine ribonucleotide metabolic process 299. GO:0072523 9.55E-09 238 purine-containing compound catabolic process 300. GO:0072521 2.57E-08 300 purine-containing compound metabolic process 301. GO:0070269 1.17E-05 8 pyroptosis 302. GO:0007265 4.60E-07 91 Ras protein signal transduction 303. GO:0072593 1.86E-06 56 reactive oxygen species metabolic process 304. GO:0006898 7.43E-06 57 receptor-mediated endocytosis 
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305. GO:0045055 1.85E-06 28 regulated secretory pathway 306. GO:0002819 7.28E-09 58 regulation of adaptive immune response 307. GO:0002822 9.66E-08 52 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains 308. GO:0042981 1.35E-05 323 regulation of apoptotic process 309. GO:0050864 7.90E-08 47 regulation of B cell activation 310. GO:0030888 4.99E-06 29 regulation of B cell proliferation 311. GO:0050855 7.19E-05 9 regulation of B cell receptor signaling pathway 312. GO:0065008 5.79E-18 752 regulation of biological quality 313. GO:0050878 8.84E-06 87 regulation of body fluid levels 314. GO:0009894 8.23E-12 244 regulation of catabolic process 315. GO:0050790 2.72E-16 501 regulation of catalytic activity 316. GO:0050865 2.76E-12 145 regulation of cell activation 317. GO:0030155 4.74E-06 100 regulation of cell adhesion 318. GO:0010646 7.67E-29 747 regulation of cell communication 319. GO:0010941 2.57E-05 340 regulation of cell death 320. GO:0045595 7.25E-06 354 regulation of cell differentiation 321. GO:0030334 1.98E-07 165 regulation of cell migration 322. GO:2000145 4.32E-07 169 regulation of cell motility 323. GO:0031344 1.53E-05 120 regulation of cell projection organisation 324. GO:0042127 5.24E-07 353 regulation of cell proliferation 325. GO:0031329 2.54E-12 225 regulation of cellular catabolic process 326. GO:0051270 5.54E-07 185 regulation of cellular component movement 327. GO:0051128 2.61E-06 420 regulation of cellular component organisation 328. GO:0060341 3.90E-09 257 regulation of cellular localisation 329. GO:0031323 1.65E-05 1134 regulation of cellular metabolic process 330. GO:0001817 1.49E-10 153 regulation of cytokine production 331. GO:0002718 4.44E-05 22 regulation of cytokine production involved in immune response 332. GO:0050707 3.91E-05 41 regulation of cytokine secretion 333. GO:0031347 9.44E-14 148 regulation of defense response 334. GO:0050793 7.65E-08 492 regulation of developmental process 335. GO:0030100 4.34E-07 61 regulation of endocytosis 336. GO:0070372 5.84E-05 54 regulation of ERK1 and ERK2 cascade 337. GO:0070201 2.36E-05 124 regulation of establishment of protein localisation 338. GO:0033124 2.29E-11 137 regulation of GTP catabolic process 339. GO:0043087 3.08E-11 136 regulation of GTPase activity 
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340. GO:0032844 6.93E-06 105 regulation of homeostatic process 341. GO:0051336 4.18E-10 288 regulation of hydrolase activity 342. GO:0043122 2.64E-08 72 regulation of I-kappaB kinase/NF-kappaB signaling 343. GO:0002697 9.38E-09 93 regulation of immune effector process 344. GO:0050776 1.63E-21 195 regulation of immune response 345. GO:0002682 4.69E-25 325 regulation of immune system process 346. GO:0050727 5.83E-07 80 regulation of inflammatory response 347. GO:0045088 1.50E-09 73 regulation of innate immune response 348. GO:0032647 2.36E-05 11 regulation of interferon-alpha production 349. GO:0032648 9.19E-06 19 regulation of interferon-beta production 350. GO:0032675 3.01E-06 40 regulation of interleukin-6 production 351. GO:1902531 1.05E-23 439 regulation of intracellular signal transduction 352. GO:0043269 9.70E-05 151 regulation of ion transport 353. GO:0043549 3.38E-07 182 regulation of kinase activity 354. GO:0002694 5.75E-11 133 regulation of leukocyte activation 355. GO:0043300 4.98E-05 15 regulation of leukocyte degranulation 356. GO:1902105 5.81E-06 78 regulation of leukocyte differentiation 357. GO:0002703 3.29E-06 54 regulation of leukocyte mediated immunity 358. GO:0002685 4.34E-05 44 regulation of leukocyte migration 359. GO:0070663 1.43E-07 70 regulation of leukocyte proliferation 360. GO:0050994 2.12E-05 23 regulation of lipid catabolic process 361. GO:0019216 4.25E-08 91 regulation of lipid metabolic process 362. GO:0032879 8.51E-17 543 regulation of localisation 363. GO:0040012 1.56E-07 185 regulation of locomotion 364. GO:0051249 6.85E-09 112 regulation of lymphocyte activation 365. GO:0050670 7.62E-07 66 regulation of lymphocyte proliferation 366. GO:0043405 4.03E-05 75 regulation of MAP kinase activity 367. GO:0043408 1.44E-08 164 regulation of MAPK cascade 368. GO:0033003 5.00E-05 17 regulation of mast cell activation 369. GO:0042391 4.18E-05 105 regulation of membrane potential 370. GO:0019222 1.66E-05 1290 regulation of metabolic process 371. GO:0065009 2.19E-18 620 regulation of molecular function 372. GO:0032944 4.59E-07 67 regulation of mononuclear cell proliferation 373. GO:2000026 1.99E-07 395 regulation of multicellular organismal development 374. GO:0051239 5.34E-14 620 regulation of multicellular 
251  
organismal process 375. GO:0043900 6.30E-06 71 regulation of multi-organism process 376. GO:0002886 6.39E-06 18 regulation of myeloid leukocyte mediated immunity 377. GO:0051960 5.54E-06 184 regulation of nervous system development 378. GO:0050767 3.30E-06 169 regulation of neurogenesis 379. GO:0045664 4.24E-05 136 regulation of neuron differentiation 380. GO:0010975 1.93E-05 99 regulation of neuron projection development 381. GO:0001505 6.27E-07 56 regulation of neurotransmitter levels 382. GO:0009118 7.09E-10 143 regulation of nucleoside metabolic process 383. GO:0030811 2.59E-09 140 regulation of nucleotide catabolic process 384. GO:0006140 8.04E-09 172 regulation of nucleotide metabolic process 385. GO:0050764 4.18E-05 26 regulation of phagocytosis 386. GO:0019220 1.76E-15 479 regulation of phosphate metabolic process 387. GO:0051174 1.34E-15 481 regulation of phosphorus metabolic process 388. GO:0042325 4.76E-09 316 regulation of phosphorylation 389. GO:0010543 4.85E-06 16 regulation of platelet activation 390. GO:0080090 4.84E-05 1100 regulation of primary metabolic process 391. GO:0002700 8.15E-05 33 regulation of production of molecular mediator of immune response 392. GO:0043067 1.06E-05 328 regulation of programmed cell death 393. GO:0045859 1.95E-06 167 regulation of protein kinase activity 394. GO:0032880 1.32E-05 146 regulation of protein localisation 395. GO:0051246 3.72E-05 409 regulation of protein metabolic process 396. GO:0031399 1.66E-05 290 regulation of protein modification process 397. GO:0001932 5.54E-07 250 regulation of protein phosphorylation 398. GO:0051223 4.22E-05 113 regulation of protein transport 399. GO:0033121 2.59E-09 140 regulation of purine nucleotide catabolic process 400. GO:1900542 1.06E-08 170 regulation of purine nucleotide metabolic process 401. GO:0032318 7.89E-08 92 regulation of Ras GTPase activity 402. GO:0046578 1.55E-10 132 regulation of Ras protein signal transduction 403. GO:0032101 1.37E-11 175 regulation of response to external stimulus 404. GO:0048583 7.64E-32 836 regulation of response to stimulus 
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405. GO:0080134 1.01E-13 257 regulation of response to stress 406. GO:0035023 1.35E-05 65 regulation of Rho protein signal transduction 407. GO:0051046 9.88E-08 170 regulation of secretion 408. GO:0009966 1.28E-25 661 regulation of signal transduction 409. GO:0023051 6.00E-29 747 regulation of signaling 410. GO:0051056 4.18E-10 136 regulation of small GTPase mediated signal transduction 411. GO:0050804 5.50E-05 81 regulation of synaptic transmission 412. GO:0050863 3.52E-06 77 regulation of T cell activation 413. GO:0034121 5.37E-05 20 regulation of toll-like receptor signaling pathway 414. GO:0051338 2.01E-07 190 regulation of transferase activity 415. GO:0051049 1.33E-13 405 regulation of transport 416. GO:0002828 2.63E-05 15 regulation of type 2 immune response 417. GO:0032479 9.06E-07 23 regulation of type I interferon production 418. GO:0060627 1.21E-06 96 regulation of vesicle-mediated transport 419. GO:0009607 3.76E-08 198 response to biotic stimulus 420. GO:0034097 2.21E-07 143 response to cytokine 421. GO:0042493 7.17E-05 69 response to drug 422. GO:0043207 8.10E-09 193 response to external biotic stimulus 423. GO:0009605 2.46E-19 480 response to external stimulus 424. GO:0009725 9.86E-05 144 response to hormone 425. GO:0002237 2.01E-05 80 response to molecule of bacterial origin 426. GO:0010033 7.89E-08 508 response to organic substance 427. GO:0051707 9.32E-09 191 response to other organism 428. GO:0006979 2.16E-06 90 response to oxidative stress 429. GO:1901700 2.68E-06 272 response to oxygen-containing compound 430. GO:0000302 2.48E-05 46 response to reactive oxygen species 431. GO:0006950 1.24E-18 736 response to stress 432. GO:0009266 1.35E-05 41 response to temperature stimulus 433. GO:0034612 3.71E-06 36 response to tumor necrosis factor 434. GO:0009615 5.49E-06 70 response to virus 435. GO:0009611 7.86E-16 256 response to wounding 436. GO:0042454 1.08E-09 231 ribonucleoside catabolic process 437. GO:0009119 7.35E-10 258 ribonucleoside metabolic process 438. GO:0009203 1.07E-08 222 ribonucleoside triphosphate catabolic process 439. GO:0009199 3.21E-09 237 ribonucleoside triphosphate metabolic process 440. GO:0009261 3.05E-09 231 ribonucleotide catabolic process 441. GO:0009259 4.76E-09 286 ribonucleotide metabolic process 442. GO:0019693 3.72E-09 288 ribose phosphate metabolic process 
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443. GO:0019932 1.59E-05 59 second-messenger-mediated signaling 444. GO:0046903 5.04E-13 268 secretion 445. GO:0032940 4.98E-13 241 secretion by cell 446. GO:0019233 2.23E-06 46 sensory perception of pain 447. GO:0023061 1.07E-05 107 signal release 448. GO:0023014 2.94E-10 195 signal transduction by phosphorylation 449. GO:0044711 1.86E-05 312 single-organism biosynthetic process 450. GO:0044723 2.81E-07 171 single-organism carbohydrate metabolic process 451. GO:0044712 7.54E-28 473 single-organism catabolic process 452. GO:0044763 3.08E-07 2752 single-organism cellular process 453. GO:0044767 1.67E-05 1144 single-organism developmental process 454. GO:1902582 4.44E-05 249 single-organism intracellular transport 455. GO:0044710 9.17E-27 1279 single-organism metabolic process 456. GO:0044699 3.79E-09 3080 single-organism process 457. GO:0044765 9.96E-32 890 single-organism transport 458. GO:0007264 5.40E-08 151 small GTPase mediated signal transduction 459. GO:0044282 2.02E-06 80 small molecule catabolic process 460. GO:0044281 1.39E-17 650 small molecule metabolic process 461. GO:0006665 2.36E-05 40 sphingolipid metabolic process 462. GO:0051403 7.89E-05 63 stress-activated MAPK cascade 463. GO:0031098 5.80E-05 65 stress-activated protein kinase signaling cascade 464. GO:0006801 1.35E-05 23 superoxide metabolic process 465. GO:0007268 5.52E-07 164 synaptic transmission 466. GO:0048731 5.72E-07 859 system development 467. GO:0042110 2.51E-07 127 T cell activation 468. GO:0030217 7.72E-05 68 T cell differentiation 469. GO:0042098 4.48E-05 55 T cell proliferation 470. GO:0042330 3.99E-06 136 taxis 471. GO:0038032 6.93E-06 20 termination of G-protein coupled receptor signaling pathway 472. GO:0023021 4.83E-07 23 termination of signal transduction 473. GO:0034162 4.22E-05 7 toll-like receptor 9 signaling pathway 474. GO:0002224 1.44E-08 37 toll-like receptor signaling pathway 475. GO:0007169 3.55E-05 125 transmembrane receptor protein tyrosine kinase signaling pathway 476. GO:0055085 1.34E-09 294 transmembrane transport 477. GO:0006810 1.80E-37 1117 transport 478. GO:0042092 2.91E-05 17 type 2 immune response 479. GO:0032606 1.68E-06 25 type I interferon production 480. GO:0033559 4.59E-05 30 unsaturated fatty acid metabolic process 
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481. GO:0007034 9.88E-05 22 vacuolar transport 482. GO:0007033 4.18E-10 40 vacuole organisation 483. GO:0051648 8.47E-05 44 vesicle localisation 484. GO:0016050 2.58E-05 45 vesicle organisation 485. GO:0016192 1.27E-18 312 vesicle-mediated transport 486. GO:0042060 4.39E-05 86 wound healing      Table S2 Biological processes (BP) revealed by gene ontology (GO) analysis associated with downregulated genes upon HP1γ knockout in male MEFs. The number of ‘count’ represent the number of dyregulated genes contribute to each term. Adjusted P-value <10-5.   GOBPID Adjusted P-value Count Term 
1.  GO:0007568 8.79E-06 44 aging 2.  GO:0000380 1.95E-06 20 alternative mRNA splicing, via spliceosome 3.  GO:0043038 2.76E-10 29 amino acid activation 4.  GO:0031145 2.56E-05 10 anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process 5.  GO:0048856 3.00E-14 969 anatomical structure development 6.  GO:0048646 1.27E-07 249 anatomical structure formation involved in morphogenesis 7.  GO:0009653 2.63E-15 569 anatomical structure morphogenesis 8.  GO:0006915 5.76E-10 399 apoptotic process 9.  GO:0048736 1.21E-05 56 appendage development 10.  GO:0035107 3.51E-06 54 appendage morphogenesis 11.  GO:0019438 1.78E-47 961 aromatic compound biosynthetic process 12.  GO:0019439 1.29E-11 284 aromatic compound catabolic process 13.  GO:0006200 1.20E-07 69 ATP catabolic process 14.  GO:0046034 1.85E-07 78 ATP metabolic process 15.  GO:0043044 3.93E-06 14 ATP-dependent chromatin remodeling 16.  GO:0008608 5.45E-07 14 attachment of spindle microtubules to kinetochore 17.  GO:0009058 2.68E-91 1447 biosynthetic process 18.  GO:0001568 4.64E-06 125 blood vessel development 19.  GO:0048514 2.78E-05 104 blood vessel morphogenesis 20.  GO:0060348 1.25E-05 47 bone development 21.  GO:0060349 6.53E-05 32 bone morphogenesis 22.  GO:0060070 4.46E-05 65 canonical Wnt signaling pathway 23.  GO:1901135 3.89E-06 354 carbohydrate derivative metabolic 
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process 24.  GO:0003205 1.54E-05 49 cardiac chamber development 25.  GO:0003206 2.21E-05 44 cardiac chamber morphogenesis 26.  GO:0048738 3.58E-05 59 cardiac muscle tissue development 27.  GO:0072358 2.25E-10 221 cardiovascular system development 28.  GO:0009056 3.78E-12 543 catabolic process 29.  GO:0007569 2.28E-06 31 cell aging 30.  GO:0007049 1.77E-80 539 cell cycle 31.  GO:0007050 8.22E-05 42 cell cycle arrest 32.  GO:0000075 1.59E-15 73 cell cycle checkpoint 33.  GO:0044839 3.51E-06 29 cell cycle G2/M phase transition 34.  GO:0022403 6.36E-05 14 cell cycle phase 35.  GO:0044770 2.04E-22 123 cell cycle phase transition 36.  GO:0022402 2.27E-67 401 cell cycle process 37.  GO:0008219 2.88E-10 426 cell death 38.  GO:0048468 3.22E-06 408 cell development 39.  GO:0030154 6.12E-05 682 cell differentiation 40.  GO:0051301 1.60E-48 306 cell division 41.  GO:0000902 1.86E-05 235 cell morphogenesis 42.  GO:0008283 8.73E-09 401 cell proliferation 43.  GO:0006520 1.91E-05 98 cellular amino acid metabolic process 44.  GO:0006725 4.46E-135 1658 cellular aromatic compound metabolic process 45.  GO:0044249 5.13E-93 1408 cellular biosynthetic process 46.  GO:0044248 1.53E-12 485 cellular catabolic process 47.  GO:0022607 7.55E-26 490 cellular component assembly 48.  GO:0044085 5.54E-45 589 cellular component biogenesis 49.  GO:0022411 8.22E-06 56 cellular component disassembly 50.  GO:0032989 1.02E-06 259 cellular component morphogenesis 51.  GO:0016043 2.43E-74 1285 cellular component organisation 52.  GO:0071840 1.96E-93 1369 cellular component organisation or biogenesis 53.  GO:0048869 2.00E-06 741 cellular developmental process 54.  GO:0051641 3.13E-09 502 cellular localisation 55.  GO:0034622 1.96E-27 212 cellular macromolecular complex assembly 56.  GO:0034645 2.06E-100 1234 cellular macromolecule biosynthetic process 57.  GO:0044265 1.36E-19 205 cellular macromolecule catabolic process 58.  GO:0070727 1.57E-10 254 cellular macromolecule localisation 59.  GO:0044260 4.00E-180 2021 cellular macromolecule metabolic process 60.  GO:0044237 3.53E-162 2446 cellular metabolic process 61.  GO:0044271 1.28E-45 966 cellular nitrogen compound biosynthetic process 62.  GO:0044270 2.11E-12 285 cellular nitrogen compound catabolic process 63.  GO:0034641 7.38E-131 1672 cellular nitrogen compound 
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metabolic process 64.  GO:0009987 9.64E-65 3265 cellular process 65.  GO:0048610 3.82E-05 125 cellular process involved in reproduction 66.  GO:0044257 7.95E-08 108 cellular protein catabolic process 67.  GO:0043623 6.56E-11 117 cellular protein complex assembly 68.  GO:0043624 1.54E-05 36 cellular protein complex disassembly 69.  GO:0034613 4.24E-10 251 cellular protein localisation 70.  GO:0044267 1.83E-67 1016 cellular protein metabolic process 71.  GO:0006464 1.70E-24 700 cellular protein modification process 72.  GO:0045333 3.04E-06 38 cellular respiration 73.  GO:0006974 7.68E-42 261 cellular response to DNA damage stimulus 74.  GO:0071479 2.65E-05 21 cellular response to ionising radiation 75.  GO:0071478 3.70E-05 35 cellular response to radiation 76.  GO:0033554 7.62E-37 413 cellular response to stress 77.  GO:0034508 1.55E-07 15 centromere complex assembly 78.  GO:0007098 5.36E-09 27 centrosome cycle 79.  GO:0051298 5.34E-07 20 centrosome duplication 80.  GO:0051297 2.24E-15 45 centrosome organisation 81.  GO:0051299 1.95E-05 7 centrosome separation 82.  GO:0043009 3.34E-13 208 chordate embryonic development 83.  GO:0006333 4.17E-06 41 chromatin assembly or disassembly 84.  GO:0016568 1.61E-25 195 chromatin modification 85.  GO:0006325 1.03E-26 217 chromatin organisation 86.  GO:0006338 7.15E-06 35 chromatin remodeling 87.  GO:0030261 4.93E-05 16 chromosome condensation 88.  GO:0050000 1.37E-07 16 chromosome localisation 89.  GO:0051276 2.26E-44 306 chromosome organisation 90.  GO:0007059 4.95E-32 99 chromosome segregation 91.  GO:0072359 2.25E-10 221 circulatory system development 92.  GO:0030199 3.13E-08 24 collagen fibril organisation 93.  GO:0016569 4.57E-21 143 covalent chromatin modification 94.  GO:0010388 1.06E-06 9 cullin deneddylation 95.  GO:0016482 7.97E-12 197 cytoplasmic transport 96.  GO:0007010 3.78E-18 275 cytoskeleton organisation 97.  GO:0016265 3.07E-10 427 death 98.  GO:0032502 7.74E-17 1132 developmental process 99.  GO:0006308 1.64E-05 27 DNA catabolic process 100. GO:0000737 8.53E-05 21 DNA catabolic process, endonucleolytic 101. GO:0071103 1.39E-13 74 DNA conformation change 102. GO:0000077 2.59E-08 40 DNA damage checkpoint 103. GO:0000729 8.09E-05 6 DNA double-strand break processing 104. GO:0032508 4.00E-09 23 DNA duplex unwinding 105. GO:0032392 3.06E-09 24 DNA geometric change 
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106. GO:0031570 8.97E-10 45 DNA integrity checkpoint 107. GO:0006259 9.74E-65 374 DNA metabolic process 108. GO:0006323 1.45E-07 49 DNA packaging 109. GO:0006310 2.99E-17 89 DNA recombination 110. GO:0006281 8.79E-44 194 DNA repair 111. GO:0006260 3.49E-39 143 DNA replication 112. GO:0006270 5.92E-07 13 DNA replication initiation 113. GO:0006261 6.76E-19 55 DNA-dependent DNA replication 114. GO:0006354 1.16E-05 22 DNA-templated transcription, elongation 115. GO:0006352 1.35E-07 35 DNA-templated transcription, initiation 116. GO:0006302 8.53E-18 66 double-strand break repair 117. GO:0000724 6.51E-09 30 double-strand break repair via homologous recombination 118. GO:0009790 7.01E-19 325 embryo development 119. GO:0009792 1.30E-13 211 embryo development ending in birth or egg hatching 120. GO:0035113 9.45E-05 44 embryonic appendage morphogenesis 121. GO:0048701 3.93E-05 21 embryonic cranial skeleton morphogenesis 122. GO:0001838 2.21E-05 44 embryonic epithelial tube formation 123. GO:0030326 9.45E-05 44 embryonic limb morphogenesis 124. GO:0048598 3.08E-09 170 embryonic morphogenesis 125. GO:0048706 7.74E-08 53 embryonic skeletal system development 126. GO:0048704 3.46E-06 40 embryonic skeletal system morphogenesis 127. GO:0015980 2.01E-05 58 energy derivation by oxidation of organic compounds 128. GO:0001837 2.20E-05 32 epithelial to mesenchymal transition 129. GO:0072175 2.21E-05 44 epithelial tube formation 130. GO:0060562 1.22E-06 97 epithelial tube morphogenesis 131. GO:0006888 1.52E-07 25 ER to Golgi vesicle-mediated transport 132. GO:0051303 3.08E-09 17 establishment of chromosome localisation 133. GO:0051649 1.99E-05 409 establishment of localisation in cell 134. GO:0045184 1.30E-06 320 establishment of protein localisation 135. GO:0072594 3.41E-05 91 establishment of protein localisation to organelle 136. GO:0051236 5.03E-26 71 establishment of RNA localisation 137. GO:0030198 1.79E-05 59 extracellular matrix organisation 138. GO:0043062 2.13E-05 59 extracellular structure organisation 139. GO:0000082 1.73E-08 56 G1/S transition of mitotic cell cycle 140. GO:0000086 3.51E-06 29 G2/M transition of mitotic cell cycle 141. GO:0010467 2.01E-119 1587 gene expression 142. GO:0016458 9.20E-05 41 gene silencing 143. GO:0006091 8.34E-05 73 generation of precursor metabolites 
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and energy 144. GO:1901659 5.27E-05 34 glycosyl compound biosynthetic process 145. GO:1901658 2.31E-05 189 glycosyl compound catabolic process 146. GO:1901657 4.95E-08 237 glycosyl compound metabolic process 147. GO:0048193 1.95E-05 47 Golgi vesicle transport 148. GO:0007507 1.00E-11 146 heart development 149. GO:0003007 1.68E-10 84 heart morphogenesis 150. GO:0018130 1.04E-48 964 heterocycle biosynthetic process 151. GO:0046700 6.83E-12 284 heterocycle catabolic process 152. GO:0046483 3.09E-139 1660 heterocycle metabolic process 153. GO:0016573 8.99E-09 51 histone acetylation 154. GO:0043968 8.42E-05 9 histone H2A acetylation 155. GO:0043966 1.19E-05 23 histone H3 acetylation 156. GO:0043967 7.81E-06 23 histone H4 acetylation 157. GO:0016571 6.07E-06 37 histone methylation 158. GO:0016570 5.17E-21 141 histone modification 159. GO:0016574 5.38E-05 17 histone ubiquitination 160. GO:0001701 3.03E-09 133 in utero embryonic development 161. GO:0018393 2.51E-08 51 internal peptidyl-lysine acetylation 162. GO:0006475 3.23E-08 52 internal protein amino acid acetylation 163. GO:0006886 3.63E-05 163 intracellular protein transport 164. GO:0046907 1.91E-09 301 intracellular transport 165. GO:0051382 1.00E-04 8 kinetochore assembly 166. GO:0051383 8.28E-06 10 kinetochore organisation 167. GO:0060173 1.21E-05 56 limb development 168. GO:0035108 3.51E-06 54 limb morphogenesis 169. GO:0065003 2.03E-27 361 macromolecular complex assembly 170. GO:0032984 1.99E-05 43 macromolecular complex disassembly 171. GO:0043933 2.02E-35 452 macromolecular complex subunit organisation 172. GO:0009059 2.58E-95 1252 macromolecule biosynthetic process 173. GO:0009057 1.30E-19 252 macromolecule catabolic process 174. GO:0033036 8.72E-13 489 macromolecule localisation 175. GO:0043170 8.25E-157 2167 macromolecule metabolic process 176. GO:0043414 2.97E-07 63 macromolecule methylation 177. GO:0043412 8.60E-28 737 macromolecule modification 178. GO:0051651 8.82E-06 39 maintenance of location in cell 179. GO:0045185 4.34E-05 38 maintenance of protein location 180. GO:0032507 1.17E-05 36 maintenance of protein location in cell 181. GO:0030490 2.83E-05 8 maturation of SSU-rRNA 182. GO:0051321 1.76E-09 69 meiotic cell cycle 183. GO:0007126 8.05E-09 65 meiotic nuclear division 
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184. GO:0008152 2.42E-137 2674 metabolic process 185. GO:0051310 9.87E-09 15 metaphase plate congression 186. GO:0044784 1.23E-07 20 metaphase/anaphase transition of cell cycle 187. GO:0007091 1.23E-07 20 metaphase/anaphase transition of mitotic cell cycle 188. GO:0032259 5.72E-09 94 methylation 189. GO:0034453 3.63E-05 18 microtubule anchoring 190. GO:0000226 2.89E-22 140 microtubule cytoskeleton organisation 191. GO:0031023 7.60E-15 46 microtubule organising center organisation 192. GO:0007017 4.92E-19 176 microtubule-based process 193. GO:0007005 6.18E-08 93 mitochondrion organisation 194. GO:0007067 1.37E-50 195 mitosis 195. GO:0000278 2.05E-58 302 mitotic cell cycle 196. GO:0007093 8.50E-11 46 mitotic cell cycle checkpoint 197. GO:0044772 3.08E-22 121 mitotic cell cycle phase transition 198. GO:0007076 2.89E-05 9 mitotic chromosome condensation 199. GO:0044774 8.53E-05 21 mitotic DNA integrity checkpoint 200. GO:0007080 2.89E-05 9 mitotic metaphase plate congression 201. GO:0000070 1.22E-14 35 mitotic sister chromatid segregation 202. GO:0007094 1.21E-05 13 mitotic spindle assembly checkpoint 203. GO:0071174 2.95E-06 15 mitotic spindle checkpoint 204. GO:0007052 1.85E-07 21 mitotic spindle organisation 205. GO:0043632 1.91E-11 125 modification-dependent macromolecule catabolic process 206. GO:0019941 4.74E-11 123 modification-dependent protein catabolic process 207. GO:0061138 7.18E-05 65 morphogenesis of a branching epithelium 208. GO:0001763 7.72E-05 68 morphogenesis of a branching structure 209. GO:0002009 9.61E-09 133 morphogenesis of an epithelium 210. GO:0016331 5.38E-05 50 morphogenesis of embryonic epithelium 211. GO:0006402 2.81E-07 38 mRNA catabolic process 212. GO:0045292 1.95E-05 7 mRNA cis splicing, via spliceosome 213. GO:0006406 9.42E-10 25 mRNA export from nucleus 214. GO:0016071 8.32E-53 219 mRNA metabolic process 215. GO:0006397 7.23E-54 201 mRNA processing 216. GO:0000398 2.65E-34 87 mRNA splicing, via spliceosome 217. GO:0051028 1.04E-24 62 mRNA transport 218. GO:0007275 6.54E-12 978 multicellular organismal development 219. GO:0055001 8.44E-05 48 muscle cell development 220. GO:0042692 1.19E-05 91 muscle cell differentiation 221. GO:0061061 2.00E-07 144 muscle structure development 222. GO:0060537 2.78E-05 107 muscle tissue development 
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223. GO:0034660 1.65E-36 151 ncRNA metabolic process 224. GO:0034470 4.38E-28 115 ncRNA processing 225. GO:0048519 2.14E-17 889 negative regulation of biological process 226. GO:0009890 4.14E-15 326 negative regulation of biosynthetic process 227. GO:0045786 1.10E-08 79 negative regulation of cell cycle 228. GO:1901988 2.36E-12 58 negative regulation of cell cycle phase transition 229. GO:0010948 3.70E-17 82 negative regulation of cell cycle process 230. GO:0031327 6.48E-16 324 negative regulation of cellular biosynthetic process 231. GO:0051129 4.71E-07 122 negative regulation of cellular component organisation 232. GO:2000113 2.42E-17 308 negative regulation of cellular macromolecule biosynthetic process 233. GO:0031324 7.01E-19 435 negative regulation of cellular metabolic process 234. GO:0048523 5.46E-20 824 negative regulation of cellular process 235. GO:0051053 2.03E-06 34 negative regulation of DNA metabolic process 236. GO:0010629 1.08E-12 302 negative regulation of gene expression 237. GO:0010558 2.83E-16 316 negative regulation of macromolecule biosynthetic process 238. GO:0010605 3.78E-20 452 negative regulation of macromolecule metabolic process 239. GO:0009892 1.62E-17 474 negative regulation of metabolic process 240. GO:1902100 1.21E-06 15 negative regulation of metaphase/anaphase transition of cell cycle 241. GO:0045839 7.55E-07 19 negative regulation of mitosis 242. GO:1901991 9.17E-13 58 negative regulation of mitotic cell cycle phase transition 243. GO:0045841 1.21E-06 15 negative regulation of mitotic metaphase/anaphase transition 244. GO:0050686 3.92E-08 14 negative regulation of mRNA processing 245. GO:0048025 6.81E-09 14 negative regulation of mRNA splicing, via spliceosome 246. GO:0051172 9.75E-19 325 negative regulation of nitrogen compound metabolic process 247. GO:0051784 4.06E-06 21 negative regulation of nuclear division 248. GO:0045934 1.24E-19 323 negative regulation of nucleobase-containing compound metabolic process 249. GO:0010639 8.73E-09 79 negative regulation of organelle 
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organisation 250. GO:0051248 9.56E-05 136 negative regulation of protein metabolic process 251. GO:2001021 9.05E-06 19 negative regulation of response to DNA damage stimulus 252. GO:1902679 6.73E-13 268 negative regulation of RNA biosynthetic process 253. GO:0051253 9.44E-16 286 negative regulation of RNA metabolic process 254. GO:0033119 4.33E-08 16 negative regulation of RNA splicing 255. GO:0000122 2.31E-09 180 negative regulation of transcription from RNA polymerase II promoter 256. GO:0045892 8.57E-13 263 negative regulation of transcription, DNA-templated 257. GO:0017148 8.78E-05 29 negative regulation of translation 258. GO:0001843 4.99E-05 32 neural tube closure 259. GO:0001841 4.34E-05 38 neural tube formation 260. GO:0006807 4.18E-126 1731 nitrogen compound metabolic process 261. GO:0000726 4.87E-05 11 non-recombinational repair 262. GO:0000280 8.19E-51 241 nuclear division 263. GO:0051168 1.87E-13 53 nuclear export 264. GO:0051170 8.36E-06 72 nuclear import 265. GO:0006999 4.64E-06 8 nuclear pore organisation 266. GO:0051169 3.02E-16 132 nuclear transport 267. GO:0000956 1.00E-05 30 nuclear-transcribed mRNA catabolic process 268. GO:0000184 5.25E-06 19 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 269. GO:0090304 1.70E-139 1394 nucleic acid metabolic process 270. GO:0090305 4.36E-08 56 nucleic acid phosphodiester bond hydrolysis 271. GO:0050657 5.03E-26 71 nucleic acid transport 272. GO:0034654 1.14E-47 945 nucleobase-containing compound biosynthetic process 273. GO:0034655 3.55E-13 280 nucleobase-containing compound catabolic process 274. GO:0006139 1.35E-140 1632 nucleobase-containing compound metabolic process 275. GO:0015931 1.88E-20 75 nucleobase-containing compound transport 276. GO:0055086 9.12E-09 307 nucleobase-containing small molecule metabolic process 277. GO:0006913 6.61E-16 130 nucleocytoplasmic transport 278. GO:0009163 4.06E-05 34 nucleoside biosynthetic process 279. GO:0009164 1.39E-05 189 nucleoside catabolic process 280. GO:0009116 1.21E-08 237 nucleoside metabolic process 281. GO:0009124 1.38E-05 30 nucleoside monophosphate biosynthetic process 282. GO:0009125 2.60E-07 70 nucleoside monophosphate 
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catabolic process 283. GO:0009123 1.70E-10 98 nucleoside monophosphate metabolic process 284. GO:1901292 4.34E-07 212 nucleoside phosphate catabolic process 285. GO:0006753 1.31E-08 297 nucleoside phosphate metabolic process 286. GO:0009143 1.24E-06 193 nucleoside triphosphate catabolic process 287. GO:0009141 1.03E-07 212 nucleoside triphosphate metabolic process 288. GO:0034728 4.06E-05 34 nucleosome organisation 289. GO:0009166 1.37E-06 207 nucleotide catabolic process 290. GO:0009117 3.04E-08 293 nucleotide metabolic process 291. GO:0006997 7.15E-06 30 nucleus organisation 292. GO:0048513 3.34E-05 559 organ development 293. GO:0009887 2.60E-07 227 organ morphogenesis 294. GO:0070925 2.73E-11 111 organelle assembly 295. GO:0048285 3.13E-50 249 organelle fission 296. GO:0006996 1.25E-83 865 organelle organisation 297. GO:1901362 1.60E-48 990 organic cyclic compound biosynthetic process 298. GO:1901361 5.45E-11 288 organic cyclic compound catabolic process 299. GO:1901360 1.21E-133 1697 organic cyclic compound metabolic process 300. GO:1901576 1.78E-92 1432 organic substance biosynthetic process 301. GO:1901575 3.83E-14 517 organic substance catabolic process 302. GO:0071704 1.17E-149 2537 organic substance metabolic process 303. GO:1901564 6.09E-06 421 organonitrogen compound metabolic process 304. GO:0046434 1.59E-06 221 organophosphate catabolic process 305. GO:0019637 3.25E-05 337 organophosphate metabolic process 306. GO:0003151 2.51E-05 25 outflow tract morphogenesis 307. GO:0060021 2.66E-05 33 palate development 308. GO:0018193 5.66E-10 216 peptidyl-amino acid modification 309. GO:0018196 6.53E-05 10 peptidyl-asparagine modification 310. GO:0018394 4.46E-08 52 peptidyl-lysine acetylation 311. GO:0018205 1.76E-08 68 peptidyl-lysine modification 312. GO:0018208 1.66E-08 21 peptidyl-proline modification 313. GO:0006796 8.99E-10 731 phosphate-containing compound metabolic process 314. GO:0006793 5.16E-10 743 phosphorus metabolic process 315. GO:0048518 9.83E-13 939 positive regulation of biological process 316. GO:0009891 2.36E-16 405 positive regulation of biosynthetic process 
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317. GO:0090263 2.42E-05 26 positive regulation of canonical Wnt signaling pathway 318. GO:1901989 1.74E-05 21 positive regulation of cell cycle phase transition 319. GO:0090068 6.78E-07 60 positive regulation of cell cycle process 320. GO:0031328 3.82E-17 401 positive regulation of cellular biosynthetic process 321. GO:0051130 5.32E-06 182 positive regulation of cellular component organisation 322. GO:0031325 2.97E-15 550 positive regulation of cellular metabolic process 323. GO:0048522 3.89E-19 885 positive regulation of cellular process 324. GO:2001252 5.21E-05 24 positive regulation of chromosome organisation 325. GO:0051054 1.13E-05 44 positive regulation of DNA metabolic process 326. GO:2000105 8.09E-05 6 positive regulation of DNA-dependent DNA replication 327. GO:0010628 6.35E-15 356 positive regulation of gene expression 328. GO:0010557 1.70E-17 380 positive regulation of macromolecule biosynthetic process 329. GO:0010604 2.63E-16 536 positive regulation of macromolecule metabolic process 330. GO:0009893 2.08E-14 577 positive regulation of metabolic process 331. GO:1901992 1.74E-05 21 positive regulation of mitotic cell cycle phase transition 332. GO:0051173 5.01E-17 387 positive regulation of nitrogen compound metabolic process 333. GO:0045935 8.53E-18 383 positive regulation of nucleobase-containing compound metabolic process 334. GO:1902680 2.97E-16 336 positive regulation of RNA biosynthetic process 335. GO:0051254 5.51E-17 344 positive regulation of RNA metabolic process 336. GO:0045944 8.35E-09 230 positive regulation of transcription from RNA polymerase II promoter 337. GO:0045893 2.43E-15 329 positive regulation of transcription, DNA-templated 338. GO:0045727 8.12E-06 26 positive regulation of translation 339. GO:0030177 4.99E-05 32 positive regulation of Wnt signaling pathway 340. GO:0010608 1.22E-15 153 posttranscriptional regulation of gene expression 341. GO:0044238 1.59E-157 2476 primary metabolic process 342. GO:0014020 3.18E-05 34 primary neural tube formation 343. GO:0012501 2.47E-09 402 programmed cell death 344. GO:0006473 1.61E-08 57 protein acetylation 
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345. GO:0043543 2.87E-08 66 protein acylation 346. GO:0008213 2.50E-05 43 protein alkylation 347. GO:0030163 2.07E-12 175 protein catabolic process 348. GO:0006461 4.56E-17 294 protein complex assembly 349. GO:0070271 3.26E-15 240 protein complex biogenesis 350. GO:0043241 4.51E-06 43 protein complex disassembly 351. GO:0031503 8.72E-05 20 protein complex localisation 352. GO:0071822 2.55E-25 383 protein complex subunit organisation 353. GO:0000338 1.06E-06 9 protein deneddylation 354. GO:0051261 3.18E-05 31 protein depolymerisation 355. GO:0006457 1.26E-17 75 protein folding 356. GO:0017038 3.25E-05 76 protein import 357. GO:0006606 1.13E-05 71 protein import into nucleus 358. GO:0008104 5.33E-12 436 protein localisation 359. GO:0034502 6.88E-07 17 protein localisation to chromosome 360. GO:0034501 1.95E-05 7 protein localisation to kinetochore 361. GO:0034504 1.20E-06 87 protein localisation to nucleus 362. GO:0033365 4.80E-11 146 protein localisation to organelle 363. GO:0019538 2.87E-53 1160 protein metabolic process 364. GO:0006479 2.50E-05 43 protein methylation 365. GO:0032446 1.66E-09 144 protein modification by small protein conjugation 366. GO:0070647 4.81E-15 183 protein modification by small protein conjugation or removal 367. GO:0070646 5.72E-08 41 protein modification by small protein removal 368. GO:0036211 1.70E-24 700 protein modification process 369. GO:0006513 3.93E-05 21 protein monoubiquitination 370. GO:0000413 1.21E-06 15 protein peptidyl-prolyl isomerisation 371. GO:0000209 8.92E-06 46 protein polyubiquitination 372. GO:0015031 6.01E-06 299 protein transport 373. GO:0016567 6.99E-09 133 protein ubiquitination 374. GO:0065004 4.57E-07 42 protein-DNA complex assembly 375. GO:0071824 1.91E-09 54 protein-DNA complex subunit organisation 376. GO:0051603 2.03E-11 136 proteolysis involved in cellular protein catabolic process 377. GO:0006152 8.29E-06 189 purine nucleoside catabolic process 378. GO:0042278 3.62E-07 218 purine nucleoside metabolic process 379. GO:0009128 3.65E-07 69 purine nucleoside monophosphate catabolic process 380. GO:0009126 4.81E-09 90 purine nucleoside monophosphate metabolic process 381. GO:0009146 3.93E-06 189 purine nucleoside triphosphate catabolic process 382. GO:0009144 7.17E-07 204 purine nucleoside triphosphate metabolic process 383. GO:0006195 4.25E-07 206 purine nucleotide catabolic process 
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384. GO:0006163 1.94E-07 257 purine nucleotide metabolic process 385. GO:0046130 8.29E-06 189 purine ribonucleoside catabolic process 386. GO:0046128 3.65E-07 217 purine ribonucleoside metabolic process 387. GO:0009169 2.92E-07 69 purine ribonucleoside monophosphate catabolic process 388. GO:0009167 3.81E-09 90 purine ribonucleoside monophosphate metabolic process 389. GO:0009207 2.96E-06 189 purine ribonucleoside triphosphate catabolic process 390. GO:0009205 5.93E-07 203 purine ribonucleoside triphosphate metabolic process 391. GO:0009154 2.44E-06 195 purine ribonucleotide catabolic process 392. GO:0009150 1.51E-06 243 purine ribonucleotide metabolic process 393. GO:0072523 5.69E-07 207 purine-containing compound catabolic process 394. GO:0072521 2.39E-07 266 purine-containing compound metabolic process 395. GO:0006221 9.33E-05 13 pyrimidine nucleotide biosynthetic process 396. GO:0000725 6.51E-09 30 recombinational repair 397. GO:0000381 2.91E-05 16 regulation of alternative mRNA splicing, via spliceosome 398. GO:0022603 2.91E-05 185 regulation of anatomical structure morphogenesis 399. GO:0042981 1.10E-07 306 regulation of apoptotic process 400. GO:0009889 9.36E-44 979 regulation of biosynthetic process 401. GO:0060828 1.32E-05 52 regulation of canonical Wnt signaling pathway 402. GO:0051726 2.29E-23 236 regulation of cell cycle 403. GO:0071156 8.72E-05 20 regulation of cell cycle arrest 404. GO:1901976 2.57E-05 13 regulation of cell cycle checkpoint 405. GO:1901987 3.74E-16 87 regulation of cell cycle phase transition 406. GO:0010564 9.02E-23 159 regulation of cell cycle process 407. GO:0010941 1.65E-08 329 regulation of cell death 408. GO:0051302 1.63E-07 72 regulation of cell division 409. GO:0022604 6.28E-05 101 regulation of cell morphogenesis 410. GO:0042127 1.41E-05 308 regulation of cell proliferation 411. GO:0031326 7.72E-46 971 regulation of cellular biosynthetic process 412. GO:0051128 2.06E-11 412 regulation of cellular component organisation 413. GO:2000112 8.44E-51 935 regulation of cellular macromolecule biosynthetic process 414. GO:0031323 8.44E-51 1286 regulation of cellular metabolic process 
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415. GO:0032268 1.80E-11 363 regulation of cellular protein metabolic process 416. GO:0080135 9.05E-06 103 regulation of cellular response to stress 417. GO:0046605 5.00E-05 13 regulation of centrosome cycle 418. GO:0033044 8.77E-07 51 regulation of chromosome organisation 419. GO:0051983 5.08E-07 18 regulation of chromosome segregation 420. GO:0051493 3.21E-06 98 regulation of cytoskeleton organisation 421. GO:0050793 6.09E-06 428 regulation of developmental process 422. GO:0051052 9.88E-14 103 regulation of DNA metabolic process 423. GO:0000018 7.87E-05 23 regulation of DNA recombination 424. GO:0006282 5.81E-07 27 regulation of DNA repair 425. GO:0006275 1.41E-07 45 regulation of DNA replication 426. GO:0090329 6.40E-06 15 regulation of DNA-dependent DNA replication 427. GO:2000779 1.84E-05 14 regulation of double-strand break repair 428. GO:2000045 3.82E-05 32 regulation of G1/S transition of mitotic cell cycle 429. GO:0010468 8.97E-46 1035 regulation of gene expression 430. GO:0040029 3.49E-05 55 regulation of gene expression, epigenetic 431. GO:0010556 7.37E-47 948 regulation of macromolecule biosynthetic process 432. GO:0060255 1.73E-50 1228 regulation of macromolecule metabolic process 433. GO:0019222 4.41E-43 1404 regulation of metabolic process 434. GO:1902099 2.60E-07 20 regulation of metaphase/anaphase transition of cell cycle 435. GO:0070507 1.05E-08 47 regulation of microtubule cytoskeleton organisation 436. GO:0032886 1.00E-07 50 regulation of microtubule-based process 437. GO:0007088 2.21E-06 38 regulation of mitosis 438. GO:0007346 2.04E-17 125 regulation of mitotic cell cycle 439. GO:1901990 1.63E-16 87 regulation of mitotic cell cycle phase transition 440. GO:0030071 2.60E-07 20 regulation of mitotic metaphase/anaphase transition 441. GO:0050684 3.85E-12 39 regulation of mRNA processing 442. GO:0048024 1.55E-11 30 regulation of mRNA splicing, via spliceosome 443. GO:0051171 6.71E-48 1034 regulation of nitrogen compound metabolic process 444. GO:0051783 1.94E-06 46 regulation of nuclear division 445. GO:0019219 2.29E-49 1027 regulation of nucleobase-containing compound metabolic process 
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446. GO:0046822 1.22E-05 59 regulation of nucleocytoplasmic transport 447. GO:0033043 2.67E-14 212 regulation of organelle organisation 448. GO:0080090 1.39E-51 1263 regulation of primary metabolic process 449. GO:0043067 1.02E-07 310 regulation of programmed cell death 450. GO:0042176 6.19E-06 66 regulation of protein catabolic process 451. GO:0051246 3.11E-09 399 regulation of protein metabolic process 452. GO:2001020 4.14E-10 52 regulation of response to DNA damage stimulus 453. GO:2001141 7.31E-38 831 regulation of RNA biosynthetic process 454. GO:0051252 4.18E-43 867 regulation of RNA metabolic process 455. GO:0043484 2.40E-11 41 regulation of RNA splicing 456. GO:0006357 9.38E-16 406 regulation of transcription from RNA polymerase II promoter 457. GO:0006355 5.50E-37 824 regulation of transcription, DNA-templated 458. GO:0006417 1.98E-17 99 regulation of translation 459. GO:0006446 1.05E-08 27 regulation of translational initiation 460. GO:0030111 3.18E-05 64 regulation of Wnt signaling pathway 461. GO:0010212 5.82E-07 43 response to ionising radiation 462. GO:0009314 8.10E-05 87 response to radiation 463. GO:0006950 2.05E-08 600 response to stress 464. GO:0009411 3.90E-05 39 response to UV 465. GO:0022618 3.22E-19 62 ribonucleoprotein complex assembly 466. GO:0022613 6.22E-52 154 ribonucleoprotein complex biogenesis 467. GO:0071826 3.95E-17 62 ribonucleoprotein complex subunit organisation 468. GO:0042455 4.06E-05 34 ribonucleoside biosynthetic process 469. GO:0042454 1.18E-05 189 ribonucleoside catabolic process 470. GO:0009119 1.24E-07 223 ribonucleoside metabolic process 471. GO:0009156 8.69E-05 26 ribonucleoside monophosphate biosynthetic process 472. GO:0009158 2.92E-07 69 ribonucleoside monophosphate catabolic process 473. GO:0009161 1.91E-09 92 ribonucleoside monophosphate metabolic process 474. GO:0009203 2.16E-06 190 ribonucleoside triphosphate catabolic process 475. GO:0009199 2.29E-07 206 ribonucleoside triphosphate metabolic process 476. GO:0009261 2.44E-06 195 ribonucleotide catabolic process 477. GO:0009259 6.88E-07 247 ribonucleotide metabolic process 478. GO:0019693 7.37E-07 248 ribose phosphate metabolic process 
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479. GO:0042273 5.81E-07 12 ribosomal large subunit biogenesis 480. GO:0000028 1.06E-06 9 ribosomal small subunit assembly 481. GO:0042274 8.43E-12 20 ribosomal small subunit biogenesis 482. GO:0042255 1.55E-07 15 ribosome assembly 483. GO:0042254 3.41E-42 113 ribosome biogenesis 484. GO:0031123 3.37E-05 26 RNA 3'-end processing 485. GO:0032774 3.17E-43 863 RNA biosynthetic process 486. GO:0006401 7.08E-09 48 RNA catabolic process 487. GO:0006405 1.42E-12 32 RNA export from nucleus 488. GO:0006403 2.62E-24 70 RNA localisation 489. GO:0016070 1.56E-98 1169 RNA metabolic process 490. GO:0009451 1.15E-05 27 RNA modification 491. GO:0006396 5.73E-81 322 RNA processing 492. GO:0008380 6.06E-52 169 RNA splicing 493. GO:0000375 7.48E-35 88 RNA splicing, via transesterification reactions 494. GO:0000377 2.65E-34 87 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 495. GO:0050658 5.03E-26 71 RNA transport 496. GO:0016072 9.88E-27 77 rRNA metabolic process 497. GO:0006364 4.46E-25 73 rRNA processing 498. GO:0009303 4.87E-05 11 rRNA transcription 499. GO:0044711 8.56E-05 276 single-organism biosynthetic process 500. GO:0044763 2.13E-05 2429 single-organism cellular process 501. GO:0044767 1.17E-16 1127 single-organism developmental process 502. GO:1902582 1.02E-06 236 single-organism intracellular transport 503. GO:0044710 4.07E-26 1150 single-organism metabolic process 504. GO:1902593 1.13E-05 71 single-organism nuclear import 505. GO:1902589 1.89E-67 622 single-organism organelle organisation 506. GO:0044699 3.21E-08 2738 single-organism process 507. GO:0000819 4.00E-15 40 sister chromatid segregation 508. GO:0001501 3.29E-12 137 skeletal system development 509. GO:0048705 1.42E-07 75 skeletal system morphogenesis 510. GO:0044281 2.31E-09 539 small molecule metabolic process 511. GO:0051225 7.89E-13 30 spindle assembly 512. GO:0071173 3.73E-07 16 spindle assembly checkpoint 513. GO:0031577 3.95E-08 21 spindle checkpoint 514. GO:0007051 3.74E-20 52 spindle organisation 515. GO:0000245 8.93E-06 16 spliceosomal complex assembly 516. GO:0000387 1.98E-10 19 spliceosomal snRNP assembly 517. GO:0002040 8.72E-05 20 sprouting angiogenesis 518. GO:0016126 1.16E-05 22 sterol biosynthetic process 519. GO:0014706 3.92E-05 102 striated muscle tissue development 520. GO:0048731 5.56E-08 781 system development 
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521. GO:0009888 2.60E-07 354 tissue development 522. GO:0048729 3.20E-09 164 tissue morphogenesis 523. GO:0006366 6.85E-17 416 transcription from RNA polymerase II promoter 524. GO:0006367 3.91E-05 22 transcription initiation from RNA polymerase II promoter 525. GO:0006351 2.57E-42 855 transcription, DNA-templated 526. GO:0006412 2.96E-61 243 translation 527. GO:0006414 1.52E-08 26 translational elongation 528. GO:0006413 2.14E-18 54 translational initiation 529. GO:0043039 2.76E-10 29 tRNA aminoacylation 530. GO:0006418 2.01E-11 29 tRNA aminoacylation for protein translation 531. GO:0006399 9.43E-12 60 tRNA metabolic process 532. GO:0030488 8.09E-05 6 tRNA methylation 533. GO:0006400 6.40E-06 15 tRNA modification 534. GO:0060606 6.53E-05 32 tube closure 535. GO:0035295 2.55E-07 140 tube development 536. GO:0035148 4.97E-05 46 tube formation 537. GO:0035239 7.61E-06 98 tube morphogenesis 538. GO:0006511 2.75E-11 122 ubiquitin-dependent protein catabolic process 539. GO:0016055 3.51E-05 100 Wnt signaling pathway     Table S3 Biological processes (BP) revealed by gene ontology (GO) analysis associated with upregulated genes upon HP1γ knockout in female MEFs. The number of ‘count’ represent the number of dyregulated genes contribute to each term. Adjusted P-value <10-5. GOBPID Adjusted P-value Count Term 1. GO:0022610 1.39E-07 61 biological adhesion 2. GO:0007155 1.39E-07 61 cell adhesion 3. GO:0000904 9.72E-05 38 cell morphogenesis involved in differentiation 4. GO:0006749 1.13E-05 9 glutathione metabolic process 5. GO:0007399 9.72E-05 81 nervous system development             
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Table S4 Biological processes (BP) revealed by gene ontology (GO) analysis associated with downregulated genes upon HP1γ knockout in female MEFs. The number of ‘count’ represent the number of dyregulated genes contribute to each term. Adjusted P-value <10-5.  GOBPID Adjusted P-value Count Term 1.  GO:0009653 1.65E-05 73 anatomical structure morphogenesis 2.  GO:0009952 1.10E-05 17 anterior/posterior pattern specification 3.  GO:0072358 7.61E-05 32 cardiovascular system development 4.  GO:0051216 5.30E-05 13 cartilage development 5.  GO:0007049 1.65E-05 50 cell cycle 6.  GO:0022402 3.56E-06 43 cell cycle process 7.  GO:0016043 5.00E-06 129 cellular component organisation 8.  GO:0071840 1.10E-05 129 cellular component organisation or biogenesis 9.  GO:0044260 1.56E-05 169 cellular macromolecule metabolic process 10.  GO:0044237 7.58E-06 219 cellular metabolic process 11.  GO:0009987 3.74E-05 325 cellular process 12.  GO:0006464 2.76E-05 81 cellular protein modification process 13.  GO:0007059 9.20E-05 12 chromosome segregation 14.  GO:0072359 7.61E-05 32 circulatory system development 15.  GO:0007010 7.61E-05 35 cytoskeleton organisation 16.  GO:0032502 8.49E-05 128 developmental process 17.  GO:0009790 3.13E-05 42 embryo development 18.  GO:0048598 1.56E-05 29 embryonic morphogenesis 19.  GO:0060429 5.43E-05 32 epithelium development 20.  GO:0051234 8.49E-05 106 establishment of localisation 21.  GO:0007507 1.32E-05 25 heart development 22.  GO:0035404 2.76E-05 4 histone-serine phosphorylation 23.  GO:0051179 3.56E-06 139 localisation 24.  GO:0033036 9.66E-05 61 macromolecule localisation 25.  GO:0043170 3.74E-05 185 macromolecule metabolic process 26.  GO:0043412 7.38E-05 81 macromolecule modification 27.  GO:0048762 9.20E-05 10 mesenchymal cell differentiation 28.  GO:0008152 5.11E-05 240 metabolic process 29.  GO:0007067 7.83E-06 23 mitosis 30.  GO:0000278 2.76E-05 30 mitotic cell cycle 31.  GO:0048519 6.61E-05 103 negative regulation of biological process 32.  GO:0048523 7.61E-05 94 negative regulation of cellular process 33.  GO:0006807 9.42E-05 147 nitrogen compound metabolic process 34.  GO:0071705 1.10E-05 30 nitrogen compound transport 35.  GO:0000280 1.65E-05 26 nuclear division 36.  GO:0048513 1.56E-05 81 organ development 37.  GO:0009887 1.93E-05 37 organ morphogenesis 
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38.  GO:0048285 1.10E-05 28 organelle fission 39.  GO:0006996 1.10E-05 82 organelle organisation 40.  GO:0071704 1.92E-05 226 organic substance metabolic process 41.  GO:0071702 1.56E-05 68 organic substance transport 42.  GO:0001503 5.42E-05 19 ossification 43.  GO:0007389 5.00E-06 27 pattern specification process 44.  GO:0006796 1.10E-05 97 phosphate-containing compound metabolic process 45.  GO:0006793 1.56E-05 97 phosphorus metabolic process 46.  GO:0016310 9.66E-05 58 phosphorylation 47.  GO:0048518 1.65E-05 116 positive regulation of biological process 48.  GO:0031325 7.61E-05 67 positive regulation of cellular metabolic process 49.  GO:0048522 1.84E-05 105 positive regulation of cellular process 50.  GO:0032270 7.96E-05 33 positive regulation of cellular protein metabolic process 51.  GO:0010604 7.61E-05 65 positive regulation of macromolecule metabolic process 52.  GO:0009893 2.77E-05 73 positive regulation of metabolic process 53.  GO:0051247 3.74E-05 37 positive regulation of protein metabolic process 54.  GO:0044238 2.57E-05 217 primary metabolic process 55.  GO:0036211 2.76E-05 81 protein modification process 56.  GO:0016567 6.89E-05 22 protein ubiquitination 57.  GO:0003002 5.43E-05 19 regionalisation 58.  GO:0010646 7.61E-05 74 regulation of cell communication 59.  GO:0031323 7.61E-05 127 regulation of cellular metabolic process 60.  GO:0046599 3.74E-05 4 regulation of centriole replication 61.  GO:0046605 7.61E-05 5 regulation of centrosome cycle 62.  GO:0010824 3.74E-05 5 regulation of centrosome duplication 63.  GO:0032879 1.84E-05 63 regulation of localisation 64.  GO:0019222 1.84E-05 147 regulation of metabolic process 65.  GO:0080090 8.49E-05 124 regulation of primary metabolic process 66.  GO:0023051 7.61E-05 74 regulation of signaling 67.  GO:0044767 7.61E-05 128 single-organism developmental process 68.  GO:1902589 1.10E-05 62 single-organism organelle organisation 69.  GO:0001501 1.65E-05 23 skeletal system development 70.  GO:0009888 3.56E-06 58 tissue development      
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Table S5 List of PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with upregulated genes upon HP1γ knockout in male MEFs. Over- or underrepresentation groups with P<0.05 are presented.  Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ PANTHER GO-Slim Biological Process 
No. of genes in mouse ref. list  
No. of up-regulated genes in male  
No. of expected genes  
Over(+)/ under(-) repre-sentation  
Fold enrich-ment 
P-value 
1. response to interferon-gamma (GO:0034341) 
48 18 4.99 + 3.61 1.13E-03 
2. antigen processing and presentation (GO:0019882) 
77 27 8.01 + 3.37 2.16E-05 
3. cell proliferation (GO:0008283) 110 28 11.44 + 2.45 5.18E-03 4. B cell mediated immunity (GO:0019724) 
155 39 16.12 + 2.42 1.95E-04 
5. cellular defense response (GO:0006968) 
238 59 24.75 + 2.38 6.18E-07 
6. macrophage activation (GO:0042116) 
173 41 17.99 + 2.28 4.48E-04 
7. immune response (GO:0006955) 537 116 55.84 + 2.08 1.38E-10 8. phospholipid metabolic process (GO:0006644) 
177 37 18.41 + 2.01 1.83E-02 
9. cell-cell adhesion (GO:0016337) 362 75 37.64 + 1.99 8.65E-06 10. polysaccharide metabolic process (GO:0005976) 
186 38 19.34 + 1.96 2.34E-02 
11. endocytosis (GO:0006897) 380 77 39.52 + 1.95 1.38E-05 12. immune system process (GO:0002376) 
1480 295 153.9 + 1.92 8.04E-24 
13. receptor-mediated endocytosis (GO:0006898) 
217 43 22.57 + 1.91 1.68E-02 
14. visual perception (GO:0007601) 223 43 23.19 + 1.85 3.00E-02 15. response to external stimulus (GO:0009605) 
404 76 42.01 + 1.81 2.65E-04 
16. cell adhesion (GO:0007155) 550 102 57.19 + 1.78 8.38E-06 17. biological adhesion (GO:0022610) 
577 107 60 + 1.78 3.91E-06 
18. vesicle-mediated transport (GO:0016192) 
891 147 92.65 + 1.59 1.33E-05 
19. phosphate-containing 931 152 96.81 + 1.57 1.47E-05 
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compound metabolic process (GO:0006796) 20. lipid metabolic process (GO:0006629) 
966 156 100.45 + 1.55 1.90E-05 
21. ion transport (GO:0006811) 723 114 75.18 + 1.52 2.92E-03 22. cation transport (GO:0006812) 579 90 60.21 + 1.49 3.64E-02 23. cell communication (GO:0007154) 
3175 492 330.16 + 1.49 1.50E-17 
24. response to stimulus (GO:0050896) 
2559 382 266.1 + 1.44 1.15E-10 
25. regulation of molecular function (GO:0065009) 
1152 171 119.79 + 1.43 7.54E-04 
26. nervous system development (GO:0007399) 
782 115 81.32 + 1.41 4.24E-02 
27. regulation of catalytic activity (GO:0050790) 
1129 166 117.4 + 1.41 1.75E-03 
28. localization (GO:0051179) 2788 401 289.92 + 1.38 3.85E-09 29. transport (GO:0006810) 2658 379 276.4 + 1.37 4.55E-08 30. cellular protein modification process (GO:0006464) 
1341 191 139.45 + 1.37 2.37E-03 
31. intracellular protein transport (GO:0006886) 
1034 146 107.52 + 1.36 3.79E-02 
32. system development (GO:0048731) 
1273 178 132.38 + 1.34 1.24E-02 
33. developmental process (GO:0032502) 
2468 319 256.64 + 1.24 7.88E-03 
34. cellular process (GO:0009987) 7033 885 731.34 + 1.21 1.84E-09 35. metabolic process (GO:0008152) 
8467 1031 880.46 + 1.17 2.23E-08 
36. RNA metabolic process (GO:0016070) 
2315 183 240.73 - 0.76 5.92E-03 
37. Unclassified (UNCLASSIFIED) 9561 745 994.22 - 0.75 0.00E+00 38. DNA metabolic process (GO:0006259) 
352 17 36.6 - 0.46 4.94E-02 
39. translation (GO:0006412) 479 22 49.81 - 0.44 1.48E-03 40. sensory perception of chemical stimulus (GO:0007606) 
295 5 30.68 -  < 0.2 2.44E-06 
41. rRNA metabolic process (GO:0016072) 
120 1 12.48 -  < 0.2 1.10E-02 
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Table S6 List of PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with downregulated genes upon HP1γ knockout in male MEFs. Over- or underrepresentation groups with P<0.05 are presented. Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/  PANTHER  GO-Slim Biological Process 
No. of genes in mouse  ref. list  
No. of up-regulated genes in male  
No. of expected genes  
Over(+)/ under(-) repre-sentation  
Fold enrich-ment 
P-value 
1. regulation of cell cycle (GO:0051726) 
27 13 1.87 + 6.94 2.11E-05 
2. DNA recombination (GO:0006310) 
50 18 3.47 + 5.19 6.47E-06 
3. DNA replication (GO:0006260) 152 49 10.54 + 4.65 1.00E-15 4. regulation of liquid surface tension (GO:0050828) 
55 16 3.81 + 4.19 5.74E-04 
5. chromosome segregation (GO:0007059) 
84 24 5.83 + 4.12 2.88E-06 
6. DNA repair (GO:0006281) 168 46 11.65 + 3.95 3.59E-12 7. DNA metabolic process (GO:0006259) 
352 85 24.41 + 3.48 7.23E-20 
8. tRNA metabolic process (GO:0006399) 
81 18 5.62 + 3.2 5.23E-03 
9. mRNA splicing, via spliceosome (GO:0000398) 
187 41 12.97 + 3.16 7.35E-08 
10. rRNA metabolic process (GO:0016072) 
120 26 8.32 + 3.12 1.46E-04 
11. cell-matrix adhesion (GO:0007160) 
88 18 6.1 + 2.95 1.49E-02 
12. RNA splicing, via transesterification reactions (GO:0000375) 
133 26 9.22 + 2.82 9.12E-04 
13. RNA splicing (GO:0008380) 136 26 9.43 + 2.76 1.34E-03 14. chromatin organization (GO:0006325) 
244 44 16.92 + 2.6 5.27E-06 
15. mitosis (GO:0007067) 365 63 25.31 + 2.49 3.02E-08 16. mRNA processing (GO:0006397) 
272 45 18.86 + 2.39 4.04E-05 
17. cell-cell adhesion (GO:0016337) 362 54 25.11 + 2.15 6.41E-05 18. cell cycle (GO:0007049) 1128 160 78.23 + 2.05 8.29E-15 19. cellular component biogenesis 
298 39 20.67 + 1.89 4.10E-02 
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(GO:0044085) 
20. biological adhesion (GO:0022610) 
577 73 40.02 + 1.82 2.83E-04 
21. ectoderm development (GO:0007398) 
621 78 43.07 + 1.81 1.61E-04 
22. cell adhesion (GO:0007155) 550 69 38.15 + 1.81 7.24E-04 23. translation (GO:0006412) 479 59 33.22 + 1.78 6.06E-03 24. organelle organization (GO:0006996) 
565 69 39.19 + 1.76 1.73E-03 
25. cellular component movement (GO:0006928) 
463 55 32.11 + 1.71 2.77E-02 
26. cellular component organization or biogenesis (GO:0071840) 
1298 154 90.02 + 1.71 3.02E-08 
27. nervous system development (GO:0007399) 
782 90 54.24 + 1.66 7.93E-04 
28. nucleobase-containing compound metabolic process (GO:0006139) 
3425 390 237.54 + 1.64 1.86E-21 
29. anatomical structure morphogenesis (GO:0009653) 
584 65 40.5 + 1.6 4.32E-02 
30. nitrogen compound metabolic process (GO:0006807) 
1064 117 73.79 + 1.59 2.47E-04 
31. cellular component organization (GO:0016043) 
1185 130 82.19 + 1.58 6.90E-05 
32. system development (GO:0048731) 
1273 138 88.29 + 1.56 5.62E-05 
33. mesoderm development (GO:0007498) 
706 76 48.96 + 1.55 3.55E-02 
34. RNA metabolic process (GO:0016070) 
2315 235 160.56 + 1.46 6.39E-07 
35. developmental process (GO:0032502) 
2468 250 171.17 + 1.46 2.15E-07 
36. primary metabolic process (GO:0044238) 
6997 651 485.28 + 1.34 1.16E-16 
37. metabolic process (GO:0008152) 
8467 746 587.23 + 1.27 3.10E-14 
38. cellular process (GO:0009987) 7033 617 487.77 + 1.26 5.58E-10 
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39. Unclassified (UNCLASSIFIED) 9561 500 663.1 - 0.75 0.00E+00    Table S7 List of PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with upregulated genes upon HP1γ knockout in female MEFs. Over- or underrepresentation groups with P<0.05 are presented. Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ PANTHER  GO-Slim Biological Process 
No. of genes in mouse  ref. list  
No. of up-regulated genes in male  
No. of expected genes  
Over(+)/ under(-) repre-sentation  
Fold enrich-ment 
P-value 
1. regulation of liquid surface tension (GO:0050828) 
55 10 2.08 + 4.81 1.37E-02 
2. cellular glucose homeostasis (GO:0001678) 
62 10 2.34 + 4.27 3.59E-02 
3. cell-cell adhesion (GO:0016337) 362 48 13.69 + 3.51 4.85E-11 4. ectoderm development (GO:0007398) 
621 72 23.48 + 3.07 3.90E-14 
5. cell adhesion (GO:0007155) 550 60 20.8 + 2.88 1.76E-10 6. homeostatic process (GO:0042592) 
208 22 7.87 + 2.8 5.14E-03 
7. biological adhesion (GO:0022610) 
577 60 21.82 + 2.75 1.21E-09 
8. nervous system development (GO:0007399) 
782 81 29.57 + 2.74 2.28E-13 
9. muscle contraction (GO:0006936) 
225 21 8.51 + 2.47 4.31E-02 
10. mesoderm development (GO:0007498) 
706 59 26.7 + 2.21 5.52E-06 
11. system development (GO:0048731) 
1273 106 48.14 + 2.2 1.11E-11 
12. cell-cell signaling (GO:0007267) 598 44 22.61 + 1.95 7.31E-03 13. developmental process (GO:0032502) 
2468 168 93.32 + 1.8 1.11E-11 
14. system process (GO:0003008) 1497 91 56.61 + 1.61 1.62E-03 15. regulation of nucleobase-containing compound metabolic process (GO:0019219) 
1621 98 61.3 + 1.6 8.77E-04 
16. single- 1828 107 69.12 + 1.55 1.24E-03 
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multicellular organism process (GO:0044707) 17. regulation of transcription from RNA polymerase II promoter (GO:0006357) 
1266 74 47.87 + 1.55 3.94E-02 
18. multicellular organismal process (GO:0032501) 
1832 107 69.27 + 1.54 1.36E-03 
19. cell communication (GO:0007154) 
3175 184 120.06 + 1.53 4.33E-07 
20. biological regulation (GO:0065007) 
4101 207 155.07 + 1.33 1.14E-03 
21. cellular process (GO:0009987) 7033 345 265.94 + 1.3 1.35E-06 22. Unclassified (UNCLASSIFIED) 9561 298 361.54 - 0.82 0.00E+00    Table S8 List of PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with downregulated genes upon HP1γ knockout in female MEFs. Over- or underrepresentation groups with P<0.05 are presented. Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/  PANTHER  GO-Slim Biological Process 
No. of genes in mouse  ref. list  
No. of up-regulated genes in male  
No. of expected genes  
Over(+)/ under(-) repre-sentation  
Fold enrich-ment 
P-value 
1. skeletal system development (GO:0001501) 
241 11 1.72 + 6.41 3.43E-04 
2. visual perception (GO:0007601) 223 8 1.59 + 5.04 4.89E-02 3. biological adhesion (GO:0022610) 577 14 4.11 + 3.41 1.65E-02 4. cell adhesion (GO:0007155) 550 13 3.92 + 3.32 3.87E-02 5. ectoderm development (GO:0007398) 
621 14 4.42 + 3.16 3.54E-02 
6. mesoderm development (GO:0007498) 
706 15 5.03 + 2.98 3.90E-02 
7. system development (GO:0048731) 1273 25 9.07 + 2.76 9.29E-04 8. developmental process (GO:0032502) 
2468 35 17.58 + 1.99 1.19E-02 
9. Unclassified (UNCLASSIFIED) 9561 55 68.11 - 0.81 0.00E+00     
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Table S9 List of the definition of the top 10 overrepresented PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with upregulated genes upon HP1γ knockout in male MEFs. Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ Class ID PANTHER  GO-Slim  Biological Process 
Definition  
1. GO:0034341 response to interferon-gamma 
"Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-gamma stimulus. Interferon-gamma is also known as type II interferon." 2. GO:0019882 antigen processing and presentation 
"The process in which an antigen-presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex." 3. GO:0008283 cell proliferation "The multiplication or reproduction of cells, resulting in the expansion of a cell population." 4. GO:0019724 B cell mediated immunity "Any process involved with the carrying out of an immune response by a B cell, through, for instance, the production of antibodies or cytokines, or antigen presentation to T cells." 5. GO:0006968 cellular defense response "A defense response that is mediated by cells." 6. GO:0042116 macrophage activation "A change in morphology and behaviour of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor." 7. GO:0006955 immune response "Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat." 8. GO:0006644 phospholipid metabolic process 
"The chemical reactions and pathways involving phospholipids, any lipid containing phosphoric acid as a mono- or diester." 9. GO:0016337 cell-cell adhesion "The attachment of one cell to another cell via adhesion molecules." 10. GO:0005976 polysaccharide metabolic process 
"The chemical reactions and pathways involving a polysaccharide, a polymer of many (typically more than 10) monosaccharide residues linked glycosidically."     
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Table S10 List of the definition of the top 10 overrepresented PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with downregulated genes upon HP1γ knockout in male MEFs. Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ Class ID PANTHER GO-Slim Biological Process 
Definition 
1. GO:0051726 regulation of cell cycle "Any process that modulates the rate or extent of progression through the cell cycle." 2. GO:0006310 DNA recombination "Any process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents. In eukaryotes genetic recombination can occur by chromosome assortment, intrachromosomal recombination, or nonreciprocal interchromosomal recombination. Intrachromosomal recombination occurs by crossing over. In bacteria it may occur by genetic transformation, conjugation, transduction, or F-duction." 3. GO:0006260 DNA replication "The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognised and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA." 4. GO:0050828 regulation of liquid surface tension 
"Any process that modulates the surface tension of a liquid. Surface tension is the property that makes a liquid behave as if it had an elastic skin on its surface at the interface with a gas or an immiscible liquid." 5. GO:0007059 chromosome segregation "The process in which genetic material, in the form of chromosomes, is organised into specific structures and then physically separated and apportioned to two or more sets. In eukaryotes, chromosome segregation begins with the alignment of chromosomes at the metaphase plate, includes chromosome separation, and 
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ends when chromosomes have completed movement to the spindle poles." 6. GO:0006281 DNA repair "The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionising radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway." 7. GO:0006259 DNA metabolic process "Any cellular metabolic process involving deoxyribonucleic acid. This is one of the two main types of nucleic acid, consisting of a long, unbranched macromolecule formed from one, or more commonly, two, strands of linked deoxyribonucleotides." 8. GO:0006399 tRNA metabolic process  "The chemical reactions and pathways involving tRNA, transfer RNA, a class of relatively small RNA molecules responsible for mediating the insertion of amino acids into the sequence of nascent polypeptide chains during protein synthesis. Transfer RNA is characterized by the presence of many unusual minor bases, the function of which has not been completely established." 9. GO:0000398 mRNA splicing, via spliceosome 
"The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced." 10. GO:0016072 rRNA metabolic process "The chemical reactions and pathways involving rRNA, ribosomal RNA, a structural constituent of ribosomes."        
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Table 11 List of the definition of the top 10 overrepresented PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with upregulated genes upon HP1γ knockout in female MEFs. Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ Class ID PANTHER GO-Slim Biological Process 
Definition 
1. GO:0050828 regulation of liquid surface tension  
"Any process that modulates the surface tension of a liquid. Surface tension is the property that makes a liquid behave as if it had an elastic skin on its surface at the interface with a gas or an immiscible liquid." 2. GO:0001678 cellular glucose homeostasis "A cellular homeostatic process involved in the maintenance of an internal steady state of glucose within a cell or between a cell and its external environment." 3. GO:0016337 cell-cell adhesion "The attachment of one cell to another cell via adhesion molecules." 4. GO:0007398 ectoderm development "The process whose specific outcome is the progression of the ectoderm over time, from its formation to the mature structure. In animal embryos, the ectoderm is the outer germ layer of the embryo, formed during gastrulation." 5. GO:0007155 cell adhesion "The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules." 6. GO:0042592 homeostatic process  "Any biological process involved in the maintenance of an internal steady state." 7. GO:0022610 biological adhesion "The attachment of a cell or organism to a substrate or other organism." 8. GO:0007399 nervous system development "The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state." 9. GO:0006936 muscle contraction "A process in which force is generated within muscle tissue, resulting in a change in muscle geometry. Force generation involves a chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis." 10. GO:0007498 mesoderm development "The process whose specific outcome is the progression of the mesoderm over time, from its formation to the mature structure. The mesoderm is the middle germ layer that develops into muscle, bone, cartilage, blood and connective tissue."  
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Table S12 List of the definition of the overrepresented PANTHER GO-Slim biological processes revealed by PANTHER overrepresentation test associated with downregulated genes upon HP1γ knockout in female MEFs. Definition of the PANTHER GO-Slim biological process can be found on the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ Class ID PANTHER GO-Slim Biological Process 
Definition 
1. GO:0001501 skeletal system development "The process whose specific outcome is the progression of the skeleton over time, from its formation to the mature structure. The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton)." 2. GO:0007601 visual perception   3. GO:0022610 biological adhesion  "The attachment of a cell or organism to a substrate or other organism." 4. GO:0007155 cell adhesion  "The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules." 5. GO:0007398 ectoderm development "The process whose specific outcome is the progression of the ectoderm over time, from its formation to the mature structure. In animal embryos, the ectoderm is the outer germ layer of the embryo, formed during gastrulation." 6. GO:0007498 mesoderm development "The process whose specific outcome is the progression of the mesoderm over time, from its formation to the mature structure. The mesoderm is the middle germ layer that develops into muscle, bone, cartilage, blood and connective tissue." 7. GO:0048731 system development "The process whose specific outcome is the progression of an organismal system over time, from its formation to the mature structure. A system is a regularly interacting or interdependent group of organs or tissues that work together to carry out a given biological process." 8. GO:0032502 developmental process "A biological process whose specific outcome is the progression of an integrated living unit: an anatomical structure (which may be a subcellular structure, cell, tissue, or organ), or organism over time from an initial condition to a later condition." 9. N/A Unclassified N/A   
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Table S13 List of genes that contribute to the biological process ‘B cell mediated immunity’. Information obtained from the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ Gene symbol Gene name  1. Clec7a C-type lectin domain family 7 member A 2. Vav1 Proto-oncogene vav 3. Slamf7 SLAM family member 7 4. Cd22 B-cell receptor CD22 5. Clec2h C-type lectin domain family 2 member H 6. Emr1 EGF-like module-containing mucin-like hormone receptor-like 1 7. Klra3 Killer cell lectin-like receptor 3 8. Gab3 GRB2-associated-binding protein 3 9. Siglec1 Sialoadhesin;Siglec1 10. Vav3 Guanine nucleotide exchange factor VAV3 11. Slamf6 SLAM family member 6 12. Il12rb2 Interleukin-12 receptor subunit beta-2 13. Il13ra2 Interleukin-13 receptor subunit alpha-2 14. Il12rb1 Interleukin-12 receptor subunit beta-1 15. Gab2 GRB2-associated-binding protein 2 16. Clec5a C-type lectin domain family 5 member A 17. Pecam1 Platelet endothelial cell adhesion molecule 18. Cd33 Myeloid cell surface antigen CD33 19. Tnfrsf17 Tumor necrosis factor receptor superfamily member 17 20. Phldb3 Protein Phldb3 21. Tnfrsf1b Tumor necrosis factor receptor superfamily member 1B 22. Ly9 T-lymphocyte surface antigen Ly-9 23. Tnfrsf26 Tumor necrosis factor receptor superfamily member 26 24. Polm DNA-directed DNA/RNA polymerase mu 25. Emr4 EGF-like module-containing mucin-like hormone receptor-like 4 26. Clec12a C-type lectin domain family 12 member A 27. Csf3r Granulocyte colony-stimulating factor receptor 28. Plekhg1 Protein Plekhg1 (Fragment) 29. Cd2 T-cell surface antigen CD2 30. Cd84 SLAM family member 5 31. Ngfr Tumor necrosis factor receptor superfamily member 16 32. Klra2 Killer cell lectin-like receptor 2 33. Fcrl1 Fc receptor-like protein 1 34. Ebi3 Interleukin-27 subunit beta 35. Tnfrsf18 Tumor necrosis factor receptor superfamily member 18 36. Sh2b2 SH2B adapter protein 2 37. Arhgef6 Rho guanine nucleotide exchange factor 6 38. Fcrlb Fc receptor-like B 39. Spata13 Spermatogenesis-associated protein 13  
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Table S14 List of genes that contribute to the biological process ‘Macrophage activation’. Information obtained from the World Wide Web site for PANTHER classification system at: http://www.pantherdb.org/ Gene symbol Gene name  1. Mrc1 Macrophage mannose receptor 1 2. Cd36 Platelet glycoprotein 4 3. Pltp Phospholipid transfer protein 4. S100a13 Protein S100-A13 5. Clec4a1 C-type lectin domain family 4, member a1 6. Gbp7 Gbp6 protein 7. Col20a1 Collagen alpha-1(XX) chain 8. Msr1 Macrophage scavenger receptor types I and II 9. Syk Lysine--tRNA ligase 10. Adra1a Alpha-1A adrenergic receptor 11. Lgals3bp Galectin-3-binding protein 12. Ccl28 C-C motif chemokine 28 13. Gab3 GRB2-associated-binding protein 3 14. Marco Macrophage receptor MARCO 15. Colec12 Collectin-12 16. Col4a6 Protein Col4a6 17. Gab2 GRB2-associated-binding protein 2 18. Pecam1 Platelet endothelial cell adhesion molecule 19. Bpifb6 BPI fold-containing family B member 6 20. Bpifb4 BPI fold-containing family B member 4 21. Gbp9 Guanylate-binding protein 9 22. Phldb3 Protein Phldb3 23. Cd5l CD5 antigen-like 24. Tnfrsf1b Tumor necrosis factor receptor superfamily member 1B 25. Tnfrsf26 Tumor necrosis factor receptor superfamily member 26 26. Clec4e C-type lectin domain family 4 member E 27. Col4a3 Collagen alpha-3(IV) chain 28. Cd209c CD209 antigen-like protein C 29. Syk Tyrosine-protein kinase SYK 30. Cxcl16 C-X-C motif chemokine 16 31. S100a1 Protein S100-A1 32. Ngfr Tumor necrosis factor receptor superfamily member 16 33. Adra2a Alpha-2A adrenergic receptor 34. Gbp4 Guanylate-binding protein 4 35. Clec4a3 C-type lectin domain family 4, member a3 36. Clec4d C-type lectin domain family 4 member D 37. Fcrl1 Fc receptor-like protein 1 38. Tnfrsf18 Tumor necrosis factor receptor superfamily member 18 39. Gbp8 Guanylate binding protein 8 40. Adra2c Alpha-2C adrenergic receptor 41. Fcrlb Fc receptor-like B 42. Csf1 Macrophage colony-stimulating factor 1 
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Table S15 List of genes with higher expression in WT male compared to WT female MEFs (for at least 1.5 fold, P-value < 0.05) Genes Chromosome  1. Eif2s3y Y 2. Ddx3y Y 3. Kdm5d Y 4. Uty Y 5. Erdr1 Y 6. Gpr165 X 7. Lrrc10b 19 8. Dkk1 19 9. Tslp 18 10. Pi16 17 11. Chodl 16 12. Col2a1 15 13. Krt75 15 14. Fgf9 14 15. Gjb6 14 16. Thbs4 13 17. Hapln1 13 18. Adcy2 13 19. Dlk1 12 20. Syndig1l 12 21. Klhl29 12 22. 2810032G03Rik 12 23. Ramp2 11 24. Ace 11 25. Krt13 11 26. Krt14 11 27. S100b 10 28. Susd2 10 29. Bmp5 9 30. Stac 9 31. 1700048O20Rik 9 32. Gsta4 9 33. Gramd2 9 34. 1700102P08Rik 9 35. Cdh8 8 36. Clgn 8 37. Lpl 8 38. Acan 7 39. Scube2 7 40. Hif3a 7 41. Ntrk3 7 42. Gpr27 6 43. Klf14 6 
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44. Tril 6 45. Eln 5 46. Col8a2 4 47. Frem1 4 48. Col9a2 4 49. Ptx3 3 50. Agtr1b 3 51. Sfrp2 3 52. Snord73a 3 53. Fam83c 2 54. Mylk2 2 55. Pcsk2 2 56. Adamtsl2 2 57. Wnt6 1 58. Pappa2 1 59. Col9a1 1 60. Gsta3 1 61. Angptl1 1 62. Darc 1    Table S16 List of genes with higher expression in WT female compared to WT male MEFs (for at least 1.5 fold, P-value < 0.05) GeneID Chromosome 1. Xist X 2. Eif2s3x X 3. 5530601H04Rik X 4. Ppef1 X 5. Gda 19 6. Malat1 19 7. Neat1 19 8. 4933411K16Rik 19 9. Pcdha10 18 10. 9430076G02Rik 18 11. Mc2r 18 12. Gm4013 18 13. Pcdha9 18 14. Abcg1 17 15. Rgs11 17 16. Xdh 17 17. Pisd-ps2 17 18. C2 17 19. Rhbdl1 17 20. Stap2 17 21. H2-DMb1 17 22. 1700071M16Rik 17 
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23. Liph 16 24. 4930565N06Rik 16 25. Nlrc3 16 26. Kcnj15 16 27. Kng2 16 28. Slc7a4 16 29. Kifc2 15 30. Parp10 15 31. Cma2 14 32. Ptger2 14 33. Gzmd 14 34. Gzmc 14 35. Mcpt8 14 36. Hist1h3d 13 37. Fam228b 12 38. 4930447C04Rik 12 39. F730043M19Rik 12 40. Ccl8 11 41. Doc2b 11 42. Pisd-ps1 11 43. Rasl10b 11 44. Fbxw10 11 45. Sfi1 11 46. Bzrap1 11 47. Cntnap1 11 48. Havcr2 11 49. Slc16a11 11 50. Arg1 10 51. Hal 10 52. Gstt2 10 53. Gm5134 10 54. Acp5 9 55. Fxyd2 9 56. Cxcr6 9 57. Mmp3 9 58. Cck 9 59. Cmtm8 9 60. Pstpip1 9 61. Mmp13 9 62. Mmp10 9 63. Hapln4 8 64. Chst5 8 65. Mboat4 8 66. Insl3 8 67. Snord68 8 68. Acta1 8 69. Lrp2bp 8 70. Slc27a1 8 
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71. Slc5a5 8 72. Nlrc5 8 73. Gpr123 7 74. Syt17 7 75. 2810047C21Rik1 7 76. Apoc2 7 77. Tnfrsf26 7 78. Crym 7 79. 0610005C13Rik 7 80. Calcb 7 81. Fam19a1 6 82. Clec2e 6 83. Vwf 6 84. B230378P21Rik 6 85. Alox5 6 86. Spp1 5 87. Plac8 5 88. Fbxo24 5 89. Ppbp 5 90. Tfr2 5 91. Bmp8b 4 92. Cdkn2a 4 93. Rex2 4 94. Tas1r1 4 95. Angptl7 4 96. 1300002K09Rik 4 97. Tnfrsf18 4 98. Rnf207 4 99. Car9 4 100. LOC100038947 3 101. Tgm2 2 102. Angpt4 2 103. Slc52a3 2 104. Gm996 2 105. 1700020A23Rik 2 106. Rhov 2 107. Siglec1 2 108. Olfr1316 2 109. Htr2b 1 110. Otos 1 111. Nphs2 1 112. Kcnh1 1 113. Fam5c 1 114. Creg2 1 
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Table S17 List of upregulated (for at least 1.5 fold, adjusted P-value < 0.05) imprinted genes upon HP1γ knockout in male MEFs.  Loci Symbol Loci Name Chromo-some Expressed Parental Allele 
Fold Change (UP) 
Adjusted P-value 
1. Ampd3 adenosine monophosphate deaminase 3 
7 M 3.92602 3.78E-11 
2. Ascl2 achaete-scute complex homolog 2 (Drosophila) 
7 M 2.57948 0.034654 
3. Calcr calcitonin receptor 6 M 6.02507 0.013862 
4. Cntn3 contactin 3 6 M 2.70799 0.012574 
5. Cobl cordon-bleu WH2 repeat 11 M 1.57141 0.018566 6. Gatm glycine amidinotransferase (L-arginine: glycine amidinotransferase) 
2 M 2.10672 0.000467 
7. Pon2 paraoxonase 2 6 M 2.53656 2.59E-20 
8. Pon3 paraoxonase 3 6 M 2.48782 3.1E-06 
9. Ppp1r9a protein phosphatase 1, regulatory (inhibitor) subunit 9A 
6 M 5.07041 3.05E-16 
10. Qpct glutaminyl-peptide cyclotransferase (glutaminyl cyclase) 
17 M 1.72828 2.18E-09 
11. Scin scinderin 12 M 11.6446 1.48E-05 
12. Slc22a18 solute carrier family 22 (organic cation transporter), member 18 
7 M 2.23488 4.87E-05 
13. Tnfrsf23 tumor necrosis factor receptor superfamily, member 23 
7 M 1.88413 6.26E-06 
14. Trappc9 trafficking protein particle complex 9 15 M 1.50205 4.93E-12 15. Xlr4b X-linked lymphocyte-regulated 4B 
X M 3.11448 0.00039 
16. Xlr4c X-linked lymphocyte-regulated 4C 
X M 3.52326 0.020336 
17. Rasgrf1 RAS protein-specific guanine nucleotide-releasing factor 1 
9 P 6.24269 1.23E-05 
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Table S18 List of downregulated (for at least 1.5 fold, adjusted P-value < 0.05) imprinted genes upon HP1γ knockout in male MEFs.  Loci Symbol Loci Name Chromo-some Expressed Parental Allele 
Fold Change (DOWN) 
Adjusted P-value 
1. AF357426 AF357426  M 2.29706 0.041699 
2. Asb4 ankyrin repeat and SOCS box-containing 4 
6 M 1.7423 0.038 
3. Atp10a ATPase, class V, type 10A 7 M 4.3064 3.35E-18 4. Cdkn1c cyclin-dependent kinase inhibitor 1C (P57) 
7 M 6.24367 2.04E-07 
5. Dcn decorin 10 M 2.36107 0.030233 
6. Dhcr7 7-dehydrocholesterol reductase 
7 M 1.74554 0.000205 
7. Dlx5 distal-less homeobox 5 6 M 1.80285 0.013625 8. Grb10 growth factor receptor bound protein 10 
11 M 3.35366 1.08E-34 
9. H19 H19, imprinted maternally expressed transcript 
7 M 13.3301 8.59E-67 
10. Htr2a 5-hydroxytryptamine (serotonin) receptor 2A 
14 M 1.69666 0.000151 
11. Igf2r insulin-like growth factor 2 receptor 17 M 2.15607 2.81E-16 12. Klf14 Kruppel-like factor 14 6 M 12.8701 4.23E-05 13. Meg3 maternally expressed 3 12 M 1.53386 0.033964 14. Rian RNA imprinted and accumulated in nucleus 
12 M 2.34174 1.29E-10 
15. Tfpi2 tissue factor pathway inhibitor 2 6 M 2.5143 0.012203 16. Zim1 zinc finger, imprinted 1 7 M 3.71557 3.36E-08 17. Airn antisense Igf2r RNA 17 P 1.96305 5.86E-05 18. Begain brain-enriched guanylate kinase-associated 
12 P 2.92865 2.39E-06 
19. Dio3 deiodinase, iodothyronine type III 
12 P 4.16246 2.85E-07 
20. Dlk1 delta-like 1 homolog (Drosophila) 
12 P 12.7392 2.84E-10 
21. Igf2 insulin-like growth factor 2 7 P 12.9434 4.78E-63 22. Magel2 melanoma 7 P 2.83145 0.015885 
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antigen, family L, 2 
23. Nap1l5 nucleosome assembly protein 1-like 5 
6 P 1.98772 0.006838 
24. Nnat neuronatin 2 P 1.67783 0.012808 
25. Peg12 paternally expressed 12 7 P 1.60317 3.07E-05 26. Peg3 paternally expressed 3 7 P 3.14558 7.9E-08 27. Plagl1 pleiomorphic adenoma gene-like 1 
10 P 3.66751 1.31E-10 
28. Rtl1 retrotransposon-like 1 12 P 2.9626 0.006971 29. Sfmbt2 Scm-like with four mbt domains 2 2 P 1.61025 5.49E-05 30. Slc38a4 solute carrier family 38, member 4 
15 P 9.74479 1.61E-48 
31. Usp29 ubiquitin specific peptidase 29 7 P 2.38313 0.006319 32. Zdbf2 zinc finger, DBF-type containing 2 1 P 7.29949 2.46E-10                                
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